

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2014227811 C1**

(54) Title
Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds

(51) International Patent Classification(s)
C12P 19/00 (2006.01) **C12P 7/00** (2006.01)
C12N 9/10 (2006.01) **C12P 15/00** (2006.01)
C12N 9/16 (2006.01) **C12P 17/00** (2006.01)
C12N 9/88 (2006.01) **C12P 23/00** (2006.01)
C12P 5/00 (2006.01) **C12P 33/00** (2006.01)

(21) Application No: **2014227811** (22) Date of Filing: **2014.03.14**

(87) WIPO No: **WO14/144135**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/800,356	2013.03.15	US

(43) Publication Date: **2014.09.18**

(44) Accepted Journal Date: **2018.03.22**

(44) Amended Journal Date: **2018.09.27**

(71) Applicant(s)
Amyris, Inc.;Total Marketing Services

(72) Inventor(s)
Hawkins, Kristy Michelle;Mahatdejkul-Meadows, Tina Tipawan;Meadows, Adam Leon;Pickens, Lauren Barbara;Tai, Anna;Tsong, Annie Ening

(74) Agent / Attorney
Phillips Ormonde Fitzpatrick, PO Box 323, Collins Street West, VIC, 8007, AU

(56) Related Art
US 2012276587 A1
EP 2546336 A1

(51) International Patent Classification:

C12P 19/00 (2006.01) C12P 15/00 (2006.01)
 C12P 23/00 (2006.01) C12P 17/00 (2006.01)
 C12P 33/00 (2006.01) C12N 9/10 (2006.01)
 C12P 5/00 (2006.01) C12N 9/16 (2006.01)
 C12P 7/00 (2006.01) C12N 9/88 (2006.01)

(21) International Application Number:

PCT/US2014/028421

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/800,356 15 March 2013 (15.03.2013) US

(71) Applicants: **AMYRIS, INC.** [US/US]; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US). **TOTAL MARKETING SERVICES** [FR/FR]; 24, Cours Michelet, F-92800 Puteaux (FR).

(72) Inventors: **HAWKINS, Kristy Michelle**; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US). **MA-HATDEJKUL-MEADOWS, Tina Tipawan**; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US). **MEADOWS, Adam Leon**; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US). **PICKENS, Lauren Barbara**; 5885 Hollis Street, Suite 100, Emeryville, Cali-

fornia 94608 (US). **TAI, Anna**; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US). **TSONG, Annie Ening**; 5885 Hollis Street, Suite 100, Emeryville, California 94608 (US).

(74) Agents: **PATHAK, Rahul** et al.; Squire Patton Boggs (US) LLP, 275 Battery Street, Suite 2600, San Francisco, California 94111 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: USE OF PHOSPHOKETOLASE AND PHOSPHOTRANSACETYLASE FOR PRODUCTION OF ACETYL-COENZYME A DERIVED COMPOUNDS

Figure 1



(57) Abstract: Provided herein are compositions and methods for improved production of acetyl-CoA and acetyl-CoA derived compounds in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a phosphoketolase (PK), and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a phosphotransacetylase (PTA). In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase. In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2. The compositions and methods described herein provide an efficient route for the heterologous production of acetyl-CoA-derived compounds, including but not limited to, isoprenoids, polyketides, and fatty acids.

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

Published:

- with international search report (Art. 21(3))

(88) Date of publication of the international search report:

23 October 2014

USE OF PHOSPHOKETOLASE AND PHOSPHOTRANSACETYLASE FOR PRODUCTION OF ACETYL-COENZYME A DERIVED COMPOUNDS

[0001] This application claims benefit of priority of U.S. Provisional Application No. 61/800,356, filed on March 15, 2013, the contents of which are hereby incorporated by reference in their entirety.

1. FIELD OF THE INVENTION

[0002] The present disclosure relates to compositions and methods for producing acetyl-CoA derived compounds in engineered host cells.

2. BACKGROUND

[0003] Acetyl coenzyme A (acetyl-CoA) is a key intermediate in the synthesis of essential biological compounds, including polyketides, fatty acids, isoprenoids, phenolics, alkaloids, vitamins, and amino acids. Among the metabolites derived from acetyl-CoA are primary and secondary metabolites, including compounds of industrial utility. In yeast, acetyl-CoA is biosynthesized from pyruvate metabolism (**FIG. 1**). However, in this biosynthetic pathway, CO₂ is lost via the reactions catalyzed by pyruvate carboxylase and/or pyruvate dehydrogenase. In an industrial fermentation setting, one benefit of providing an alternative to pyruvate metabolism and lower glycolysis is that less CO₂ is produced in the decarboxylation of pyruvate, and thus more carbon can be captured in the end product, thereby increasing the maximum theoretical yield. A second benefit is that less NADH is produced, and therefore significantly less oxygen is needed to reoxidize it. This can be accomplished by expressing phosphoketolase (PK; EC 4.1.2.9) in conjunction with phosphoacetyltransferase (PTA; EC 2.3.1.8).

[0004] PK and PTA catalyze the reactions to convert fructose-6-phosphate (F6P) or xylulose-5-phosphate (X5P) to acetyl-CoA. As shown in **FIG. 1**, PK draws from the pentose phosphate intermediate xylulose 5-phosphate, or from the upper glycolysis intermediate D-fructose 6-phosphate (F6P). PK splits X5P into glyceraldehyde 3-phosphate (G3P) and acetyl phosphate, or F6P into erythrose 4-phosphate (E4P) and acetyl phosphate. PTA then converts the acetyl phosphate into acetyl-CoA. G3P can re-enter lower glycolysis, and E4P can re-enter the pentose phosphate pathway or glycolysis by cycling through the non-oxidative pentose phosphate pathway network of transaldolases and transketolases.

[0005] The applicants have previously described the improved efficiency of heterologous isoprenoid production that can be gained with the introduction of PK and PTA enzymes. See U.S. Application No. 13/673,819 (now U.S. Patent No. 8,415,136), filed on

November 9, 2012, the contents of which are hereby incorporated by reference in their entirety. In particular, when cytosolic acetyl-CoA is synthesized from glucose using only the chemical reactions which occur in the native yeast metabolic network, the maximum possible stoichiometric yield for conversion of glucose to the isoprenoid farnesene via the mevalonate pathway is 23.6 wt%. By including the reactions catalyzed by acetaldehyde dehydrogenase, acetylating (ADA; EC 1.2.1.10) and NADH-using HMG-CoA reductase into the metabolic network for mevalonate production, the maximum theoretical stoichiometric yield is improved to 25.2 wt%. With the further introduction of PK and PTA, the reaction network, at optimality, is able to reach 29.8 wt% mass yield or greater, a significant increase in maximum theoretical yield.

[0006] Sondregger *et al.* have also described the benefits of PK and PTA with respect to ethanol production in a xylose-utilizing yeast strain. See Sondregger *et al.*, *Applied and Environmental Microbiology* 70(5):2892-2897 (2004), the contents of which are hereby incorporated by reference in their entirety. The heterologous phosphoketolase pathway (PK, PTA, and ADA) was introduced in *S. cerevisiae* to address low ethanol yields that result from overexpression of NAD(P)H-dependent xylose reductase and NAD⁺-dependent xylitol dehydrogenase from *Pichia stipitis*. The different cofactor preferences in the two oxidoreductase reactions caused an anaerobic redox balancing problem that manifested in the extensive accumulation of the reduced reaction intermediate xylitol, and thus, low ethanol yields. Redox metabolism was balanced by introducing the phosphoketolase pathway, which lead to the net reoxidation of one NADH per xylose converted to ethanol, and an improvement in ethanol yield by 25%. However, overexpression of PK also leads to an increase in acetate accumulation and a reduction in fermentation rate. Although some acetate accumulation could be reduced by combining the phosphoketolase pathway with a mutation of ALD6, which converts acetaldehyde to acetate, the flux through the recombinant phosphoketolase pathway was about 30% of the optimum flux that would be required to completely eliminate xylitol and glycerol accumulation. The authors suggested that higher activities of phosphotransacetylase and/or acetaldehyde dehydrogenase may be necessary to prevent phosphoketolase pathway-based acetate formation.

[0007] Thus, while the introduction of a heterologous PK pathway can lead to substantial improvements in the yields of acetyl-CoA derived compounds, further improvements in the implementation of this pathway appear to be required to achieve optimal

carbon flux through PK and PTA. The compositions and methods provided herein address this need and provide related advantages as well.

3. SUMMARY OF THE INVENTION

[0008] Provided herein are compositions and methods for the improved utilization of phosphoketolase (PK) and phosphotransacetylase (PTA) for the production of industrially useful compounds. These compositions and methods are based on the surprising discovery that phosphoketolase pathway-based acetate accumulation results from the enzyme-catalyzed hydrolysis of acetyl phosphate, the product of PK catalysis. Hydrolysis of acetyl phosphate is an undesirable side-reaction that can negatively impact production, via depletion of carbon, of any type of product derived from acetyl-CoA, including isoprenoids, polyketides, and fatty acids. By functionally disrupting native enzymes in the host cell that catalyze acetyl phosphate hydrolysis, acetate accumulation is reduced and carbon flux through the PK/PTA pathway towards acetyl-CoA production is increased.

[0009] The compositions and methods provided herein are further based on the unexpected discovery of native enzymes in yeast that catalyze the hydrolysis of acetyl phosphate to acetate, namely GPP1/RHR2, and its closely related homolog GPP2/HOR2. Both of these enzymes have only been previously characterized as having glycerol-1-phosphatase (EC 3.1.3.21; alternately referred to as “glycerol-3-phosphatase”) activity, and thus, the promiscuous acetyl-phosphatase activity of these enzymes is unexpected. In cells heterologously expressing PK and PTA, deletion of one or both of the genes encoding RHR2 and HOR2 leads to a reduction in acetate accumulation, with deletion of the gene encoding RHR2 alone leading to a substantial reduction in acetate levels. Moreover, deletion of the *RHR2* gene in cells engineered to comprise PK, PTA and a mevalonate pathway resulted in a substantial increase in the production of farnesene, an acetyl-CoA derived isoprenoid.

[0010] Thus, provided herein are genetically modified host cells and methods of their use for the production of industrially useful compounds. In one aspect, provided herein is a genetically modified host cell comprising: a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9); and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8).

[0011] In another aspect, provided herein is a genetically modified host cell comprising: a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC

2.3.1.8); and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9).

[0012] In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is selected from the group consisting of GPP1/RHR2, GPP2HOR2, and homologues and variants thereof. In some embodiments, the genetically modified host cell comprises a functional disruption of GPP1/RHR2. In some embodiments, the genetically modified host cell comprises a functional disruption of GPP2/HOR2. In some embodiments, the genetically modified host cell comprises a functional disruption of both GPP1/RHR2 and GPP2/HOR2.

[0013] In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an acylating acetaldehyde dehydrogenase (ADA; EC 1.2.1.10). In some embodiments, the genetically modified host cell further comprises a functional disruption of one or more enzymes of the native pyruvate dehydrogenase (PDH) - bypass. In some embodiments, the one or more enzymes of the PDH-bypass are selected from acetyl-CoA synthetase 1 (ACS1), acetyl-CoA synthetase 2 (ACS2), and aldehyde dehydrogenase 6 (ALD6).

[0014] In some embodiments, the genetically modified host cell is capable of producing a heterologous acetyl-CoA derived compound. In some embodiments, the heterologous acetyl-CoA derived compound is selected from the group consisting of an isoprenoid, a polyketide, and a fatty acid. In particular embodiments, the genetically modified host cell is capable of producing an isoprenoid.

[0015] In some embodiments, the genetically modified host cell comprises one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate. In some embodiments, the one or more enzymes of the MEV pathway comprise an NADH-using HMG-CoA reductase. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that converts HMG-CoA to mevalonate. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate. In some embodiments, the one or

more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate. In some embodiments, the one or more enzymes of the MEV pathway are selected from HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase and mevalonate pyrophosphate decarboxylase. In some embodiments, the host cell comprises a plurality of heterologous nucleic acids encoding all of the enzymes of the MEV pathway. In some embodiments, the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of a single transcriptional regulator. In some embodiments, the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of multiple heterologous transcriptional regulators. In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an enzyme that can convert isopentenyl pyrophosphate (IPP) into dimethylallyl pyrophosphate (DMAPP). In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an enzyme that can condense IPP and/or DMAPP molecules to form a polyprenyl compound. In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound.

[0016] In some embodiments, the enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound is selected from the group consisting of carene synthase, geraniol synthase, linalool synthase, limonene synthase, myrcene synthase, ocimene synthase, α -pinene synthase, β -pinene synthase, γ -terpinene synthase, terpinolene synthase, amorphadiene synthase, α -farnesene synthase, β -farnesene synthase, farnesol synthase, nerolidol synthase, patchouliol synthase, nootkatone synthase, and abietadiene synthase.

[0017] In some embodiments, the isoprenoid is selected from the group consisting of a hemiterpene, monoterpene, diterpene, triterpene, tetraterpene, sesquiterpene, and polyterpene. In some embodiments, the isoprenoid is a sesquiterpene. In some embodiments, the isoprenoid is a C₅-C₂₀ isoprenoid. In some embodiments, the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpinolene, and valencene.

[0018] In another aspect, provided herein is a genetically modified host cell capable of producing an isoprenoid, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate; a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0019] In another aspect, provided herein is a genetically modified host cell capable of producing an isoprenoid, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate; a heterologous nucleic acid encoding an acetylaldehyde dehydrogenase, acetylating (ADA); a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0020] In another aspect, provided herein is a genetically modified host cell capable of producing an isoprenoid, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate; a heterologous nucleic acid encoding an acetylaldehyde dehydrogenase, acetylating (ADA); a functional disruption of at least one enzyme of the native PDH-bypass selected from the group consisting of acetyl-CoA synthetase 1 (ACS1), acetyl-CoA synthetase 2 (ACS2), and aldehyde dehydrogenase 6 (ALD6); a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0021] In another aspect, provided herein is a genetically modified host cell capable of producing an isoprenoid, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate, wherein the one or more enzymes comprise a NADH-using HMG-CoA

reductase; a heterologous nucleic acid encoding an acetylaldehyde dehydrogenase, acetylating (ADA); a functional disruption of at least one enzyme of the native PDH-bypass selected from the group consisting of acetyl-CoA synthetase 1 (ACS1), acetyl-CoA synthetase 2 (ACS2), and aldehyde dehydrogenase 6 (ALD6); a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0022] In another aspect, provided herein is genetically modified host cell capable of producing an isoprenoid, the cell comprising: one or more heterologous nucleic acids encoding a plurality of enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate, wherein the plurality of enzymes comprise an acetyl-CoA:malonyl-CoA acyltransferase; a heterologous nucleic acid encoding an acetylaldehyde dehydrogenase, acetylating (ADA); a functional disruption of at least one enzyme of the native PDH-bypass selected from the group consisting of acetyl-CoA synthetase 1 (ACS1), acetyl-CoA synthetase 2 (ACS2), and aldehyde dehydrogenase 6 (ALD6); a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0023] In another aspect, provided herein is a genetically modified host cell capable of producing a polyketide, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of polyketide biosynthetic pathway; a heterologous nucleic acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0024] In another aspect, provided herein is a genetically modified host cell capable of producing a fatty acid, the cell comprising: one or more heterologous nucleic acids encoding one or more enzymes of fatty acid biosynthetic pathway; a heterologous nucleic

acid encoding a phosphoketolase (PK); a heterologous nucleic acid encoding a phosphotransacetylase (PTA); and a functional disruption of a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2, or a homologue or variant thereof. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2, or a homologue or variant thereof.

[0025] In some embodiments, the genetically modified host cell provided herein is selected from the group consisting of a bacterial cell, a fungal cell, an algal cell, an insect cell, and a plant cell. In some embodiments, the cell is a yeast cell. In some embodiments, the yeast is *Saccharomyces cerevisiae*.

[0026] In some embodiments, the genetically modified host cell produces an increased amount of an acetyl-CoA derived compound (e.g., an isoprenoid, polyketide, or fatty acid) compared to a yeast cell not comprising a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate.

[0027] In another aspect, provided herein are methods for producing a heterologous acetyl-CoA derived compound, the method comprising: culturing a population of genetically modified host cells, capable of producing a heterologous acetyl-CoA derived compound as described herein, in a medium with a carbon source under conditions suitable for making said heterologous acetyl-CoA derived compound; and recovering said heterologous acetyl-CoA derived compound from the medium. In some embodiments, heterologous acetyl-CoA derived compound is selected from the group consisting of an isoprenoid, a polyketide, and a fatty acid.

[0028] In another aspect, provided herein is a method for increasing the production of acetyl-CoA or an acetyl-CoA derived compound in a host cell, the method comprising: expressing in the host cell a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9); and functionally disrupting an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the method further comprises expressing in the host cell a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8).

[0029] In another aspect, provided herein is a method for increasing the production of acetyl-CoA in a host cell, the method comprising: expressing in the host cell a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8); and functionally disrupting an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the method further comprises expressing in the host cell a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9).

[0030] In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the glycerol-1-phosphatase is selected from GPP1/RHR2, GPP2/HOR2, and homologues and variants thereof. In some embodiments, GPP1/RHR2, or a homologue or variant thereof, is functionally disrupted. In some embodiments, GPP2/HOR2, or a homologue or variant thereof, is functionally disrupted. In some embodiments, both GPP1/RHR2 and GPP2/HOR2, or both a homologue or variant of GPP1/RHR2 and a homologue or variant of GPP2/HOR2, are functionally disrupted. In some embodiments, the host cell is selected from the group consisting of a bacterial cell, a fungal cell, an algal cell, an insect cell, and a plant cell. In some embodiments, the host cell is a yeast cell. In some embodiments, the yeast is *Saccharomyces cerevisiae*. In some embodiments, the host cell produces an increased amount of acetyl-CoA or an acetyl-CoA derived compound compared to a yeast cell not comprising a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate.

[0030a] In one aspect, provided herein is a genetically modified yeast host cell comprising: (a) a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9); (b) a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8); and (c) a functional disruption of an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate, wherein conversion from acetyl phosphate to acetate is functionally disrupted.

[0030b] In another aspect, provided herein is a method for increasing the production of acetyl-CoA or an isoprenoid in a yeast host cell, the method comprising: (a) expressing in the yeast host cell a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9) and a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8); and (b) functionally disrupting an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate, wherein conversion from acetyl phosphate to acetate is functionally disrupted.

4. BRIEF DESCRIPTION OF THE FIGURES

[0031] **FIG. 1** provides a schematic representation of the pathways involved in the conversion of sugar (glucose and xylose) to acetyl-CoA, and acetyl-CoA derived compounds, in a yeast host cell. The bold arrows indicate the recombinant phosphoketolase pathway. Acetyl phosphate is an intermediate of the phosphoketolase (PK) / phosphotransacetylase (PTA) pathway to acetyl-CoA, and is hydrolyzed to acetate by RHR2 and HOR2.

Abbreviations: G6P, glucose-6-phosphate; R5P, ribulose-5-phosphate; X5P, xyulose-5-phosphate; F6P, fructose-6-phosphate; E4P, eryhtrose-4-phosphate; FBP, fructose-1,6-biphosphate; DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde-3-phosphate; PEP, phosphoenolpyruvate; ADA, acetaldehyde dehydrogenase, acetylating; ACP, acetyl phosphate.

[0032] **FIG. 2** provides representative enzymes of the mevalonate pathway for isoprenoid production. Abbreviations: AcCoA, acetyl-CoA; AcAcCoA, acetoacetyl-CoA; HMGC_oA, 3-hydroxy-3-methylglutaryl-CoA; Mev5P, mevalonate-5-phosphate; Mev5DP, mevalonate-5-diphosphate; IPP, isopentenyl diphosphate; DMAPP, dimethylallyl pyrophosphate; Erg10, acetyl-CoA thiolase; ACC1, acetyl-CoA carboxylase; AAC_S, acetoacetyl-CoA synthase; Erg13, 3-hydroxy-3-methylglutaryl-CoA synthase; HMGr, 3-hydroxy-3-methylglutaryl-CoA reductase; Erg12, mevalonate kinase; Erg8, phosphomevalonate kinase; Erg19, mevalonate pyrophosphate decarboxylase.

[0033] **FIGS. 3A-3B** provides the sugar consumption (**A**) and acetate production (**B**) of wild-type (strain Y967, left) and recombinant yeast cells (middle, right) comprising: a heterologous acetaldehyde dehydrogenase acylating (Dz.eutE) and deletion of the native PDH-bypass (*acs1Δ acs2 Δ ald6Δ*) (strain Y12869; middle); and further comprising a heterologous phosphoketolase (Lm.PK) and phosphotransacetylase (Ck.PTA) (strain Y12746; right).

[0034] **FIGS. 3C-3D** provides the sugar consumption (**C**) and acetate production (**D**) of recombinant yeast cells comprising: a heterologous acetaldehyde dehydrogenase acylating (Dz.eutE) and deletion of the native PDH-bypass (*acs1Δ acs2 Δ ald6Δ*) (strain Y12869; left); and further comprising a heterologous phosphoketolase (Lm.PK) (strain Y19390; middle) or phosphotransacetylase (Ck.PTA) (strain Y19391; right).

[0035] **FIG. 4** provides a demonstration of acetyl phosphate hydrolysis in cell free extracts (CFE) of wild-type *S. cerevisiae* strain Y967 over a 120 minute timecourse. Shown are CFE only (left); CFE plus 30 mM sodium fluoride, a broad spectrum phosphatase inhibitor (middle); and CFE that has been heat inactivated (right).

[0036] **FIG. 5** provides results of anion exchange chromatography on Y967 cell free extracts. Protein was eluted with a 0-100% gradient of buffer B (20 mM Tris-Cl pH 7, 1M NaCl, 10% glycerol) over 30 column volumes at a flow rate of 0.5 mL/minute, and 1 mL fractions were collected, analyzed by protein gel electrophoresis (**FIG. 5B**), and assayed for acetyl phosphatase activity (**FIG. 5A**). ACP, acetyl phosphate.

[0037] **FIG. 6A** provides results of anion exchange chromatography on fraction #10 of Y967. The most active fraction from this purification, # 14, was analyzed by mass spectrometry to determine the identity of the proteins in the fraction (**FIG. 6B**). RHR2 was identified as a phosphatase in the active fraction.

[0038] **FIG. 7** provides results of acetyl phosphatase activity assays on CFEs of a wild-type yeast strain (Y968) or recombinant yeast strains comprising a deletion of *RHR2*, *HOR2* or both *RHR2* and *HOR2*.

[0039] **FIGS. 8A-8C** provides acetate levels (**A**), glycerol levels (**B**) and optical densities (**C**) of recombinant yeast strain populations. Strain Y12746.ms63909.ms64472 comprises a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), and heterologously expresses acetaldehyde dehydrogenase acylating (Dz.eutE), phosphoketolase (Lm.PK), phosphotransacetylase (Ck.PTA), and genes in the farnesene production pathway. Strain

Y12746.ms63909.ms64472 *rhr2*^Δ is isogenic to strain Y12746.ms63909.ms64472 but further comprises a deletion of *RHR2* (*rhr2*^Δ).

[0040] **FIGS. 8D-8E** provides acetate levels (**D**) and optical densities (**E**) of recombinant yeast strain populations. Strain Y12745 comprises a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), and heterologously expresses acetaldehyde dehydrogenase acetylating (Dz.eutE), phosphoketolase (Lm.PK), and phosphotransacetylase (Ck.PTA). Strain Y12746 *rhr2*^Δ is isogenic to strain Y12746 but further comprises a deletion of *RHR2* (*rhr2*^Δ).

[0041] **FIG. 9** provides relative farnesene levels (top) and relative optical densities (bottom) of recombinant yeast strain populations wherein the *RHR2* gene is intact (*RHR2*⁺) or deleted (*rhr2*^Δ). Y968 (right panel) is a wild-type yeast strain. Y12869.ms63907.ms64472 (“Y12869”; 2nd from right panel) comprises a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), and heterologously expresses acetaldehyde dehydrogenase acetylating (Dz.eutE) and genes in the farnesene production pathway, but does not express phosphoketolase or phosphotransacetylase. Y12746.ms63907.ms64472 (“Y12746”; 2nd from left panel) comprises a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), and heterologously expresses acetaldehyde dehydrogenase acetylating (Dz.eutE) and genes in the farnesene production pathway, and uses phosphoketolase and phosphotransacetylase as a pathway to produce cytosolic acetyl-CoA, which is used for synthesis of farnesene. Y12745.ms63907.ms64472 (“Y12745”; left panel) comprises a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), and genes in the farnesene production pathway, and uses phosphoketolase and phosphotransacetylase as a pathway to produce cytosolic acetyl-CoA, which is used for synthesis of farnesene.

5. DETAILED DESCRIPTION OF THE EMBODIMENTS

5.1 Terminology

[0042] As used herein, the term “heterologous” refers to what is not normally found in nature. The term “heterologous nucleotide sequence” refers to a nucleotide sequence not normally found in a given cell in nature. As such, a heterologous nucleotide sequence may be: (a) foreign to its host cell (*i.e.*, is “exogenous” to the cell); (b) naturally found in the host cell (*i.e.*, “endogenous”) but present at an unnatural quantity in the cell (*i.e.*, greater or lesser quantity than naturally found in the host cell); or (c) be naturally found in the host cell but positioned outside of its natural locus. The term “heterologous enzyme” refers to an enzyme that is not normally found in a given cell in nature. The term encompasses an enzyme that is: (a) exogenous to a given cell (*i.e.*, encoded by a nucleotide sequence that is not naturally

present in the host cell or not naturally present in a given context in the host cell); and
(b) naturally found in the host cell (*e.g.*, the enzyme is encoded by a nucleotide sequence that is endogenous to the cell) but that is produced in an unnatural amount (*e.g.*, greater or lesser than that naturally found) in the host cell.

[0043] On the other hand, the term “native” or “endogenous” as used herein with reference to molecules, and in particular enzymes and nucleic acids, indicates molecules that are expressed in the organism in which they originated or are found in nature, independently of the level of expression that can be lower, equal, or higher than the level of expression of the molecule in the native microorganism. It is understood that expression of native enzymes or polynucleotides may be modified in recombinant microorganisms.

[0044] As used herein, to “functionally disrupt” or a “functional disruption” *e.g.*, of a target gene, for example, one or more genes of the PDH-bypass, means that the target gene is altered in such a way as to decrease in the host cell the activity of the protein encoded by the target gene. In some embodiments the functional disruption of a target gene results in a reduction by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the expression level of the target gene compared to its expression when not functionally disrupted. Similarly, to “functionally disrupt” or a “functional disruption” *e.g.*, of a target protein, for example, a protein having acetyl phosphatase activity, means that the target protein is altered in such a way as to decrease in the host cell the activity of the protein. In some embodiments the functional disruption of a target protein results in a reduction by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the activity or expression level of the target protein compared to its activity or expression when not functionally disrupted. In some embodiments, the activity of the target protein encoded by the target gene is eliminated in the host cell. In other embodiments, the activity of the target protein encoded by the target gene is decreased in the host cell. Functional disruption of the target gene may be achieved by deleting all or a part of the gene so that gene expression is eliminated or reduced, or so that the activity of the gene product is eliminated or reduced. Functional disruption of the target gene may also be achieved by mutating a regulatory element of the gene, *e.g.*, the promoter of the gene so that expression is eliminated or reduced, or by mutating the coding sequence of the gene so that the activity of the gene product is eliminated or reduced. In some embodiments, functional disruption of the target gene results in the removal of the complete open reading frame of the target gene.

[0045] As used herein, the term “parent cell” refers to a cell that has an identical genetic background as a genetically modified host cell disclosed herein except that it does not comprise one or more particular genetic modifications engineered into the modified host cell, for example, one or more modifications selected from the group consisting of: heterologous expression of an ADA, heterologous expression of an NADH-using HMG-CoA reductase, heterologous expression of an AACS, heterologous expression of a phosphoketolase, heterologous expression of a phosphotransacetylase, and heterologous expression of one or more enzymes of the mevalonate pathway.

[0046] As used herein, the term “production” generally refers to an amount of an isoprenoid produced by a genetically modified host cell provided herein. In some embodiments, production is expressed as a yield of isoprenoid by the host cell. In other embodiments, production is expressed as a productivity of the host cell in producing the isoprenoid.

[0047] As used herein, the term “productivity” refers to production of an isoprenoid by a host cell, expressed as the amount of isoprenoid produced (by weight) per amount of fermentation broth in which the host cell is cultured (by volume) over time (per hour).

[0048] As used herein, the term “yield” refers to production of an isoprenoid by a host cell, expressed as the amount of isoprenoid produced per amount of carbon source consumed by the host cell, by weight.

[0049] As used herein, the phrase “acetyl-CoA derived compound” refers to a compound which uses acetyl-CoA as a substrate in its biosynthesis. Exemplary acetyl-CoA derived compounds include, but are not limited to, isoprenoids, polyketides, fatty acids, and alcohols. In some embodiments, an acetyl-CoA derived compound is ethanol, for example, bioethanol produced from pentose substrates, as described in U.S. Patent No. 7,253,001, the contents of which are hereby incorporated by reference in their entirety.

[0050] As used herein, the term “variant” refers to a polypeptide differing from a specifically recited “reference” polypeptide (*e.g.*, a wild-type sequence) by amino acid insertions, deletions, mutations, and substitutions, but retains an activity that is substantially similar to the reference polypeptide. In some embodiments, the variant is created by recombinant DNA techniques, such as mutagenesis. In some embodiments, a variant polypeptide differs from its reference polypeptide by the substitution of one basic residue for another (*i.e.* Arg for Lys), the substitution of one hydrophobic residue for another (*i.e.* Leu for Ile), or the substitution of one aromatic residue for another (*i.e.* Phe for Tyr), *etc.* In some

embodiments, variants include analogs wherein conservative substitutions resulting in a substantial structural analogy of the reference sequence are obtained. Examples of such conservative substitutions, without limitation, include glutamic acid for aspartic acid and vice-versa; glutamine for asparagine and vice-versa; serine for threonine and vice-versa; lysine for arginine and vice-versa; or any of isoleucine, valine or leucine for each other.

5.2 Host Cells

[0051] Host cells useful compositions and methods provided herein include archae, prokaryotic, or eukaryotic cells.

[0052] Suitable prokaryotic hosts include, but are not limited, to any of a variety of gram-positive, gram-negative, or gram-variable bacteria. Examples include, but are not limited to, cells belonging to the genera: *Agrobacterium*, *Alicyclobacillus*, *Anabaena*, *Anacystis*, *Arthrobacter*, *Azobacter*, *Bacillus*, *Brevibacterium*, *Chromatium*, *Clostridium*, *Corynebacterium*, *Enterobacter*, *Erwinia*, *Escherichia*, *Lactobacillus*, *Lactococcus*, *Mesorhizobium*, *Methylobacterium*, *Microbacterium*, *Phormidium*, *Pseudomonas*, *Rhodobacter*, *Rhodopseudomonas*, *Rhodospirillum*, *Rhodococcus*, *Salmonella*, *Scenedesmun*, *Serratia*, *Shigella*, *Staphylococcus*, *Streptomyces*, *Synnecoccus*, and *Zymomonas*. Examples of prokaryotic strains include, but are not limited to: *Bacillus subtilis*, *Bacillus amyloliquefacines*, *Brevibacterium ammoniagenes*, *Brevibacterium immariophilum*, *Clostridium beigerinckii*, *Enterobacter sakazakii*, *Escherichia coli*, *Lactococcus lactis*, *Mesorhizobium loti*, *Pseudomonas aeruginosa*, *Pseudomonas mevalonii*, *Pseudomonas pudica*, *Rhodobacter capsulatus*, *Rhodobacter sphaeroides*, *Rhodospirillum rubrum*, *Salmonella enterica*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, and *Staphylococcus aureus*. In a particular embodiment, the host cell is an *Escherichia coli* cell.

[0053] Suitable archae hosts include, but are not limited to, cells belonging to the genera: *Aeropyrum*, *Archaeoglobus*, *Halobacterium*, *Methanococcus*, *Methanobacterium*, *Pyrococcus*, *Sulfolobus*, and *Thermoplasma*. Examples of archae strains include, but are not limited to: *Archaeoglobus fulgidus*, *Halobacterium sp.*, *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Thermoplasma acidophilum*, *Thermoplasma volcanium*, *Pyrococcus horikoshii*, *Pyrococcus abyssi*, and *Aeropyrum pernix*.

[0054] Suitable eukaryotic hosts include, but are not limited to, fungal cells, algal cells, insect cells, and plant cells. In some embodiments, yeasts useful in the present methods include yeasts that have been deposited with microorganism depositories (e.g. IFO, ATCC,

etc.) and belong to the genera *Aciculoconidium*, *Ambrosiozyma*, *Arthroascus*, *Arxiozyma*, *Ashbya*, *Babjevia*, *Bensingtonia*, *Botryoascus*, *Botryozyma*, *Brettanomyces*, *Bullera*, *Bulleromyces*, *Candida*, *Citeromyces*, *Clavispora*, *Cryptococcus*, *Cystofilobasidium*, *Debaryomyces*, *Dekkara*, *Dipodascopsis*, *Dipodascus*, *Eeniella*, *Endomycopsella*, *Eremascus*, *Eremothecium*, *Erythrobasidium*, *Fellomyces*, *Filobasidium*, *Galactomyces*, *Geotrichum*, *Guilliermondella*, *Hanseniaspora*, *Hansenula*, *Hasegawaea*, *Holtermannia*, *Hormoascus*, *Hyphopichia*, *Issatchenkia*, *Kloeckera*, *Kloeckeraspora*, *Kluyveromyces*, *Kondoa*, *Kuraishia*, *Kurtzmanomyces*, *Leucosporidium*, *Lipomyces*, *Lodderomyces*, *Malassezia*, *Metschnikowia*, *Mrakia*, *Myxozyma*, *Nadsonia*, *Nakazawaea*, *Nematospora*, *Ogataea*, *Oosporidium*, *Pachysolen*, *Phachytichospora*, *Phaffia*, *Pichia*, *Rhodosporidium*, *Rhodotorula*, *Saccharomyces*, *Saccharomycodes*, *Saccharomycopsis*, *Saitoella*, *Sakaguchia*, *Saturnospora*, *Schizoblastosporion*, *Schizosaccharomyces*, *Schwanniomyces*, *Sporidiobolus*, *Sporobolomyces*, *Sporopachydermia*, *Stephanoascus*, *Sterigmatomyces*, *Sterigmatosporidium*, *Symbiotaphrina*, *Sympodiomyces*, *Sympodiomycopsis*, *Torulaspora*, *Trichosporiella*, *Trichosporon*, *Trigonopsis*, *Tsuchiyaea*, *Udeniomyces*, *Waltomyces*, *Wickerhamia*, *Wickerhamiella*, *Williopsis*, *Yamadazyma*, *Yarrowia*, *Zygoascus*, *Zygosaccharomyces*, *Zygowilliopsis*, and *Zygozyma*, among others.

[0055] In some embodiments, the host microbe is *Saccharomyces cerevisiae*, *Pichia pastoris*, *Schizosaccharomyces pombe*, *Dekkera bruxellensis*, *Kluyveromyces lactis* (previously called *Saccharomyces lactis*), *Kluveromyces marxianus*, *Arxula adeninivorans*, or *Hansenula polymorpha* (now known as *Pichia angusta*). In some embodiments, the host microbe is a strain of the genus *Candida*, such as *Candida lipolytica*, *Candida guilliermondii*, *Candida krusei*, *Candida pseudotropicalis*, or *Candida utilis*.

[0056] In a particular embodiment, the host microbe is *Saccharomyces cerevisiae*. In some embodiments, the host is a strain of *Saccharomyces cerevisiae* selected from the group consisting of Baker's yeast, CBS 7959, CBS 7960, CBS 7961, CBS 7962, CBS 7963, CBS 7964, IZ-1904, TA, BG-1, CR-1, SA-1, M-26, Y-904, PE-2, PE-5, VR-1, BR-1, BR-2, ME-2, VR-2, MA-3, MA-4, CAT-1, CB-1, NR-1, BT-1, and AL-1. In some embodiments, the host microbe is a strain of *Saccharomyces cerevisiae* selected from the group consisting of PE-2, CAT-1, VR-1, BG-1, CR-1, and SA-1. In a particular embodiment, the strain of *Saccharomyces cerevisiae* is PE-2. In another particular embodiment, the strain of *Saccharomyces cerevisiae* is CAT-1. In another particular embodiment, the strain of *Saccharomyces cerevisiae* is BG-1.

[0057] In some embodiments, the host microbe is a microbe that is suitable for industrial fermentation. In particular embodiments, the microbe is conditioned to subsist under high solvent concentration, high temperature, expanded substrate utilization, nutrient limitation, osmotic stress due to sugar and salts, acidity, sulfite and bacterial contamination, or combinations thereof, which are recognized stress conditions of the industrial fermentation environment.

5.3 The Phosphoketolase (PK) / Phosphotransacetylase (PTA) Pathway to Acetyl-CoA

[0058] In some embodiments, the phosphoketolase pathway is activated in the genetically modified host cells provided herein by engineering the cells to express polynucleotides and/or polypeptides encoding phosphoketolase and, optionally, phosphotransacetylase. Thus, in some embodiments, the genetically modified host cells provided herein comprise a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. In other embodiments, particularly where acetyl phosphate can be supplied as a metabolic intermediate independent of phosphoketolase activity, the genetically modified host cells provided herein comprise a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity. In other embodiments, the genetically modified host cells provided herein comprise both a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity and a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity.

5.3.1 Phosphoketolase (PK)

[0059] Phosphoketolase (EC 4.1.2.9) catalyzes the conversion of xylulose 5-phosphate into glyceraldehyde 3-phosphate and acetyl phosphate; and/or the conversion of fructose-6-phosphate into erythrose-4-phosphate and acetyl phosphate. Phosphoketolase activity has been identified in several yeast strains growing with xylose as the sole carbon source but not in yeast strains grown with glucose (Evans and Ratledge, *Arch. Microbiol.* 139: 48-52; 1984). Inhibitors of phosphoketolase include, but are not limited to, erythrose 4-phosphate and glyceraldehyde 3-phosphate.

[0060] Numerous examples of polynucleotides, genes and polypeptides encoding phosphoketolase activity are known in the art and can be used in the genetically modified host cell provided herein. In some embodiments, such a polynucleotide, gene and/or polypeptide is the xylulose 5-phosphateketolase (XpkA) of *Lactobacillus pentosus* MD363 (Posthuma *et al.*, *Appl. Environ. Microbiol.* 68: 831-7; 2002). XpkA is the central enzyme of

the phosphoketolase pathway (PKP) in lactic acid bacteria, and exhibits a specific activity of 4.455 $\mu\text{mol}/\text{min}/\text{mg}$ (Posthuma *et al.*, *Appl. Environ. Microbiol.* 68: 831-7; 2002). In other embodiments, such a polynucleotide, gene and/or polypeptide is the phosphoketolase of *Leuconostoc mesenteroides* (Lee *et al.*, *Biotechnol Lett.* 27(12);853-858 (2005)), which exhibits a specific activity of 9.9 $\mu\text{mol}/\text{min}/\text{mg}$ and is stable at pH above 4.5 (Goldberg *et al.*, *Methods Enzymol.* 9: 515-520; 1966). This phosphoketolase exhibits a K_m of 4.7 mM for D-xylulose 5-phosphate and a K_m of 29 mM for fructose 6-phosphate (Goldberg *et al.*, *Methods Enzymol.* 9: 515-520; 1966). Representative phosphoketolase nucleotide sequences of *Leuconostoc mesenteroides* includes accession number AY804190, and SEQ ID NO: 1 as provided herein. Representative phosphoketolase protein sequences of *Leuconostoc mesenteroides* include accession numbers YP_819405, AAV66077.1, and SEQ ID NO: 2 as provided herein. In other embodiments, such a polynucleotide, gene and/or polypeptide is the D-xylulose 5-phosphate/D-fructose 6-phosphate phosphoketolase gene xfp from *B. lactis*, as described, for example, in a pentose-metabolizing *S. cerevisiae* strain by Sonderegger *et al.* (*Appl. Environ. Microbiol.* 70: 2892-7; 2004).

[0061] Other useful phosphoketolases include, but are not limited to, those from *Bifidobacterium dentium* ATCC 27678 (ABIX02000002.1:2350400..2352877; EDT46356.1); *Bifidobacterium animalis* (NC_017834.1:1127580..1130057; YP_006280131.1); and *Bifidobacterium pseudolongum* (AY518216.1:988..3465; AAR98788.1); *Aspergillus nidulans* FGSC A4 (CBF76492.1); *Bifidobacterium longum* (AAR98787.1); *Bifidobacterium bifidum* NCIMB 41171 (ZP_03646196.1); *Bifidobacterium animalis* subsp. *lactis* HN019 (ZP_02962870.1); *Lactobacillus plantarum* WCFS1 (NP_786060.1); *Lactobacillus brevis* subsp. *gravesensis* ATCC 27305 (ZP_03940142.1); *Lactobacillus reuteri* 100-23 (ZP_03073172.1); and *Leuconostoc mesenteroides* subsp. *mesenteroides* ATCC 8293 (YP_818922.1).

[0062] Other useful phosphoketolases include those described in International Publication No. WO 2011/15985, the contents of which are hereby incorporated by reference in their entirety. These phosphoketolases include: (YP_001601863.1; *Gluconacetobacter diazotrophicus* Pal 5), (YP_001093221.1; *Shewanella loihica* PV-4), (YP_926792.1; *Shewanella amazonensis* SB2B), (YP_735093.1; *Shewanella* sp. MR-4), (YP_001049439.1; *Shewanella baltica* OS155), (ZP_02157884.1; *Shewanella benthica* KT99), (YP_001472925.1; *Shewanella sediminis* HAW-EB3), (YP_001759669.1; *Shewanella woodyi* ATCC 51908), (YP_001673352.1; *Shewanella halifaxensis* HA W-EB4), (YP_563733.1;

Shewanella denitrificans OS217), (ZP_05111697.1; *Legionella drancourtii* LLAP 12), (EEQ84307.1; *Ajellomyces dermatitidis* ER-3), (XP_002626734.1; *Ajellomyces dermatitidis* SLH14081), (XP_001539009.1; *Ajellomyces capsulatus* NAm1), (EEH04133.1; *Ajellomyces capsulatus* G186AR), (EEH20258.1; *Paracoccidioides brasiliensis* Pb03), (EEH44652.1; *Paracoccidioides brasiliensis* Pb 18), (XP_002582752.1; *Uncinocarpus reesii* 1704), (EER26377.1; *Coccidioides posadasii* C735 delta SOWgp), (EEQ28085.1; *Microsporum canis* CBS 113480), (XP_001819785.1; *Aspergillus oryzae* RIB40), (XP_001399780.1; *Aspergillus niger*), (XP_001263382.1; *Neosartorya fischeri* NRRL 181), (XP_001271080.1; *Aspergillus clavatus* NRRL 1), (XP_001213784.1; *Aspergillus terreus* NIH2624), (CBF76492.1; *Aspergillus nidulans* FGSC44), (XP_002561913.1; *Penicillium chrysogenum* Wisconsin 54-1255), (XP_002480391.1; *Talaromyces stipitatus* ATCC 10500), (XP_002144014.1; *Penicillium stipitatus* ATCC 10500), (XP_002144014.1; *Penicillium mameffei* ATCC 18224), (XP_754543.1; *Aspergillus fumigatus* Af293), (XP_001556635.1; *Botryotinia fuckeliana* B05.1 0), (XP_001592549.1; *Sclerotinia sclerotiorum* 1980), (XP_386729.1; *Gibberella zeae* PH-1), (EEU47171.1; *Nectria haematococca* mp VI 77-13-4), (EEY16637.1; *Verticillium alboatrum* VaMs.1 02), (XP_956649.1; *Neurospora crassa* OR74A), (XP_364271.2; *Magnaporthe grisea* 70-15), (XP_001904585.1; *Podospora anserine*), (XP_001836159.1; *Coprinopsis cinerea* okayama7#130), (NP_595963.1; *Schizosaccharomyces pombe*), (XP_002173441.1; *Schizosaccharomyces japonicus* yFS275), (XP_570860.1; *Cryptococcus neoformans* var. *neoformans* JEC21), (XP_759561.1; *Ustilago maydis* 521), (ZP_05027078.1; *Microcoleus chthonoplastes* PCC 7420), (YP_003101114.1; *Actinosynnema mirum* DSM 43827), (ZP_03568244.1; *Atopobium rimae* ATCC 49626), (YP_003180237.1; *Atopobium parvulum* DSM 20469), (ZP_03946928.1; *Atopobium vaginae* DSM 15829), (ZP_03296299.1; *Collinsella stercoris* DSM 13279), (AAR98787.1; *Bifidobacterium longum*), (ZP_03618909.1; *Bifidobacterium breve* DSM 20213), (ZP_03646196.1; *Bifidobacterium bifidum* NCIMB 41171), (ZP_04448101.1; *Bifidobacterium angulatum* DSM 20098), (ZP_03324204.1; *Bifidobacterium catenulatum* DSM 16992), (AAR98790.1; *Bifidobacterium* sp. CFAR 172), (AAR98789.1; *Bifidobacterium pullorum*), (ZP_03937610.1; *Gardnerella vaginalis* ATCC 14019), (ZP_05965201.1; *Bifidobacterium gallicum* DSM 20093), (ZP_02962870.1; *Bifidobacterium animalis* subsp. *lactis* HNO19), (AAR98788.1; *Bifidobacterium pseudolongum* subsp. *Globosum*), (ZP_03946518.1; *Atopobium vaginae* DSM 15829), (YP_001511171.1; *Frankia* sp. *EANlpec*), (YP_713678.1; *Frankia alni* ACN14a), (YP_002778395.1; *Rhodococcus*

opacus B4), (YP_701466.1; *Rhodococcus jostii* RHAI), (ZP_04383880.1; *Rhodococcus erythropolis* SK121), (YP_947598.1; *Arthrobacter aurescens* TC 1), (CAD48946.1; *Propionibacterium freudenreichii* subsp. *Shermanii*), (NP_791495.1; *Pseudomonas syringae* pv. *Tomato* str. DC3000), (YP_003125992.1; *Chitinophaga pinensis* DSM 2588), (ABX56639.1; *Verrucomicrobiae bacterium V4*), (YP_002371883.1; *Cyanothece* sp. PCC 8801), (YP_001806596.1; *Cyanothece* sp. ATCC 51142), (ZP_01730652.1; *Cyanothece* sp. CCY0110), (CAQ48286.1; *Planktothrix rubescens* NIVA-CYA 98), (ZP_03276298.1; *Arthrospira maxima* CS-328), (ZP_03157277.1; *Cyanothece* sp. PCC 7822), (YP_002379031.1; *Cyanothece* sp. PCC 7424), (YP_001658501.1; *Microcystis aeruginosa* NIES-843), (ZP_01621774.1; *Lyngbya* sp. PCC 8106), (NP_485524.1; *Nostoc* sp. PCC 7120), (ZP_05036350.1; *Synechococcus* sp. PCC 7335), (YP_001514813.1; *Acaryochloris marina* MBIC 11 017), (ZP_05039537.1; *Synechococcus* sp. PCC 7335), (ZP_02886235.1; *Burkholderia graminis* C4 DIM), (ZP_03264503.1; *Burkholderia* sp. H160), (ZP_01085819.1; *Synechococcus* sp. WH 5701), (ZP_05045603.1; *Cyanobium* sp. PCC 7001), (ZP_01123645.1; *Synechococcus* sp. WH 7805), (YP_001223932.1; *Synechococcus* sp. WH 7803), (ZP_01079038.1; *Synechococcus* sp. RS9917), (YP_001889002.1; *Burkholderia phytofirmans* PsJN), (YP_553967.1; *Burkholderia xenovorans* LB400), (ZP_02881709.1; *Burkholderia graminis* C4DIM), (ZP_03270532.1; *Burkholderia* sp. H160), (YP_001861620.1; *Burkholderia phymatum* STM815), (YP_002755285.1; *Acidobacterium capsulatum* ATCC 51196), (EDZ38884.1; *Leptospirillum* sp. Group II '5-way CO'), (EES53204.1; *Leptospirillum ferrodiazotrophum*), (YP_172723.1; *Synechococcus elongatus* PCC 6301), (NP_681976.1; *Thermosynechococcus elongatus* BP-1), (YP_114037.1; *Methylococcus capsulatus* str. Bath), (YP_002482577.1; *Cyanothece* sp. PCC 7425), (NP_442996.1; *Synechocystis* sp. PCC 6803), (YP_002482735.1; *Cyanothece* sp. PCC 7425), (ZP_04774866.1; *Allochromatium vinosum* DSM 180), (ZP_01453148.1; *Mariprofundus ferrooxydans* PV-1), (ZP_04830548.1; *Gallionella ferruginea* ES-2), (XP_001273863.1; *Aspergillus clavatus* NRRL 1), (XP_001258643.1; *Neosartorya fischeri* NRRL 181), (XP_001727680.1; *Aspergillus oryzae* RIB40), (XP_001396306.1; *Aspergillus niger*), (XP_001216075.1; *Aspergillus terreus* NIH2624), (XP_002567130.1; *Penicillium chrysogenum* Wisconsin 54-1255), (XP_002143851.1; *Penicillium marneffei* ATCC 18224), (XP_002480216.1; *Talaromyces stipitatus* ATCC 10500), (XP_001559949.1; *Botryotinia fuckeliana* B05.10), (XP_001593100.1; *Sclerotinia sclerotiorum* 1980), (XP_001932192.1; *Pyrenophora tritici-repentis* Pt-1C-BFP), (XP_001793729.1; *Phaeosphaeria nodorum* SN 15),

(XP_567776.1; *Cryptococcus neoformans* var. *neoformans* JEC21), (XP_386504.1; *Oibberella zeae* PH-1), (EEU46265.1; *Nectria haematococca* mp VI 77-13-4), (AC024516.1; *Metarhizium anisopliae*), (XP_959985.1; *Neurospora crassa* OR74A), (XP_001904686.1; *Podospora anserine*), (YP_002220141.1; *Acidithiobacillus ferrooxidans* ATCC 53993), (YP_001220128.1; *Acidiphilium cryptum* JF -5), (YP_001471202.1; *Thermotoga lettingae* TMO), (YP_002352287.1; *Dictyoglomus turgidum* DSM 6724), (YP_571790.1; *Nitrobacter hamburgensis* X14), (ZP_01092401.1; *Blastopirellula marina* DSM 3645), (YP_001340809.1; *Marinomonas* sp. MWYLI), (NP_866384.1; *Rhodopirellula baltica* SH 1), (ZP_05108502.1; *Legionella drancourtii* LLAP 12), (ZP_04995817.1; *Streptomyces* sp. Mg1), (ZP_04023055.1; *Lactobacillus reuteri* SD2112), (ZP_03960060.1; *Lactobacillus vaginalis* ATCC 49540), (ZP_03073172.1; *Lactobacillus reuteri* 100-23), (ZP_05553031.1; *Lactobacillus coleohominis* 101-4-CHN), (ZP_05863347.1; *Lactobacillus fermentum* 28-3-CHN), (ZP_04021289.1; *Lactobacillus acidophilus* ATCC 4796), (ZP_03995194.1; *Lactobacillus crispatus* IV-V01), (ZP_04010922.1; *Lactobacillus ultunensis* DSM 16047), (ZP_05549961.1; *Lactobacillus crispatus* 125-2-CRN), (ZP_03951361.1; *Lactobacillus gasseri* IV-V03), (ZP_05744515.1; *Lactobacillus iners* DSM 13335), (YP_618635.1; *Lactobacillus delbrueckii* subsp. *bulgaricus* ATCC 11842), (ZP_03955917.1; *Lactobacillus jensenii* IV-VI6), (ZP_03942415.1; *Lactobacillus buchneri* ATCC 11577), (ZP_01544800.1; *Oenococcus oeni* ATCC BAA-1163), (NP_786060.1; *Lactobacillus plantarum* WCFS1), (Q937F6; XPKA_LACPE), (YP_394903.1; *Lactobacillus sakei* subsp. *sakei* 23K), (YP_803891.1; *Pediococcus pentosaceus* ATCC 25745), (BAI40727.1; *Lactobacillus rhamnosus* GG), (ZP_03940142.1; *Lactobacillus brevis* subsp. *Gravesensis* ATCC 27305), (ZP_04009273.1; *Lactobacillus salivarius* ATCC 11741), (ZP_03958643.1; *Lactobacillus ruminis* ATCC 25644), (ZP_04431433.1; *Bacillus coagulans* 36D1), (ZP_04601906.1; *Kingella oralis* ATCC 51147), (ZP_05736927.1; *Granulicatella adiacens* ATCC 49175), (YP_001449631.1; *Streptococcus gordonii* str. *Challis* substr. *CHI*), (NP_736274.1; *Streptococcus agalactiae* NEM316), (ZP_04442854.1; *Listeria grayi* DSM 20601), (ZP_05646360.1; *Enterococcus casseliflavus* EC30), (ZP_05650322.1; *Enterococcus gallinarum* EG2), (ZP_05675307.1; *Enterococcus faecium* Com12), (BAH69929.1; *Mycoplasma fermentans* PG 18), (YP_002000006.1; *Mycoplasma arthritidis* 15 8L3-1), (YP_001256266.1; *Mycoplasma agalactiae* PG2), (YP_001988835.1; *Lactobacillus casei* BL23), (NP_786753.1; *Lactobacillus plantarum* WCFS 1), (ZP_04009976.1; *Lactobacillus salivarius* ATCC 11741), (YP_818922.1; *Leuconostoc mesenteroides* subsp. *Mesenteroides*

ATCC 8293), (YP_794669.1; *Lactobacillus brevis* ATCC 367), (ZP_04782553.1; *Weissella paramesenteroides* ATCC 33313), (YP_001727454.1; *Leuconostoc citreum* KM20), (YP_819405.1; *Leuconostoc mesenteroides* subsp. *mesenteroides* ATCC 8293), (ABX75772.1; *Lactococcus lactis* subsp. *Lactis*), (YP_811314.1; *Oenococcus oeni* PSU-1), (ZP_02951191.1; *Clostridium butyricum* 5521), (ZP_05390294.1; *Clostridium carboxidivorans* P7), (NP_347971.1; *Clostridium acetobutylicum* ATCC 824), (ZP_03800296.1; *Coprococcus comes* ATCC 27758), (ZP_04857624.1; *Ruminococcus* sp. 5_1_39B FAA), (ZP_04743029.2; *Roseburia intestinalis* L 1-82), (ZP_02038271.1; *Bacteroides capillosus* ATCC 29799), (XP_002180542.1; *Phaeodactylum tricomutum* CCAP 1055/I), (YP_568630.1; *Rhodopseudomonas palustris* BisB5), (YP_487462.1; *Rhodopseudomonas palustris* HaA2), (NP_947019.1; *Rhodopseudomonas palustris* CGA009), (YP_533660.1; *Rhodopseudomonas palustris* BisB18), (YP_973512.1; *Polaromonas naphthalenivorans* CJ2), (ZP_01464191.1; *Stigmatella aurantiaca* DW4/3-1), (YP_001267778.1; *Pseudomonas putida* Fl), (YP_829644.1; *Arthrobacter* sp. FB24), (YP_002486392.1; *Arthrobacter chlorophenolicus* A6), (ZP_05816651.1; *Sanguibacter keddiei* DSM 10542), (YP_002883053.1; *Beutenbergia cavemae* DSM 12333), (YP_003161540.1; *Jonesia denitrificans* DSM 20603), (ZP_03911482.1; *Xylanimonas cellulositytica* DSM 15894), (CAJ57850.1; *Cellulomonas flavigena*), (YP_001134605.1; *Mycobacterium gilvum* PYR-GCK), (YP_953877.1; *Mycobacterium vanbaalenii* PYR-I), (YP_003155611.1; *Brachybacterium faecium* DSM 4810), (YP_003148127.1; *Kytococcus sedentarius* DSM 20547), (YP_001221168.1; *Clavibacter michiganensis* subsp. *michiganensis* NCPPB 382), (YP_001158426.1; *Salinispora tropica* CNB-440), (YP_001536420.1; *Salinispora arenicola* CNS-205), (ZP_04608302.1; *Micromonospora* sp. ATCC 39149), (YP_887914.1; *Mycobacterium smegmatis* str. MC2 155), (YP_639956.1; *Mycobacterium* sp. MCS), (ZP_04749157.1; *Mycobacterium kansasii* ATCC 12478), (YP_001851039.1; *Mycobacterium marinum* M), (NP_960507.1; *Mycobacterium avium* subsp. *paratuberculosis* K-10), (ZP_05224330.1; *Mycobacterium intracellulare* ATCC 13950), (YP_001703240.1; *Mycobacterium abscessus*), (ZP_00995133.1; *Janibacter* sp. HTCC2649), (YP_291026.1; *Thermobifida fusca* YX), (ZP_04031845.1; *Thermomonospora curvata* DSM 43183), (ZP_04475514.1; *Streptosporangium roseum* DSM 43021), (ZP_04335641.1; *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43111), (ZP_04482201.1; *Stackebrandtia nassauensis* DSM 44728), (YP_003099712.1; *Actinosynnema mirum* DSM 43827), (NP_733508.1; *Streptomyces coelicolor* A3(2)),

(CAJ88379.1; *Streptomyces ambofaciens* ATCC 23877), (ZP_05536883.1; *Streptomyces griseoflavus* Tu4000), (ZP_05020421.1; *Streptomyces sviveus* ATCC 29083), (CBG67625.1; *Streptomyces scabiei* 87.22), (NP_822448.1; *Streptomyces avermitilis* MA-4680), (ZP_04689547.1; *Streptomyces ghanaensis* ATCC 14672), (ZP_05530021.1; *Streptomyces viridochromogenes* DSM 40736), (ZP_05512501.1; *Streptomyces hygroscopicus* ATCC 53653), (ZP_05800927.1; *Streptomyces flayogriseus* ATCC 33331), (YP_001828275.1; *Streptomyces griseus* subsp. *griseus* NBRC 13350), (ZP_04705493.1; *Streptomyces albus* J1074), (ZP_04996963.1; *Streptomyces* sp. *Mgl*), (ZP_05485309.1; *Streptomyces* sp. *SPB78*), (ZP_03860882.1; *Kribbella flayida* DSM 17836), (YP_117539.1; *Nocardia farcinica* IFM 10152), (YP_001505556.1; *Frankia* sp. *EANlpec*), (YP_482627.1; *Frankia* sp. *Ccl3*), (YP_003116893.1; *Catenulispora acidiphila* DSM 44928), (YP_872280.1; *Acidothermus lolyticus* IIB), (YP_924807.1; *Nocardioides* sp. *JS614*), (YP_001104157.1; *Saccharopolyspora erythraea* NRRL 2338), (YP_002282673.1; *Rhizobium leguminosarum* by. *trifolii* WSM2304), (YP_002977256.1; *Rhizobium leguminosarum* by. *trifolii* WSM1325), (YP_001979796.1; *Rhizobium etli* CIAT 652), (YP_470926.1; *Rhizobium etli* CFN 42), (YP_002540633.1; *Agrobacterium radiobacter* K84), (ZP_05182366.1; *Brucella* sp. 83/13), (ZP_04683384.1; *Ochrobactrum intermedium* LMG 3301), (YP_001373254.1; *Ochrobactrum anthropi* ATCC 49188), (YP_001204109.1; *Bradyrhizobium* sp. *ORS278*), (YP_001238418.1; *Bradyrhizobium* sp. *BTAil*), (NP_769158.1; *Bradyrhizobium japonicum* USDA 110), (YP_577164.1; *Nitrobacter hamburgensis* X14), (YP_002961612.1; *Methylobacterium extorquens* AM 1), (YP_674792.1; *Mesorhizobium* sp. *BNCI*), (ZP_05813617.1; *Mesorhizobium opportunistum* WSM2075), (YP_318559.1; *Nitrobacter winogradskyi* Nb-255), (YP_001755280.1; *Methylobacterium radiotolerans* JCM 2831), (YP_001753119.1; *Methylobacterium radiotolerans* JCM 2831), (YP_003066011.1; *Methylobacterium extorquens* DM4), (YP_002964777.1; *Methylobacterium extorquens* AM 1), (YP_002501292.1; *Methylobacterium nodulans* ORS 2060), (YP_002495265.1; *Methylobacterium nodulans* ORS 2060), (YP_001770387.1; *Methylobacterium* sp. 4-46), (YP_002944712.1; *Variovorax paradoxus* S110), (ZP_01156757.1; *Oceanicola granulosus* HTCC2516), (ZP_01628787.1; *Nodularia spumigena* CCY9414), (YP_001865546.1; *Nostoc punctiforme* PCC 73102), (YP_321015.1; *Anabaena variabilis* ATCC 29413), (ZP_03769140.1; *Nostoc azollae* 0708), (NP_923943.1; *Gloeobacter violaceus* PCC 7421), (YP_477385.1; *Synechococcus* sp. *JA-2-3B'a(2-13)*), (YP_001328659.1; *Sinorhizobium medicae* WSM419), (YP_765670.1; *Rhizobium leguminosarum* bv. *viciae* 3841),

(NP_384212.2; *Sinorhizobium meliloti* 1021), (ZP_02928455.1; *Verrucomicrobium spinosum* DSM 4136), (YP_001637539.1; *Methylobacterium extorquens* Pal), (ZP_01045825.1; *Nitrobacter* sp. Nb-311A), (ZP_02736602.1; *Gemmata obscuriglobus* UQM 2246), (YP_003157871.1; *Desulfomicrobium baculatum* DSM 4028), (ZP_03631304.1; *bacterium* Ellin514), (ZP_04577558.1; *Oxalobacter formigenes* HOxBLS), (ZP_04579712.1; *Oxalobacter formigenes* OXCC13), (YP_826169.1; *Solibacter usitatus* Ellin6076), (YP_002018753.1; *Pelodictyon phaeoclathratiforme* BU-1), (YP_002016285.1; *Prosthecochloris aestuarii* DSM 271), (YP_001943369.1; *Chlorobium limicola* DSM 245), (NP_662409.1; *Chlorobium tepidum* TLS), (ZP_01386179.1; *Chlorobium ferrooxidans* DSM 13031), (YP_375422.1; *Chlorobium luteolum* DSM 273), (YP_285277.1; *Dechloromonas aromatica* RCB), (YP_314589.1; *Thiobacillus denitrificans* ATCC 25259), (YP_545002.1; *Methylobacillus flagellatus* KT), (NP_842139.1; *Nitrosomonas europaea* ATCC 19718), (YP_748274.1; *Nitrosomonas eutropha* C91), (YP_411688.1; *Nitrospira multiformis* ATCC 25196), (YP_344700.1; *Nitrosococcus oceani* ATCC 19707), (YP_007004.1; *Candidatus Protochlamydia amoebophila* UWE25), (NP_435833.1; *Sinorhizobium meliloti* 1021), (ZP_04421874.1; *Sulfurospirillum deleyianum* DSM 6946), (NP_107054.1; *Mesorhizobium loti* MAFF303099), (YP_002289797.1; *Oligotropha carboxidovorans* OM5), (YP_001833312.1; *Beijerinckia indica* subsp. *indica* ATCC 9039).

[0063] Phosphoketolases also useful in the compositions and methods provided herein include those molecules which are said to be “derivatives” of any of the phosphoketolases described herein. Such a “derivative” has the following characteristics: (1) it shares substantial homology with any of the phosphoketolases described herein; and (2) is capable of catalyzing the conversion of X5P into glyceraldehyde 3-phosphate (G3P) and acetyl phosphate; or F6P into erythrose 4-phosphate (E4P) and acetyl phosphate. A derivative of a phosphoketolase is said to share “substantial homology” with the phosphoketolase if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of the phosphoketolase.

5.3.2 Phosphotransacetylase (PTA)

[0064] In some embodiments, the genetically modified host cell provided herein comprises a heterologous nucleotide sequence encoding a phosphotransacetylase. Phosphotransacetylase (EC 2.3.1.8) converts acetyl phosphate into acetyl-CoA.

[0065] Numerous examples of polynucleotides, genes and polypeptides encoding phosphotransacetylase activity are known in the art and can be used in the genetically modified host cell provided herein. In some embodiments, such a polynucleotide, gene and/or polypeptide is the phosphotransacetylase from *Clostridium kluyveri*. Representative phosphotransacetylase nucleotide sequences of *Clostridium kluyveri* includes accession number NC_009706.1:1428554..1429555, and SEQ ID NO: 3 as provided herein. Representative phosphotransacetylase protein sequences of *Clostridium kluyveri* include accession number YP_001394780 and SEQ ID NO: 4 as provided herein. Other useful phosphotransacetylases include, but are not limited to, those from *Lactobacillus reuteri* (NC_010609.1:460303..461277; YP_001841389.10); *Bacillus subtilis* (NC_014479.1:3671865..3672836; YP_003868063.1); *Methanosarcina thermophila* (L23147.1:207..1208; AAA72041.1); *Lactobacillus sanfranciscensis* (BAB19267.1); *Lactobacillus plantarum* WCFS1 (NP_784550.1); *Lactobacillus fermentum* ATCC 14931 (ZP_03944466.1); *Bacillus subtilis* subsp. *subtilis* str. 168 (NP_391646.1); *Methanosarcina thermophila* (AAA72041.1); *Clostridium thermocellum* DSM 4150 (ZP_03152606.1); *Clostridium acetobutylicum* ATCC 824 (NP_348368.1); *Clostridium kluyveri* DSM 555 (YP_001394780.1); *Veillonella parvula* DSM 2008 (ZP_03855267.1); and *Salmonella enterica* subsp. *enterica* serovar *Paratyphi A* str. ATCC 9150 (YP_149725.1).

[0066] Other useful phosphotransacetylases include those described in International Publication No. WO 2011/15985, the contents of which are hereby incorporated by reference in their entirety. These phosphotransacetylases include: (ZP_05427766.1; *Eubacterium saphenum* ATCC 49989), (ZP_03627696.1; *bacterium Ellin514*), (ZP_03131770.1; *Chthonio bacter flavus* Ellin428), (YP_001878031.1; *Akkermansia muciniphila* TCCBAA-835), (ZP_04562924.1; *Citrobacter* sp.30_2), (YP_001451936.1; *Citrobacter koseri* ATCC BAA-895), (YP_149725.1; *Salmonella enterica* subsp. *enterica* serovar *Paratyphi A* str. ATCC 9150), (YP_001569496.1; *Salmonella enterica* subsp. *anzonae* serovar 62:z4,z23:--), (NP_416953.1; *Escherichia coli* str. K-12 substr. MG1655), (YP_002920654.1; *Klebsiella pneumoniae* NTUH-K2044), (ZP_04637797.1; *Yersinia intermedia* ATCC 29909), (ZP_01222604.1; *Photobacterium profundum* 3TCK), (ZP_02156855.1; *Shewanella benthica* KT99), (YP_958508.1; *Marinobacter aquaeolei* VT8), (YP_066771.1; *Desulfotalea psychrophila* LSV54), (YP_002780531.1; *Rhodococcus opacus* B4), (YP_703506.1; *Rhodococcus jostii* RHAI), (ZP_05479963.1; *Streptomyces* sp. AA4), (YP_002761398.1; *Gemmatimonas aurantiaca* T-27), (ZP_04670189.1; *Clostridiales bacterium* 1_7_47FAA),

(ZP_05493958.1; *Clostridium papyrosolvens* DSM 2782), (YP_003143506.1; *Slackia heliotrinireducens* DSM 20476), (ZP_05090822.1; *Ruegeria* sp. R11), (ZP_01748021.1; *Sagittula stellata* E-37), (NP_604069.1; *Fusobacterium nucleatum* subsp. *nucleatum* ATCC 25586), (ZP_05814734.1; *Fusobacterium* sp. 3_1_33), (ZP_06026613.1; *Fusobacterium periodonticum* ATCC 33693), (ZP_05617632.1; *Fusobacterium* sp. 3_1_5R), (ZP_05628030.1; *Fusobacterium* sp. D12), (ZP_04860946.1; *Fusobacterium* vanum ATCC 27725), (ZP_04567444.1; *Fusobacterium mortiferum* ATCC 9817), (YP_001489437.1; *Arcobacter butzleri* RM4018), (YP_003163236.1; *Leptotrichia buccalis* C-1013-b), (ZP_05902420.1; *Leptotrichia hofstadii* F0254), (ZP_06011308.1; *Leptotrichia goodfellowii* F0264), (ZP_04479548.1; *Streptobacillus moniliformis* DSM 12112), (ZP_03855267.1; *Veillonella parvula* DSM 2008), (ZP_03928523.1; *Acidaminococcus* sp. D21), (NP_970659.1; *Treponema denticola* ATCC 35405), (ZP_05621510.1; *Treponema vincentii* ATCC 35580), (NP_218534.1; *Treponema pallidum* subsp. *pallidum* str. Nichols), (ZP_04047318.1; *Brachyspira murdochii* DSM 12563), (YP_002720478.1; *Brachyspira hyodysenteriae* WAI), (YP_001740706.1; *Candidatus Cloacamonas acidaminovorans*), (EER05013.1; *Perkinsus manni* ATCC 50983), (YP_945582.1; *Borrelia turicatae* 91E135), (YP_001884013.1; *Borrelia hermsii* DAH), (YP_002222233.1; *Borrelia duttonii* Ly), (ZP_03675306.1; *Borrelia spielmanii* A14S), (ZP_03435394.1; *Borrelia afzelii* ACA-I), (ZP_03540018.1; *Borrelia garinii* Far04), (ZP_03672928.1; *Borrelia valaisiana* VS116), (NP_212723.1; *Borrelia burgdorferi* B31), (YP_001956287.1; uncultured Termite group 1 bacterium phylotype Rs-D17), (NP_975268.1; *Mycoplasma mycoides* subsp. *mycoides* SC str. PGI), (YP_424216.1; *Mycoplasma capricolum* subsp. *capricolum* ATCC 27343), (YP_053283.1; *Mesoplasma florum* LI), (CAK99540.1; *Spiroplasma citri*), (NP_072966.1; *Mycoplasma genitalium* G37), (NP_110116.1; *Mycoplasma pneumomae* M129), (NP_853403.1; *Mycoplasma gallisepticum* R), (NP_757889.1; *Mycoplasma penetrans* HF-2), (YP_116016.1; *Mycoplasma hyopneumoniae* 232), (YP_002960607.1; *Mycoplasma conjunctivae*), (YP_001256282.1; *Mycoplasma agalactiae* PG2), (BAH69503.1; *Mycoplasma fermentans* PG18), (YP_278771.1; *Mycoplasma synoviae* 53), (NP_326068.1; *Mycoplasma pulmonis* UAB CTIP), (YP_015865.1; *Mycoplasma mobile* 163K), (YP_001256630.1; *Mycoplasma agalactiae* PG2), (YP_802685.1; *Buchnera aphidicola* str. Cc (*Cinara cedri*)), (YP_001885432.1; *Clostridium botulinum* B str. Eklund 17B), (YP_001308302.1; *Clostridium beijerinckii* NCIMB 8052), (ZP_05131280.1; *Clostridium* sp. 7_2_43FAA), (ZP_02948604.1; *Clostridium butyricum* 5521), (NP_562641.1; *Clostridium*

perfringens str. 13), (ZP_05391232.1; *Clostridium carboxidivorans P7*), (YP_001394780.1; *Clostridium kluyveri DSM 555*), (ZP_02995419.1; *Clostridium sporogenes ATCC 15579*), (NP_781870.1; *Clostridium tetani E88*), (ZP_04862192.1; *Clostridium botulinum D str. 1873*), (YP_878298.1; *Clostridium novyi NT*), (ZP_04804960.1; *Clostridium cellulovorans 743B*), (NP_348368.1; *Clostridium acetobutylicum ATCC 824*), (ACA51668.1; *Thermoanaero bacterium saccharolyticum*), (ZP_05336886.1; *Thermoanaero bacterium thermosaccharolyticum SM 571*), (NP_623097.1; *Thermoanaero bacter tengcongensis MB4*), (YP_001663354.1; *Thermoanaero bacter sp. X514*), (YP_002508771.1; *Halothermothrix orenii H 168*), (YP_003190679.1; *Desulfotomaculum acetoxidans DSM 771*), (YP_001917776.1; *Natranaerobius thermophiles JWINM-WN-LF*), (YP_360288.1; *Carboxydotherrmus hydrogenoformans Z-2901*), (EY83551.1; *Bacteroides sp.2_1_33B*), (ZP_02033408.1; *Parabacteroides merdae ATCC 43184*), (NP_905297.1; *Porphyromonas gingivalis W83*), (ZP_04056000.1; *Porphyromonas uenonis 60-3*), (ZP_04389884.1; *Porphyromonas endodontalis ATCC 35406*), (ZP_02068815.1; *Bacteroides uniformis ATCC 8492*), (ZP_03460749.1; *Bacteroides eggerthii DSM 20697*), (ZP_03676944.1; *Bacteroides cellulosilyticus DSM 14838*), (YP_097761.1; *Bacteroides fragilis YCH46*), (ZP_04545825.1; *Bacteroides sp. D1*), (ZP_03643544.1; *Bacteroides coprophilus DSM 18228*), (ZP_03207078.1; *Bacteroides plebeius DSM 17135*), (YP_001297855.1; *Bacteroides vulgatus ATCC 8482*), (ZP_05736702.1; *Prevotella tannerae ATCC 51259*), (ZP_06007587.1; *Prevotella bergensis DSM 17361*), (ZP_05858935.1; *Prevotella veroralis F0319*), (ZP_05916997.1; *Prevotella sp. oral taxon 472 str. F0295*), (YP_002308782.1; *Candidatus Azo bacteroides pseudotrichon ymphae genomovar. CFP2*), (YP_753459.1; *Syntrophomonas wolfei subsp. wolfei str. Goettingen*), (ZP_01771389.1; *Collinsella aerofaciens ATCC 25986*), (ZP_03296849.1; *Collinsella stercoris DSM 13279*), (ZP_04445308.1; *Collinsella ntestinalis DSM 13280*), (ZP_03567515.1; *Atopobium rimae ATCC 49626*), (YP_003179667.1; *Atopobium parvulum DSM 20469*), (ZP_03946133.1; *Atopobium vaginae DSM 15829*), (ZP_03990654.1; *Oribacterium sinus F0268*), (ZP_04450849.1; *Abiotrophia defective ATCC 49176*), (ZP_05797601.1; *Oribacterium sp. oral taxon 078 str. F0262*), (ZP_03730247.1; *Clostridium sp. M62/I*), (ZP_04856252.1; *Ruminococcus sp. 5_1_39BFAA*), (ZP_01966332.1; *Ruminococcus obeum ATCC 29174*), (ZP_05345616.1; *Bryantella formatexigens DSM 14469*), (ZP_03780829.1; *Blautia hydrogenotrophica DSM 10507*), (ZP_03289360.1; *Clostridium nexile DSM 1787*), (ZP_02042092.1; *Ruminococcus gnavus ATCC 29149*), (ZP_03168112.1; *Ruminococcus*

lactaris ATCC 29176), (ZP_01968837.1; *Ruminococcus torques* ATCC 27756),
 (ZP_02430426.1; *Clostridium scindens* ATCC 35704), (ZP_03779744.1; *Clostridium*
hylemonae DSM 15053), (ZP_02234595.1; *Dorea formicigenerans* ATCC 27755),
 (ZP_01994673.1; *Dorea longicatena* DSM 13814), (YP_001558442.1; *Clostridium*
phytofermentans ISDg), (ZP_04667085.1; *Clostridiales bacterium 1_7_47FAA*),
 (ZP_02085391.1; *Clostridium bolteae* ATCC BAA-613), (ZP_05790853.1; *Butyrivibrio*
crossotus DSM 2876), (ZP_02026034.1; *Eubacterium ventriosum* ATCC 27560),
 (YP_002930513.1; *Eubacterium eligens* ATCC 27750), (ZP_04808213.1; *Helicobacter*
pullorum MIT 98-5489), (ZP_03656120.1; *Helicobacter Canadensis* MIT 98-5491),
 (ZP_04583217.1; *Helicobacter winthamensis* ATCCBAA-430), (NP_860840.1; *Helicobacter*
hepaticus ATCC 51449), (ZP_03657896.1; *Helicobacter cinaedi* CCUG 18818),
 (ZP_02417779.1; *Anaerostipes caccae* DSM 14662), (ZP_02437622.1; *Clostridium* sp.
 SS211), (ZP_02205430.1; *Coprococcus eutactus* ATCC 27759), (ZP_02692616.1;
Epulopiscium sp. 'N.t. morphotype B'), (YP_003182082.1; *Eggerthella lenta* DSM 2243),
 (YP_003151027.1; *Cryptobacterium curtum* DSM 15641), (YP_003143601.1; *Slackia*
heliotrinireducens DSM 20476), (ZP_05498135.1; *Clostridium papyrosolvans* DSM 2782),
 (ZP_03152606.1; *Clostridium thermocellum* JW20), (YP_001180817.1; *Caldicellulosiruptor*
saccharolyticus DSM 8903), (AAA72041.1; *Methanosarcina thermophila*), (NP_618482.1;
Methanosarcina acetivorans C2A), (YP_305342.1; *Methanosarcina barkeri* str. Fusaro),
 (ZP_02142278.1; *Roseobacter litoralis* Och 149), (YP_681184.1; *Roseobacter denitrificans*
 Och 114), (YP_001533168.1; *Dinoroseo bacter shibae* DFL 12), (ZP_05124935.1;
Rhodobacteraceae bacterium KLH11), (ZP_05786337.1; *Silicibacter lacuscaerulensis* ITI-
 1157), (YP_001313586.1; *Sinorhizobium medicae* WSM419), (NP_437512.1; *Sinorhizobium*
meliloti 1021), (ZP_04682129.1; *Ochrobactrum intermedium* LMG 3301),
 (YP_001372036.1; *Ochrobactrum anthropic* ATCC 49188), (YP_001888115.1; *Burkholderia*
phytofirmans PsJN), (YP_554613.1; *Burkholderia xenovorans* LB400), (YP_001862297.1;
Burkholderia phymatum STM815), (YP_297974.1; *Ralstonia eutropha* JMP134),
 (YP_002008219.1; *Cupriavidus taiwanensis*), (YP_001584488.1; *Burkholderia multivorans*
multivorans), (YP_002233797.1; *Burkholderia cenocepacia* J2315), (ZP_01220235.1;
Photobacterium profundum 3TCK), (ZP_03698361.1; *Lutiella nitroferrum* 2002),
 (ZP_01811515.1; *Vibrionales bacterium SWAT-3*), (ZP_00988349.1; *Vibrio splendidus*
 12B01), (ZP_01866234.1; *Vibrio shilonii* AK1), (ZP_05885163.1; *Vibrio coralliilyticus*
 ATCCBAA-450), (AAS78789.1; *Paracoccus denitrificans*), (YP_345196.1; *Rhodobacter*

sphaeroides 2.4.1), (AAN08490.1; *Castellaniella defragrans*), (ZP_00961345.1; *Roseovarius nubinhibens* ISM), (YP_168755.1; *Ruegeria pomeroyi* DSS-3), (ZP_01901193.1; *Roseobacter* sp. AzwK-3b), (ZP_01752570.1; *Roseobacter* sp. SK209-2-6), (ZP_02140073.1; *Roseobacter litoralis* Och 149), (YP_510789.1; *Jannaschia* sp. CCS1), (ZP_05073153.1; *Rhodobacter* sp. bacterium HTCC2083), (YP_822367.1; *Candidatus Solibacter usitatus* Ellin6076), (ZP_01313101.1; *Desulfuromonas acetoxidans* DSM 684), (YP_357950.1; *Pelobacter carbinolicus* DSM 2380), (YP_002537084.1; *Geobacter* sp. FRC-32), (YP_001232124.1; *Geobacter uraniireducens* Rf4), (NP_953751.1; *Geobacter sulfurreducens* PCA), (YP_384000.1; *Geobacter metallireducens* GS-15), (YP_900968.1; *Pelobacter propionicus* DSM 2379), (YP_001951452.1; *Geobacter lovleyi* SZ), (ZP_05311922.1; *Geobacter* sp. M18), (YP_003021758.1; *Geobacter* sp. M21), (YP_358255.1; *Pelobacter carbinolicus* DSM 2380), (ZP_03906856.1; *Denitrovibrio acetiphilus* DSM 12809), (YP_001997093.1; *Chloroherpeton thalassium* ATCC 35110), (ZP_01924858.1; *Vitrocellum vadensis* ATCCBAA-548), (ZP_03439825.1; *Helicobacter pylori* 98-10), (YP_003057614.1; *Helicobacter pylori* B38), (YP_001910417.1; *Helicobacter pylori* Shi470), (NP_223559.1; *Helicobacter pylori* J99), (YP_665033.1; *Helicobacter acinonychis* str. Sheeba), (ZP_01810337.1; *Campylobacter jejuni* subsp. *jejuni* CG8486), (ZP_00366840.1; *Campylobacter coli* RM2228), (ZP_00370527.1; *Campylobacter upsaliensis* RM3195), (YP_002575219.1; *Campylobacter lari* RM2100), (YP_001406718.1; *Campylobacter hominis* ATCCBAA-381), (ZP_05624820.1; *Campylobacter gracilis* RM3268), (YP_891988.1; *Campylobacter fetus* subsp. *fetus* 82-40), (YP_001466901.1; *Campylobacter concisus* 13826), (YP_001408221.1; *Campylobacter curvus* 525.92), (ZP_05363348.1; *Campylobacter showae* RM3277), (ZP_03742933.1; *Bifidobacterium pseudocatenulatum* DSM 20438), (ZP_02918887.1; *Bifidobacterium dentium* ATCC 27678), (ZP_02028883.1; *Bifidobacterium adolescentis* L2-32), (ZP_04448100.1; *Bifidobacterium angulatum* DSM 20098), (ZP_03618886.1; *Bifidobacterium breve* DSM 20213), (ZP_03976084.1; *Bifidobacterium longum* subsp. *infantis* ATCC 55813), (YP_002323183.1; *Bifidobacterium longum* subsp. *infantis* ATCC 15697), (ZP_03646187.1; *Bifidobacterium bifidum* NCI MB 41171), (ZP_03937611.1; *Gardnerella vaginalis* ATCC 14019), (ZP_02962869.1; *Bifidobacterium animalis* subsp. *lactis* HN019), (ZP_05965185.1; *Bifidobacterium gallicum* DSM 20093), (ZP_02043408.1; *Actinomyces odontolyticus* ATCC 17982), (ZP_03925176.1; *Actinomyces colecanis* DSM 15436), (NP_601948.1; *Corynebacterium glutamicum* ATCC 13032), (NP_739201.1; *Corynebacterium efficiens* YS-

314), (NP_940379.1; *Corynebacterium diphtheria* NCTC 13129), (ZP_04835255.1; *Corynebacterium glucuronolyticum* ATCC 51867), (ZP_05708623.1; *Corynebacterium genitalium* ATCC 33030), (ZP_03977910.1; *Corynebacterium lipophiloflavum* DSM 44291), (ZP_03932064.1; *Corynebacterium accolens* ATCC 49725), (ZP_05366890.1; *Corynebacterium tuberculostearicum* SK141), (YP_002835817.1; *Corynebacterium anmucosum* ATCC 700975), (YP_250020.1; *Corynebacterium jeikeium* K411), (YP_001801132.1; *Corynebacterium urealyticum* DSM 7109), (YP_002906954.1; *Corynebacterium kroppenstedtii* DSM 44385), (ZP_03393297.1; *Corynebacterium amycolatum* SK46), (ZP_03718987.1; *Neisseria flavescens* NRL30031/H 210), (ZP_05318956.1; *Neisseria sicca* ATCC 29256), (YP_001598731.1; *Neisseria meningitidis* 053442), (ZP_04602977.1; *Kingella oralis* ATCC 51147), (YP_426466.1; *Rhodospirillum rubrum* ATCC 11170), (NP_871183.1; *Wigglesworthia glossinidia* endosymbiont of *Glossina brevipalpis*), (NP_777793.1; *Buchnera aphidicola* str. Bp (*Baizongia pistaciae*)), (YP_003249406.1; *Fibrobacter succmogenes* subsp. *succmogenes* S85), (ZP_03535302.1; *Mycobacterium tuberculosis* T17), (ZP_04056438.1; *Capnocytophaga gingivalis* ATCC 33624), (YP_003108500.1; *Candidatus Sulcia muelleri* SMDSEM), (P77844; *Corynebacterium glutamicum*), (ZP_03994160.1; *Mobiluncus mulieris* ATCC 35243), (ZP_03922640.1; *Mobiluncus curtisii* ATCC 43063), (ZP_03716209.1; *Eubacterium hallii* DSM 3353), (ZP_03718143.1; *Eubacterium hallii* DSM 3353), (ZP_05614434.1; *Faecalibacterium prausnitzii* A2-165), (ZP_02034852.1; *Bacteroides capillosus* ATCC 29799), (ZP_03753543.1; *Roseburia inulinivorans* DSM 16841), (ZP_04745275.2; *Roseburia intestinalis* L1-82), (YP_002937332.1; *Eubacterium rectale* ATCC 33656), (ZP_02074244.1; *Clostridium* sp. L2-50), (ZP_04455374.1; *Shuttleworthia satellites* DSM 14600), (ZP_03488480.1; *Eubacterium bifforme* DSM 3989), (ZP_02078327.1; *Eubacterium dolichum* DSM 3991), (ZP_02077559.1; *Eubacterium dolichum* DSM 3991), (ZP_03305532.1; *Anaerococcus hydrogenalis* DSM 7454), (ZP_05473291.1; *Anaerococcus vaginalis* ATCC 51170), (ZP_03931050.1; *Anaerococcus tetradius* ATCC 35098), (YP_003153463.1; *Anaerococcus prevotii* DSM 20548), (ZP_03916048.1; *Anaerococcus lactolyticus* ATCC 51172), (NP_607213.1; *Streptococcus pyogenes* MGAS8232), (AAK34003.1; *Streptococcus pyogenes* MIGAS), (YP_002562185.1; *Streptococcus uberis* 01401), (YP_002744451.1; *Streptococcus equi* subsp. *Zooepidemicus*), (BAH88016.1; *Streptococcus mutans* NN2025), (ZP_02920305.1; *Streptococcus infantarius* subsp. *infantarius* ATCCBAA-102), (YP_329798.1; *Streptococcus agalactiae* A909),

(ZP_04061789.1; *Streptococcus salivarius* SK126), (YP_139881.1; *Streptococcus thermophiles* LMG 18311), (ZP_04525024.1; *Streptococcus pneumomae* CCRI 1974), (ZP_06060573.1; *Streptococcus* sp. 2_1_36FAA), (YP_001198423.1; *Streptococcus suis* 05ZYH33), (NP_964739.1; *Lactobacillus johnsonii* NCC 533), (YP_193610.1; *Lactobacillus acidophilus* NCFM), (ZP_04011019.1; *Lactobacillus ultunensis* DSM 16047), (ZP_03995297.1; *Lactobacillus crispatus* JV- VOI), (ZP_05752753.1; *Lactobacillus helveticus* DSM 20075), (ZP_03956024.1; *Lactobacillus jensenii* JV-VI6), (ZP_04645187.1; *Lactobacillus jensenii* 269-3), (YP_618719.1; *Lactobacillus delbrueckii* subsp. *bulgaricus* ATCC 11842), (ZP_05744366.1; *Lactobacillus iners* DSM 13335), (NP_391646.1; *Bacillus subtilis* subsp. *subtilis* str. 168), (YP_001423045.1; *Bacillus amyloliquefaciens* FZB42), (YP_081073.1; *Bacillus licheniformis* ATCC 14580), (ZP_03055101.1; *Bacillus pumilus* ATCC 7061), (YP_002317098.1; *Anoxybacillus flavithermus* WKI), (YP_002951270.1; *Geobacillus* sp. WCH70), (YP_001127443.1; *Geobacillus thermodenitrificans* NG80-2), (YP_149268.1; *Geobacillus kaustophilus* HTA426), (ZP_01861251.1; *Bacillus* sp. SG-I), (ZP_03228176.1; *Bacillus coahuilensis* m4-4), (ZP_01173945.1; *Bacillus* sp. NRRLB-14911), (NP_693944.1; *Oceanobacillus iheyensis* HTE831), (ZP_04314753.1; *Bacillus cereus* BGSC 6EI), (YP_014727.1; *Listeria monocytogenes* str. 4b F2365), (ZP_04443757.1; *Listeria grayi* DSM 20601), (NP_244690.1; *Bacillus halodurans* C-125), (YP_177402.1; *Bacillus clausii* KSM-K16), (YP_002885816.1; *Exiguobacterium* sp. AT1b), (YP_001812721.1; *Exiguobacterium sibiricum* 255-15), (ZP_02169346.1; *Bacillus selenitireducens* MLS10), (ZP_04818386.1; *Staphylococcus epidermidis* M23864:WI), (ZP_03612973.1; *Staphylococcus capitis* SK14), (ZP_04677798.1; *Staphylococcus wamerei* L37603), (NP_763914.1; *Staphylococcus epidermidis* ATCC 12228), (ZP_05685678.1; *Staphylococcus aureus* A9635), (YP_254319.1; *Staphylococcus haemolyticus* JCSC1435), (ZP_04059818.1; *Staphylococcus hominis* SK119), (ABR57177.1; *Staphylococcus xylosus*), (YP_302214.1; *Staphylococcus saprophyticus* subsp. *saprophyticus* ATCC 15305), (YP_002633340.1; *Staphylococcus camosus* subsp. *camosus* TM300), (YP_002561236.1; *Macrococcus caseolyticus* JCSC5402), (ZP_03944466.1; *Lactobacillus fermentum* ATCC 14931), (ZP_05553502.1; *Lactobacillus coleohominis* 101-4-CHN), (ZP_03959629.1; *Lactobacillus vaginalis* ATCC 49540), (YP_001271004.1; *Lactobacillus reuteri* DSM 20016), (ZP_05745668.1; *Lactobacillus antri* DSM 16041), (YP_818931.1; *Leuconostoc mesenteroides* subsp. *mesenteroides* ATCC 8293), (YP_001727831.1; *Leuconostoc citreum* KM20), (ZP_04782044.1; *Weissella paramesenteroides* ATCC 33313), (ZP_01544468.1;

Oenococcus oeni ATCC BAA-1163), (ZP_05737294.1; *Granulicatella adiacens* ATCC 49175), (ZP_05851915.1; *Granulicatella elegans* ATCC 700633), (ZP_02183965.1; *Camobacterium sp.* AT7), (ZP_05649755.1; *Enterococcus gallinarum* EG2), (ZP_03947918.1; *Enterococcus faecalis* TX0104), (ZP_03982224.1; *Enterococcus faecium* TX1330), (YP_395954.1; *Lactobacillus sakei* subsp. *sakei* 23K), (ZP_04449762.1; *Catonella morbi* ATCC 51271), (YP_001032100.1; *Lactococcus lactis* subsp. *cremons* MG1363), (YP_806234.1; *Lactobacillus casei* ATCC 334), (NP_784550.1; *Lactobacillus plantarum* WCFS1), (YP_794848.1; *Lactobacillus brevis* ATCC 367), (ZP_03954831.1; *Lactobacillus hilgardii* ATCC 8290), (BABI9267.1; *Lactobacillus sanfranciscensis*), (ZP_03958288.1; *Lactobacillus ruminis* ATCC 25644), (YP_536042.1; *Lactobacillus salivarius* UCC118), (ZP_05747635.1; *Erysipelothrix rhusiopathiae* ATCC 19414), (YP_803875.1; *Pediococcus pentosaceus* ATCC 25745), (ZP_02093784.1; *Parvimonas micra* ATCC 33270), (YP_001692923.1; *Fingoldia magna* ATCC 29328), (ZP_04431499.1; *Bacillus coagulans* 36DI), (ZP_04775813.1; *Gemella haemolysans* ATCC 10379), (YP_001360609.1; *Kineococcus radiotolerans* SRS30216), (ZP_01115869.1; *Reinekea blandensis* MED297), (YP_003074238.1; *Teredinibac turnterrae* T7901), (YP_958411.1; *Marinobacter quaeolei* VT8), (YP_435580.1; *Hahella chejuensis* KCTC 2396), (YP_001189125.1; *Pseudomonas mendocina* ymp), (YP_792443.1; *Pseudomonas aerugmosa* UCBPP-PA14), (NP_791001.1; *Pseudomonas synnngae* pv. *tomato* str. DC3000), (YP_258069.1; *Pseudomonas fluorescens* Pf-5), (YP_606637.1; *Pseudomonas entomophila* L48), (YP_002800579.1; *Azotobacter vinelandii* DJ), (YP_001171663.1; *Pseudomonas stutzeri* A1501), (NP_840385.1; *Nitrosomonas europaea* ATCC 19718), (YP_002801221.1; *Azotobacter vinelandii* DJ), (YP_002787111.1; *Deinococcus deserti* VCD115), (YP_603523.1; *Deinococcus geothermalis* DSM 11300), (NP_293799.1; *Deinococcus radiodurans* R1), (YP_521550.1; *Rhodospirillum rubrum* ATCC 11170), (YP_530535.1; *Rhodospirillum rubrum* ATCC 11170), (YP_530535.1; *Rhodospirillum rubrum* ATCC 11170), (NP_901200.1; *Chromobacterium violaceum* ATCC 12472), (ZP_03698345.1; *Luticola nitroferum* 2002), (YP_001279250.1; *Psychrobacter* sp. PRwf-1), (YP_579484.1; *Psychrobacter cryohalolentis* K5), (ZP_05618978.1; *Enhydrobacter aerosaccus* SK60), (ZP_05362319.1; *Acinetobacter radioresistens* SK82), (YP_045288.1; *Acinetobacter* sp. ADPI), (ZP_05823314.1; *Acinetobacter* sp. RUH2624), (ZP_03824416.1; *Acinetobacter* sp. ATCC 27244), (YP_001380280.1; *Anaeromyxobacter* sp.

Fw109-5), (YP_466103.1; *Anaeromyxobacter dehalogenans* 2CP-C), (YP_088190.1; *Mannheimia succiniciproducens* MBEL55E), (YP_001344949.1; *Actinobacillus succmogenes* 130Z), (YP_003007411.1; *Aggregatibacter aphrophilus* NJ8700), (ZP_01788798.1; *Haemophilus influenzae* 3655), (YP_719012.1; *Haemophilus somnus* 129PT), (NP_245642.1; *Pasteurella multocida* subsp. *multocida* str. *Pm70*), (ZP_05920444.1; *Pasteurella dagmatis* ATCC 43325), (ZP_00133992.2; *Actinobacillus pleuropneumoniae* serovar 1 str. 4074), (ZP_04753547.1; *Actinobacillus minor* NM305), (NP_873873.1; *Haemophilus ducreyi* 35000HP), (ZP_04978908.1; *Mannheimia haemolytica* PHL213), (YP_002475022.1; *Haemophilus parasuis* SH0165), (ZP_05730581.1; *Pantoea* sp. *At-9b*), (YP_001907133.1; *Erwinia tasmaniensis* Et1/99), (YP_455287.1; *Sodalis glossinidius* str. 'morsitans'), (ZP_05723922.1; *Dickeya dadantii* Ech586), (YP_003258889.1; *Pectobacterium wasabiae* WPP163), (YP_002988159.1; *Dickeya dadantii* Ech703), (NP_668938.1; *Yersinia pestis* KIM 10), (YP_001479543.1; *Serratia proteamaculans* 568), (YP_002934098.1; *Edwardsiella ictaluri* 93-146), (YP_002151502.1; *Proteus mirabilis* HI4320), (NP_930328.1; *Photobacterium luminescens* subsp. *laumondii* TTO1), (YP_002920553.1; *Klebsiella pneumoniae* NTUH-K2044), (YP_001177557.1; *Enterobacter* sp.638), (YP_003211286.1; *Cronobacter turicensis*), (BAA04663.1; *Escherichia coli*), (YP_002924403.1; *Candidatus Hamiltonella defensa* 5AT (*Acyrtosiphon pisum*)), (ZP_03827735.1; *Pectobacterium carotovorum* subsp. *brasiliensis* PBR1692), (ZP_01159282.1; *Photobacterium* sp. *SKA34*), (YP_130973.1; *Photobacterium profundum* SS9), (ZP_06052481.1; *Grimontia hollisae* CIP 101886), (ZP_05877035.1; *Vibrio fumiissii* CIP 102972), (ZP_05881960.1; *Vibrio metschnikoyii* CIP 69.14), (ZP_05881960.1; *Vibrio metschnikoyii* CIP 69.14), (ZP_02196748.1; *Vibrio* sp. *AND4*), (NP_934927.1; *Vibrio vulnificus* YJ016), (ZP_01866446.1; *Vibrio shilonii* AKI), (YP_002416612.1; *Vibrio splendidus* LGP32), (YP_002263486.1; *Aliiyibrio salmonicida* LFI1238), (ZP_04415114.1; *Vibrio cholerae* by. *albensis* VL426), (YP_001143125.1; *Aeromonas salmonicida* subsp. *salmonicida* A449), (YP_002892091.1; *Tolumonas auensis* DSM 9187), (ZP_01215350.1; *Psychromonas* sp. *CNPT3*), (YP_944598.1; *Psychromonas ingrahamii* 37), (YP_001473443.1; *Shewanella sediminis* HAW-EB3), (YP_001761257.1; *Shewanella woodyi* ATCC 51908), (YP_001094519.1; *Shewanella loihica* PV -4), (YP_001674811.1; *Shewanella halifaxensis* HAW-EB4), (YP_869191.1; *Shewanella* sp. *ANA-3*), (YP_927371.1; *Shewanella amazonensis* SB2B), (YP_751160.1; *Shewanella frigidimarina* NCIMB 400), (YP_563413.1; *Shewanella denitrificans* OS217), (YP_001475272.1; *Shewanella sediminis* HAW-EB3),

(YP_001674949.1; *Shewanella halifaxensis* HAW-EB4), (ZP_04716660.1; *Alteromonas macleodii* ATCC 27126), (YP_662160.1; *Pseudoalteromonas atlantica* T6c), (ZP_01612225.1; *Alteromonadales bacterium* TW-7), (ZP_01134640.1; *Pseudoalteromonas tunicate* D2), (YP_269873.1; *Colwellia psychrerythrae* a 34H), (YP_001341167.1; *Marinomonas* sp. MWYL1), (ZP_01077352.1; *Marinomonas* sp. MED121), (YP_001209362.1; *Dichelobacter nodosus* VCSI703A), (ZP_05705193.1; *Cardiobacterium hominis* ATCC 15826), (EEY62817.1; *Phytophthora infestans* T30-4), (EEY62816.1; *Phytophthora infestans* T30-4), (XP_001694504.1; *Chlamydomonas reinhardtii*), (XP_001753120.1; *Physcomitrella patens* subsp. *Patens*), (YP_001804510.1; *Cyanothece* sp. ATCC 51142), (ZP_01729220.1; *Cyanothece* sp. CCY0110), (YP_003138337.1; *Cyanothece* sp. PCC 8802), (YP_002380034.1; *Cyanothece* sp. PCC 7424), (YP_001661110.1; *Microcystis aeruginosa* NIES-843), (YP_002485151.1; *Cyanothece* sp. PCC 7425), (NP_441027.1; *Synechocystis* sp. PCC 6803), (ZP_01061171.1; *Leeuwenhoekeiella blandensis* MED217), (YP_001195862.1; *Flavobacterium johnsoniae* UW101), (YP_003194927.1; *Robiginitalea biformata* HTCC2501), (ZP_01107792.1; *Flavobacteriales bacterium* HTCC2170), (ZP_01051731.1; *Polaribacter* sp. MED152), (ZP_01119204.1; *Polaribacter irgensii* 23-P), (ZP_03390929.1; *Capnocytophaga sputigena* ATCC 33612), (YP_003141977.1; *Capnocytophaga ochracea* DSM 7271), (YP_012240.1; *Desulfovibrio vulgaris* str. *Hildenborough*), (YP_002436276.1; *Desulfovibrio vulgaris* str. 'Miyazaki F'), (YP_389730.1; *Desulfovibrio desulfuricans* subsp. *desulfuricans* str. G20), (YP_002992165.1; *Desulfovibrio salexigens* DSM 2638), (YP_003197901.1; *Desulfohalobium retbaense* DSM 5692), (YP_003157577.1; *Desulfomicrobium baculatum* DSM 4028), (ZP_03737911.1; *Desulfonatronospira thiodismutans* AS03-1), (YP_002990332.1; *Desulfovibrio salexigens* DSM 2638), (ZP_03312237.1; *Desulfovibrio piger* ATCC 29098), (YP_002478890.1; *Desulfovibrio desulfuricans* subsp. *desulfuricans* str. ATCC 27774), (YP_064294.1; *Desulfotalea psychrophila* LSv54), (YP_594656.1; *Lawsonia intracellularis* PHE/MN1-00), (ZP_01621820.1; *Lyngbya* sp. PCC 8106), (ZP_03272899.1; *Arthrospira maxima* CS-328), (YP_845596.1; *Syntrophobacter fumaroxidans* MPOB), (ZP_04773932.1; *Allochromatium vinosum* DSM 180), (NP_869002.1; *Rhodopirellula baltica* SH 1), (YP_392571.1; *Sulfurimonas denitrificans* DSM 1251), (ZP_05071717.1; *Campylobacteriales bacterium* GD 1), (ZP_04421899.1; *Sulfurospirillum deleyianum* DSM 6946), (YP_001359295.1; *Sulfurovum* sp. NBC37-1), (YP_951544.1; *Mycobacterium vanbaalenii* PYR-1), (YP_001131488.1; *Mycobacterium gilvum* PYR-GCK), (YP_637714.1;

Mycobacterium sp. MCS), (YP_885188.1; *Mycobacterium smegmatis* str. MC2 155), (YP_001704953.1; *Mycobacterium abscessus*), (ZP_04747529.1; *Mycobacterium kansasii* ATCC 12478), (YP_001849024.1; *Mycobacterium marinum* M), (NP_214922.1; *Mycobacterium tuberculosis* H37Rv), (NP_962819.1; *Mycobacterium avium* subsp. *paratuberculosis* K-10), (ZP_05223872.1; *Mycobacterium intracellulare* ATCC 13950), (YP_002764919.1; *Rhodococcus erythropolis* PR4), (YP_702162.1; *Rhodococcus jostii* RHA1), (YP_121562.1; *Nocardia farcinica* IFM 10152), (ZP_04025361.1; *Tsukamurella paurometabola* DSM 20162), (YP_003275431.1; *Gordonia bronchialis* DSM 43247), (YP_003160610.1; *Jonesia denitrificans* DSM 20603), (ZP_05816650.1; *Sanguibacter keddieii* DSM 10542), (ZP_04368027.1; *Cellulomonas flavigena* DSM 20109), (YP_002883054.1; *Beutenbergia cavemae* DSM 12333), (ZP_03911481.1; *Xylanimonas cellulositytica* DSM 15894), (YP_924143.1; *Nocardioides* sp. 1S614), (ZP_03864789.1; *Kribbella flavida* DSM 17836), (ZP_01131057.1; *marine actinobacterium* PHSC20C1), (YP_001708941.1; *Clavibacter michiganensis* subsp. *Sepedonicus*), (YP_061462.1; *Leifsonia xyli* subsp. *xyli* str. CTCB07), (YP_748183.1; *Nitrosomonas eutropha* C91), (YP_003116892.1; *Catenulispora acidiphila* DSM 44928), (YP_003199983.1; *Nakamurella multipartita* DSM 44233), (YP_003154321.1; *Brachybacterium faecium* DSM 4810), (ZP_03927492.1; *Actinomyces urogenitalis* DSM 15434), (YP_003148931.1; *Kytococcus sedentarius* DSM 20547), (ZP_05803950.1; *Streptomyces flavogriseus* ATCC 33331), (YP_001823623.1; *Streptomyces griseus* subsp. *griseus* NBRC 13350), (ZP_05002693.1; *Streptomyces clavuligerus* ATCC 27064), (ZP_05015493.1; *Streptomyces sviveus* ATCC 29083), (ZP_05538660.1; *Streptomyces griseoflavus* Tu4000), (ZP_04685789.1; *Streptomyces ghanaensis* ATCC 14672), (ZP_05534308.1; *Streptomyces viridochromogenes* DSM 40736), (ZP_05523554.1; *Streptomyces lividans* TK24), (NP_823999.1; *Streptomyces avermitilis* MA-4680), (CBG69921.1; *Streptomyces scabiei* 87.22), (ZP_04704905.1; *Streptomyces albus* 11074), (ZP_04997745.1; *Streptomyces* sp. Mgl), (ZP_05509147.1; *Streptomyces* sp. C), (ZP_05514718.1; *Streptomyces hygrosopicus* ATCC 53653), (ZP_04994290.1; *Streptomyces* sp. SPB74), (ZP_04474082.1; *Streptosporangium roseum* DSM 43021), (YP_001160501.1; *Salinispora tropica* CNB-440), (YP_001538853.1; *Salinispora arenicola* CNS-205), (ZP_04605575.1; *Micromonospora* sp. ATCC 39149), (YP_832716.1; *Arthrobacter* sp. FB24), (ABR13603.1; *Arthrobacter oxydans*), (YP_002956296.1; *Micrococcus luteus* NCTC 2665), (ZP_05367249.1; *Rothia mucilaginosa* ATCC 25296), (YP_001854004.1; *Kocuria rhizophila* DC2201), (ZP_04984463.1;

Francisella tularensis subsp. *holarctica* FSC022), (YP_001677422.1; *Francisella philomiragia* subsp. *philomiragia* ATCC 25017), (YP_588827.1; *Baumannia cicadellinicola* str. *Hc* (*Homalodisca oagulata*)), (NP_240007.1; *Buchnera aphidicola* str. *APS* (*Acyrtosiphonpisum*)), (ZP_05057494.1; *Verrucomicrobiae bacterium* DG1235), (ZP_02930252.1; *Verrucomicrobium spinosum* DSM 4136), (ZP_01452386.1; *Mariprofundus ferrooxydans* PV-1), and (ZP_01307392.1; *Bermanella marisrubri*).

[0067] Phosphotransacetylases also useful in the compositions and methods provided herein include those molecules which are said to be “derivatives” of any of the phosphotransacetylases described herein. Such a “derivative” has the following characteristics: (1) it shares substantial homology with any of the phosphotransacetylases described herein; and (2) is capable of catalyzing the conversion of acetyl phosphate into acetyl-CoA. A derivative of a phosphotransacetylase is said to share “substantial homology” with the phosphotransacetylase if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of the phosphotransacetylase.

5.4 Functional Disruption of Acetyl Phosphatase Activity

[0068] In some embodiments, the genetically modified host cell provided herein comprises a functional disruption in an enzyme that converts acetyl phosphate to acetate. In some embodiments, the enzyme is native to the host cell.

[0069] In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase (EC 3.1.3.21). In some embodiments, the enzyme having glycerol-1-phosphatase activity is RHR2 (GPP1/RHR2; systematic name: YIL053W), or a homolog or variant thereof. GPP1/RHR2 is a constitutively expressed glycerol-1-phosphatase involved in glycerol biosynthesis, and is induced in response to both anaerobic and osmotic stress. See, e.g., Norbeck *et al.*, *J Biol Chem* 271(23): 13875-13881 (1996); Norbeck *et al.*, *J Biol Chem* 272(9): 13875-13881 (1996); Pahlman *et al.*, *J Biol Chem* 276(5): 3555-3563 (2001); Nevoigt and Stahl, *FEMS Microbiol Rev* 21(3):231-41 (1997); Byrne and Wolf, *Genome Res* 15(10):1456-61; and Hirayama *et al.*, *Mol Gen Genet* 249(2):127-38, the contents of each of which are hereby incorporated by reference in their entireties. The sequence of the *GPP1/RHR2* gene of *S. cerevisiae* has been previously described. See, e.g., Norbeck *et al.*, *J Biol Chem* 271(23): 13875-13881 (1996); and Pahlman *et al.*, *J Biol Chem* 276(5): 3555-3563 (2001). Gpp1/Rhr2 has been previously described as catalyzing the following reaction:

[0070] glycerol-1-phosphate + H₂O ⇌ glycerol + phosphate.

[0071] Representative *GPP1/RHR2* nucleotide sequences of *Saccharomyces cerevisiae* include accession number NM_001179403.1, and SEQ ID NO:5 as provided herein. Representative *Gpp1/Rhr2* protein sequences of *Saccharomyces cerevisiae* include accession number NP_012211, and SEQ ID NO:6 as provided herein.

[0072] A closely related homolog of *GPP1/RHR2* which also catalyzes the hydrolysis of acetyl phosphate to acetate is *HOR2* (*GPP2/HOR2*; systematic name: YER062C). *Gpp2/Hor2* has also been previously described as a glycerol-1-phosphatase capable of catalyzing the following reaction: glycerol-1-phosphate + H₂O ⇌ glycerol + phosphate. Accordingly, functional disruption of *GPP2/HOR2* also finds use in the compositions and methods provided herein. The sequence of the *GPP2/HOR2* gene of *S. cerevisiae* has been previously described. See, e.g., Norbeck *et al.*, *J. of Biological Chemistry* 271(23): 13875-13881 (1996); and Pahlman *et al.*, *J. of Biological Chemistry* 276(5): 3555-3563 (2001). Representative *GPP2/HOR2* nucleotide sequences of *Saccharomyces cerevisiae* include accession number NM_001178953.3, and SEQ ID NO:7 as provided herein. Representative *Gpp1/Rhr2* protein sequences of *Saccharomyces cerevisiae* include accession number NP_010984, and SEQ ID NO:8 as provided herein.

[0073] As would be understood in the art, naturally occurring homologs of *GPP1/RHR2* and/or *GPP2/HOR2* in yeast other than *S. cerevisiae* can similarly be inactivated using the methods described herein. Moreover, a polynucleotide, gene and/or polypeptide encoding acetyl-phosphatase activity (e.g., *RHR2* and/or *HOR2*) can be used to identify other polynucleotide, gene and/or polypeptide sequences or to identify homologs having acetyl-phosphatase activity in other host cells. Such sequences can be identified, for example, in the literature and/or in bioinformatics databases well known to the skilled person. For example, the identification of sequences encoding acetyl-phosphatase activity in other cell types using bioinformatics can be accomplished through BLAST (as described above) searching of publicly available databases with known DNA and polypeptide sequences encoding acetyl-phosphatase and/or glycerol-1-phosphatase activity, such as those provided herein. Identities can be based on the Clustal W method of alignment using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.

[0074] In some embodiments, the activity or expression of an endogenous enzyme that converts acetyl phosphate to acetate (e.g., *RHR2* or *HOR2*) is reduced by at least about 50%. In another embodiment, the activity or expression of an endogenous enzyme that

converts acetyl phosphate to acetate is reduced by at least about 60%, by at least about 65%, by at least about 70%, by at least about 75%, by at least about 80%, by at least about 85%, by at least about 90%, by at least about 95%, or by at least about 99% as compared to a recombinant microorganism not comprising a reduction or deletion of the activity or expression of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the endogenous enzyme that converts acetyl phosphate to acetate is RHR2, or homologues thereof. In some embodiments, the endogenous enzyme that converts acetyl phosphate to acetate is HOR2, or homologues thereof.

[0075] As is understood by those skilled in the art, there are several mechanisms available for reducing or disrupting the activity of a protein that converts acetyl phosphate to acetate, such as a glycerol-1-phosphatase (*e.g.*, RHR2 and/or HOR2), including, but not limited to, the use of a regulated promoter, use of a weak constitutive promoter, disruption of one of the two copies of the gene encoding the protein in a diploid yeast, disruption of both copies of the gene in a diploid yeast, expression of an anti-sense nucleic acid, expression of an siRNA, over expression of a negative regulator of the endogenous promoter, alteration of the activity of an endogenous or heterologous gene, use of a heterologous gene with lower specific activity, the like or combinations thereof.

[0076] In some embodiments, the genetically modified host cell comprises a mutation in at least one gene encoding acetyl-phosphatase activity (*e.g.*, RHR2, HOR2 or a homolog or variant thereof), resulting in a reduction of activity of a polypeptide encoded by said gene. In another embodiment, the genetically modified host cell comprises a partial deletion of a gene encoding acetyl-phosphatase activity (*e.g.*, RHR2, HOR2 or a homolog or variant thereof), resulting in a reduction of activity of a polypeptide encoded by the gene. In another embodiment, the genetically modified host cell comprises a complete deletion of a gene encoding acetyl-phosphatase activity (*e.g.*, RHR2, HOR2 or a homolog or variant thereof), resulting in a reduction of activity of a polypeptide encoded by the gene. In yet another embodiment, the genetically modified host cell comprises a modification of the regulatory region associated with the gene encoding acetyl-phosphatase activity (*e.g.*, RHR2, HOR2 or a homolog or variant thereof), resulting in a reduction of expression of a polypeptide encoded by said gene. In yet another embodiment, the genetically modified host cell comprises a modification of the transcriptional regulator resulting in a reduction of transcription of a gene encoding acetyl-phosphatase activity (*e.g.*, RHR2, HOR2 or a homolog or variant thereof).

[0077] In some embodiments, disruption of one or more genes encoding a protein capable of catalyzing the conversion of acetyl phosphate to acetate is achieved by using a “disruption construct” that is capable of specifically disrupting such a gene (*e.g.*, *RHR2* or *HOR2*) upon introduction of the construct into the microbial cell, thereby rendering the disrupted gene non-functional. In some embodiments, disruption of the target gene prevents the expression of a functional protein. In some embodiments, disruption of the target gene results in expression of a non-functional protein from the disrupted gene. In some embodiments, disruption of a gene encoding a protein capable of converting acetyl phosphate to acetate is achieved by integration of a “disrupting sequence” within the target gene locus by homologous recombination. In such embodiments, the disruption construct comprises a disrupting sequence flanked by a pair of nucleotide sequences that are homologous to a pair of nucleotide sequences of the target gene locus (homologous sequences). Upon replacement of the targeted portion of the target gene by the disruption construct, the disrupting sequence prevents the expression of a functional protein, or causes expression of a non-functional protein, from the target gene.

[0078] Disruption constructs capable of disrupting a gene may be constructed using standard molecular biology techniques well known in the art. *See, e.g.*, Sambrook *et al.*, 2001, *Molecular Cloning -- A Laboratory Manual*, 3rd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, and Ausubel *et al.*, eds., Current Edition, *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley Interscience, NY. Parameters of disruption constructs that may be varied in the practice of the present methods include, but are not limited to, the lengths of the homologous sequences; the nucleotide sequence of the homologous sequences; the length of the disrupting sequence; the nucleotide sequence of the disrupting sequence; and the nucleotide sequence of the target gene. In some embodiments, an effective range for the length of each homologous sequence is 50 to 5,000 base pairs. In particular embodiments, the length of each homologous sequence is about 500 base pairs. For a discussion of the length of homology required for gene targeting, *see* Hasty *et al.*, *Mol Cell Biol* 11:5586-91 (1991). In some embodiments, the homologous sequences comprise coding sequences of the target gene. In other embodiments, the homologous sequences comprise upstream or downstream sequences of the target gene. In some embodiments, one homologous sequence comprises a nucleotide sequence that is homologous to a nucleotide sequence located 5' of the coding sequence of the target gene, and the other homologous sequence comprises a nucleotide sequence that is homologous to a

nucleotide sequence located 3' of the coding sequence of the target gene. In some embodiments, the disrupting sequence comprises a nucleotide sequence encoding a selectable marker that enables selection of microbial cells comprising the disrupting sequence. Thus, in such embodiments, the disruption construct has a dual function, *i.e.*, to functionally disrupt the target gene and to provide a selectable marker for the identification of cells in which the target gene is functionally disrupted. In some embodiments, a termination codon is positioned in-frame with and downstream of the nucleotide sequence encoding the selectable marker to prevent translational read-through that might yield a fusion protein having some degree of activity of the wild type protein encoded by the target gene. In some embodiments, the length of the disrupting sequence is one base pair. Insertion of a single base pair can suffice to disrupt a target gene because insertion of the single base pair in a coding sequence could constitute a frame shift mutation that could prevent expression of a functional protein. In some embodiments, the sequence of the disruption sequence differs from the nucleotide sequence of the target gene located between the homologous sequences by a single base pair. Upon replacement of the nucleotide sequence within the target gene with the disrupting sequence, the single base pair substitution that is introduced could result in a single amino acid substitution at a critical site in the protein and the expression of a non-functional protein. It should be recognized, however, that disruptions effected using very short disrupting sequences are susceptible to reversion to the wild type sequence through spontaneous mutation, thus leading to restoration of acetyl-phosphatase function to the host strain. Accordingly, in particular embodiments, the disrupting sequences are longer than one to a few base pairs. At the other extreme, a disrupting sequence of excessive length is unlikely to confer any advantage over a disrupting sequence of moderate length, and might diminish efficiency of transfection or targeting. Excessive length in this context is many times longer than the distance between the chosen homologous sequences in the target gene. Thus, in certain embodiments, the length for the disrupting sequence can be from 2 to 2,000 base pairs. In other embodiments, the length for the disrupting sequence is a length approximately equivalent to the distance between the regions of the target gene locus that match the homologous sequences in the disruption construct.

[0079] In some embodiments, the disruption construct is a linear DNA molecule. In other embodiments, the disruption construct is a circular DNA molecule. In some embodiments, the circular disruption construct comprises a pair of homologous sequences separated by a disrupting sequence, as described above. In some embodiments, the circular

disruption construct comprises a single homologous sequence. Such circular disruption constructs, upon integration at the target gene locus, would become linearized, with a portion of the homologous sequence positioned at each end and the remaining segments of the disruption construct inserting into and disrupting the target gene without replacing any of the target gene nucleotide sequence. In particular embodiments, the single homologous sequence of a circular disruption construct is homologous to a sequence located within the coding sequence of the target gene.

[0080] Disruption constructs can be introduced into a microbial cell by any method known to one of skill in the art without limitation. Such methods include, but are not limited to, direct uptake of the molecule by a cell from solution, or facilitated uptake through lipofection using, *e.g.*, liposomes or immunoliposomes; particle-mediated transfection; *etc.* See, *e.g.*, U.S. Patent No. 5,272,065; Goeddel et al., eds, 1990, *Methods in Enzymology*, vol. 185, Academic Press, Inc., CA; Krieger, 1990, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, NY; Sambrook et al., 1989, *Molecular Cloning -- A Laboratory Manual*, Cold Spring Harbor Laboratory, NY; and Ausubel et al., eds., *Current Edition, Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley Interscience, NY. Particular methods for transforming yeast cells are well known in the art. See Hinnen *et al.*, *Proc. Natl. Acad. Sci. USA* 75:1292-3 (1978); Cregg *et al.*, *Mol. Cell. Biol.* 5:3376-3385 (1985). Exemplary techniques include, but are not limited to, spheroplasting, electroporation, PEG 1000 mediated transformation, and lithium acetate or lithium chloride mediated transformation.

5.5 Additional Modifications to Improve Acetyl-CoA Production

5.5.1 ADA

[0081] In some embodiments, the genetically modified host cells provided herein further comprise one or more heterologous nucleotide sequences encoding acylating acetaldehyde dehydrogenase (alternately referred to as “acetylaldehyde dehydrogenase, acylating,” “acetylaldehyde dehydrogenase, acylating,” or ADA (EC 1.2.1.10)).

[0082] Proteins capable of catalyzing this reaction that are useful for the compositions and methods provided herein include the following four types of proteins:

[0083] (1) Bifunctional proteins that catalyze the reversible conversion of acetyl-CoA to acetaldehyde, and the subsequent reversible conversion of acetaldehyde to ethanol. An example of this type of protein is the AdhE protein in *E. coli* (Gen Bank No: NP_415757). AdhE appears to be the evolutionary product of a gene fusion. The NH₂-terminal region of

the AdhE protein is highly homologous to aldehyde:NAD⁺ oxidoreductases, whereas the COOH-terminal region is homologous to a family of Fe²⁺-dependent ethanol:NAD⁺ oxidoreductases (Membrillo-Hernandez *et al.*, (2000) *J. Biol. Chem.* 275: 33869-33875). The *E. coli* AdhE is subject to metal-catalyzed oxidation and therefore oxygen-sensitive (Tamarit *et al.* (1998) *J. Biol. Chem.* 273:3027-32).

[0084] (2) Proteins that catalyze the reversible conversion of acetyl-CoA to acetaldehyde in strictly or facultative anaerobic microbes but do not possess alcohol dehydrogenase activity. An example of this type of protein has been reported in *Clostridium kluyveri* (Smith *et al.* (1980) *Arch. Biochem. Biophys.* 203: 663-675). An ADA has been annotated in the genome of *Clostridium kluyveri* DSM 555 (accession no: EDK33116). A homologous protein AcdH is identified in the genome of *Lactobacillus plantarum* (accession no: NP_784141). Another example of this type of protein is the *ald* gene product in *Clostridium beijerinckii* NRRL B593 (Toth *et al.* (1999) *Appl. Environ. Microbiol.* 65: 4973-4980, accession no: AAD31841).

[0085] (3) Proteins that are involved in ethanolamine catabolism. Ethanolamine can be utilized both as carbon and nitrogen source by many enterobacteria (Stojiljkovic *et al.* (1995) *J. Bacteriol.* 177: 1357-1366). Ethanolamine is first converted by ethanolamine ammonia lyase to ammonia and acetaldehyde, subsequently, acetaldehyde is converted by ADA to acetyl-CoA. An example of this type of ADA is the EutE protein in *Salmonella typhimurium* (Stojiljkovic *et al.* (1995) *J. Bacteriol.* 177: 1357-1366, accession no: AAL21357; see also U18560.1). *E. coli* is also able to utilize ethanolamine (Scarlett *et al.* (1976) *J. Gen. Microbiol.* 95:173-176) and has an EutE protein (accession no: AAG57564; see also EU897722.1) which is homologous to the EutE protein in *S. typhimurium*.

[0086] (4) Proteins that are part of a bifunctional aldolase-dehydrogenase complex involved in 4-hydroxy-2-ketovalerate catabolism. Such bifunctional enzymes catalyze the final two steps of the meta-cleavage pathway for catechol, an intermediate in many bacterial species in the degradation of phenols, toluates, naphthalene, biphenyls and other aromatic compounds (Powlowski and Shingler (1994) *Biodegradation* 5, 219-236). 4-Hydroxy-2-ketovalerate is first converted by 4-hydroxy-2-ketovalerate aldolase to pyruvate and acetaldehyde, subsequently acetaldehyde is converted by ADA to acetyl-CoA. An example of this type of ADA is the DmpF protein in *Pseudomonas sp* CF600 (accession no: CAA43226) (Shingler *et al.* (1992) *J. Bacteriol.* 174:71 1-24). *E. coli* has a homologous

MphF protein (Ferrandez *et al.* (1997) J. Bacteriol. 179: 2573-2581 , accession no: NP_414885) to the DmpF protein in *Pseudomonas sp.* CF600.

[0087] In some embodiments, an ADA (or nucleic acid sequence encoding such activity) useful for the compositions and methods described herein is selected from the group consisting of *Escherichia coli* adhE, *Entamoeba histolytica* adh2, *Staphylococcus aureus* adhE, *Piromyces sp.*E2 adhE, *Clostridium khuyveri* (EDK33116), *Lactobacillus plantarum* acdH, and *Pseudomonas putida* (YP 001268189), as described in International Publication No. WO 2009/013159, the contents of which are incorporated by reference in their entirety. In some embodiments, the ADA is selected from the group consisting of *Clostridium botulinum* eutE (FR745875.1), *Desulfotalea psychrophila* eutE (CR522870.1), *Acinetobacter sp.* HBS-2 eutE (ABQ44511.2), *Caldithrix abyssi* eutE (ZP_09549576), and *Halorubrum lacusprofundi* ATCC 49239 (YP_002565337.1).

[0088] In particular embodiments, the ADA useful for the compositions and methods provided herein is eutE from *Dickeya zeae*. A representative eutE nucleotide sequence of *Dickeya zeae* includes accession number NC_012912.1:1110476..1111855, and SEQ ID NO: 9 as provided herein. A representative eutE protein sequence of *Dickeya zeae* includes accession number YP_003003316, and SEQ ID NO: 10 as provided herein.

[0089] ADAs also useful in the compositions and methods provided herein include those molecules which are said to be “derivatives” of any of the ADAs described herein. Such a “derivative” has the following characteristics: (1) it shares substantial homology with any of the ADAs described herein; and (2) is capable of catalyzing the conversion of acetaldehyde to acetyl-CoA. A derivative of an ADA is said to share “substantial homology” with ADA if the amino acid sequences of the derivative is at least 80%, at least 85% and more preferably at least 90%, and most preferably at least 95%, the same as that of any of the ADAs described herein.

5.5.2 Functional Disruption of the PDH-bypass

[0090] Acetyl-CoA can be formed in the mitochondria by oxidative decarboxylation of pyruvate catalyzed by the PDH complex. However, due to the inability of *S. cerevisiae* to transport acetyl-CoA out of the mitochondria, the PDH bypass has an essential role in providing acetyl-CoA in the cytosolic compartment, and provides an alternative route to the PDH reaction for the conversion of pyruvate to acetyl-CoA. The PDH bypass involves the enzymes pyruvate decarboxylase (PDC; EC 4.1.1.1), acetaldehyde dehydrogenase (ACDH; EC 1.2.1.5 and EC 1.2.1.4), and acetyl-CoA synthetase (ACS; EC 6.2.1.1). Pyruvate

decarboxylase catalyzes the decarboxylation of pyruvate to acetaldehyde and carbon dioxide. Acetaldehyde dehydrogenase oxidizes acetaldehyde to acetic acid. In *S. cerevisiae*, the family of aldehyde dehydrogenases contains five members. *ALD2* (YMR170c), *ALD3* (YMR169c), and *ALD6* (YPL061w) correspond to the cytosolic isoforms, while *ALD4* (YOR374w) and *ALD5* (YER073w) encode the mitochondrial enzyme. The main cytosolic acetaldehyde dehydrogenase isoform is encoded by *ALD6*. The formation of acetyl-CoA from acetate is catalyzed by ACS and involves hydrolysis of ATP. Two structural genes, *ACS1* and *ACS2*, encode ACS.

[0091] In some embodiments, the genetically modified host cell provided herein further comprises a functional disruption in one or more genes of the PDH-bypass pathway. In some embodiments, disruption of the one or more genes of the PDH-bypass of the host cell results in a genetically modified microbial cell that is impaired in its ability to catalyze one or more of the following reactions: (1) the decarboxylation of pyruvate into acetaldehyde by pyruvate decarboxylase; (2) the conversion of acetaldehyde into acetate by acetaldehyde dehydrogenase; and (3) the synthesis of acetyl-CoA from acetate and CoA by acetyl-CoA synthetase.

[0092] In some embodiments, compared to a parent cell, a host cell comprises a functional disruption in one or more genes of the PDH-bypass pathway, wherein the activity of the reduced-function or non-functional PDH-bypass pathway alone or in combination with a weak ADA is not sufficient to support host cell growth, viability, and/or health.

[0093] In some embodiments, the activity or expression of one or more endogenous proteins of the PDH-bypass is reduced by at least about 50%. In another embodiment, the activity or expression of one or more endogenous proteins of the PDH-bypass is reduced by at least about 60%, by at least about 65%, by at least about 70%, by at least about 75%, by at least about 80%, by at least about 85%, by at least about 90%, by at least about 95%, or by at least about 99% as compared to a recombinant microorganism not comprising a reduction or deletion of the activity or expression of one or more endogenous proteins of the PDH-bypass.

5.5.2.1 ALD4 and ALD6

[0094] In some embodiments, one or more genes encoding aldehyde dehydrogenase (ACDH) activity are functionally disrupted in the host cell. In some embodiments, the aldehyde dehydrogenase is encoded by a gene selected from the group consisting of *ALD2*, *ALD3*, *ALD4*, *ALD5*, *ALD6*, and homologs and variants thereof.

[0095] In some embodiments, the genetically modified host cell comprises a functional disruption of ALD4. Representative *ALD4* nucleotide sequences of *Saccharomyces cerevisiae* include accession number NM_001183794, and SEQ ID NO:11 as provided herein. Representative Ald4 protein sequences of *Saccharomyces cerevisiae* include accession number NP_015019.1, and SEQ ID NO:12 as provided herein.

[0096] In some embodiments, the genetically modified host cell comprises a functional disruption of cytosolic aldehyde dehydrogenase (ALD6). Ald6p functions in the native PDH-bypass to convert acetaldehyde to acetate. Representative *ALD6* nucleotide sequences of *Saccharomyces cerevisiae* include accession number SCU56604, and SEQ ID NO:13 as provided herein. Representative Ald6 protein sequences of *Saccharomyces cerevisiae* include accession number AAB01219, and SEQ ID NO:14 as provided herein.

[0097] As would be understood in the art, naturally occurring homologs of aldehyde dehydrogenase in yeast other than *S. cerevisiae* can similarly be inactivated using the methods described herein.

[0098] As would be understood by one skilled in the art, the activity or expression of more than one aldehyde dehydrogenase can be reduced or eliminated. In one specific embodiment, the activity or expression of ALD4 and ALD6 or homologs or variants thereof is reduced or eliminated. In another specific embodiment, the activity or expression of ALD5 and ALD6 or homologs or variants thereof is reduced or eliminated. In yet another specific embodiment, the activity or expression of ALD4, ALD5, and ALD6 or homologs or variants thereof is reduced or eliminated. In yet another specific embodiment, the activity or expression of the cytosolically localized aldehyde dehydrogenases ALD2, ALD3, and ALD6 or homologs or variants thereof is reduced or eliminated. In yet another specific embodiment, the activity or expression of the mitochondrially localized aldehyde dehydrogenases, ALD4 and ALD5 or homologs or variants thereof, is reduced or eliminated.

5.5.2.2 ACS1 and ACS2

[0099] In some embodiments, one or more genes encoding acetyl-CoA synthetase (ACS) activity are functionally disrupted in the host cell. In some embodiments, the acetyl-CoA synthetase is encoded by a gene selected from the group consisting of ACS1, ACS2, and homologs and variants thereof.

[00100] In some embodiments, one or more genes encoding acetyl-CoA synthetase (ACS) activity is functionally disrupted in the host cell. ACS1 and ACS2 are both acetyl-CoA synthetases that can convert acetate to acetyl-CoA. ACS1 is expressed only under

respiratory conditions, whereas ACS2 is expressed constitutively. When ACS2 is knocked out, strains are able to grow on respiratory conditions (*e.g.* ethanol, glycerol, or acetate media), but die on fermentable carbon sources (*e.g.* sucrose, glucose).

[00101] In some embodiments, the genetically modified host cell comprises a functional disruption of ACS1. The sequence of the *ACS1* gene of *S. cerevisiae* has been previously described. *See, e.g., Nagasu et al., Gene* 37 (1-3):247-253 (1985). Representative *ACS1* nucleotide sequences of *Saccharomyces cerevisiae* include accession number X66425, and SEQ ID NO:15 as provided herein. Representative Acs1 protein sequences of *Saccharomyces cerevisiae* include accession number AAC04979, and SEQ ID NO:16 as provided herein.

[00102] In some embodiments, the genetically modified host cell comprises a functional disruption of ACS2. The sequence of the *ACS2* gene of *S. cerevisiae* has been previously described. *See, e.g., Van den Berg et al., Eur. J. Biochem.* 231(3):704-713 (1995). Representative *ACS2* nucleotide sequences of *Saccharomyces cerevisiae* include accession number S79456, and SEQ ID NO:17 as provided herein. Representative Acs2 protein sequences of *Saccharomyces cerevisiae* include accession number CAA97725, and SEQ ID NO:18 as provided herein.

[00103] As would be understood in the art, naturally occurring homologs of acetyl-CoA synthetase in yeast other than *S. cerevisiae* can similarly be inactivated using the methods described herein.

[00104] In some embodiments, the host cell comprises a cytosolic acetyl-coA synthetase activity that can convert acetate to acetyl-CoA under respiratory conditions (*i.e.*, when the host cell is grown in the presence of *e.g.* ethanol, glycerol, or acetate). In some such embodiments, the host cell is a yeast cell that comprises ACS1 activity. In other embodiments, the host cell compared to a parent cell comprises no or reduced endogenous acetyl-CoA synthetase activity under respiratory conditions. In some such embodiments, the host cell is a yeast cell that compared to a parent cell comprises no or reduced ACS1 activity.

[00105] In some embodiments, the host cell comprises a cytosolic acetyl-coA synthetase activity that can convert acetate to acetyl-CoA under non-respiratory conditions (*i.e.*, when the host cell is grown in the presence of fermentable carbon sources (*e.g.* sucrose, glucose)). In some such embodiments, the host cell is a yeast cell that comprises ACS2 activity. In other embodiments, the host cell compared to a parent cell comprises no or reduced endogenous acetyl-CoA synthetase activity under non-respiratory conditions. In

some such embodiments, the host cell is a yeast cell that compared to a parent cell comprises no or reduced ACS2 activity.

[00106] In some embodiments, the host cell comprises a heterologous PK and a cytosolic acetyl-coA synthetase activity (*e.g.*, ACS1 and/or ACS2). In such embodiments, PK produces acetyl phosphate in the host cell. The intact cytosolic ACS activity can convert acetate that accumulates as a result of RHR2 and/or HOR2-catalyzed acetyl phosphate hydrolysis into acetyl-CoA.

5.6 MEV Pathway for Isoprenoid Production

[00107] In some embodiments, the genetically modified host cell provided herein comprises one or more heterologous enzymes of the MEV pathway. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that condenses acetyl-CoA with malonyl-CoA to form acetoacetyl-CoA. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that converts HMG-CoA to mevalonate. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate. In some embodiments, the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

[00108] In some embodiments, the one or more enzymes of the MEV pathway are selected from the group consisting of acetyl-CoA thiolase, acetoacetyl-CoA synthetase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase and mevalonate pyrophosphate decarboxylase. In some embodiments, with regard to the enzyme of the MEV pathway capable of catalyzing the formation of acetoacetyl-CoA, the genetically modified host cell comprises either an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA, *e.g.*, acetyl-CoA thiolase; or an enzyme that condenses acetyl-CoA with malonyl-CoA to form acetoacetyl-CoA, *e.g.*, acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell comprises both an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA, *e.g.*, acetyl-CoA thiolase;

and an enzyme that condenses acetyl-CoA with malonyl-CoA to form acetoacetyl-CoA, *e.g.*, acetoacetyl-CoA synthase.

[00109] In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding more than one enzyme of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding two enzymes of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding an enzyme that can convert HMG-CoA into mevalonate and an enzyme that can convert mevalonate into mevalonate 5-phosphate. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding three enzymes of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding four enzymes of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding five enzymes of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding six enzymes of the MEV pathway. In some embodiments, the host cell comprises one or more heterologous nucleotide sequences encoding seven enzymes of the MEV pathway. In some embodiments, the host cell comprises a plurality of heterologous nucleic acids encoding all of the enzymes of the MEV pathway.

[00110] In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an enzyme that can convert isopentenyl pyrophosphate (IPP) into dimethylallyl pyrophosphate (DMAPP). In some embodiments, the genetically modified host cell further comprises a heterologous nucleic acid encoding an enzyme that can condense IPP and/or DMAPP molecules to form a polyprenyl compound. In some embodiments, the genetically modified host cell further comprise a heterologous nucleic acid encoding an enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound.

5.6.1 Conversion of Acetyl-CoA to Acetoacetyl-CoA

[00111] In some embodiments, the genetically modified host cell comprises a heterologous nucleotide sequence encoding an enzyme that can condense two molecules of acetyl-coenzyme A to form acetoacetyl-CoA, *e.g.*, an acetyl-CoA thiolase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (NC_000913 REGION: 2324131.2325315; *Escherichia coli*), (D49362; *Paracoccus denitrificans*), and (L20428; *Saccharomyces cerevisiae*).

[00112] Acetyl-CoA thiolase catalyzes the reversible condensation of two molecules of acetyl-CoA to yield acetoacetyl-CoA, but this reaction is thermodynamically unfavorable; acetoacetyl-CoA thiolysis is favored over acetoacetyl-CoA synthesis. Acetoacetyl-CoA synthase (AACS) (alternately referred to as acetyl-CoA:malonyl-CoA acyltransferase; EC 2.3.1.194) condenses acetyl-CoA with malonyl-CoA to form acetoacetyl-CoA. In contrast to acetyl-CoA thiolase, AACS-catalyzed acetoacetyl-CoA synthesis is essentially an energy-favored reaction, due to the associated decarboxylation of malonyl-CoA. In addition, AACS exhibits no thiolysis activity against acetoacetyl-CoA, and thus the reaction is irreversible.

[00113] In host cells comprising acetyl-CoA thiolase and a heterologous ADA and/or phosphotransacetylase (PTA), the reversible reaction catalyzed by acetyl-CoA thiolase, which favors acetoacetyl-CoA thiolysis, may result in a large acetyl-CoA pool. In view of the reversible activity of ADA, this acetyl-CoA pool may in turn drive ADA towards the reverse reaction of converting acetyl-CoA to acetaldehyde, thereby diminishing the benefits provided by ADA towards acetyl-CoA production. Similarly, the activity of PTA is reversible, and thus, a large acetyl-CoA pool may drive PTA towards the reverse reaction of converting acetyl-CoA to acetyl phosphate. Therefore, in some embodiments, in order to provide a strong pull on acetyl-CoA to drive the forward reaction of ADA and PTA, the MEV pathway of the genetically modified host cell provided herein utilizes an acetoacetyl-CoA synthase to form acetoacetyl-CoA from acetyl-CoA and malonyl-CoA.

[00114] In some embodiments, the AACS is from *Streptomyces* sp. strain CL190 (Okamura *et al.*, *Proc Natl Acad Sci USA* 107(25):11265-70 (2010). Representative AACS nucleotide sequences of *Streptomyces* sp. strain CL190 include accession number AB540131.1, and SEQ ID NO:19 as provided herein. Representative AACS protein sequences of *Streptomyces* sp. strain CL190 include accession numbers D7URV0, BAJ10048, and SEQ ID NO:20 as provided herein. Other acetoacetyl-CoA synthases useful for the compositions and methods provided herein include, but are not limited to, *Streptomyces* sp. (AB183750; KO-3988 BAD86806); *S. anulatus* strain 9663 (FN178498; CAX48662); *Streptomyces* sp. KO-3988 (AB212624; BAE78983); *Actinoplanes* sp. A40644 (AB113568; BAD07381); *Streptomyces* sp. C (NZ_ACEW010000640; ZP_05511702); *Nocardiopsis dassonvillei* DSM 43111 (NZ_ABUI01000023; ZP_04335288); *Mycobacterium ulcerans* Agy99 (NC_008611; YP_907152); *Mycobacterium marinum* M (NC_010612; YP_001851502); *Streptomyces* sp. Mg1 (NZ_DS570501; ZP_05002626); *Streptomyces* sp. AA4 (NZ_ACEV01000037; ZP_05478992); *S. roseosporus* NRRL 15998

(NZ_ABYB01000295; ZP_04696763); *Streptomyces* sp. ACTE (NZ_ADFD01000030; ZP_06275834); *S. viridochromogenes* DSM 40736 (NZ_ACEZ01000031; ZP_05529691); *Frankia* sp. CcI3 (NC_007777; YP_480101); *Nocardia brasiliensis* (NC_018681; YP_006812440.1); and *Austwickia chelonae* (NZ_BAGZ01000005; ZP_10950493.1). Additional suitable acetoacetyl-CoA synthases include those described in U.S. Patent Application Publication Nos. 2010/0285549 and 2011/0281315, the contents of which are incorporated by reference in their entireties.

[00115] Acetoacetyl-CoA synthases also useful in the compositions and methods provided herein include those molecules which are said to be “derivatives” of any of the acetoacetyl-CoA synthases described herein. Such a “derivative” has the following characteristics: (1) it shares substantial homology with any of the acetoacetyl-CoA synthases described herein; and (2) is capable of catalyzing the irreversible condensation of acetyl-CoA with malonyl-CoA to form acetoacetyl-CoA. A derivative of an acetoacetyl-CoA synthase is said to share “substantial homology” with acetoacetyl-CoA synthase if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of acetoacetyl-CoA synthase.

5.6.2 Conversion of Acetoacetyl-CoA to HMG-CoA

[00116] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can condense acetoacetyl-CoA with another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), *e.g.*, a HMG-CoA synthase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (NC_001145, complement 19061.20536; *Saccharomyces cerevisiae*), (X96617; *Saccharomyces cerevisiae*), (X83882; *Arabidopsis thaliana*), (AB037907; *Kitasatospora griseola*), (BT007302; *Homo sapiens*), and (NC_002758, Locus tag SAV2546, GeneID 1122571; *Staphylococcus aureus*).

5.6.3 Conversion of HMG-CoA to Mevalonate

[00117] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can convert HMG-CoA into mevalonate, *e.g.*, a HMG-CoA reductase. In some embodiments, HMG-CoA reductase is an NADH-using hydroxymethylglutaryl-CoA reductase-CoA reductase. HMG-CoA reductases (EC 1.1.1.34; EC 1.1.1.88) catalyze the reductive deacylation of (S)-HMG-CoA to (R)-mevalonate, and can be categorized into two classes, class I and class II HMGRs. Class I includes the enzymes from eukaryotes and most archaea, and class II includes the HMG-CoA reductases of certain

prokaryotes and archaea. In addition to the divergence in the sequences, the enzymes of the two classes also differ with regard to their cofactor specificity. Unlike the class I enzymes, which utilize NADPH exclusively, the class II HMG-CoA reductases vary in the ability to discriminate between NADPH and NADH. *See, e.g., Hedl et al., Journal of Bacteriology* 186 (7): 1927-1932 (2004). Co-factor specificities for select class II HMG-CoA reductases are provided below.

[00118] **Table 1. Co-factor specificities for select class II HMG-CoA reductases**

Source	Coenzyme specificity	K_m^{NADPH} (μM)	K_m^{NADH} (μM)
<i>P. mevalonii</i>	NADH		80
<i>A. fulgidus</i>	NAD(P)H	500	160
<i>S. aureus</i>	NAD(P)H	70	100
<i>E. faecalis</i>	NADPH	30	

[00119] Useful HMG-CoA reductases for the compositions and methods provided herein include HMG-CoA reductases that are capable of utilizing NADH as a cofactor, *e.g.*, HMG-CoA reductase from *P. mevalonii*, *A. fulgidus* or *S. aureus*. In particular embodiments, the HMG-CoA reductase is capable of only utilizing NADH as a cofactor, *e.g.*, HMG-CoA reductase from *P. mevalonii*, *S. pomeroyi* or *D. acidovorans*.

[00120] In some embodiments, the NADH-using HMG-CoA reductase is from *Pseudomonas mevalonii*. The sequence of the wild-type *mvaA* gene of *Pseudomonas mevalonii*, which encodes HMG-CoA reductase (EC 1.1.1.88), has been previously described. *See* Beach and Rodwell, *J. Bacteriol.* 171:2994-3001 (1989). Representative *mvaA* nucleotide sequences of *Pseudomonas mevalonii* include accession number M24015, and SEQ ID NO: 21 as provided herein. Representative HMG-CoA reductase protein sequences of *Pseudomonas mevalonii* include accession numbers AAA25837, P13702, MVAA_PSEMV, and SEQ ID NO: 22 as provided herein.

[00121] In some embodiments, the NADH-using HMG-CoA reductase is from *Silicibacter pomeroyi*. Representative HMG-CoA reductase nucleotide sequences of *Silicibacter pomeroyi* include accession number NC_006569.1, and SEQ ID NO: 23 as provided herein. Representative HMG-CoA reductase protein sequences of *Silicibacter pomeroyi* include accession number YP_164994, and SEQ ID NO: 24 as provided herein.

[00122] In some embodiments, the NADH-using HMG-CoA reductase is from *Delftia acidovorans*. A representative HMG-CoA reductase nucleotide sequences of *Delftia acidovorans* includes NC_010002 REGION: complement(319980..321269), and SEQ ID NO: 25 as provided herein. Representative HMG-CoA reductase protein sequences of *Delftia acidovorans* include accession number YP_001561318, and SEQ ID NO: 26 as provided herein.

[00123] In some embodiments, the NADH-using HMG-CoA reductases is from *Solanum tuberosum* (Crane *et al.*, *J. Plant Physiol.* 159:1301-1307 (2002)).

[00124] NADH-using HMG-CoA reductases also useful in the compositions and methods provided herein include those molecules which are said to be “derivatives” of any of the NADH-using HMG-CoA reductases described herein, *e.g.*, from *P. mevalonii*, *S. pomeroyi* and *D. acidovorans*. Such a “derivative” has the following characteristics: (1) it shares substantial homology with any of the NADH-using HMG-CoA reductases described herein; and (2) is capable of catalyzing the reductive deacylation of (S)-HMG-CoA to (R)-mevalonate while preferentially using NADH as a cofactor. A derivative of an NADH-using HMG-CoA reductase is said to share “substantial homology” with NADH-using HMG-CoA reductase if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of NADH-using HMG-CoA reductase.

[00125] As used herein, the phrase “NADH-using” means that the NADH-using HMG-CoA reductase is selective for NADH over NADPH as a cofactor, for example, by demonstrating a higher specific activity for NADH than for NADPH. In some embodiments, selectivity for NADH as a cofactor is expressed as a $k_{\text{cat}}^{(\text{NADH})} / k_{\text{cat}}^{(\text{NADPH})}$ ratio. In some embodiments, the NADH-using HMG-CoA reductase has a $k_{\text{cat}}^{(\text{NADH})} / k_{\text{cat}}^{(\text{NADPH})}$ ratio of at least 5, 10, 15, 20, 25 or greater than 25. In some embodiments, the NADH-using HMG-CoA reductase uses NADH exclusively. For example, an NADH-using HMG-CoA reductase that uses NADH exclusively displays some activity with NADH supplied as the sole cofactor *in vitro*, and displays no detectable activity when NADPH is supplied as the sole cofactor. Any method for determining cofactor specificity known in the art can be utilized to identify HMG-CoA reductases having a preference for NADH as cofactor, including those described by Kim *et al.*, *Protein Science* 9:1226-1234 (2000); and Wilding *et al.*, *J. Bacteriol.* 182(18):5147-52 (2000), the contents of which are hereby incorporated in their entireties.

[00126] In some embodiments, the NADH-using HMG-CoA reductase is engineered to be selective for NADH over NADPH, for example, through site-directed mutagenesis of the cofactor-binding pocket. Methods for engineering NADH-selectivity are described in Watanabe *et al.*, *Microbiology* 153:3044-3054 (2007), and methods for determining the cofactor specificity of HMG-CoA reductases are described in Kim *et al.*, *Protein Sci.* 9:1226-1234 (2000), the contents of which are hereby incorporated by reference in their entireties.

[00127] In some embodiments, the NADH-using HMG-CoA reductase is derived from a host species that natively comprises a mevalonate degradative pathway, for example, a host species that catabolizes mevalonate as its sole carbon source. Within these embodiments, the NADH-using HMG-CoA reductase, which normally catalyzes the oxidative acylation of internalized (R)-mevalonate to (S)-HMG-CoA within its native host cell, is utilized to catalyze the reverse reaction, that is, the reductive deacylation of (S)-HMG-CoA to (R)-mevalonate, in a genetically modified host cell comprising a mevalonate biosynthetic pathway. Prokaryotes capable of growth on mevalonate as their sole carbon source have been described by: Anderson *et al.*, *J. Bacteriol.* 171(12):6468-6472 (1989); Beach *et al.*, *J. Bacteriol.* 171:2994-3001 (1989); Bensch *et al.*, *J. Biol. Chem.* 245:3755-3762; Fimongnari *et al.*, *Biochemistry* 4:2086-2090 (1965); Siddiqi *et al.*, *Biochem. Biophys. Res. Commun.* 8:110-113 (1962); Siddiqi *et al.*, *J. Bacteriol.* 93:207-214 (1967); and Takatsuji *et al.*, *Biochem. Biophys. Res. Commun.* 110:187-193 (1983), the contents of which are hereby incorporated by reference in their entireties.

[00128] In some embodiments of the compositions and methods provided herein, the host cell comprises both a NADH-using HMGr and an NADPH-using HMG-CoA reductase. Illustrative examples of nucleotide sequences encoding an NADPH-using HMG-CoA reductase include, but are not limited to: (NM_206548; *Drosophila melanogaster*), (NC_002758, Locus tag SAV2545, GeneID 1122570; *Staphylococcus aureus*), (AB015627; *Streptomyces sp.* KO 3988), (AX128213, providing the sequence encoding a truncated HMG-CoA reductase; *Saccharomyces cerevisiae*), and (NC_001145: complement (115734.118898; *Saccharomyces cerevisiae*).

5.6.4 Conversion of Mevalonate to Mevalonate-5-Phosphate

[00129] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can convert mevalonate into mevalonate 5-phosphate, *e.g.*, a mevalonate kinase. Illustrative examples of nucleotide sequences encoding such an

enzyme include, but are not limited to: (L77688; *Arabidopsis thaliana*), and (X55875; *Saccharomyces cerevisiae*).

5.6.5 Conversion of Mevalonate-5-Phosphate to Mevalonate-5-Pyrophosphate

[00130] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can convert mevalonate 5-phosphate into mevalonate 5-pyrophosphate, *e.g.*, a phosphomevalonate kinase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (AF429385; *Hevea brasiliensis*), (NM_006556; *Homo sapiens*), and (NC_001145. complement 712315.713670; *Saccharomyces cerevisiae*).

5.6.6 Conversion of Mevalonate-5-Pyrophosphate to IPP

[00131] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can convert mevalonate 5-pyrophosphate into isopentenyl diphosphate (IPP), *e.g.*, a mevalonate pyrophosphate decarboxylase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (X97557; *Saccharomyces cerevisiae*), (AF290095; *Enterococcus faecium*), and (U49260; *Homo sapiens*).

5.6.7 Conversion of IPP to DMAPP

[00132] In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding an enzyme that can convert IPP generated via the MEV pathway into dimethylallyl pyrophosphate (DMAPP), *e.g.*, an IPP isomerase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (NC_000913, 3031087.3031635; *Escherichia coli*), and (AF082326; *Haematococcus pluvialis*).

5.6.8 Polyprenyl Synthases

[00133] In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a polyprenyl synthase that can condense IPP and/or DMAPP molecules to form polyprenyl compounds containing more than five carbons.

[00134] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can condense one molecule of IPP with one molecule of DMAPP to form one molecule of geranyl pyrophosphate ("GPP"), *e.g.*, a GPP synthase. Illustrative examples of nucleotide sequences encoding such an enzyme include, but are not limited to: (AF513111; *Abies grandis*), (AF513112; *Abies grandis*), (AF513113; *Abies grandis*), (AY534686; *Antirrhinum majus*), (AY534687; *Antirrhinum majus*), (Y17376;

Arabidopsis thaliana), (AE016877, Locus AP11092; *Bacillus cereus*; ATCC 14579), (AJ243739; *Citrus sinensis*), (AY534745; *Clarkia breweri*), (AY953508; *Ips pini*), (DQ286930; *Lycopersicon esculentum*), (AF182828; *Mentha x piperita*), (AF182827; *Mentha x piperita*), (MPI249453; *Mentha x piperita*), (PZE431697, Locus CAD24425; *Paracoccus zeaxanthinifaciens*), (AY866498; *Picrorhiza kurrooa*), (AY351862; *Vitis vinifera*), and (AF203881, Locus AAF12843; *Zymomonas mobilis*).

[00135] In some embodiments, the host cell comprises a heterologous nucleotide sequence encoding an enzyme that can condense two molecules of IPP with one molecule of DMAPP, or add a molecule of IPP to a molecule of GPP, to form a molecule of farnesyl pyrophosphate ("FPP"), e.g., a FPP synthase. Illustrative examples of nucleotide sequences that encode such an enzyme include, but are not limited to: (ATU80605; *Arabidopsis thaliana*), (ATHFPS2R; *Arabidopsis thaliana*), (AAU36376; *Artemisia annua*), (AF461050; *Bos taurus*), (D00694; *Escherichia coli* K-12), (AE009951, Locus AAL95523; *Fusobacterium nucleatum subsp. nucleatum* ATCC 25586), (GFFPPSGEN; *Gibberella fujikuroi*), (CP000009, Locus AAW60034; *Gluconobacter oxydans* 621H), (AF019892; *Helianthus annuus*), (HUMFAPS; *Homo sapiens*), (KLPFPSQCR; *Kluyveromyces lactis*), (LAU15777; *Lupinus albus*), (LAU20771; *Lupinus albus*), (AF309508; *Mus musculus*), (NCFPPSGEN; *Neurospora crassa*), (PAFPS1; *Parthenium argentatum*), (PAFPS2; *Parthenium argentatum*), (RATFAPS; *Rattus norvegicus*), (YSCFPP; *Saccharomyces cerevisiae*), (D89104; *Schizosaccharomyces pombe*), (CP000003, Locus AAT87386; *Streptococcus pyogenes*), (CP000017, Locus AAZ51849; *Streptococcus pyogenes*), (NC_008022, Locus YP_598856; *Streptococcus pyogenes* MGAS10270), (NC_008023, Locus YP_600845; *Streptococcus pyogenes* MGAS2096), (NC_008024, Locus YP_602832; *Streptococcus pyogenes* MGAS10750), (MZEFPS; *Zea mays*), (AE000657, Locus AAC06913; *Aquifex aeolicus* VF5), (NM_202836; *Arabidopsis thaliana*), (D84432, Locus BAA12575; *Bacillus subtilis*), (U12678, Locus AAC28894; *Bradyrhizobium japonicum* USDA 110), (BACFDPS; *Geobacillus stearothermophilus*), (NC_002940, Locus NP_873754; *Haemophilus ducreyi* 35000HP), (L42023, Locus AAC23087; *Haemophilus influenzae* Rd KW20), (J05262; *Homo sapiens*), (YP_395294; *Lactobacillus sakei subsp. sakei* 23K), (NC_005823, Locus YP_000273; *Leptospira interrogans serovar Copenhageni str. Fiocruz L1-130*), (AB003187; *Micrococcus luteus*), (NC_002946, Locus YP_208768; *Neisseria gonorrhoeae* FA 1090), (U00090, Locus AAB91752; *Rhizobium sp.* NGR234), (J05091; *Saccharomyces cerevisiae*), (CP000031, Locus AAV93568; *Silicibacter pomeroyi*

DSS-3), (AE008481, Locus AAK99890; *Streptococcus pneumoniae* R6), and (NC_004556, Locus NP_779706; *Xylella fastidiosa* Temecula1).

[00136] In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding an enzyme that can combine IPP and DMAPP or IPP and FPP to form geranylgeranyl pyrophosphate (“GGPP”). Illustrative examples of nucleotide sequences that encode such an enzyme include, but are not limited to: (ATHGERPYRS; *Arabidopsis thaliana*), (BT005328; *Arabidopsis thaliana*), (NM_119845; *Arabidopsis thaliana*), (NZ_AAJM01000380, Locus ZP_00743052; *Bacillus thuringiensis* serovar *israelensis*, ATCC 35646 sq1563), (CRGGPPS; *Catharanthus roseus*), (NZ_AABF02000074, Locus ZP_00144509; *Fusobacterium nucleatum* subsp. *vincentii*, ATCC 49256), (GFGGPPSGN; *Gibberella fujikuroi*), (AY371321; *Ginkgo biloba*), (AB055496; *Hevea brasiliensis*), (AB017971; *Homo sapiens*), (MCI276129; *Mucor circinelloides* f. *lusitanicus*), (AB016044; *Mus musculus*), (AABX01000298, Locus NCU01427; *Neurospora crassa*), (NCU20940; *Neurospora crassa*), (NZ_AAKL01000008, Locus ZP_00943566; *Ralstonia solanacearum* UW551), (AB118238; *Rattus norvegicus*), (SCU31632; *Saccharomyces cerevisiae*), (AB016095; *Synechococcus elongates*), (SAGGPS; *Sinapis alba*), (SSOGDS; *Sulfolobus acidocaldarius*), (NC_007759, Locus YP_461832; *Syntrophus aciditrophicus* SB), (NC_006840, Locus YP_204095; *Vibrio fischeri* ES114), (NM_112315; *Arabidopsis thaliana*), (ERWCRTE; *Pantoea agglomerans*), (D90087, Locus BAA14124; *Pantoea ananatis*), (X52291, Locus CAA36538; *Rhodobacter capsulatus*), (AF195122, Locus AAF24294; *Rhodobacter sphaeroides*), and (NC_004350, Locus NP_721015; *Streptococcus mutans* UA159).

5.6.9 Terpene Synthases

[00137] In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding an enzyme that can modify a polyprenyl to form a hemiterpene, a monoterpene, a sesquiterpene, a diterpene, a triterpene, a tetraterpene, a polyterpene, a steroid compound, a carotenoid, or a modified isoprenoid compound.

[00138] In some embodiments, the heterologous nucleotide encodes a carene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (AF461460, REGION 43.1926; *Picea abies*) and (AF527416, REGION: 78.1871; *Salvia stenophylla*).

[00139] In some embodiments, the heterologous nucleotide encodes a geraniol synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited

to: (AJ457070; *Cinnamomum tenuipilum*), (AY362553; *Ocimum basilicum*), (DQ234300; *Perilla frutescens* strain 1864), (DQ234299; *Perilla citriodora* strain 1861), (DQ234298; *Perilla citriodora* strain 4935), and (DQ088667; *Perilla citriodora*).

[00140] In some embodiments, the heterologous nucleotide encodes a linalool synthase. Illustrative examples of a suitable nucleotide sequence include, but are not limited to: (AF497485; *Arabidopsis thaliana*), (AC002294, Locus AAB71482; *Arabidopsis thaliana*), (AY059757; *Arabidopsis thaliana*), (NM_104793; *Arabidopsis thaliana*), (AF154124; *Artemisia annua*), (AF067603; *Clarkia breweri*), (AF067602; *Clarkia concinna*), (AF067601; *Clarkia breweri*), (U58314; *Clarkia breweri*), (AY840091; *Lycopersicon esculentum*), (DQ263741; *Lavandula angustifolia*), (AY083653; *Mentha citrate*), (AY693647; *Ocimum basilicum*), (XM_463918; *Oryza sativa*), (AP004078, Locus BAD07605; *Oryza sativa*), (XM_463918, Locus XP_463918; *Oryza sativa*), (AY917193; *Perilla citriodora*), (AF271259; *Perilla frutescens*), (AY473623; *Picea abies*), (DQ195274; *Picea sitchensis*), and (AF444798; *Perilla frutescens* var. *crispa* cultivar No. 79).

[00141] In some embodiments, the heterologous nucleotide encodes a limonene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (+)-limonene synthases (AF514287, REGION: 47.1867; *Citrus limon*) and (AY055214, REGION: 48.1889; *Agastache rugosa*) and (-)-limonene synthases (DQ195275, REGION: 1.1905; *Picea sitchensis*), (AF006193, REGION: 73.1986; *Abies grandis*), and (MHC4SLSP, REGION: 29.1828; *Mentha spicata*).

[00142] In some embodiments, the heterologous nucleotide encodes a myrcene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (U87908; *Abies grandis*), (AY195609; *Antirrhinum majus*), (AY195608; *Antirrhinum majus*), (NM_127982; *Arabidopsis thaliana* TPS10), (NM_113485; *Arabidopsis thaliana* ATTPS-CIN), (NM_113483; *Arabidopsis thaliana* ATTPS-CIN), (AF271259; *Perilla frutescens*), (AY473626; *Picea abies*), (AF369919; *Picea abies*), and (AJ304839; *Quercus ilex*).

[00143] In some embodiments, the heterologous nucleotide encodes a ocimene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (AY195607; *Antirrhinum majus*), (AY195609; *Antirrhinum majus*), (AY195608; *Antirrhinum majus*), (AK221024; *Arabidopsis thaliana*), (NM_113485; *Arabidopsis thaliana* ATTPS-CIN), (NM_113483; *Arabidopsis thaliana* ATTPS-CIN), (NM_117775; *Arabidopsis thaliana* ATTPS03), (NM_001036574; *Arabidopsis thaliana* ATTPS03), (NM_127982;

Arabidopsis thaliana TPS10), (AB110642; *Citrus unshiu* CitMTSL4), and (AY575970; *Lotus corniculatus* var. *japonicus*).

[00144] In some embodiments, the heterologous nucleotide encodes an α -pinene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (+) α -pinene synthase (AF543530, REGION: 1.1887; *Pinus taeda*), (-) α -pinene synthase (AF543527, REGION: 32.1921; *Pinus taeda*), and (+)/(-) α -pinene synthase (AGU87909, REGION: 6111892; *Abies grandis*).

[00145] In some embodiments, the heterologous nucleotide encodes a β -pinene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (-) β -pinene synthases (AF276072, REGION: 1.1749; *Artemisia annua*) and (AF514288, REGION: 26.1834; *Citrus limon*).

[00146] In some embodiments, the heterologous nucleotide encodes a sabinene synthase. An illustrative example of a suitable nucleotide sequence includes but is not limited to AF051901, REGION: 26.1798 from *Salvia officinalis*.

[00147] In some embodiments, the heterologous nucleotide encodes a γ -terpinene synthase. Illustrative examples of suitable nucleotide sequences include: (AF514286, REGION: 30.1832 from *Citrus limon*) and (AB110640, REGION 1.1803 from *Citrus unshiu*).

[00148] In some embodiments, the heterologous nucleotide encodes a terpinolene synthase. Illustrative examples of a suitable nucleotide sequence include, but are not limited to: (AY693650 from *Oscimum basilicum*) and (AY906866, REGION: 10.1887 from *Pseudotsuga menziesii*).

[00149] In some embodiments, the heterologous nucleotide encodes an amorphadiene synthase. An illustrative example of a suitable nucleotide sequence is SEQ ID NO. 37 of U.S. Patent Publication No. 2004/0005678.

[00150] In some embodiments, the heterologous nucleotide encodes a α -farnesene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to DQ309034 from *Pyrus communis* cultivar *d'Anjou* (pear; gene name AFS1) and AY182241 from *Malus domestica* (apple; gene AFS1). Pechouus *et al.*, *Planta* 219(1):84-94 (2004).

[00151] In some embodiments, the heterologous nucleotide encodes a β -farnesene synthase. Illustrative examples of suitable nucleotide sequences include but is not limited to

accession number AF024615 from *Mentha x piperita* (peppermint; gene Tspa11), and AY835398 from *Artemisia annua*. Picaud *et al.*, *Phytochemistry* 66(9): 961-967 (2005).

[00152] In some embodiments, the heterologous nucleotide encodes a farnesol synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to accession number AF529266 from *Zea mays* and YDR481C from *Saccharomyces cerevisiae* (gene Pho8). Song, L., *Applied Biochemistry and Biotechnology* 128:149-158 (2006).

[00153] In some embodiments, the heterologous nucleotide encodes a nerolidol synthase. An illustrative example of a suitable nucleotide sequence includes, but is not limited to AF529266 from *Zea mays* (maize; gene tps1).

[00154] In some embodiments, the heterologous nucleotide encodes a patchouliol synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to AY508730 REGION: 1.1659 from *Pogostemon cablin*.

[00155] In some embodiments, the heterologous nucleotide encodes a nootkatone synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to AF441124 REGION: 1.1647 from *Citrus sinensis* and AY917195 REGION: 1.1653 from *Perilla frutescens*.

[00156] In some embodiments, the heterologous nucleotide encodes an abietadiene synthase. Illustrative examples of suitable nucleotide sequences include, but are not limited to: (U50768; *Abies grandis*) and (AY473621; *Picea abies*).

[00157] In some embodiments, the host cell produces a C₅ isoprenoid. These compounds are derived from one isoprene unit and are also called hemiterpenes. An illustrative example of a hemiterpene is isoprene. In other embodiments, the isoprenoid is a C₁₀ isoprenoid. These compounds are derived from two isoprene units and are also called monoterpenes. Illustrative examples of monoterpenes are limonene, citranellol, geraniol, menthol, perillyl alcohol, linalool, thujone, and myrcene. In other embodiments, the isoprenoid is a C₁₅ isoprenoid. These compounds are derived from three isoprene units and are also called sesquiterpenes. Illustrative examples of sesquiterpenes are periplanone B, ginkgolide B, amorphadiene, artemisinin, artemisinic acid, valencene, nootkatone, epi-cedrol, epi-aristolochene, farnesol, gossypol, sanonin, periplanone, forskolin, and patchoulol (which is also known as patchouli alcohol). In other embodiments, the isoprenoid is a C₂₀ isoprenoid. These compounds are derived from four isoprene units and also called diterpenes. Illustrative examples of diterpenes are casbene, eleutherobin, paclitaxel,

prostratin, pseudopterosin, and taxadiene. In yet other examples, the isoprenoid is a C₂₀₊ isoprenoid. These compounds are derived from more than four isoprene units and include: triterpenes (C₃₀ isoprenoid compounds derived from 6 isoprene units) such as arbrusideE, bruceantin, testosterone, progesterone, cortisone, digitoxin, and squalene; tetraterpenes (C₄₀ isoprenoid compounds derived from 8 isoprenoids) such as β -carotene; and polyterpenes (C₄₀₊ isoprenoid compounds derived from more than 8 isoprene units) such as polyisoprene. In some embodiments, the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpinolene and valencene. Isoprenoid compounds also include, but are not limited to, carotenoids (such as lycopene, α - and β -carotene, α - and β -cryptoxanthin, bixin, zeaxanthin, astaxanthin, and lutein), steroid compounds, and compounds that are composed of isoprenoids modified by other chemical groups, such as mixed terpene-alkaloids, and coenzyme Q-10.

5.6.10 Methods of Producing Isoprenoids

[00158] In another aspect, provided herein is a method for the production of an isoprenoid, the method comprising the steps of: (a) culturing a population of any of the genetically modified host cells described herein that are capable of producing an isoprenoid in a medium with a carbon source under conditions suitable for making an isoprenoid compound; and (b) recovering said isoprenoid compound from the medium.

[00159] In some embodiments, the genetically modified host cell comprises one or more modifications selected from the group consisting of: heterologous expression of a phosphoketolase, heterologous expression of a phosphotransacetylase, heterologous expression of one or more enzymes of the mevalonate pathway; and optionally, heterologous expression of an ADA, heterologous expression of an NADH-using HMG-CoA reductase, and heterologous expression of an AACs; and the genetically modified host cell produces an increased amount of the isoprenoid compound compared to a parent cell not comprising the one or more modifications, or a parent cell comprising only a subset of the one or more modifications of the genetically modified host cell, but is otherwise genetically identical. In some embodiments, the increased amount is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or greater than 100%, as measured, for example, in yield, production, productivity, in grams per liter of cell culture, milligrams per gram of dry cell weight, on a per unit volume of cell culture basis,

on a per unit dry cell weight basis, on a per unit volume of cell culture per unit time basis, or on a per unit dry cell weight per unit time basis.

[00160] In some embodiments, the host cell produces an elevated level of isoprenoid that is greater than about 10 grams per liter of fermentation medium. In some such embodiments, the isoprenoid is produced in an amount from about 10 to about 50 grams, more than about 15 grams, more than about 20 grams, more than about 25 grams, or more than about 30 grams per liter of cell culture.

[00161] In some embodiments, the host cell produces an elevated level of isoprenoid that is greater than about 50 milligrams per gram of dry cell weight. In some such embodiments, the isoprenoid is produced in an amount from about 50 to about 1500 milligrams, more than about 100 milligrams, more than about 150 milligrams, more than about 200 milligrams, more than about 250 milligrams, more than about 500 milligrams, more than about 750 milligrams, or more than about 1000 milligrams per gram of dry cell weight.

[00162] In some embodiments, the host cell produces an elevated level of isoprenoid that is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, or at least about 1,000-fold, or more, higher than the level of isoprenoid produced by a parent cell, on a per unit volume of cell culture basis.

[00163] In some embodiments, the host cell produces an elevated level of isoprenoid that is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, or at least about 1,000-fold, or more, higher than the level of isoprenoid produced by the parent cell, on a per unit dry cell weight basis.

[00164] In some embodiments, the host cell produces an elevated level of an isoprenoid that is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, or at least about 1,000-fold, or more, higher than the level of isoprenoid produced by the parent cell, on a per unit volume of cell culture per unit time basis.

[00165] In some embodiments, the host cell produces an elevated isoprenoid that is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, or at least about 1,000-fold, or more, higher than the level of isoprenoid produced by the parent cell, on a per unit dry cell weight per unit time basis.

[00166] In most embodiments, the production of the elevated level of isoprenoid by the host cell is inducible by an inducing compound. Such a host cell can be manipulated with ease in the absence of the inducing compound. The inducing compound is then added to induce the production of the elevated level of isoprenoid by the host cell. In other embodiments, production of the elevated level of isoprenoid by the host cell is inducible by changing culture conditions, such as, for example, the growth temperature, media constituents, and the like.

5.6.11 Culture Media and Conditions

[00167] Materials and methods for the maintenance and growth of microbial cultures are well known to those skilled in the art of microbiology or fermentation science (*see*, for example, Bailey *et al.*, Biochemical Engineering Fundamentals, second edition, McGraw Hill, New York, 1986). Consideration must be given to appropriate culture medium, pH, temperature, and requirements for aerobic, microaerobic, or anaerobic conditions, depending on the specific requirements of the host cell, the fermentation, and the process.

[00168] The methods of producing isoprenoids provided herein may be performed in a suitable culture medium (*e.g.*, with or without pantothenate supplementation) in a suitable container, including but not limited to a cell culture plate, a flask, or a fermentor. Further, the methods can be performed at any scale of fermentation known in the art to support industrial production of microbial products. Any suitable fermentor may be used including a stirred tank fermentor, an airlift fermentor, a bubble fermentor, or any combination thereof. In particular embodiments utilizing *Saccharomyces cerevisiae* as the host cell, strains can be grown in a fermentor as described in detail by Kosaric, *et al*, in Ullmann's Encyclopedia of Industrial Chemistry, Sixth Edition, Volume 12, pages 398-473, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.

[00169] In some embodiments, the culture medium is any culture medium in which a genetically modified microorganism capable of producing an isoprenoid can subsist, *i.e.*, maintain growth and viability. In some embodiments, the culture medium is an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources. Such a medium can also include appropriate salts, minerals, metals and other nutrients. In some embodiments, the carbon source and each of the essential cell nutrients, are added incrementally or continuously to the fermentation media, and each required nutrient is maintained at essentially the minimum level needed for efficient assimilation by growing cells, for example, in accordance with a predetermined cell growth curve based on the metabolic or respiratory function of the cells which convert the carbon source to a biomass.

[00170] Suitable conditions and suitable media for culturing microorganisms are well known in the art. In some embodiments, the suitable medium is supplemented with one or more additional agents, such as, for example, an inducer (*e.g.*, when one or more nucleotide sequences encoding a gene product are under the control of an inducible promoter), a repressor (*e.g.*, when one or more nucleotide sequences encoding a gene product are under the control of a repressible promoter), or a selection agent (*e.g.*, an antibiotic to select for microorganisms comprising the genetic modifications).

[00171] In some embodiments, the carbon source is a monosaccharide (simple sugar), a disaccharide, a polysaccharide, a non-fermentable carbon source, or one or more combinations thereof. Non-limiting examples of suitable monosaccharides include glucose, galactose, mannose, fructose, xylose, ribose, and combinations thereof. Non-limiting examples of suitable disaccharides include sucrose, lactose, maltose, trehalose, cellobiose, and combinations thereof. Non-limiting examples of suitable polysaccharides include starch,

glycogen, cellulose, chitin, and combinations thereof. Non-limiting examples of suitable non-fermentable carbon sources include acetate and glycerol.

[00172] The concentration of a carbon source, such as glucose, in the culture medium should promote cell growth, but not be so high as to repress growth of the microorganism used. Typically, cultures are run with a carbon source, such as glucose, being added at levels to achieve the desired level of growth and biomass, but at undetectable levels (with detection limits being about <0.1 g/l). In other embodiments, the concentration of a carbon source, such as glucose, in the culture medium is greater than about 1 g/L, preferably greater than about 2 g/L, and more preferably greater than about 5 g/L. In addition, the concentration of a carbon source, such as glucose, in the culture medium is typically less than about 100 g/L, preferably less than about 50 g/L, and more preferably less than about 20 g/L. It should be noted that references to culture component concentrations can refer to both initial and/or ongoing component concentrations. In some cases, it may be desirable to allow the culture medium to become depleted of a carbon source during culture.

[00173] Sources of assimilable nitrogen that can be used in a suitable culture medium include, but are not limited to, simple nitrogen sources, organic nitrogen sources and complex nitrogen sources. Such nitrogen sources include anhydrous ammonia, ammonium salts and substances of animal, vegetable and/or microbial origin. Suitable nitrogen sources include, but are not limited to, protein hydrolysates, microbial biomass hydrolysates, peptone, yeast extract, ammonium sulfate, urea, and amino acids. Typically, the concentration of the nitrogen sources, in the culture medium is greater than about 0.1 g/L, preferably greater than about 0.25 g/L, and more preferably greater than about 1.0 g/L. Beyond certain concentrations, however, the addition of a nitrogen source to the culture medium is not advantageous for the growth of the microorganisms. As a result, the concentration of the nitrogen sources, in the culture medium is less than about 20 g/L, preferably less than about 10 g/L and more preferably less than about 5 g/L. Further, in some instances it may be desirable to allow the culture medium to become depleted of the nitrogen sources during culture.

[00174] The effective culture medium can contain other compounds such as inorganic salts, vitamins, trace metals or growth promoters. Such other compounds can also be present in carbon, nitrogen or mineral sources in the effective medium or can be added specifically to the medium.

[00175] The culture medium can also contain a suitable phosphate source. Such phosphate sources include both inorganic and organic phosphate sources. Preferred phosphate sources include, but are not limited to, phosphate salts such as mono or dibasic sodium and potassium phosphates, ammonium phosphate and mixtures thereof. Typically, the concentration of phosphate in the culture medium is greater than about 1.0 g/L, preferably greater than about 2.0 g/L and more preferably greater than about 5.0 g/L. Beyond certain concentrations, however, the addition of phosphate to the culture medium is not advantageous for the growth of the microorganisms. Accordingly, the concentration of phosphate in the culture medium is typically less than about 20 g/L, preferably less than about 15 g/L and more preferably less than about 10 g/L.

[00176] A suitable culture medium can also include a source of magnesium, preferably in the form of a physiologically acceptable salt, such as magnesium sulfate heptahydrate, although other magnesium sources in concentrations that contribute similar amounts of magnesium can be used. Typically, the concentration of magnesium in the culture medium is greater than about 0.5 g/L, preferably greater than about 1.0 g/L, and more preferably greater than about 2.0 g/L. Beyond certain concentrations, however, the addition of magnesium to the culture medium is not advantageous for the growth of the microorganisms. Accordingly, the concentration of magnesium in the culture medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 3 g/L. Further, in some instances it may be desirable to allow the culture medium to become depleted of a magnesium source during culture.

[00177] In some embodiments, the culture medium can also include a biologically acceptable chelating agent, such as the dihydrate of trisodium citrate. In such instance, the concentration of a chelating agent in the culture medium is greater than about 0.2 g/L, preferably greater than about 0.5 g/L, and more preferably greater than about 1 g/L. Beyond certain concentrations, however, the addition of a chelating agent to the culture medium is not advantageous for the growth of the microorganisms. Accordingly, the concentration of a chelating agent in the culture medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 2 g/L.

[00178] The culture medium can also initially include a biologically acceptable acid or base to maintain the desired pH of the culture medium. Biologically acceptable acids include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and mixtures thereof. Biologically acceptable bases include, but are not limited to,

ammonium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof. In some embodiments, the base used is ammonium hydroxide.

[00179] The culture medium can also include a biologically acceptable calcium source, including, but not limited to, calcium chloride. Typically, the concentration of the calcium source, such as calcium chloride, dihydrate, in the culture medium is within the range of from about 5 mg/L to about 2000 mg/L, preferably within the range of from about 20 mg/L to about 1000 mg/L, and more preferably in the range of from about 50 mg/L to about 500 mg/L.

[00180] The culture medium can also include sodium chloride. Typically, the concentration of sodium chloride in the culture medium is within the range of from about 0.1 g/L to about 5 g/L, preferably within the range of from about 1 g/L to about 4 g/L, and more preferably in the range of from about 2 g/L to about 4 g/L.

[00181] In some embodiments, the culture medium can also include trace metals. Such trace metals can be added to the culture medium as a stock solution that, for convenience, can be prepared separately from the rest of the culture medium. Typically, the amount of such a trace metals solution added to the culture medium is greater than about 1 mL/L, preferably greater than about 5 mL/L, and more preferably greater than about 10 mL/L. Beyond certain concentrations, however, the addition of a trace metals to the culture medium is not advantageous for the growth of the microorganisms. Accordingly, the amount of such a trace metals solution added to the culture medium is typically less than about 100 mL/L, preferably less than about 50 mL/L, and more preferably less than about 30 mL/L. It should be noted that, in addition to adding trace metals in a stock solution, the individual components can be added separately, each within ranges corresponding independently to the amounts of the components dictated by the above ranges of the trace metals solution.

[00182] The culture media can include other vitamins, such as pantothenate, biotin, calcium, pantothenate, inositol, pyridoxine-HCl, and thiamine-HCl. Such vitamins can be added to the culture medium as a stock solution that, for convenience, can be prepared separately from the rest of the culture medium. Beyond certain concentrations, however, the addition of vitamins to the culture medium is not advantageous for the growth of the microorganisms.

[00183] The fermentation methods described herein can be performed in conventional culture modes, which include, but are not limited to, batch, fed-batch, cell recycle, continuous and semi-continuous. In some embodiments, the fermentation is carried out in fed-batch

mode. In such a case, some of the components of the medium are depleted during culture, including pantothenate during the production stage of the fermentation. In some embodiments, the culture may be supplemented with relatively high concentrations of such components at the outset, for example, of the production stage, so that growth and/or isoprenoid production is supported for a period of time before additions are required. The preferred ranges of these components are maintained throughout the culture by making additions as levels are depleted by culture. Levels of components in the culture medium can be monitored by, for example, sampling the culture medium periodically and assaying for concentrations. Alternatively, once a standard culture procedure is developed, additions can be made at timed intervals corresponding to known levels at particular times throughout the culture. As will be recognized by those in the art, the rate of consumption of nutrient increases during culture as the cell density of the medium increases. Moreover, to avoid introduction of foreign microorganisms into the culture medium, addition is performed using aseptic addition methods, as are known in the art. In addition, a small amount of anti-foaming agent may be added during the culture.

[00184] The temperature of the culture medium can be any temperature suitable for growth of the genetically modified cells and/or production of isoprenoids. For example, prior to inoculation of the culture medium with an inoculum, the culture medium can be brought to and maintained at a temperature in the range of from about 20°C to about 45°C, preferably to a temperature in the range of from about 25°C to about 40°C, and more preferably in the range of from about 28°C to about 32°C.

[00185] The pH of the culture medium can be controlled by the addition of acid or base to the culture medium. In such cases when ammonia is used to control pH, it also conveniently serves as a nitrogen source in the culture medium. Preferably, the pH is maintained from about 3.0 to about 8.0, more preferably from about 3.5 to about 7.0, and most preferably from about 4.0 to about 6.5.

[00186] In some embodiments, the carbon source concentration, such as the glucose concentration, of the culture medium is monitored during culture. Glucose concentration of the culture medium can be monitored using known techniques, such as, for example, use of the glucose oxidase enzyme test or high pressure liquid chromatography, which can be used to monitor glucose concentration in the supernatant, *e.g.*, a cell-free component of the culture medium. As stated previously, the carbon source concentration should be kept below the level at which cell growth inhibition occurs. Although such concentration may vary from

organism to organism, for glucose as a carbon source, cell growth inhibition occurs at glucose concentrations greater than at about 60 g/L, and can be determined readily by trial.

Accordingly, when glucose is used as a carbon source the glucose is preferably fed to the fermentor and maintained below detection limits. Alternatively, the glucose concentration in the culture medium is maintained in the range of from about 1 g/L to about 100 g/L, more preferably in the range of from about 2 g/L to about 50 g/L, and yet more preferably in the range of from about 5 g/L to about 20 g/L. Although the carbon source concentration can be maintained within desired levels by addition of, for example, a substantially pure glucose solution, it is acceptable, and may be preferred, to maintain the carbon source concentration of the culture medium by addition of aliquots of the original culture medium. The use of aliquots of the original culture medium may be desirable because the concentrations of other nutrients in the medium (*e.g.* the nitrogen and phosphate sources) can be maintained simultaneously. Likewise, the trace metals concentrations can be maintained in the culture medium by addition of aliquots of the trace metals solution.

5.6.12 Recovery of Isoprenoids

[00187] Once the isoprenoid is produced by the host cell, it may be recovered or isolated for subsequent use using any suitable separation and purification methods known in the art. In some embodiments, an organic phase comprising the isoprenoid is separated from the fermentation by centrifugation. In other embodiments, an organic phase comprising the isoprenoid separates from the fermentation spontaneously. In other embodiments, an organic phase comprising the isoprenoid is separated from the fermentation by adding a demulsifier and/or a nucleating agent into the fermentation reaction. Illustrative examples of demulsifiers include flocculants and coagulants. Illustrative examples of nucleating agents include droplets of the isoprenoid itself and organic solvents such as dodecane, isopropyl myristate, and methyl oleate.

[00188] The isoprenoid produced in these cells may be present in the culture supernatant and/or associated with the host cells. In embodiments where the isoprenoid is associated with the host cell, the recovery of the isoprenoid may comprise a method of permeabilizing or lysing the cells. Alternatively or simultaneously, the isoprenoid in the culture medium can be recovered using a recovery process including, but not limited to, chromatography, extraction, solvent extraction, membrane separation, electrodialysis, reverse osmosis, distillation, chemical derivatization and crystallization.

[00189] In some embodiments, the isoprenoid is separated from other products that may be present in the organic phase. In some embodiments, separation is achieved using adsorption, distillation, gas-liquid extraction (stripping), liquid-liquid extraction (solvent extraction), ultrafiltration, and standard chromatographic techniques.

5.7 Polyketides

[00190] In some embodiments, the genetically modified host cell provided herein is capable of producing a polyketide from acetyl-CoA. Polyketides are synthesized by sequential reactions catalyzed by a collection of enzyme activities called polyketide synthases (PKSs), which are large multi-enzyme protein complexes that contain a coordinated group of active sites. Polyketide biosynthesis proceeds stepwise starting from simple 2-, 3-, 4-carbon building blocks such as acetyl-CoA, propionyl CoA, butyryl-CoA and their activated derivatives, malonyl-, methylmalonyl- and ethylmalonyl-CoA, primarily through decarboxylative condensation of malonyl-CoA-derived units via Claisen condensation reactions. The PKS genes are usually organized in one operon in bacteria and in gene clusters in eukaryotes. Three types of polyketide synthases have been characterized: Type I polyketide synthases are large, highly modular proteins subdivided into two classes: 1) iterative PKSs, which reuse domains in a cyclic fashion and 2) modular PKSs, which contain a sequence of separate modules and do not repeat domains. Type II polyketide synthases are aggregates of monofunctional proteins, and Type III polyketide synthases do not use acyl carrier protein domains.

[00191] Unlike fatty acid biosynthesis, in which each successive chain elongation step is followed by a fixed sequence of ketoreduction, dehydration and enoyl, reduction as described below, the individual chain elongation intermediates of polyketide biosynthesis undergo all, some, or no functional group modifications, resulting in a large number of chemically diverse products. Additional degrees of complexity arise from the use of different starter units and chain elongation units as well as the generation of new stereo-isomers.

[00192] The order of complete polyketide-synthesis as directed by a polyketide synthase follows (in the order N-terminus to C-terminus): starting or loading the initial carbon building blocks onto an acyl carrier protein, elongation modules which catalyze the extension of the growing macrolide chain and termination modules that catalyze the release of the synthesized macrolide. Component domains or separate enzyme functionalities active in this biosynthesis include acyl-transferases for the loading of starter, extender and intermediate acyl units; acyl carrier proteins which hold the growing macrolide as a thiol

ester; β -keto-acyl synthases which catalyze chain extension; β -keto reductases responsible for the first reduction to an alcohol functionality; dehydratases which eliminate water to give an unsaturated thiolester; enoyl reductases which catalyze the final reduction to full saturation; and thioesterases which catalyze macrolide release and cyclization.

[00193] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can condense at least one of acetyl-CoA and malonyl-CoA with an acyl carrier protein, *e.g.* an acyl-transferase.

[00194] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can condense a first reactant selected from the group consisting of acetyl-CoA and malonyl-CoA with a second reactant selected from the group consisting of malonyl-CoA or methylmalonyl-CoA to form a polyketide product, *e.g.* a β -keto-acyl synthase.

[00195] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can reduce a β -keto chemical group on a polyketide compound to a β -hydroxy group, *e.g.* a β -keto reductase.

[00196] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can dehydrate an alkane chemical group in a polyketide compound to produce an α - β -unsaturated alkene, *e.g.* a dehydratase.

[00197] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can reduce an α - β -double-bond in a polyketide compound to a saturated alkane, *e.g.* an enoyl-reductase.

[00198] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can hydrolyze a polyketide compound from an acyl carrier protein, *e.g.* a thioesterase.

[00199] In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a KS catalytic region. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising an AT catalytic region. In some embodiments, the polyketide producing cell comprises more than one heterologous nucleotide sequence encoding an enzyme comprising an AT catalytic region. In some

embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a CLF catalytic region. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising an ACP activity. In some embodiments, the polyketide producing cell comprises more than one heterologous nucleotide sequence encoding an enzyme comprising an ACP activity.

[00200] In a particular embodiment, the polyketide producing cell comprises a minimal aromatic PKS system, *e.g.*, heterologous nucleotide sequences encoding an enzyme comprising a KS catalytic region, an enzyme comprising an AT catalytic region, an enzyme comprising a CLF catalytic region, and an enzyme comprising an ACP activity, respectively. In a particular embodiment, the polyketide producing cell comprises a minimal modular PKS system, *e.g.*, heterologous nucleotide sequences encoding an enzyme comprising a KS catalytic region, an enzyme comprising an AT catalytic region, and an enzyme comprising an ACP activity, respectively. In yet another particular embodiment, the polyketide producing cell comprises a modular aromatic PKS system for *de novo* polyketide synthesis, *e.g.*, heterologous nucleotide sequences encoding an enzyme comprising a KS catalytic region, one or more enzymes comprising an AT catalytic region, and one or more enzymes comprising an ACP activity, respectively.

[00201] In some embodiments, the polyketide producing cell comprising a minimal PKS system, *e.g.*, a minimal aromatic PKS system or minimal modular PKS system, further comprises additional catalytic activities which can contribute to production of the end-product polyketide. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a cyclase (CYC) catalytic region, which facilitates the cyclization of the nascent polyketide backbone. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a ketoreductase (KR) catalytic region. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising an aromatase (ARO) catalytic region. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising an enoylreductase (ER) catalytic region. In some embodiments, the polyketide producing cell comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a thioesterase (TE) catalytic region. In some embodiments, the polyketide producing cell further comprises one

or more heterologous nucleotide sequences encoding an enzyme comprising a holo ACP synthase activity, which effects pantetheinylation of the ACP.

[00202] In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences conferring a postsynthesis polyketide modifying activity. In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a glycosylase activity, which effects postsynthesis modifications of polyketides, for example, where polyketides having antibiotic activity are desired. In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a hydroxylase activity. In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences encoding an enzyme comprising an epoxidase activity. In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences encoding an enzyme comprising a methylase activity.

[00203] In some embodiments, the polyketide producing cell further comprises one or more heterologous nucleotide sequences encoding a biosynthetic enzyme including, but not limited to, at least one polyketide synthesis pathway enzyme, and enzymes that can modify an acetyl-CoA compound to form a polyketide product such as a macrolide, an antibiotic, an antifungal, a cytostatic compound, an anticholesterolemic compound, an antiparasitic compound, a coccidiostatic compound, an animal growth promoter or an insecticide. In some embodiments, the HACD compound is a polyene. In some embodiments, the HACD compound is a cyclic lactone. In some embodiments, the HACD compound comprises a 14, 15, or 16-membered lactone ring. In some embodiments, the HACD compound is a polyketide selected from the group consisting of a polyketide macrolide, antibiotic, antifungal, cytostatic, anticholesterolemic, antiparasitic, a coccidiostatic, animal growth promoter and insecticide.

[00204] In some embodiments, the polyketide producing cell comprises heterologous nucleotide sequences, for example sequences encoding PKS enzymes and polyketide modification enzymes, capable of producing a polyketide selected from, but not limited to, the following polyketides: Avermectin (*see, e.g.*, U.S. Pat. No. 5,252,474; U.S. Pat. No. 4,703,009; EP Pub. No. 118,367; MacNeil *et al.*, 1993, "Industrial Microorganisms: Basic and Applied Molecular Genetics"; Baltz, Hegeman, & Skatrud, eds. (ASM), pp. 245-256, "A Comparison of the Genes Encoding the Polyketide Synthases for Avermectin, Erythromycin,

and Nemadectin"; MacNeil *et al.*, 1992, *Gene* 115: 119-125; and Ikeda and Omura, 1997, *Chem. Res.* 97: 2599-2609); Candicidin (FR008) (*see, e.g.*, Hu *et al.*, 1994, *Mol. Microbiol.* 14: 163-172); Carbomycin, Curamycin (*see, e.g.*, Bergh *et al.*, *Biotechnol Appl Biochem.* 1992 Feb;15(1):80-9); Daunorubicin (*see, e.g.*, *J Bacteriol.* 1994 Oct;176(20):6270-80); Epothilone (*see, e.g.*, PCT Pub. No. 99/66028; and PCT Pub. No. 00/031247); Erythromycin (*see, e.g.*, PCT Pub. No. 93/13663; U.S. Pat. No. 6,004,787; U.S. Pat. No. 5,824,513; Donadio *et al.*, 1991, *Science* 252:675-9; and Cortes *et al.*, Nov. 8, 1990, *Nature* 348:176-8); FK-506 (*see, e.g.*, Motamedi *et al.*, 1998; *Eur. J Biochem.* 256: 528-534; and Motamedi *et al.*, 1997, *Eur. J Biochem.* 244: 74-80); FK-520 (*see, e.g.*, PCT Pub. No. 00/020601; and Nielsen *et al.*, 1991, *Biochem.* 30:5789-96); Griseusin (*see, e.g.*, Yu *et al.*, *J Bacteriol.* 1994 May;176(9):2627-34); Lovastatin (*see, e.g.*, U.S. Pat. No. 5,744,350); Frenolycin (*see, e.g.*, Khosla *et al.*, *Bacteriol.* 1993 Apr;175(8):2197-204; and Bibb *et al.*, *Gene* 1994 May 3;142(1):31-9); Granaticin (*see, e.g.*, Sherman *et al.*, *EMBO J.* 1989 Sep;8(9):2717-25; and Bechtold *et al.*, *Mol Gen Genet.* 1995 Sep 20;248(5):610-20); Medermycin (*see, e.g.*, Ichinose *et al.*, *Microbiology* 2003 Jul;149(Pt 7):1633-45); Monensin (*see, e.g.*, Arrowsmith *et al.*, *Mol Gen Genet.* 1992 Aug;234(2):254-64); Nonactin (*see, e.g.*, *FEMS Microbiol Lett.* 2000 Feb 1;183(1):171-5); Nanaomycin (*see, e.g.*, Kitao *et al.*, *J Antibiot* (Tokyo). 1980 Jul;33(7):711-6); Nemadectin (*see, e.g.*, MacNeil *et al.*, 1993, *supra*); Niddamycin (*see, e.g.*, PCT Pub. No. 98/51695; and Kakavas *et al.*, 1997, *J. Bacteriol.* 179: 7515-7522); Oleandomycin (*see e.g.*, Swan *et al.*, 1994, *Mol. Gen. Genet.* 242: 358-362; PCT Pub. No. 00/026349; Olano *et al.*, 1998, *Mol. Gen. Genet.* 259(3): 299-308; and PCT Pat. App. Pub. No. WO 99/05283); Oxytetracycline (*see, e.g.*, Kim *et al.*, *Gene.* 1994 Apr 8;141(1):141-2); Picromycin (*see, e.g.*, PCT Pub. No. 99/61599; PCT Pub. No. 00/00620; Xue *et al.*, 1998, *Chemistry & Biology* 5(11): 661-667; Xue *et al.*, October 1998, *Proc. Natl. Acad. Sci. USA* 95: 12111 12116); Platenolide (*see, e.g.*, EP Pub. No. 791,656; and U.S. Pat. No. 5,945,320); Rapamycin (*see, e.g.*, Schwecke *et al.*, August 1995, *Proc. Natl. Acad. Sci. USA* 92:7839-7843; and Aparicio *et al.*, 1996, *Gene* 169: 9-16); Rifamycin (*see, e.g.*, PCT Pub. No. WO 98/07868; and August *et al.*, Feb. 13, 1998, *Chemistry & Biology*, 5(2): 69-79); Sorangium (*see, e.g.*, U.S. Pat. No. 6,090,601); Soraphen (*see, e.g.*, U.S. Pat. No. 5,716,849; Schupp *et al.*, 1995, *J. Bacteriology* 177: 3673-3679); Spinocyn (*see, e.g.*, PCT Pub. No. 99/46387); Spiramycin (*see, e.g.*, U.S. Pat. No. 5,098,837); Tetracenomycin (*see, e.g.*, Summers *et al.*, *J Bacteriol.* 1992 Mar;174(6):1810-20; and Shen *et al.*, *J Bacteriol.* 1992 Jun;174(11):3818-21); Tetracycline (*see, e.g.*, *J Am Chem Soc.* 2009 Dec 9;131(48):17677-89); Tylosin (*see,*

e.g., U.S. Pat. No. 5,876,991; U.S. Pat. No. 5,672,497; U.S. Pat. No. 5,149,638; EP Pub. No. 791,655; EP Pub. No. 238,323; Kuhstoss *et al.*, 1996, *Gene* 183:231-6; and Merson-Davies and Cundliffe, 1994, *Mol. Microbiol.* 13: 349-355); and 6-methylsalicylic acid (*see, e.g.*, Richardson *et al.*, *Metab Eng.* 1999 Apr;1(2):180-7; and Shao *et al.*, *Biochem Biophys Res Commun.* 2006 Jun 23;345(1):133-9).

5.8 Fatty Acids

[00205] In some embodiments, the genetically modified host cell provided herein is capable of producing a fatty acid from acetyl-CoA. Fatty acids are synthesized by a series of decarboxylative Claisen condensation reactions from acetyl-CoA and malonyl-CoA catalyzed by fatty acid synthases. Similar to polyketide synthases, fatty acid synthases are not a single enzyme but an enzymatic system composed of 272 kDa multifunctional polypeptide in which substrates are handed from one functional domain to the next. Two principal classes of fatty acid synthases have been characterized: Type I fatty acid synthases are single, multifunctional polypeptides common to mammals and fungi (although the structural arrangement of fungal and mammalian synthases differ) and the CMN group of bacteria (corynebacteria, mycobacteria, and nocardia). Type II synthases, found in archaeobacteria and eubacteria, are a series of discrete, monofunctional enzymes that participate in the synthesis of fatty acids. The mechanisms fatty acid elongation and reduction is the same in the two classes of synthases, as the enzyme domains responsible for these catalytic events are largely homologous amongst the two classes.

[00206] Following each round of elongation of the fatty acid chain in the decarboxylative Claisen condensation reactions, the β -keto group is reduced to a fully saturated carbon chain by the sequential action of a ketoreductase, a dehydratase, and an enol reductase. The growing fatty acid chain moves between these active sites attached to an acyl carrier protein and is ultimately released by the action of a thioesterase upon reaching a carbon chain length of 16 (palmitic acid).

[00207] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding a biosynthetic enzyme including, but not limited to, at least one fatty acid synthesis pathway enzyme, and enzymes that can modify an acetyl-CoA compound to form a fatty acid product such as a palmitate, palmitoyl CoA, palmitoleic acid, sapienic acid, oleic acid, linoleic acid, α -linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid. In some embodiments, the HACD compound is a fatty acid selected from the group consisting of

palmitate, palmitoyl CoA, palmitoleic acid, sapienic acid, oleic acid, linoleic acid, α -linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.

[00208] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can covalently link at least one of acetyl-CoA and malonyl-CoA with an acyl carrier protein, *e.g.* an acyl-transferase.

[00209] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can condense acetyl chemical moiety and a malonyl chemical moiety, each bound to an acyl carrier protein (ACP), to form acetoacetyl-ACP, *e.g.* a β -Ketoacyl-ACP synthase.

[00210] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can reduce the double bond in acetoacetyl-ACP with NADPH to form a hydroxyl group in D-3-hydroxybutyryl hydroxylase-ACP, *e.g.* a β -Ketoacyl-ACP reductase.

[00211] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can dehydrate D-3-Hydroxybutyryl hydroxylase-ACP to create a double bond between the beta- and gamma-carbons forming crotonyl-ACP, *e.g.* a β -hydroxyacyl-ACP dehydrase.

[00212] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can reduce crotonyl ACP with NADPH to form butyryl-ACP, *e.g.* an enoyl ACP reductase.

[00213] In some embodiments, the genetically modified microorganism disclosed herein comprises a heterologous nucleotide sequence encoding an enzyme that can hydrolyze a C16 acyl compound from an acyl carrier protein to form palmitate, *e.g.* a thioesterase.

[00214] In some embodiments, the fatty acid producing cell comprises one or more heterologous nucleotide sequences encoding acetyl-CoA synthase and/or malonyl-CoA synthase, to effect increased production of one or more fatty acids as compared to a genetically unmodified parent cell.

[00215] For example, to increase acetyl-CoA production, one or more of the following genes can be expressed in the cell: *pdh*, *panK*, *aceEF* (encoding the E1p dehydrogenase component and the E2p dihydrolipoamide acyltransferase component of the pyruvate and 2-oxoglutarate dehydrogenase complexes), *fabH*, *fabD*, *fabG*, *acpP*, and *fabF*. Illustrative examples of nucleotide sequences encoding such enzymes include, but are not limited to: *pdh*

(BAB34380, AAC73227, AAC73226), *panK* (also known as *coaA*, AAC76952), *aceEF* (AAC73227, AAC73226), *fabH* (AAC74175), *fabD* (AAC74176), *fabG* (AAC74177), *acpP* (AAC74178), *fabF* (AAC74179).

[00216] In some embodiments, increased fatty acid levels can be effected in the cell by attenuating or knocking out genes encoding proteins involved in fatty acid degradation. For example, the expression levels of *fadE*, *gspA*, *idhA*, *pflb*, *adhE*, *pta*, *poxB*, *ackA*, and/or *ackB* can be attenuated or knocked-out in an engineered host cell using techniques known in the art. Illustrative examples of nucleotide sequences encoding such proteins include, but are not limited to: *fadE* (AAC73325), *gspA* (AAC76632), *IdhA* (AAC74462), *pflb* (AAC73989), *adhE* (AAC74323), *pta* (AAC75357), *poxB* (AAC73958), *ackA* (AAC75356), and *ackB* (BAB81430). The resulting host cells will have increased acetyl-CoA production levels when grown in an appropriate environment.

[00217] In some embodiments, the fatty acid producing cell comprises a heterologous nucleotide sequence encoding an enzyme that can convert acetyl-CoA into malonyl-CoA, e.g., the multisubunit AccABCD protein. An illustrative example of a suitable nucleotide sequence encoding AccABCD includes but is not limited to accession number AAC73296, EC 6.4.1.2.

[00218] In some embodiments, the fatty acid producing cell comprises a heterologous nucleotide sequence encoding a lipase. Illustrative examples of suitable nucleotide sequences encoding a lipase include, but are not limited to accession numbers CAA89087 and CAA98876.

[00219] In some embodiments, increased fatty acid levels can be effected in the cell by inhibiting PlsB, which can lead to an increase in the levels of long chain acyl-ACP, which will inhibit early steps in the fatty acid biosynthesis pathway (e.g., *accABCD*, *fabH*, and *fabI*). The expression level of PlsB can be attenuated or knocked-out in an engineered host cell using techniques known in the art. An illustrative example of a suitable nucleotide sequence encoding PlsB includes but is not limited to accession number AAC77011. In particular embodiments, the *plsB* D31 IE mutation can be used to increase the amount of available acyl-CoA in the cell.

[00220] In some embodiments, increased production of monounsaturated fatty acids can be effected in the cell by overexpressing an *sfa* gene, which would result in suppression of *fabA*. An illustrative example of a suitable nucleotide sequence encoding *sfa* includes but is not limited to accession number AAN79592.

[00221] In some embodiments, increased fatty acid levels can be effected in the cell by modulating the expression of an enzyme which controls the chain length of a fatty acid substrate, *e.g.*, a thioesterase. In some embodiments, the fatty acid producing cell has been modified to overexpress a *tes* or *fat* gene. Illustrative examples of suitable *tes* nucleotide sequences include but are not limited to accession numbers: (*tesA*: AAC73596, from *E. coli*, capable of producing C_{18:1} fatty acids) and (*tesB*: AAC73555 from *E. coli*). Illustrative examples of suitable *fat* nucleotide sequences include but are not limited to: (*fatB*: Q41635 and AAA34215, from *Umbellularia californica*, capable of producing C_{12:0} fatty acids), (*fatB2*: Q39513 and AAC49269, from *Cuphea hookeriana*, capable of producing C_{8:0} – C_{10:0} fatty acids), (*fatB3*: AAC49269 and AAC72881, from *Cuphea hookeriana*, capable of producing C_{14:0} – C_{16:0} fatty acids), (*fatB*: Q39473 and AAC49151, from *Cinnamomum camphorum*, capable of producing C_{14:0} fatty acids), (*fatB [M141T]*: CAA85388, from *mArabidopsis thaliana*, capable of producing C_{16:1} fatty acids), (*fatA*: NP 189147 and NP 193041, from *Arabidopsis thaliana*, capable of producing C_{18:1} fatty acids), (*fatA*: CAC39106, from *Bradyrhizobium japonicum*, capable of preferentially producing C_{18:1} fatty acids), (*fatA*: AAC72883, from *Cuphea hookeriana*, capable of producing C_{18:1} fatty acids), and (*fatA1*, AAL79361 from *Helianthus annuus*).

[00222] In some embodiments, increased levels of C₁₀ fatty acids can be effected in the cell by attenuating the expression or activity of thioesterase C₁₈ using techniques known in the art. Illustrative examples of suitable nucleotide sequences encoding thioesterase C₁₈ include, but are not limited to accession numbers AAC73596 and P0ADA1. In other embodiments, increased levels of C₁₀ fatty acids can be effected in the cell by increasing the expression or activity of thioesterase C₁₀ using techniques known in the art. An illustrative example of a suitable nucleotide sequence encoding thioesterase C₁₀ includes, but is not limited to accession number Q39513.

[00223] In some embodiments, increased levels of C₁₄ fatty acids can be effected in the cell by attenuating the expression or activity of endogenous thioesterases that produce non-C₁₄ fatty acids, using techniques known in the art. In other embodiments, increased levels of C₁₄ fatty acids can be effected in the cell by increasing the expression or activity of thioesterases that use the substrate C₁₄-ACP, using techniques known in the art. An illustrative example of a suitable nucleotide sequence encoding such a thioesterase includes, but is not limited to accession number Q39473.

[00224] In some embodiments, increased levels of C₁₂ fatty acids can be effected in the cell by attenuating the expression or activity of endogenous thioesterases that produce non-C₁₂ fatty acids, using techniques known in the art. In other embodiments, increased levels of C₁₂ fatty acids can be effected in the cell by increasing the expression or activity of thioesterases that use the substrate C₁₂-ACP, using techniques known in the art. An illustrative example of a suitable nucleotide sequence encoding such a thioesterase includes, but is not limited to accession number Q41635.

5.9 PK/PTA for the Production of Other Compounds

[00225] In some embodiments, the genetically modified host cell provided herein (*e.g.*, a host cell comprising PK/PTA and a functional disruption of a polypeptide encoding acetyl phosphatase activity, *e.g.*, RHR2, HOR2, or homologues thereof) is engineered for the expression of biosynthetic pathways that initiate with cellular pyruvate to produce, for example, 2,3-butanediol, 2-butanol, 2-butanone, valine, leucine, lactic acid, malate, isoamyl alcohol, and isobutanol, as described in U.S. Patent Application Publication No. 20120156735. The disruption of the enzyme pyruvate decarboxylase (PDC) in recombinant host cells engineered to express a pyruvate-utilizing biosynthetic pathway has been used to increase the availability of pyruvate for product formation via the biosynthetic pathway. While PDC-KO recombinant host cells can be used to produce the products of pyruvate-utilizing biosynthetic pathways, PDC-KO recombinant host cells require exogenous carbon substrate supplementation (*e.g.*, ethanol or acetate) for their growth. In particular, two exogenous carbon substrates are needed: one of which is converted to a desired product, the other fully or partly converted into acetyl-CoA by recombinant host cells requiring such supplementation for growth. However, expression of a heterologous phosphoketolase pathway reduces or eliminates the need for providing these exogenous carbon substrates for their growth compared to PDC-KO cells not heterologously PK/PTA. Thus, the additional functional disruption of RHR2, HOR2, or homologues thereof capable of catalyzing the hydrolysis of acetyl phosphate to acetate, is expected to further improve the ability of PK/PTA to increase the supply of acetyl-CoA available as a substrate for cellular growth in these cells.

5.10 Methods of Making Genetically Modified Cells

[00226] Also provided herein are methods for producing a host cell that is genetically engineered to comprise one or more of the modifications described above, *e.g.*, one or more nucleic heterologous nucleic acids encoding PK, PTA, and/or biosynthetic pathway enzymes,

e.g., for an acetyl-CoA derived compound. Expression of a heterologous enzyme in a host cell can be accomplished by introducing into the host cells a nucleic acid comprising a nucleotide sequence encoding the enzyme under the control of regulatory elements that permit expression in the host cell. In some embodiments, the nucleic acid is an extrachromosomal plasmid. In other embodiments, the nucleic acid is a chromosomal integration vector that can integrate the nucleotide sequence into the chromosome of the host cell.

[00227] Nucleic acids encoding these proteins can be introduced into the host cell by any method known to one of skill in the art without limitation (*see, for example, Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1292-3; Cregg et al. (1985) Mol. Cell. Biol. 5:3376-3385; Goeddel et al. eds, 1990, Methods in Enzymology, vol. 185, Academic Press, Inc. , CA; Krieger, 1990, Gene Transfer and Expression -- A Laboratory Manual, Stockton Press, NY; Sambrook et al. , 1989, Molecular Cloning -- A Laboratory Manual, Cold Spring Harbor Laboratory, NY; and Ausubel et al. , eds. , Current Edition, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY*). Exemplary techniques include, but are not limited to, spheroplasting, electroporation, PEG 1000 mediated transformation, and lithium acetate or lithium chloride mediated transformation.

[00228] The copy number of an enzyme in a host cell may be altered by modifying the transcription of the gene that encodes the enzyme. This can be achieved for example by modifying the copy number of the nucleotide sequence encoding the enzyme (*e.g.*, by using a higher or lower copy number expression vector comprising the nucleotide sequence, or by introducing additional copies of the nucleotide sequence into the genome of the host cell or by deleting or disrupting the nucleotide sequence in the genome of the host cell), by changing the order of coding sequences on a polycistronic mRNA of an operon or breaking up an operon into individual genes each with its own control elements, or by increasing the strength of the promoter or operator to which the nucleotide sequence is operably linked.

Alternatively or in addition, the copy number of an enzyme in a host cell may be altered by modifying the level of translation of an mRNA that encodes the enzyme. This can be achieved for example by modifying the stability of the mRNA, modifying the sequence of the ribosome binding site, modifying the distance or sequence between the ribosome binding site and the start codon of the enzyme coding sequence, modifying the entire intercistronic region located “upstream of” or adjacent to the 5’ side of the start codon of the enzyme coding region, stabilizing the 3’-end of the mRNA transcript using hairpins and specialized

sequences, modifying the codon usage of enzyme, altering expression of rare codon tRNAs used in the biosynthesis of the enzyme, and/or increasing the stability of the enzyme, as, for example, via mutation of its coding sequence.

[00229] The activity of an enzyme in a host cell can be altered in a number of ways, including, but not limited to, expressing a modified form of the enzyme that exhibits increased or decreased solubility in the host cell, expressing an altered form of the enzyme that lacks a domain through which the activity of the enzyme is inhibited, expressing a modified form of the enzyme that has a higher or lower K_{cat} or a lower or higher K_m for the substrate, or expressing an altered form of the enzyme that is more or less affected by feed-back or feed-forward regulation by another molecule in the pathway.

[00230] In some embodiments, a nucleic acid used to genetically modify a host cell comprises one or more selectable markers useful for the selection of transformed host cells and for placing selective pressure on the host cell to maintain the foreign DNA.

[00231] In some embodiments, the selectable marker is an antibiotic resistance marker. Illustrative examples of antibiotic resistance markers include, but are not limited to, the *BLA*, *NAT1*, *PAT*, *AURI-C*, *PDR4*, *SMR1*, *CAT*, mouse dhfr, *HPH*, *DSDA*, *KAN^R*, and *SH BLE* gene products. The *BLA* gene product from *E. coli* confers resistance to beta-lactam antibiotics (e.g., narrow-spectrum cephalosporins, cephamycins, and carbapenems (ertapenem), cefamandole, and cefoperazone) and to all the anti-gram-negative-bacterium penicillins except temocillin; the *NAT1* gene product from *S. noursei* confers resistance to nourseothricin; the *PAT* gene product from *S. viridochromogenes* Tu94 confers resistance to bialaphos; the *AURI-C* gene product from *Saccharomyces cerevisiae* confers resistance to Auerobasidin A (AbA); the *PDR4* gene product confers resistance to cerulenin; the *SMR1* gene product confers resistance to sulfometuron methyl; the *CAT* gene product from Tn9 transposon confers resistance to chloramphenicol; the mouse dhfr gene product confers resistance to methotrexate; the *HPH* gene product of *Klebsiella pneumonia* confers resistance to Hygromycin B; the *DSDA* gene product of *E. coli* allows cells to grow on plates with D-serine as the sole nitrogen source; the *KAN^R* gene of the Tn903 transposon confers resistance to G418; and the *SH BLE* gene product from *Streptoalloteichus hindustanus* confers resistance to Zeocin (bleomycin). In some embodiments, the antibiotic resistance marker is deleted after the genetically modified host cell disclosed herein is isolated.

[00232] In some embodiments, the selectable marker rescues an auxotrophy (e.g., a nutritional auxotrophy) in the genetically modified microorganism. In such embodiments, a

parent microorganism comprises a functional disruption in one or more gene products that function in an amino acid or nucleotide biosynthetic pathway and that when non-functional renders a parent cell incapable of growing in media without supplementation with one or more nutrients. Such gene products include, but are not limited to, the *HIS3*, *LEU2*, *LYS1*, *LYS2*, *MET15*, *TRP1*, *ADE2*, and *URA3* gene products in yeast. The auxotrophic phenotype can then be rescued by transforming the parent cell with an expression vector or chromosomal integration construct encoding a functional copy of the disrupted gene product, and the genetically modified host cell generated can be selected for based on the loss of the auxotrophic phenotype of the parent cell. Utilization of the *URA3*, *TRP1*, and *LYS2* genes as selectable markers has a marked advantage because both positive and negative selections are possible. Positive selection is carried out by auxotrophic complementation of the *URA3*, *TRP1*, and *LYS2* mutations, whereas negative selection is based on specific inhibitors, *i.e.*, 5-fluoro-orotic acid (FOA), 5-fluoroanthranilic acid, and aminoadipic acid (aAA), respectively, that prevent growth of the prototrophic strains but allows growth of the *URA3*, *TRP1*, and *LYS2* mutants, respectively. In other embodiments, the selectable marker rescues other non-lethal deficiencies or phenotypes that can be identified by a known selection method.

[00233] Described herein are specific genes and proteins useful in the methods, compositions and organisms of the disclosure; however it will be recognized that absolute identity to such genes is not necessary. For example, changes in a particular gene or polynucleotide comprising a sequence encoding a polypeptide or enzyme can be performed and screened for activity. Typically such changes comprise conservative mutations and silent mutations. Such modified or mutated polynucleotides and polypeptides can be screened for expression of a functional enzyme using methods known in the art.

[00234] Due to the inherent degeneracy of the genetic code, other polynucleotides which encode substantially the same or functionally equivalent polypeptides can also be used to clone and express the polynucleotides encoding such enzymes.

[00235] As will be understood by those of skill in the art, it can be advantageous to modify a coding sequence to enhance its expression in a particular host. The genetic code is redundant with 64 possible codons, but most organisms typically use a subset of these codons. The codons that are utilized most often in a species are called optimal codons, and those not utilized very often are classified as rare or low-usage codons. Codons can be substituted to reflect the preferred codon usage of the host, in a process sometimes called “codon optimization” or “controlling for species codon bias.”

[00236] Optimized coding sequences containing codons preferred by a particular prokaryotic or eukaryotic host (Murray *et al.*, 1989, *Nucl Acids Res.* 17: 477-508) can be prepared, for example, to increase the rate of translation or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, as compared with transcripts produced from a non-optimized sequence. Translation stop codons can also be modified to reflect host preference. For example, typical stop codons for *S. cerevisiae* and mammals are UAA and UGA, respectively. The typical stop codon for monocotyledonous plants is UGA, whereas insects and *E. coli* commonly use UAA as the stop codon (Dalphin *et al.*, 1996, *Nucl Acids Res.* 24: 216-8).

[00237] Those of skill in the art will recognize that, due to the degenerate nature of the genetic code, a variety of DNA molecules differing in their nucleotide sequences can be used to encode a given enzyme of the disclosure. The native DNA sequence encoding the biosynthetic enzymes described above are referenced herein merely to illustrate an embodiment of the disclosure, and the disclosure includes DNA molecules of any sequence that encode the amino acid sequences of the polypeptides and proteins of the enzymes utilized in the methods of the disclosure. In similar fashion, a polypeptide can typically tolerate one or more amino acid substitutions, deletions, and insertions in its amino acid sequence without loss or significant loss of a desired activity. The disclosure includes such polypeptides with different amino acid sequences than the specific proteins described herein so long as the modified or variant polypeptides have the enzymatic anabolic or catabolic activity of the reference polypeptide. Furthermore, the amino acid sequences encoded by the DNA sequences shown herein merely illustrate embodiments of the disclosure.

[00238] In addition, homologs of enzymes useful for the compositions and methods provided herein are encompassed by the disclosure. In some embodiments, two proteins (or a region of the proteins) are substantially homologous when the amino acid sequences have at least about 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In one embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, typically at least 40%, more typically at least 50%, even more typically at least 60%, and even more typically at least

70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[00239] When “homologous” is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of homology may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art (See, e.g., Pearson W. R., 1994, *Methods in Mol Biol* 25: 365-89).

[00240] The following six groups each contain amino acids that are conservative substitutions for one another: 1) Serine (S), Threonine (T); 2) Aspartic Acid (D), Glutamic Acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Alanine (A), Valine (V), and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

[00241] Sequence homology for polypeptides, which is also referred to as percent sequence identity, is typically measured using sequence analysis software. A typical algorithm used comparing a molecule sequence to a database containing a large number of sequences from different organisms is the computer program BLAST. When searching a database containing sequences from a large number of different organisms, it is typical to compare amino acid sequences.

[00242] Furthermore, any of the genes encoding the foregoing enzymes (or any others mentioned herein (or any of the regulatory elements that control or modulate expression

thereof)) may be optimized by genetic/protein engineering techniques, such as directed evolution or rational mutagenesis, which are known to those of ordinary skill in the art. Such action allows those of ordinary skill in the art to optimize the enzymes for expression and activity in yeast.

[00243] In addition, genes encoding these enzymes can be identified from other fungal and bacterial species and can be expressed for the modulation of this pathway. A variety of organisms could serve as sources for these enzymes, including, but not limited to, *Saccharomyces spp.*, including *S. cerevisiae* and *S. uvarum*, *Kluyveromyces spp.*, including *K. thermotolerans*, *K. lactis*, and *K. marxianus*, *Pichia spp.*, *Hansenula spp.*, including *H. polymorpha*, *Candida spp.*, *Trichosporon spp.*, *Yamadazyma spp.*, including *Y. spp. stipitis*, *Torulaspora pretoriensis*, *Issatchenkia orientalis*, *Schizosaccharomyces spp.*, including *S. pombe*, *Cryptococcus spp.*, *Aspergillus spp.*, *Neurospora spp.*, or *Ustilago spp.* Sources of genes from anaerobic fungi include, but are not limited to, *Piromyces spp.*, *Orpinomyces spp.*, or *Neocallimastix spp.* Sources of prokaryotic enzymes that are useful include, but are not limited to, *Escherichia. coli*, *Zymomonas mobilis*, *Staphylococcus aureus*, *Bacillus spp.*, *Clostridium spp.*, *Corynebacterium spp.*, *Pseudomonas spp.*, *Lactococcus spp.*, *Enterobacter spp.*, and *Salmonella spp.*

[00244] Techniques known to those skilled in the art may be suitable to identify additional homologous genes and homologous enzymes. Generally, analogous genes and/or analogous enzymes can be identified by functional analysis and will have functional similarities. Techniques known to those skilled in the art may be suitable to identify analogous genes and analogous enzymes. For example, to identify homologous or analogous PK, PTA, RHR2 or HOR2 genes, proteins, or enzymes, techniques may include, but are not limited to, cloning a gene by PCR using primers based on a published sequence of a gene/enzyme of interest, or by degenerate PCR using degenerate primers designed to amplify a conserved region among a gene of interest. Further, one skilled in the art can use techniques to identify homologous or analogous genes, proteins, or enzymes with functional homology or similarity. Techniques include examining a cell or cell culture for the catalytic activity of an enzyme through *in vitro* enzyme assays for said activity (e.g. as described herein or in Kiritani, K., *Branched-Chain Amino Acids Methods Enzymology*, 1970), then isolating the enzyme with said activity through purification, determining the protein sequence of the enzyme through techniques such as Edman degradation, design of PCR primers to the likely nucleic acid sequence, amplification of said DNA sequence through PCR, and cloning

of said nucleic acid sequence. To identify homologous or similar genes and/or homologous or similar enzymes, analogous genes and/or analogous enzymes or proteins, techniques also include comparison of data concerning a candidate gene or enzyme with databases such as BRENDA, KEGG, or MetaCYC. The candidate gene or enzyme may be identified within the above mentioned databases in accordance with the teachings herein.

6. EXAMPLES

6.1 Example 1:

Acetate Production in Host Cells Expressing PK and PTA

[00245] This example describes the production of acetate in yeast strains heterologously expressing phosphoketolase and phosphotransacetylase.

6.1.1 Materials and Methods

6.1.1.1 Strain Engineering

6.1.1.1.1 Y967 and Y968

[00246] Y967 and Y968 are wildtype prototrophic *Saccharomyces cerevisiae* CEN.PK2, Y967 is MatA, and Y968 is Matalpha. The starting strain for Y12869, Y12746, and all of their derivatives, was *Saccharomyces cerevisiae* strain Y003 (CEN.PK2, Mat alpha, ura3-52, trp1-289, leu2-3,122, his3⁺1). All DNA-mediated transformation into *S. cerevisiae* was conducted using the standard lithium acetate procedure as described by Gietz RW and Woods RA, *Guide to Yeast Genetics and Molecular and Cell Biology. Part B*. San Diego, CA: Academic Press Inc. pp. 87–96 (2002), and in all cases integration of the constructs were confirmed by PCR amplification of genomic DNA.

6.1.1.1.2 Y12869

[00247] Y12869 was generated through three successive integrations into Y003. First, the gene *ACS2* was deleted by introducing an integration construct (i2235; SEQ ID NO:27) consisting of the native *S. cerevisiae* *LEU2* gene, flanked by sequences consisting of upstream and downstream nucleotide sequences of the *ACS2* locus. Upon introduction of a *S. cerevisiae* host cell, this construct can integrate by homologous recombination into the *ACS2* locus of the genome, functionally disrupting *ACS2* by replacing the *ACS2* coding sequence with its integrating sequence. Transformants were plated onto CSM –leu plates containing 2% EtOH as the sole carbon source, and were confirmed by PCR amplification. The resulting strain was Y4940.

[00248] Next, *ALD6* was deleted and *Dickeya zeae eutE* was introduced in Y4940 with the integration construct (i74804; SEQ ID NO:28) pictured below.

ALD6US	pTDH3	Dz.eutE	tTEF2	TRP1	Z4313	310070	EHQ1d	ALD6DS
--------	-------	---------	-------	------	-------	--------	-------	--------

[00249] This integration construct comprises a selectable marker (TRP1), as well as two copies a yeast-codon-optimized sequence encoding the gene *eutE* from *Dickeya zeae* (NCBI Reference Sequence: YP_003003316.1) under control of the *TDH3* promoter (840 basepairs upstream of the native *S. cerevisiae* *TDH3* coding region), and the *TEF2* terminator (508 basepairs downstream of the native *S. cerevisiae* *TEF2* coding region). These components are flanked by upstream and downstream nucleotide sequences of the *ALD6* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *ALD6* by replacing the *ALD6* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. The construct was transformed into Y4940, and transformants were selected on CSM-TRP plates with 2% glucose and confirmed by PCR amplification. The resulting strain was y12602.

[00250] Next, ACS1 was deleted in Y12602 by introducing an integration construct (i76220; SEQ ID NO:29) consisting of the upstream and downstream nucleotide sequences of *ACS1*, flanking the native *S. cerevisiae* *HIS3* gene under its own promoter and terminator. Transformants were plated onto CSM –his plates containing 2% glucose as the sole carbon source, and were confirmed by PCR amplification. The resulting strain was Y12747.

[00251] Next, Y12747 was transformed with a PCR product amplified from the native *URA3* sequence. This sequence restores the *ura3-52* mutation. See Rose and Winston, *Mol Gen Genet* 193:557-560 (1984). Transformants were plated onto CSM-ura plates containing 2% glucose as the sole carbon source, and were confirmed by PCR amplification. The resulting strain was Y12869.

6.1.1.1.3 Y12745

[00252] Y12745 was generated through three successive integrations into Y4940. First, Y4940 was transformed with the integration construct (i73830; SEQ ID NO:30) pictured below.

8UD9US	pTDH3	Lm.PK	tTDH3	URA3	179d1	41d70	EHQ1d	8UD9DS
--------	-------	-------	-------	------	-------	-------	-------	--------

[00253] This integration construct comprises a selectable marker (URA3); a yeast codon-optimized version of phosphoketolase from *Leuconostoc mesenteroides* (NCBI Reference Sequence YP_819405.1) under the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and *TDH3* terminator (259 bp downstream of the *TDH3* coding sequence);

a yeast codon-optimized version of *Clostridium kluyveri* phosphotransacetylase (NCBI Reference Sequence: YP_001394780.1) under control of the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and the *PGK1* terminator (259 bp downstream of the *PGK1* coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *S. cerevisiae BUD9* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *BUD9* by replacing the *BUD9* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose. The resulting strain was transformed with the construct (i74810; SEQ ID NO:31) shown below.

ALD6US	pTDH3	Lm.PK	tTDH3	TRP1	EHQ13	Lm.PK	pTDH3	ALD6DS
--------	-------	-------	-------	------	-------	-------	-------	--------

[00254] This construct comprising a selectable marker (*TRP1*); two copies of phosphoketolase from *Leuconostoc mesenteroides* under the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and *TDH3* terminator (259 bp downstream of the *TDH3* coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *ALD6* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *ALD6* by replacing the *ALD6* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose and confirmed by PCR amplification.

[00255] Next, ACS1 was deleted in by introducing an integration construct (i76220; SEQ ID NO:29) consisting of the upstream and downstream nucleotide sequences of *ACS1*, flanking the native *S. cerevisiae HIS3* gene under its own promoter and terminator. Transformants were plated onto CSM –his plates containing 2% glucose as the sole carbon source, and were confirmed by PCR amplification.

6.1.1.1.4 Y12746

[00256] Y12746 was generated through three successive integrations into Y4940. First, Y4940 was transformed with the integration construct (i73830; SEQ ID NO:30) pictured below.

BUD9US	pTDH3	Lm.PK	tTDH3	URA3	tPGK1	CK.PTA	pTDH3	BUD9DS
--------	-------	-------	-------	------	-------	--------	-------	--------

[00257] This integration construct comprises a selectable marker (URA3); a yeast codon-optimized version of phosphoketolase from *Leuconostoc mesenteroides* (NCBI Reference Sequence YP_819405.1) under the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and *TDH3* terminator (259 bp downstream of the *TDH3* coding sequence); a yeast codon-optimized version of *Clostridium kluyveri* phosphotransacetylase (NCBI Reference Sequence: YP_001394780.1) under control of the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and the *PGK1* terminator (259 bp downstream of the *PGK1* coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *S. cerevisiae BUD9* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *BUD9* by replacing the *BUD9* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose.

[00258] The resulting strain was transformed with the construct (i74810; SEQ ID NO:31) shown below.

ALD6US	pTDH3	Lm.PK	tTDH3	TRP1	EHQ13	Xd'W7	EHQ1d	ALD6DS
--------	-------	-------	-------	------	-------	-------	-------	--------

[00259] This construct comprising a selectable marker (*TRP1*); two copies of phosphoketolase from *Leuconostoc mesenteroides* under the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and *TDH3* terminator (259 bp downstream of the *TDH3* coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *ALD6* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *ALD6* by replacing the *ALD6* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose and confirmed by PCR amplification.

[00260] Finally, the resulting strain was transformed with the construct (i76221; SEQ ID NO:32) shown below.

ACS1US	pTDH3	Dz.eutE	tTEF2	HIS3	ZJ313	31n9'2G	EHQ1d	ACS1DS
--------	-------	---------	-------	------	-------	---------	-------	--------

[00261] This construct comprises a selectable marker (*HIS3*); as well as two copies a yeast-codon-optimized sequence encoding the gene *eutE* from *Dickeya Zeae* (NCBI Reference Sequence: YP_003003316.1) under control of the *TDH3* promoter (840 basepairs

upstream of the native *S. cerevisiae* *TDH3* coding region) and the *TEF2* terminator (508 basepairs downstream of the native *S. cerevisiae* *TEF2* coding region). These components are flanked by upstream and downstream nucleotide sequences of the *ACSI* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *ACSI* by replacing the *ACSI* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-HIS plates with 2% glucose and confirmed by PCR amplification. The resulting strain was Y12746.

6.1.1.1.5 Y19390

[00262] Y19390 is a direct descendant of Y12869. A *ura*- auxotrophic derivative of Y12869 was transformed with the integration construct MS49253 (SEQ ID NO:36) shown below:

BUD9US	pTDH3	Lm.PK	tTDH3	URA3	tTDH3	Lm.PK	pTDH3	BUD9DS
--------	-------	-------	-------	------	-------	-------	-------	--------

[00263] This integration construct comprises a selectable marker (URA3); two copies of a yeast codon-optimized version of phosphoketolase from *Leuconostoc mesenteroides* (NCBI Reference Sequence YP_819405.1) under the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and *TDH3* terminator (259 bp downstream of the *TDH3* coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *S. cerevisiae* *BUD9* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *BUD9* by replacing the *BUD9* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982.

Transformants were selected on CSM-URA plates with 2% glucose.

6.1.1.1.6 Y19391

[00264] Y19391 is a direct descendant of Y12869. A *ura*- auxotrophic derivative of Y12869 was transformed with the integration construct MS49298 (SEQ ID NO:37) shown below:

BUD9US	pTDH3	Ck.PTA	tPGK1	URA3	tPGK1	Ck.PTA	pTDH3	BUD9DS
--------	-------	--------	-------	------	-------	--------	-------	--------

[00265] This integration construct comprises a selectable marker (URA3); two copies of a yeast codon-optimized version of phosphotransacetylase from *Clostridium kluyveri* (NCBI Reference Sequence: YP_001394780.1) under control of the *TDH3* promoter (870 bp upstream of the *TDH3* coding sequence) and the *PGK1* terminator (259 bp downstream of the

PGK1 coding sequence); flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of the *S. cerevisiae BUD9* locus. Upon introduction into a host cell, this construct integrates by homologous recombination into the host cell genome, functionally disrupting *BUD9* by replacing the *BUD9* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose.

6.1.1.2 Culture conditions

[00266] Inoculum cultures of Y967, Y12869, Y12745, Y12746, Y19390 and Y19391 were grown from single colonies overnight in 5 ml of seed media at 30C and 200rpm (15 g/L ammonium sulfate, 8 g/L potassium phosphate, 6.1 g/L magnesium sulfate, 150 mg/L EDTA, 57.5 mg/L zinc sulfate, 4.8 mg/L cobalt chloride, 3.24 mg/L manganese chloride, 5 mg/L copper sulfate, 29.4 mg/L calcium chloride, 27.8 mg/L iron sulfate, 4.8 mg/L sodium molybdate, 0.6 mg/L biotin, 12 mg/L calcium pantothenate, 12 mg/L nicotinic acid, 30 mg/L inositol, 12 mg/L thiamin hydrochloride, 12 mg/L pyridoxine hydrochloride, 0.24 mg/L para-aminobenzoic acid) with 50 mM succinate pH 5.0, and 20 g/L sucrose. The precultures were then inoculated into a 125 ml flask carrying 25 ml of seed media with 50 mM succinate pH 5.0, and 40 g/L sucrose to an initial OD600 of 0.1, and grown at 30C and 200rpm.

6.1.1.3 Quantitation of acetate, fructose, glucose, and sucrose

[00267] Acetate and sugars (fructose, glucose, sucrose) were quantitated by transferring 1 ml of whole cell broth to a 1.5 ml eppendorf tubes, and spinning at 13,000 RPM for 1 minute using a tabletop centrifuge to clarify the supernatant. The supernatant was then diluted (1:1 v/v) in 8mM sulfuric acid, vortexed, and recentrifuged before transferring to a 1.8ml vial. Samples were analyzed with an Agilent 1200 HPLC, with variable wavelength and refractive index detection, using a BioRad Aminex HPX-87H 300mm x 7.8mm column. The mobile phase was 4mM sulfuric acid, column temperature was 40C, and the flow rate was 0.5 ml/min.

6.1.1.4 Results

[00268] **FIG. 3B** shows that wildtype Cen.PK2, Y967, produces acetate during growth in batch defined sucrose shakeflask cultures. Y12869, comprising a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*) and heterologously expressing acetaldehyde dehydrogenase acylating (Dz.eutE), produces far less acetate than the wildtype control which uses the PDH-bypass, likely due to the deletion of ALD6, the cytosolic acetaldehyde dehydrogenase that converts acetaldehyde to acetate. In the strain Y12746, comprising a deletion of the PDH-

bypass (*acs1Δ acs2 Δ ald6Δ*) and heterologously expressing acetaldehyde dehydrogenase acylating (*Dz.eutE*) as well as phosphoketolase (*Lm.PK*) and phosphotransacetylase (*Ck.PTA*), a large increase in acetate is observed, surpassing the amount produced by wildtype Y967. The results with Y12869 indicate that the baseline level of acetate is extremely low in a strain that is *acs1Δ acs2 Δ ald6Δ* and uses ADA to carry flux to cytosolic acetyl-CoA. In all cases, the rate of sugar consumption is comparable (sugars here are defined as the sum of sucrose, glucose, and fructose in the media), illustrating that the differences in acetate levels are not due to differential consumption of feedstock (**FIG. 3A**). These results suggest that the increase in acetate in Y12746 is attributable to the presence of phosphoketolase and/or phosphotransacetylase. The catalytic activity of both phosphoketolase and phosphotransacetylase produces acetyl phosphate. Therefore, acetate accumulation may arise from spontaneous or catalyzed hydrolysis of acetyl phosphate in Y12746.

[00269] To determine the source of acetate in the strain expressing ADA, PK and PTA (Y12746), we transformed a strain which uses only ADA to provide cytosolic AcCoA (Y12869, comprising a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*) and heterologously expressing acetaldehyde dehydrogenase acylating (*Dz.eutE*)) with either (1) an integration construct encoding two overexpressed copies of PK driven by the strong promoter P_{TDH3} , resulting in Y19390, or (2) an integration construct encoding two overexpressed copies of PTA driven by the strong promoter P_{TDH3} , resulting in Y19391. As shown in **FIG. 3D**, we observed an increase in acetate accumulation in strains that expressed either PK or PTA relative to the parent strain. Sugar consumption is shown in **FIG. 3C** to illustrate that acetate levels are not due to differential sugar consumption. PK converts X5P to Acetyl phosphate and G3P, whereas PTA can interconvert Acetyl CoA + Pi to Acetyl Phosphate + CoA. These observations suggest that acetyl phosphate, whether derived from X5P by PK, or derived from AcCoA by PTA, can be hydrolyzed to acetate as shown in **FIG. 1**.

6.2 Example 2:

Identification of a Major Acetyl Phosphatase in *Saccharomyces cerevisiae*

[00270] This example describes the identification of an enzyme capable of hydrolyzing acetyl phosphate in yeast.

6.2.1 Materials and Methods

6.2.1.1 Cell Culture

[00271] A single colony of a given yeast strain was cultured in 5 mL Yeast Extract Peptone media with 2% dextrose (YPD) as an overnight starter culture. The following day, 50 ml YPD was inoculated with this starter culture to an OD600 of 0.2. The flasks were incubated at 30 °C by shaking at 200 RPM for 24 hours unless otherwise specified.

6.2.1.2 Cell-Free Extract Preparation

[00272] Cell culture was divided into three 15 mL falcon tubes and harvested by centrifugation at 4000 x g for 5 minutes. The supernatant was then discarded and cells were washed by resuspending in 10 mL ice cold buffer W (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol) followed by centrifugation at 4000 x g for 5 minutes. Supernatant was discarded and cells were resuspended in 1 mL lysis buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 1 mM DTT, 1 EDTA free protease inhibitor tablet (Roche) per 10mL). The cells were then transferred to a 2 mL plastic screw cap microfuge tube with O ring cap (Fisher Brand 520-GRD) and cells were lysed using disruption beads (Disruption beads, 0.5Mm, Fisher) and a bead beater for 1 minute at 6 M/S. The tubes were immediately placed in an ice water bath for at least 5 minutes. The tubes were then placed back in the bead beater again for 1 minute at 6 M/S and returned to the ice bath for 5 minutes. Tubes were spun at a minimum of 16000 x g for 20 minutes to pellet cell debris. The supernatant was then transferred to a new cold tube. Protein concentration was measured using the classic Bradford assay for proteins (Bradford MM A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem* 72, 248-254 (1976)).

6.2.1.3 Acetyl phosphatase reaction and quantitation of acetyl phosphate

[00273] Acetyl phosphatase activity assays were carried out at 30 °C in reaction buffer consisting of 100 mM Tris-HCl pH 7.5, 150 mM NaCl, and 1 mM $MgCl^{2+}$. Acetyl phosphate was added to a starting concentration of either 5 mM or 10 mM as indicated. The reaction was initiated by the addition of cell free extract in the amounts indicated. To test for phosphatase inhibition, sodium fluoride was added to select wells at 30 mM concentration. The reactions were carried out in a sealed 96 well plate and total reaction volume of 250 μ l. Acetylphosphate concentration was measured by the method developed by Lipmann and Tuttle (Lipmann F, Tuttle LC, *J. Biol. Chem.* 159, 21-28 (1945)). 50 μ l reaction mixture was added to 50 μ l 2M hydroxylamine pH 6.8, mixed well and incubated at room temperature for at least 10 minutes. 34 μ l 15% trichloroacetic acid was then added and mixed followed by 34

μl 4N HCl and 34 μl 5% FeCl₃ mixing well after each addition. Plates were then centrifuged in a Beckman centrifuge J-E with swinging bucket rotor JS-5.3 for 5 minutes at 3000 rpm to pellet precipitated protein. 150 μl supernatant was then transferred to a fresh 96-well clear flat bottom plate (Greiner Bio-One Cat.-No.: 655161). Plate was read by a Molecular Devices SpectraMax M5 plate reader at a wavelength of 505 nm.

6.2.1.4 Purification of Active Phosphatase Fraction

[00274] A single colony of a given yeast strain was cultured in 5 mL Yeast Extract Peptone media with 2% dextrose (YPD) as an overnight starter culture. The following day, two 2.8L Fermbach flasks with 500 ml YPD were inoculated with this starter culture to an OD₆₀₀ of 0.2. The flasks were incubated at 30 °C by shaking at 160 RPM for 24 hours. The culture was harvested by centrifugation at 4000x g for 5 minutes. The cell pellet was washed with 500mL sterile water and centrifuged at 4000x g for 5 minutes. The cell pellet was then resuspended in 50 mL ice cold lysis buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 1 mM DTT, 1 EDTA free protease inhibitor tablet (Roche) per 10mL). Cell suspension was split into six 15 mL falcon tubes filled with 5 mL disruption beads (Disruption beads, 0.5Mm, Fisher). Tubes were then placed in a bead beater for 45 seconds at 6 M/S. The tubes were immediately placed in an ice water bath for at least 5 minutes. Bead beating was repeated 3 additional times with at least 5 minutes in an ice water bath in between each disruption segment. Tubes were spun for 30 minutes at 16,000 rpm (30,966 x g) in a Beckman centrifuge J-E in a JA-20 rotor chilled to 4 °C to pellet cell debris. Cell lysate was additionally clarified by the selective flocculation method described by Salt *et al.* (Selective flocculation of cellular contaminants from soluble proteins using polyethyleneimine: A study of several organisms and polymer molecular weights. *Enzyme and Microbial Technology* 17, 107-113(1995)) as follows: cell free lysate was adjusted to pH 7.4 by addition of 5mM NaOH stock solution. Then equal volume of PEI/Borax solution (0.5M NaCl 0.25% PEI, 100mM Borax) was added to the cell lysate and mixed well. Mixture was then centrifuged for 30 minutes at 2,500 x g at 4 °C. Protein was then precipitated by slowly adding ammonium sulfate with constant stirring until 80% of saturation concentration was reached. Stirring continued for 10 more minutes, and then precipitated protein was harvested by centrifugation at 15,000 rpm at 4 °C in a Beckman JA-20 rotor for 10 minutes. Supernatant was removed and protein was gently resuspended in Buffer A (20 mM Tris-Cl, pH 7, 10% glycerol). Protein was then added to a 0.5-3mL 3,500 Da molecular weight cut off dialysis cassette (Pierce #66300) and dialyzed overnight at 4 °C

in 1.5L buffer A. Dialyzed sample was centrifuged 16000 x g for 10 minutes to pellet precipitated protein. Protein concentration was measured using the classic Bradford assay for proteins (Bradford MM, A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem* 72, 248-254 (1976)). 20 mg protein was loaded onto a Source 15Q 4.6/100 PE anion exchange column on a GE ÄKTAexplorer FPLC. Protein was eluted with a 0-100% gradient of buffer B (20 mM Tris-Cl pH 7, 1M NaCl, 10% glycerol) over 30 column volumes at a flow rate of 0.5 mL/minute and 1 mL samples were collected. To assay activity of each fraction, 75 μ L each fraction was added to 8 mM ACP in a 250 μ L reaction containing 100mM Tris-Cl pH 7, 150 mM NaCl, 1 mM MgCl₂ and assayed as described above. The active fraction from this separation was again dialyzed against buffer A overnight. The entire sample was then loaded onto the same a Source 15Q 4.6/100 PE anion exchange column and eluted with a gradient of 0-45% buffer B over 30 column volumes at a flow rate of 0.5 mL/minute and 1 mL samples were collected. Samples were assayed for activity as above.

6.2.1.5 Protein Gel Electrophoresis

[00275] Protein fractions were analyzed using a Criterion gel electrophoresis system. 10 μ L of fraction was added to 10 μ L of 2X Laemmli sample buffer (BioRad Cat # 161-0737) with 5% v/v 2-mercaptoethanol and boiled for 10 minutes. Samples were then briefly centrifuged and 15 μ L was loaded on a 26 well 4–15% Criterion™ TGX™ Precast Gel and run in 1X Tris-Glycine-SDS buffer (prepared from BioRad 10x Tris/Glycine/SDS #161-0732) for 50 minutes at 130 volts. The gel was rinsed in 200 mL deionized water three times for 5 minutes each. SimplyBlue™ SafeStain (Life Technologies Cat # LC6060) was then added to the gel to completely cover the gel and then incubated at room temperature for 1 hour with gentle rocking. The SafeStain was then discarded and the gel was washed with 200 mL deionized water for 1 hour with rocking.

6.2.1.6 Identification of Proteins in Active Phosphatase Fraction

[00276] Proteolytic digestion and separation of peptides

[00277] 100 μ g of total protein was subjected to proteolysis by trypsin for subsequent identification by LC-MS/MS. 100 μ g total protein was reduced with Tris-carboxyethylphosphine (4 mM) for 30 minutes at 37 °C, then alkylated with Iodoacetamide (15 mM) for 30 minutes at RT in the dark. 5 μ g Trypsin was added to the digest mixture and the entire digestion was allowed to go for 12 hours at 37 °C. The reaction was quenched with 0.1% formic acid and injected onto an Ascentis Peptide express column (5cmx2.1mm ID, 2.1

um particle size), and separated over a 90 minute gradient from low acetonitrile to high acetonitrile, with 0.1% formic acid as a modifier. The LC pumps were two Shimadzu LC20AD's operated by a Shimadzu CBM20A LC Controller.

[00278] Mass Spectrometry Parameters:

[00279] A QTRAP 4000 hybrid triple-quadrupole linear ion trap mass spectrometer was used to identify peptides being eluted from the column. IDA parameters were as follows: Select ions from 350 to 1300 da; ER Scan used for charge state determination; 1+ ions rejected, unknowns allowed; Rolling collision energy: yes (AB SCIEX standard for qtrap 4000); Max fill time for each MS/MS: 950 ms.

[00280] Peptide identification by Mascot

[00281] Mascot, by Matrix Science was used to identify peptides from a CENPK2 sequence database with the following parameters. Fixed modifications: Carbamidomethyl. Variable modifications: deamidation (NQ), oxidation (MW). Precursor mass tolerance: 0.5 da. Product mass tolerance: 1.0 da. Missed cleavages allowed: 1.

6.2.1.7 Strain Engineering

[00282] A version of Y968 lacking a functional *URA3* gene was transformed with either ms59858 to knock out *RHR2* or ms59971 to knock out *HOR2*. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose and confirmed by PCR amplification. The *URA3* marker in this construct is flanked by direct repeats, facilitating its recycling. To recycle the *URA3* marker, cells were grown in YPD overnight, then plated on 5'FOA. The loopout of *URA3* was confirmed by PCR amplification and inability to grow on CSM-URA plates. The ura- version of Y968.ms59858 was then transformed with ms59971 to generate a double *RHR2* and *HOR2* knockout strain Y968.ms59858.ms59971

6.2.2 Results

6.2.2.1 Hydrolysis of acetyl phosphate is enzyme-catalyzed and inhibited by heat and a broad spectrum phosphatase inhibitor


[00283] As shown in **FIG 4**, addition of cell free extract from wild type *S. cerevisiae* strain Y967 catalyzes the hydrolysis of acetyl phosphate, and the rate of hydrolysis is dependent on the amount of cell free extract added. Increasing the amount of cell free extract increases the rate of hydrolysis. When the cell free extract is boiled, the addition of increasing amounts of cell free extract no longer has an effect on the hydrolysis rate of acetyl phosphate, indicating that the responsible component has been inactivated by heat. Similarly, the addition of 30 mM sodium fluoride, a broad spectrum phosphatase inhibitor, renders the

cell free extract ineffective at hydrolyzing acetyl phosphate. These results suggest that a phosphatase is likely responsible for the catalysis of acetyl phosphate hydrolysis.

6.2.2.2 Protein fractionation isolates a single enriched active fraction

[00284] Anion exchange chromatography was used to separate soluble protein in the cell free extracts. **FIG. 5A** shows that nearly all of the phosphatase activity was concentrated in one fraction, and the remaining activity in adjacent fractions. This indicates that the enzyme responsible for this activity in the cell free extract is either a single protein or proteins with similar ionic interactions which co-elute when separated by anion exchange chromatography.

[00285] The active fraction #10 from FPLC anion exchange purification was purified a second time using a more shallow gradient 0-45% buffer B. The most active fraction from this purification, # 14, shown in **FIG. 6A**, was analyzed by mass spectrometry to determine the identity of the proteins in the fraction. Of the proteins identified in the active fraction (**FIG. 6B**), Rhr2 and its homolog Hor2, which cannot be distinguished by mass spectrometry due to significant sequence similarity, were the only proteins on the list identified as phosphatases by the SGD database. Rhr2 is a glycerol-1-phosphatase that is expressed constitutively at high levels. Hor2 catalyzes the identical reaction but is expressed only at low levels under normal conditions and is induced by osmotic stress (Norbeck *et. al.*, Purification and Characterization of Two Isoenzymes of DL-Glycerol-3-phosphatase from *Saccharomyces cerevisiae*, *J. Biol. Chem.*, 271, 13875-13881 (1996)). Acetyl phosphate is not a metabolite that is native to yeast, therefore it is expected that the hydrolysis is caused by a promiscuous reaction of an enzyme that targets a similar substrate. Rhr2/Hor2 were top candidates for this reaction since their native substrate, glycerol-1-phosphate, is also a low molecular weight phosphorylated compound similar to acetyl phosphate, as shown below.



6.2.2.3 Deletion of *RHR2* and/or *HOR2* reduces phosphatase activity

[00286] In order to determine whether Rhr2 and/or Hor2 were responsible for the phosphatase activity observed in *S. cerevisiae*, new strains were created lacking either *RHR2*

or *HOR2* and one strain lacking both *RHR2* and *HOR2*. These strains were cultured as described previously, and cell free extract was prepared and tested for acetyl phosphatase activity. As shown in **FIG. 7**, deletion of *RHR2* dramatically reduces phosphatase activity, while deletion of *HOR2* has no effect on the rate of hydrolysis of acetyl phosphate. Deletion of *HOR2* does however reduce hydrolysis of acetyl phosphate in a strain that already has *RHR2* deleted. This is consistent with published work that indicates that expression of *Hor2* is upregulated following deletion of *RHR2* (DeLuna *et. al.*, Need-Based Up-Regulation of Protein Levels in Response to Deletion of Their Duplicate Genes, *PLOS Biol.*, 8, e10000347 (2010)). Elimination of both of these phosphatases results in near background levels of acetyl phosphate hydrolysis as shown in **FIG. 7**. These results confirm that glycerol-1-phosphatases *Rhr2* and *Hor2* are responsible for the majority of the acetyl phosphatase activity in *S. cerevisiae*.

6.3 Example 3:

Deletion of the acetyl phosphate phosphatase reduces acetate secretion and improves production of a compound derived from Acetyl-CoA

6.3.1 Materials and Methods

6.3.1.1 Strain construction

[00287] Versions of Y968, Y12869, and Y12746, lacking a functional *URA3* gene, were transformed with either ms63907 or ms63909, and with ms64472, to convert them to farnesene producers.

[00288] The ms63907 integration construct (i84022; SEQ ID NO:33) is shown below.

HO US	GAL4	DOWNSTREAM	UPSTREAM	pGAL10	ERG10	URA3	ERG13	DOWNSTREAM	pGAL1	Sp.HMGr	HO DS
-------	------	------------	----------	--------	-------	------	-------	------------	-------	---------	-------

This construct comprises nucleotide sequences that encode a selectable marker (*URA3*); a copy of the native yeast *GAL4* transcription factor under its own promoter; two native yeast enzymes of the mevalonate pathway (*ERG10* which encodes Acetoacetyl-CoA thiolase, and *ERG13*, which encodes HMG-CoA synthase), as well as two copies of a yeast codon-optimized version of *Silicibacter pomeroyi* HMG-CoA reductase, all under galactose-inducible promoters (promoters of the *S. cerevisiae* genes *GAL1* and *GAL10*, flanked by homologous sequences consisting of upstream and downstream nucleotide sequences of the *S. cerevisiae* *HO* endonuclease locus. Upon introduction into a host cell, the ms63907 construct integrates by homologous integration into the host cell genome, functionally disrupting *HO* by replacing the *HO* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982.

Transformants were selected on CSM-URA plates with 2% glucose and confirmed by PCR amplification. The URA3 marker in this construct is flanked by direct repeats, facilitating its recycling. To recycle the URA3 marker, cells were grown in YPD overnight, then plated on 5'FOA. The loopout of URA3 was confirmed by PCR amplification and inability to grow on CSM-URA plates. The ms63909 integration construct (i84026; SEQ ID NO:34) is identical to ms63907, with one exception: the sequences encoding *S. pomeroi* HMG-CoA reductase are replaced by *tHMG*, the truncated *HMG1* coding sequence which encodes the native *S. cerevisiae* HMG-CoA reductase.

[00289] The ms64472 integration construct (i85207; SEQ ID NO:35) is shown below.

GAL80 US	pGAL7	ID11	SFV	TYD	pGAL10	ERG20	URA3	SDS	TYD	ERG8	TYD	pGAL1	ERG12	GAL80 DS
-------------	-------	------	-----	-----	--------	-------	------	-----	-----	------	-----	-------	-------	-------------

This construct comprises nucleotide sequences that encode a selectable marker (*URA3*); five native yeast enzymes of the ergosterol pathway (*ERG12* which encodes mevalonate kinase, *ERG8* which encodes phosphomevalonate kinase, *ERG19* which encodes mevalonate pyrophosphate decarboxylase, *ID11* which encodes dimethylallyl diphosphate isomerase, and *ERG20* which encodes farnesyl pyrophosphate synthetase), as well as an evolved, yeast codon-optimized version of *Artemisia annua* farnesene synthase, all under galactose-inducible promoters (Promoters of the *S. cerevisiae* genes *GAL1*, *GAL10*, and *GAL7*). These sequences are flanked by homologous sequences consisting of the upstream and downstream nucleotide sequences of *GAL80*. Upon introduction into a host cell, the ms64472 construct integrates by homologous integration into the host cell genome, functionally disrupting *GAL80* by replacing the *GAL80* coding sequence with its integrating sequence. The construct was assembled using the methods described in U.S. Patent No. 8,221,982. Transformants were selected on CSM-URA plates with 2% glucose and confirmed by PCR amplification. The URA3 marker in this construct is flanked by direct repeats, facilitating its recycling. To recycle the URA3 marker, cells were grown in YPD overnight, then plated on 5'FOA. The loopout of URA3 was confirmed by PCR amplification and inability to grow on CSM-URA plates.

[00290] Next, ura- versions of Y968.ms63907.ms64472, Y12869.ms63907.ms64472, and Y12747.ms63907.ms64472, were transformed with ms59858 to knock out the RHR2 ORF. This integration construct consists of the upstream and downstream nucleotide sequences of *RHR2*, flanking the native *S. cerevisiae* *URA3* gene under its own promoter and terminator. Transformants were plated onto CSM –his plates containing 2% glucose as the sole carbon source, and were confirmed by PCR amplification.

6.3.1.2 Culture conditions

[00291] Single colonies were inoculated in wells of a 96-well plate in 360 µl of seed media (described in Example 1), and grown at 34°C for three days by shaking at 1000 rpm. Then, 14.4 µl of culture was subcultured into 360 µl of seed media with 50 mM succinate pH 5.0 and 40 g/L galactose, and grown at 34°C for two days by shaking at 1000 rpm.

6.3.1.3 Quantitation of acetate and glycerol

[00292] Acetate and glycerol were quantitated by transferring 1 ml of whole cell broth to a 1.5 ml eppendorf tubes, and spinning at 13,000 RPM for 1 minute using a tabletop centrifuge to clarify the supernatant. The supernatant was then diluted (1:1 v/v) in 8mM sulfuric acid, vortexed, and recentrifuged before transferring to a 1.8ml vial. Samples were analyzed with an Agilent 1200 HPLC, with variable wavelength and refractive index detection, using a BioRad Aminex HPX-87H 300mm x 7.8mm column. The mobile phase was 4mM sulfuric acid, column temperature was 40C, and the flow rate was 0.5 ml/min.

6.3.1.4 Quantitation of farnesene

[00293] At the end of two days incubation at 34°C, 98 µl of whole cell broth was mixed with 2 µl of Nile Red solution (100 µg/ml in DMSO) in a flat-bottom 96-well assay plate (Costar 3916), and mixed for 30 seconds on a 96-well plate shaker. The plates were then read on a Beckman M5 plate reader with excitation at 500nm and emission at 550nm.

6.3.1.5 Quantitation of optical density

[00294] In a 96-well assay plate, 8 µl of culture was mixed with 92 µl of diluent (20% PEG 200, 20% Ethanol, 2% Triton X-114) and incubated for 30 minutes at room temperature. The assay plate was vortexed before measuring OD₆₀₀ on a Beckman M5 plate reader.

6.3.2 Results

[00295] **FIG. 8A** shows that strain Y12746.ms63909.ms64472, comprising a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), heterologously expressing acetaldehyde dehydrogenase acetylating (Dz.eutE) as well as phosphoketolase (Lm.PK) and phosphotransacetylase (Ck.PTA) and overexpressing genes in the farnesene production pathway, secretes more acetate than a version of Y12746.ms63909.ms64472 in which the *RHR2* gene has been deleted. As shown in **FIG. 8B**, deletion of *RHR2* does not impact glycerol production, as glycerol levels of Y12746.ms63909.ms64472 *rhr2*^Δ are largely unchanged compared to Y12746.ms63909.ms64472. As shown in **FIG. 8C**, the substantially reduced levels of acetate in Y12746.ms63909.ms64472 *rhr2*^Δ are not due to reduced cell growth, as cell densities are similar for both *RHR2*⁺ and *rhr2*^Δ populations. These results

demonstrate that Rhr2, which was responsible for the acetyl phosphate phosphatase activity in cell free extract, is also the primary cause behind the hydrolysis of acetyl phosphate to acetate *in vivo*.

[00296] To determine whether the reduction of acetate observed upon deletion of RHR2 occurs independent of farnesene production, acetate production was measured in versions of strain 12746 with an intact or deleted *RHR2* gene, but not expressing genes in the farnesene production pathway. **FIG. 8D** shows that strain Y12746, comprising a deletion of the PDH-bypass (*acs1Δ acs2 Δ ald6Δ*), heterologously expressing acetaldehyde dehydrogenase acetylating (Dz.eutE) as well as phosphoketolase (Lm.PK) and phosphotransacetylase (Ck.PTA), secretes more acetate than a version of Y12746 in which the RHR2 gene has been deleted. As shown in **FIG. 8E**, the substantially reduced levels of acetate in Y12746.ms63909.ms64472 *rhr2*⁻ are not due to reduced cell growth, as cell densities are similar for both RHR2⁺ and *rhr2*⁻ populations. These data illustrate that the reduction in acetate occurs regardless of the presence of an overexpressed farnesene production pathway.

[00297] **FIG. 9** shows that the deletion of *rhr2* improves farnesene production in Y12746.ms63907.ms64472 by 2.1-fold, and in Y12745.ms63907.ms64472 by 1.4-fold (In each strain background, the *RHR2*⁺ parent is normalized to 1). Moreover, deletion of *rhr2* improves the final optical density of Y12746.ms63907.ms64472 at carbon exhaustion. Both Y12745.ms63907.ms64472 and Y12746.ms63907.ms64472 use phosphoketolase and phosphotransacetylase, and thus acetyl phosphate as a pathway intermediate, to produce cytosolic acetyl-CoA, which is used for synthesis of farnesene. Strains Y968.ms63907.ms64472 and Y12869.ms63907.ms64472 do not express phosphoketolase or phosphotransacetylase, and do not use acetyl phosphate as a pathway intermediate. Deletion of *rhr2* in these strain backgrounds has no effect on farnesene production or optical density in either strain background. This indicates that the benefit of knocking out *rhr2* specifically applies to strains which use acetyl phosphate as an intermediate metabolite, *e.g.*, strains comprising heterologous PK and/or PTA.

[00298] All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in

the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

[00299] Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises”, is not intended to exclude other additives, components, integers or steps.

[00300] The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

WHAT IS CLAIMED:

1. A genetically modified yeast host cell comprising:
 - (a) a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9);
 - (b) a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8);
 and
 - (c) a functional disruption of an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate, wherein conversion from acetyl phosphate to acetate is functionally disrupted.

2. The genetically modified yeast host cell of claim 1, wherein the glycerol-1-phosphatase is selected from GPP1/RHR2, GPP2/HOR2, and homologues and variants thereof.

3. The genetically modified yeast host cell of claim 2, wherein:
 - (a) GPP1/RHR2, or a homologue or variant thereof, is functionally disrupted;
 - (b) GPP2/HOR2, or a homologue or variant thereof, is functionally disrupted; or
 - (c) both GPP1/RHR2 and GPP2/HOR2, or both a homologue or variant of GPP1/RHR2 and a homologue or variant of GPP2/HOR2, are functionally disrupted.

4. The genetically modified yeast host cell of any one of claims 1 to 3, wherein the genetically modified host cell further comprises a heterologous nucleic acid encoding an acylating acetaldehyde dehydrogenase (ADA; EC 1.2.1.10).

5. The genetically modified yeast host cell of any one of claims 1 to 4, wherein the genetically modified host cell is capable of producing an isoprenoid.

6. The genetically modified yeast host cell of claim 5, wherein the genetically modified host cell comprises one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate.

7. The genetically modified yeast host cell of claim 6, wherein:
 - (a) the one or more enzymes of the MEV pathway comprise an NADH-using HMG-CoA reductase;
 - (b) the one or more enzymes of the MEV pathway comprise an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA;
 - (c) the one or more enzymes of the MEV pathway comprise an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA;
 - (d) the one or more enzymes of the MEV pathway comprise an enzyme that converts HMG-CoA to mevalonate;
 - (e) the one or more enzymes of the MEV pathway comprise an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate;
 - (f) the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate;
 - (g) the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate;
 - (h) the one or more enzymes of the MEV pathway are selected from HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase and mevalonate pyrophosphate decarboxylase;
 - (i) the host cell comprises a plurality of heterologous nucleic acids encoding all of the enzymes of the MEV pathway;
 - (j) the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of a single transcriptional regulator;
 - (k) the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of multiple heterologous transcriptional regulators;
 - (l) the host cell further comprises a heterologous nucleic acid encoding an enzyme that can convert isopentenyl pyrophosphate (IPP) into dimethylallyl pyrophosphate (DMAPP);
 - (m) the host cell further comprises a heterologous nucleic acid encoding an enzyme that can condense IPP and/or DMAPP molecules to form a polyprenyl compound; or
 - (n) the host cell further comprises a heterologous nucleic acid encoding an enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound.

8. The genetically modified yeast host cell of claim 7,
wherein the enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound is selected from the group consisting of carene synthase, geraniol synthase, linalool synthase, limonene synthase, myrcene synthase, ocimene synthase, α -pinene synthase, β -pinene synthase, γ -terpinene synthase, terpinolene synthase, amorphadiene synthase, α -farnesene synthase, β -farnesene synthase, farnesol synthase, nerolidol synthase, patchouliol synthase, nootkatone synthase, and abietadiene synthase, or

wherein

- (a) the isoprenoid is selected from the group consisting of a hemiterpene, monoterpene, diterpene, triterpene, tetraterpene, sesquiterpene, and polyterpene;
- (b) the isoprenoid is a C5-C20 isoprenoid; or
- (c) the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpinolene, and valencene.

9. The genetically modified yeast host cell of any one of claims 1 to 8, wherein the genetically modified yeast host cell is *Saccharomyces cerevisiae*.

10. The genetically modified yeast host cell of any one of claims 1 to 9, wherein the genetically modified host cell produces an increased amount of an isoprenoid compared to a yeast cell not comprising a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate.

11. A method for producing an isoprenoid comprising:

- (a) culturing a population of the genetically modified yeast host cells of any one of claims 4 to 9 in a medium with a carbon source under conditions suitable for making said isoprenoid compound; and
- (b) recovering said isoprenoid compound from the medium.

12. A method for increasing the production of acetyl-CoA or an isoprenoid in a yeast host cell, the method comprising:

(a) expressing in the yeast host cell a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9) and a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC2.3.1.8); and

(b) functionally disrupting an endogenous glycerol-1-phosphatase enzyme EC 3.1.3.21) that converts acetyl phosphate to acetate, wherein conversion from acetyl phosphate to acetate is functionally disrupted.

13. The method of claim 12, wherein the glycerol-1-phosphatase is selected from GPP1/RHR2, GPP2/HOR2, and homologues and variants thereof.

14. The method of claim 13, wherein:

- (a) GPP1/RHR2, or a homologue or variant thereof, is functionally disrupted;
- (b) GPP2/HOR2, or a homologue or variant thereof, is functionally disrupted; or
- (c) both GPP1/RHR2 and GPP2/HOR2, or both a homologue or variant of GPP1/RHR2 and a homologue or variant of GPP2/HOR2, are functionally disrupted.

15. The method of any one of claims 12 to 14, wherein the yeast host cell is *Saccharomyces cerevisiae*.

16. The method of any one of claims 12 to 15, wherein the yeast host cell produces an increased amount of acetyl-CoA or an acetyl-CoA derived compound compared to a yeast cell not comprising a functional disruption of an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate.

Figure 1




Figure 2





Figure 3A & 3B



	Y967	Y12069	Y12746
ACS1, ACS2, ADG6 genes	+	-	-
Heterologous ADA	-	+	+
Heterologous PK	-	-	+
Heterologous PTA	-	-	+

Figure 3C & 3D



	Y12869	Y19390	Y19391
ACS1, ACS2, ALD6 status	-	-	-
Heterologous ADA	+	+	+
Heterologous PK	-	+	-
Heterologous PTA	-	-	+






FIG. 4

6/11

A**B****FIG. 5**

7/11




FIG. 6

8/11




FIG. 7

9/11




FIG. 8A




FIG. 8B




FIG. 8C

10/11




FIG. 8D




FIG. 8E




FIG. 9

2014_03_12_107345_00466_ST25
SEQUENCE LISTING

<110> HAWKINS, Kristy Michelle
MEADOWS, Adam Leon
TSONG, Annie Ening
MAHATDEJKUL-MEADOWS, Tina Tipawan
PICKENS, Lauren Barbara
TAI, Anna

<120> USE OF PHOSPHOKETOLASE AND PHOSPHOTRANSACETYLASE FOR PRODUCTION
OF ACETYL-COENZYME A DERIVED COMPOUNDS

<130> 107345.00466

<150> US 61/800,356
<151> 2013-03-15

<160> 37

<170> PatentIn version 3.5

<210> 1
<211> 2749
<212> DNA
<213> Leuconostoc mesenteroides

<220>
<221> misc_feature
<222> (1)..(2749)
<223> Leuconostoc mesenteroides Phosphoketolase (PK) gene sequence

<400> 1
gttacggaag aagtcgtggt ttacggtggt tatgattcctt gcaaaaaata aggagtactt 60
aatctcatgg cagatttcga ttcaaaagag tacttggaac ttgttgataa gtggtggcgc 120
gcaactaact atttgtcagc tgggatgatc tttttgaaga gcaaccatt gttctcagtt 180
actaatacac ctatcaaggc tgaagatgta aaagttaagc caatcggaca ctgggggtact 240
atctcaggtc agacattcct gtatgcacat gctaaccgtt tgatcaacaa gtatggtttg 300
aacatgtttt acgttggtgg tcctgggtcac ggtggccaag ttatggttac taacgcttac 360
ttagacggcg catatactga agattatcct gaaattactc aagatatcga aggtatgagc 420
cacttggtca agcgtttctc attccctggc ggtattggat cacacatgac agctcaaaca 480
cctggttcat tacacgaagg tggatgaattg ggctattcat tgagccacgc ttttggtgcc 540
gttttggaac atcctgacca agttgctttc gcagttgttg gtgatggtga agctgaaaca 600
ggctcctcaa tggcttcatg gcactcaatt aagtttttga atgctaagaa tgatggtgcc 660
gttttgccctg tcttggaattt gaacggattc aagatttcaa acccaactat cttctcacgt 720
atgagtgatg aagaaatcac aaagttcctt gaagggttgg gttattcacc tcgcttcac 780
gaaaacgatg atattcatga ctacgcaaca taccaccaac ttgcagcaaa ctttttgat 840
caagctattg aagatattca agctattcaa aatgatgcac gtgaaaatgg taagtatcaa 900
gatggtgaaa tccctgcatg gccagtaatt attgctcgct tgccaaaggg ctgggggtgga 960
ccaacgcacg atgcaagtaa caatcctatt gaaaactcat tccgtgcgca ccaagtgcc 1020
ttgcctcttg aacaacacga tcttgcaaca ttgcctgaat tcgaagactg gatgaactca 1080

2014_03_12_107345_00466_ST25

tacaagcctg	aagaattatt	caatgctgat	ggttctttga	aggatgaatt	gaaagctatc	1140
gctcctaagg	gtgacaagcg	tatgtcagct	aaccctatta	caaatggtgg	tgctgatcgt	1200
tcagacttga	agttgcctaa	ctggagagaa	ttcgctaacg	atatcaatga	tgatacacgt	1260
ggtaaggaat	tcgctgatag	caagcgcaat	atggacatgg	caacattgtc	aaactacttg	1320
ggtgctgttt	cacaattgaa	cccaactcgt	ttccgcttct	tcggtcctga	tgaaacaatg	1380
tcaaaccggt	tgtggggatt	gttcaatggt	acaccacgtc	aatggatgga	agaaatcaag	1440
gaaccacaag	atcaattggt	gagccctacg	ggtcgcatta	ttgattcaca	attgtctgaa	1500
catcaagctg	aaggttggct	tgaaggatat	actttgactg	gtcgtgttgg	aatcttcgca	1560
tcatacgagt	cattcttgcg	tgttgtcgat	acaatggtta	cgcaacactt	caagtggttg	1620
cgtcacgctt	cagaacaagc	atggcgtaat	gactatccat	cattgaactt	gattgcaact	1680
tcaactgctt	tccaacaaga	tcacaatgga	tatactcacc	aagatccagg	tatgttgact	1740
cacttggtcg	aaaagaagtc	taactttatt	cgtgaatatt	tgccagctga	tggttaactca	1800
ttgttggtcg	ttcaagaacg	tgctttctca	gaacgtcata	aggttaactt	gttgattgct	1860
tctaagcaac	cacgtcaaca	atggtttaca	gttgaagaag	ctgaagtatt	ggctaacgaa	1920
ggtttgaaga	tcattgattg	ggcttctact	gcaccttcta	gtgatgttga	tattacattc	1980
gcatctgctg	gtactgaacc	aacaattgaa	actttggctg	ctttgtgggt	gattaaccaa	2040
gcattcccag	atgttaagtt	ccgttatggt	aacgttggtg	aattactacg	tttgcaaaag	2100
aagtcagaac	ctaacatgaa	tgatgaacgt	gaattatcag	ccgaagaatt	caacaagtat	2160
ttccaagctg	atacaccagt	tatcttcggt	ttccatgctt	atgaaaactt	gattgaatca	2220
ttcttcttcg	aacgtaagtt	cacgggtgat	gtatacgttc	atggatatcg	tgaagatggt	2280
gacatcacia	cgacatatga	tatgcgtgta	tattcacact	tgatcgctt	ccatcaagct	2340
aaggaagctg	ctgaaatctt	gtctgcaa	ggtaagattg	atcaagctgc	tgctgataca	2400
ttcatcgcta	agatggatga	tactttggca	aagcatttcc	aagttactcg	taacgaaggt	2460
cgtgatatcg	aagaattcac	tgactggaca	tggtcaccac	ttaagtaatt	taaaattatt	2520
ttatcaaaaac	caactattat	ttttaatagt	tggttttttt	atggctaaat	tgactacata	2580
ctaaacgaaa	ccatgtaaaa	gtgccacata	gttttactta	ataagttcct	tttatttttt	2640
gatttgcaat	gcaaaattgt	aagcgtaata	tgaataataa	aaaccccaa	ttagttagct	2700
aattgggggt	tttgtaa	accatatcag	ccgctcatag	tcttagacg		2749

<210> 2
 <211> 813
 <212> PRT
 <213> Leuconostoc mesenteroides

<220>
 <221> misc_feature
 <222> (1)..(813)
 <223> Leuconostoc mesenteroides Phosphoketolase (PK) protein sequence

<400> 2

Met Ala Asp Phe Asp Ser Lys Glu Tyr Leu Glu Leu Val Asp Lys Trp
1 5 10 15

Trp Arg Ala Thr Asn Tyr Leu Ser Ala Gly Met Ile Phe Leu Lys Ser
20 25 30

Asn Pro Leu Phe Ser Val Thr Asn Thr Pro Ile Lys Ala Glu Asp Val
35 40 45

Lys Val Lys Pro Ile Gly His Trp Gly Thr Ile Ser Gly Gln Thr Phe
50 55 60

Leu Tyr Ala His Ala Asn Arg Leu Ile Asn Lys Tyr Gly Leu Asn Met
65 70 75 80

Phe Tyr Val Gly Gly Pro Gly His Gly Gly Gln Val Met Val Thr Asn
85 90 95

Ala Tyr Leu Asp Gly Ala Tyr Thr Glu Asp Tyr Pro Glu Ile Thr Gln
100 105 110

Asp Ile Glu Gly Met Ser His Leu Phe Lys Arg Phe Ser Phe Pro Gly
115 120 125

Gly Ile Gly Ser His Met Thr Ala Gln Thr Pro Gly Ser Leu His Glu
130 135 140

Gly Gly Glu Leu Gly Tyr Ser Leu Ser His Ala Phe Gly Ala Val Leu
145 150 155 160

Asp Asn Pro Asp Gln Val Ala Phe Ala Val Val Gly Asp Gly Glu Ala
165 170 175

Glu Thr Gly Pro Ser Met Ala Ser Trp His Ser Ile Lys Phe Leu Asn
180 185 190

Ala Lys Asn Asp Gly Ala Val Leu Pro Val Leu Asp Leu Asn Gly Phe
195 200 205

Lys Ile Ser Asn Pro Thr Ile Phe Ser Arg Met Ser Asp Glu Glu Ile
210 215 220

Thr Lys Phe Phe Glu Gly Leu Gly Tyr Ser Pro Arg Phe Ile Glu Asn
225 230 235 240

Asp Asp Ile His Asp Tyr Ala Thr Tyr His Gln Leu Ala Ala Asn Ile
245 250 255

Leu Asp Gln Ala Ile Glu Asp Ile Gln Ala Ile Gln Asn Asp Ala Arg

260

265

270

Glu Asn Gly Lys Tyr Gln Asp Gly Glu Ile Pro Ala Trp Pro Val Ile
 275 280 285

Ile Ala Arg Leu Pro Lys Gly Trp Gly Gly Pro Thr His Asp Ala Ser
 290 295 300

Asn Asn Pro Ile Glu Asn Ser Phe Arg Ala His Gln Val Pro Leu Pro
 305 310 315 320

Leu Glu Gln His Asp Leu Ala Thr Leu Pro Glu Phe Glu Asp Trp Met
 325 330 335

Asn Ser Tyr Lys Pro Glu Glu Leu Phe Asn Ala Asp Gly Ser Leu Lys
 340 345 350

Asp Glu Leu Lys Ala Ile Ala Pro Lys Gly Asp Lys Arg Met Ser Ala
 355 360 365

Asn Pro Ile Thr Asn Gly Gly Ala Asp Arg Ser Asp Leu Lys Leu Pro
 370 375 380

Asn Trp Arg Glu Phe Ala Asn Asp Ile Asn Asp Asp Thr Arg Gly Lys
 385 390 395 400

Glu Phe Ala Asp Ser Lys Arg Asn Met Asp Met Ala Thr Leu Ser Asn
 405 410 415

Tyr Leu Gly Ala Val Ser Gln Leu Asn Pro Thr Arg Phe Arg Phe Phe
 420 425 430

Gly Pro Asp Glu Thr Met Ser Asn Arg Leu Trp Gly Leu Phe Asn Val
 435 440 445

Thr Pro Arg Gln Trp Met Glu Glu Ile Lys Glu Pro Gln Asp Gln Leu
 450 455 460

Leu Ser Pro Thr Gly Arg Ile Ile Asp Ser Gln Leu Ser Glu His Gln
 465 470 475 480

Ala Glu Gly Trp Leu Glu Gly Tyr Thr Leu Thr Gly Arg Val Gly Ile
 485 490 495

Phe Ala Ser Tyr Glu Ser Phe Leu Arg Val Val Asp Thr Met Val Thr
 500 505 510

Gln His Phe Lys Trp Leu Arg His Ala Ser Glu Gln Ala Trp Arg Asn
 515 520 525

Asp Tyr Pro Ser Leu Asn Leu Ile Ala Thr Ser Thr Ala Phe Gln Gln

530

535

540

Asp His Asn Gly Tyr Thr His Gln Asp Pro Gly Met Leu Thr His Leu
545 550 555 560

Ala Glu Lys Lys Ser Asn Phe Ile Arg Glu Tyr Leu Pro Ala Asp Gly
565 570 575

Asn Ser Leu Leu Ala Val Gln Glu Arg Ala Phe Ser Glu Arg His Lys
580 585 590

Val Asn Leu Leu Ile Ala Ser Lys Gln Pro Arg Gln Gln Trp Phe Thr
595 600 605

Val Glu Glu Ala Glu Val Leu Ala Asn Glu Gly Leu Lys Ile Ile Asp
610 615 620

Trp Ala Ser Thr Ala Pro Ser Ser Asp Val Asp Ile Thr Phe Ala Ser
625 630 635 640

Ala Gly Thr Glu Pro Thr Ile Glu Thr Leu Ala Ala Leu Trp Leu Ile
645 650 655

Asn Gln Ala Phe Pro Asp Val Lys Phe Arg Tyr Val Asn Val Val Glu
660 665 670

Leu Leu Arg Leu Gln Lys Lys Ser Glu Pro Asn Met Asn Asp Glu Arg
675 680 685

Glu Leu Ser Ala Glu Glu Phe Asn Lys Tyr Phe Gln Ala Asp Thr Pro
690 695 700

Val Ile Phe Gly Phe His Ala Tyr Glu Asn Leu Ile Glu Ser Phe Phe
705 710 715 720

Phe Glu Arg Lys Phe Thr Gly Asp Val Tyr Val His Gly Tyr Arg Glu
725 730 735

Asp Gly Asp Ile Thr Thr Thr Tyr Asp Met Arg Val Tyr Ser His Leu
740 745 750

Asp Arg Phe His Gln Ala Lys Glu Ala Ala Glu Ile Leu Ser Ala Asn
755 760 765

Gly Lys Ile Asp Gln Ala Ala Ala Asp Thr Phe Ile Ala Lys Met Asp
770 775 780

Asp Thr Leu Ala Lys His Phe Gln Val Thr Arg Asn Glu Gly Arg Asp
785 790 795 800

Ile Glu Glu Phe Thr Asp Trp Thr Trp Ser Pro Leu Lys

<210> 3
 <211> 1002
 <212> DNA
 <213> Clostridium kluyveri

<220>
 <221> misc_feature
 <222> (1)..(1002)
 <223> Clostridium kluyveri Phosphotransacetylase (PTA) gene sequence

```
<400> 3
atgaaattaa tggaaaatat ttttggttta gccaaagcag ataagaaaa aattgttttg      60
gcagaaggag aagaagaaag gaacattaga gcttccgaag aaataataag ggatgggtatt    120
gcagatataa ttttagtagg aagtgaaagt gtaataaaag agaatgcagc taaatttggg      180
gttaacttag ctggagtgga aatagtagat cctgaaactt caagtaaaac tgcaggctat      240
gccaatgctt tttatgaaat tagaagaat aaaggagtta cactggaaaa agcagataaa      300
atagttagag atcctatata ttttgcaaca atgatggtga aacttggaga tgcagatggt      360
ttagtttcag gtgcaataca tacaacggga gatcttttga gaccaggact tcaaatagtg      420
aagacagttc cagggtgcttc tgtggtttcc agtgtatfff taatgagtgt accagattgt      480
gaatatggag aagatggatt cttgttattt gctgattgtg ctgtaaatgt atgtcctact      540
gctgaagaat tatcttcaat tgcaataact acagcagaaa ctgcaaaaaa tttgtgtaaa      600
atagaaccaa gagttgccat gctttcattt tctactatgg gaagtgctag tcatgaattg      660
gtagataaag ttacaaaagc aacaaaactt gctaaagaag ctagacctga tttggatata      720
gatggagaac ttcaattgga tgcttccta gtaaaaaaag ttgcagactt aaaagctccg      780
ggcagtaaag tggcaggaaa agccaatgta cttatattcc ctgatataca agcaggaaat      840
ataggatata agttagtcca aagatttgca aaagctgagg ctataggacc tatatgtcag      900
ggatttgcaa agcctataaa tgatttatca agaggctgca gcgttgatga tatagtaaag      960
gtagtggctg taactgcagt tcaagcacag gcacagggtt ag                          1002
```

<210> 4
 <211> 333
 <212> PRT
 <213> Clostridium kluyveri

<220>
 <221> misc_feature
 <222> (1)..(333)
 <223> Clostridium kluyveri Phosphotransacetylase (PTA) protein sequence

```
<400> 4
Met Lys Leu Met Glu Asn Ile Phe Gly Leu Ala Lys Ala Asp Lys Lys
1          5          10          15
```

```
Lys Ile Val Leu Ala Glu Gly Glu Glu Glu Arg Asn Ile Arg Ala Ser
Page 6
```

Glu Glu Ile Ile Arg Asp Gly Ile Ala Asp Ile Ile Leu Val Gly Ser
35 40 45

Glu Ser Val Ile Lys Glu Asn Ala Ala Lys Phe Gly Val Asn Leu Ala
50 55 60

Gly Val Glu Ile Val Asp Pro Glu Thr Ser Ser Lys Thr Ala Gly Tyr
65 70 75 80

Ala Asn Ala Phe Tyr Glu Ile Arg Lys Asn Lys Gly Val Thr Leu Glu
85 90 95

Lys Ala Asp Lys Ile Val Arg Asp Pro Ile Tyr Phe Ala Thr Met Met
100 105 110

Val Lys Leu Gly Asp Ala Asp Gly Leu Val Ser Gly Ala Ile His Thr
115 120 125

Thr Gly Asp Leu Leu Arg Pro Gly Leu Gln Ile Val Lys Thr Val Pro
130 135 140

Gly Ala Ser Val Val Ser Ser Val Phe Leu Met Ser Val Pro Asp Cys
145 150 155 160

Glu Tyr Gly Glu Asp Gly Phe Leu Leu Phe Ala Asp Cys Ala Val Asn
165 170 175

Val Cys Pro Thr Ala Glu Glu Leu Ser Ser Ile Ala Ile Thr Thr Ala
180 185 190

Glu Thr Ala Lys Asn Leu Cys Lys Ile Glu Pro Arg Val Ala Met Leu
195 200 205

Ser Phe Ser Thr Met Gly Ser Ala Ser His Glu Leu Val Asp Lys Val
210 215 220

Thr Lys Ala Thr Lys Leu Ala Lys Glu Ala Arg Pro Asp Leu Asp Ile
225 230 235 240

Asp Gly Glu Leu Gln Leu Asp Ala Ser Leu Val Lys Lys Val Ala Asp
245 250 255

Leu Lys Ala Pro Gly Ser Lys Val Ala Gly Lys Ala Asn Val Leu Ile
260 265 270

Phe Pro Asp Ile Gln Ala Gly Asn Ile Gly Tyr Lys Leu Val Gln Arg
275 280 285

Phe Ala Lys Ala Glu Ala Ile Gly Pro Ile Cys Gln Gly Phe Ala Lys

290 2014_03_12_107345_00466_ST25 295 300

Pro Ile Asn Asp Leu Ser Arg Gly Cys Ser Val Asp Asp Ile Val Lys
305 310 315 320

Val Val Ala Val Thr Ala Val Gln Ala Gln Ala Gln Gly
325 330

<210> 5
<211> 753
<212> DNA
<213> S. cerevisiae

<220>
<221> misc_feature
<222> (1)..(753)
<223> Nucleotide sequence of GPP1/RHR2 of S. cerevisiae

<400> 5
atgcctttga ccacaaaacc tttatctttg aaaatcaacg ccgctctatt cgatgttgac 60
ggatccatca tcattcttca accagccatt gctgctttct ggagagattt cggtaaagac 120
aagccttact tcgatgccga acacgttatt cacatctctc acggttggag aacttacgat 180
gccattgcca agttcgtctc agactttgct gatgaagaat acgttaacaa gctagaaggt 240
gaaatcccag aaaagtacgg tgaacactcc atcgaagttc caggtgctgt caagttgtgt 300
aatgctttga acgccttgcc aaaggaaaaa tgggctgtcg ccacctctgg taccctgac 360
atggccaaga aatgggttcga ctttttgaag atcaagagac cagaatactt catcaccgcc 420
aatgatgtca agcaaggtaa gcctcaccca gaaccatact taaagggttag aaacggtttg 480
ggtttcccaa ttaatgaaca agacccatcc aaatctaagg ttgttgctctt tgaagacgca 540
ccagctggta ttgctgctgg taaggctgct ggctgtaaaa tcgttggtat tgctaccact 600
ttcgatttgg acttcttgaa ggaaaagggt tgtgacatca ttgtcaagaa ccacgaatct 660
atcagagtcg gtgaatacaa cgctgaaacc gatgaagtcg aattgatctt tgatgactac 720
ttatacgcta aggatgactt gttgaaatgg taa 753

<210> 6
<211> 250
<212> PRT
<213> S. cerevisiae

<220>
<221> misc_feature
<222> (1)..(250)
<223> Protein sequence of Gpp1/Rhr2 of S. cerevisiae

<400> 6

Met Pro Leu Thr Thr Lys Pro Leu Ser Leu Lys Ile Asn Ala Ala Leu
1 5 10 15

Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln Pro Ala Ile Ala Ala
Page 8

Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr Phe Asp Ala Glu His
35 40 45

Val Ile His Ile Ser His Gly Trp Arg Thr Tyr Asp Ala Ile Ala Lys
50 55 60

Phe Ala Pro Asp Phe Ala Asp Glu Glu Tyr Val Asn Lys Leu Glu Gly
65 70 75 80

Glu Ile Pro Glu Lys Tyr Gly Glu His Ser Ile Glu Val Pro Gly Ala
85 90 95

Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro Lys Glu Lys Trp Ala
100 105 110

Val Ala Thr Ser Gly Thr Arg Asp Met Ala Lys Lys Trp Phe Asp Ile
115 120 125

Leu Lys Ile Lys Arg Pro Glu Tyr Phe Ile Thr Ala Asn Asp Val Lys
130 135 140

Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys Gly Arg Asn Gly Leu
145 150 155 160

Gly Phe Pro Ile Asn Glu Gln Asp Pro Ser Lys Ser Lys Val Val Val
165 170 175

Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly Lys Ala Ala Gly Cys
180 185 190

Lys Ile Val Gly Ile Ala Thr Thr Phe Asp Leu Asp Phe Leu Lys Glu
195 200 205

Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu Ser Ile Arg Val Gly
210 215 220

Glu Tyr Asn Ala Glu Thr Asp Glu Val Glu Leu Ile Phe Asp Asp Tyr
225 230 235 240

Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
245 250

<210> 7
<211> 753
<212> DNA
<213> S. cerevisiae

<220>
<221> misc_feature
<222> (1)..(753)

<223> Nucleotide sequence of GPP2/HOR2 of *S. cerevisiae*

<400> 7

```

atgggattga ctactaaacc tctatctttg aaagttaacg cgcgtttggt cgacgtcgac      60
ggtaccatta tcattctctca accagccatt gctgcattct ggagggattt cggtaaggac      120
aaaccttatt tcgatgctga acacgttatc caagtctcgc atggttggag aacgtttgat      180
gccattgcta agttcgtcc agactttgcc aatgaagagt atgttaacaa attagaagct      240
gaaattccgg tcaagtacgg tgaaaaatcc attgaagtcc caggtgcagt taagctgtgc      300
aacgctttga acgctctacc aaaagagaaa tgggctgtgg caacttccgg taccctgtgat      360
atggcacaaa aatgggttcga gcatctggga atcaggagac caaagtactt cattaccgct      420
aatgatgtca aacagggtaa gcctcatcca gaaccatata tgaagggcag gaatggctta      480
ggatatccga tcaatgagca agacccttcc aaatctaagg tagtagtatt tgaagacgct      540
ccagcaggtg ttgccgccgg aaaagccgcc ggttgtaaga tcattggtat tgccactact      600
ttcgacttgg acttcctaaa ggaaaaaggc tgtgacatca ttgtcaaaaa ccacgaatcc      660
atcagagttg gcggctacaa tgccgaaaca gacgaagttg aattcatttt tgacgactac      720
ttatatgcta aggacgatct gttgaaatgg taa                                     753

```

<210> 8

<211> 250

<212> PRT

<213> *S. cerevisiae*

<220>

<221> misc_feature

<222> (1)..(250)

<223> Protein sequence of Gpp2/Hor2 of *S. cerevisiae*

<400> 8

```

Met Gly Leu Thr Thr Lys Pro Leu Ser Leu Lys Val Asn Ala Ala Leu
1           5           10          15

```

```

Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln Pro Ala Ile Ala Ala
          20          25          30

```

```

Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr Phe Asp Ala Glu His
          35          40          45

```

```

Val Ile Gln Val Ser His Gly Trp Arg Thr Phe Asp Ala Ile Ala Lys
          50          55          60

```

```

Phe Ala Pro Asp Phe Ala Asn Glu Glu Tyr Val Asn Lys Leu Glu Ala
65          70          75          80

```

```

Glu Ile Pro Val Lys Tyr Gly Glu Lys Ser Ile Glu Val Pro Gly Ala
          85          90          95

```

```

Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro Lys Glu Lys Trp Ala

```

100

105

110

Val Ala Thr Ser Gly Thr Arg Asp Met Ala Gln Lys Trp Phe Glu His
 115 120 125

Leu Gly Ile Arg Arg Pro Lys Tyr Phe Ile Thr Ala Asn Asp Val Lys
 130 135 140

Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys Gly Arg Asn Gly Leu
 145 150 155 160

Gly Tyr Pro Ile Asn Glu Gln Asp Pro Ser Lys Ser Lys Val Val Val
 165 170 175

Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly Lys Ala Ala Gly Cys
 180 185 190

Lys Ile Ile Gly Ile Ala Thr Thr Phe Asp Leu Asp Phe Leu Lys Glu
 195 200 205

Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu Ser Ile Arg Val Gly
 210 215 220

Gly Tyr Asn Ala Glu Thr Asp Glu Val Glu Phe Ile Phe Asp Asp Tyr
 225 230 235 240

Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
 245 250

<210> 9
 <211> 1380
 <212> DNA
 <213> Dickeya zeae

<220>
 <221> misc_feature
 <222> (1)..(1380)
 <223> Dickeya zeae eutE gene sequence

<400> 9
 atggagcatt cagttatcga accgacagt cccatgccgc tgccagccat gtttgacgcg 60
 ccatctggaa tcttttctag cctggacgat gcagtccagg cggcaaccct ggcacaacaa 120
 cagttgtcgt ctgtggagtt acgccagcaa gttattaaag caattagagt tgcaggcgaa 180
 cgctatgcac aggttctggc ggaaatggcg gtggctgaaa caggtatggg tcgggtagtg 240
 gataaataca ttaaaaatgt ttcacaggct cgccatacac ccggcattga atgtctgagc 300
 gcggaagttc tgacaggcga caatggcctg acactgattg aaaatgcccc ttggggagtg 360
 gtggcttccg tgacgccaag cacgaacca gccgccacag tcatcaataa tgcaatttcc 420
 atgattgcgg cagggaattc agtcgttttt gcaccgcacc catccgcaa aaatgtgtcc 480
 ttacgcacaa tatcgcttct taacaaagca attgtggcga caggtgggcc agaaaatctg 540

```

ctggtatccg tcgcaaattcc caacatcgaa acagctcaac gcctgttccg ttatccaggt      600
attggattac tcgtcgtaac aggtgggtgag gcgggtggtg aagcggcgcg caaacacact      660
gataaacgtt taattgccgc aggcgccgga aacccccag tagtcgttga cgaaacagcg      720
gatataccga aagccgctcg cgcaatagta aagggcgctt cgtttgacaa caatattatt      780
tgtgccgacg agaaagtatt aatcgtggtt gatcgcgtag ccgacgcctt attagccgaa      840
atgcaacgca acaatgctgt tttactgacg cctgaacaga cagaacgact tctgcccgt      900
ttgctgagcg atatagatga gcaggggaag ggacgcgtga accgcgatta tgtggggagg      960
gatgccgcta aactagcggc ggccattggt ttagaagtgt cagaacacac aagattatta     1020
cttgctgaaa cagatgctga tcatcctttt gcagtaaccg aattaatgat gcccgatttg     1080
cctgttatcc gtgtaaaaaa cgttgatgac gccattgccc tcgctgtaaa acttgagagt     1140
ggttgtcgtc acactgcagc aatgcattcg acaaacatta ggaacctgaa tcggatggca     1200
aatgctataa atacatcaat ttttgttaaa aatgggtccgt gtatcgctgg gctgggcctg     1260
ggtgggcagg gctggacgtc gatgactata tctacacca caggggaagg agttacctca     1320
gcacgcacct tcgtacgttt acgtagatgt gtattggttg acatgttcag aatcgcgtaa     1380

```

```

<210> 10
<211> 459
<212> PRT
<213> Dickeya zeae

```

```

<220>
<221> misc_feature
<222> (1)..(459)
<223> Dickeya zeae eutE protein sequence

```

```

<400> 10

```

```

Met Glu His Ser Val Ile Glu Pro Thr Val Pro Met Pro Leu Pro Ala
1           5           10           15

```

```

Met Phe Asp Ala Pro Ser Gly Ile Phe Ser Ser Leu Asp Asp Ala Val
          20           25           30

```

```

Gln Ala Ala Thr Leu Ala Gln Gln Gln Leu Ser Ser Val Glu Leu Arg
          35           40           45

```

```

Gln Gln Val Ile Lys Ala Ile Arg Val Ala Gly Glu Arg Tyr Ala Gln
          50           55           60

```

```

Val Leu Ala Glu Met Ala Val Ala Glu Thr Gly Met Gly Arg Val Val
65           70           75           80

```

```

Asp Lys Tyr Ile Lys Asn Val Ser Gln Ala Arg His Thr Pro Gly Ile
          85           90           95

```

```

Glu Cys Leu Ser Ala Glu Val Leu Thr Gly Asp Asn Gly Leu Thr Leu

```

100

105

110

Ile Glu Asn Ala Pro Trp Gly Val Val Ala Ser Val Thr Pro Ser Thr
 115 120 125

Asn Pro Ala Ala Thr Val Ile Asn Asn Ala Ile Ser Met Ile Ala Ala
 130 135 140

Gly Asn Ser Val Val Phe Ala Pro His Pro Ser Ala Lys Asn Val Ser
 145 150 155 160

Leu Arg Thr Ile Ser Leu Leu Asn Lys Ala Ile Val Ala Thr Gly Gly
 165 170 175

Pro Glu Asn Leu Leu Val Ser Val Ala Asn Pro Asn Ile Glu Thr Ala
 180 185 190

Gln Arg Leu Phe Arg Tyr Pro Gly Ile Gly Leu Leu Val Val Thr Gly
 195 200 205

Gly Glu Ala Val Val Glu Ala Ala Arg Lys His Thr Asp Lys Arg Leu
 210 215 220

Ile Ala Ala Gly Ala Gly Asn Pro Pro Val Val Val Asp Glu Thr Ala
 225 230 235 240

Asp Ile Pro Lys Ala Ala Arg Ala Ile Val Lys Gly Ala Ser Phe Asp
 245 250 255

Asn Asn Ile Ile Cys Ala Asp Glu Lys Val Leu Ile Val Val Asp Arg
 260 265 270

Val Ala Asp Ala Leu Leu Ala Glu Met Gln Arg Asn Asn Ala Val Leu
 275 280 285

Leu Thr Pro Glu Gln Thr Glu Arg Leu Leu Pro Ala Leu Leu Ser Asp
 290 295 300

Ile Asp Glu Gln Gly Lys Gly Arg Val Asn Arg Asp Tyr Val Gly Arg
 305 310 315 320

Asp Ala Ala Lys Leu Ala Ala Ala Ile Gly Leu Glu Val Ser Glu His
 325 330 335

Thr Arg Leu Leu Leu Ala Glu Thr Asp Ala Asp His Pro Phe Ala Val
 340 345 350

Thr Glu Leu Met Met Pro Val Leu Pro Val Ile Arg Val Lys Asn Val
 355 360 365

Asp Asp Ala Ile Ala Leu Ala Val Lys Leu Glu Ser Gly Cys Arg His

Thr Ala Ala Met His Ser Thr Asn Ile Arg Asn Leu Asn Arg Met Ala
385 390 395 400

Asn Ala Ile Asn Thr Ser Ile Phe Val Lys Asn Gly Pro Cys Ile Ala
405 410 415

Gly Leu Gly Leu Gly Gly Glu Gly Trp Thr Ser Met Thr Ile Ser Thr
420 425 430

Pro Thr Gly Glu Gly Val Thr Ser Ala Arg Thr Phe Val Arg Leu Arg
435 440 445

Arg Cys Val Leu Val Asp Met Phe Arg Ile Ala
450 455

<210> 11
<211> 1798
<212> DNA
<213> Saccharomyces cerevisiae

<220>
<221> misc_feature
<222> (1)..(1798)
<223> Saccharomyces cerevisiae ALD4 nucleotide sequence

<400> 11
gcacccaggg acacacagca gcgaagtatt ttcagaatgt tcagtagatc tacgctctgc 60
ttaaagacgt ctgcatcctc cattgggaga cttcaattga gatatttctc acaccttcct 120
atgacagtgc ctatcaagct gcccaatggg ttggaatatg agcaaccaac ggggttggtc 180
atcaacaaca agtttggttc ttctaaacag aacaagacct tcgaagtcac taacccttcc 240
acggaagaag aaatatgtca tatttatgaa ggtagagagg acgatgtgga agaggccgtg 300
caggccgccc accgtgcctt ctctaattggg tcttggaacg gtatcgaccc tattgacagg 360
ggtaaggctt tgtacagggt agccgaatta attgaacagg acaaggatgt cattgcttcc 420
atcgagactt tggataacgg taaagctatc tcttcctcga gaggagatgt tgatttagtc 480
atcaactatt tgaatcttc tgctggcttt gctgataaaa ttgatggtag aatgattgat 540
actggtagaa cccatttttc ttactactaag agacagcctt tgggtgtttg tgggcagatt 600
attccttgga atttcccact gttgatgtgg gcctggaaga ttgccctgc tttggtcacc 660
ggtaacaccg tcgtgttgaa gactgccgaa tccaccccat tgtccgcttt gtatgtgtct 720
aaatacatcc cacaggcggg tattccacct ggtgtgatca acattgtatc cgggtttggt 780
aagattgtgg gtgaggccat tacaaccat ccaaaaatca aaaagggtgc cttcacaggg 840
tccacggcta cgggtagaca catttaccag tccgcagccg caggcttgaa aaaagtgact 900
ttggagctgg gtggtaaatc accaaacatt gtcttcgcgg acgccgagtt gaaaaagcc 960
gtgcaaaaca ttatccttgg tatctactac aattctggtg aggtctgttg tgcgggttca 1020

```

agggtgtatg ttgaagaatc tatttacgac aaattcattg aagagttcaa agccgcttct 1080
gaatccatca aggtgggcca cccattcgat gaatctactt tccaagggtgc acaaacctct 1140
caaatgcaac taaacaaaat cttgaaatac gttgacattg gtaagaatga aggtgctact 1200
ttgattaccg gtggtgaaag attaggtagc aagggttact tcattaagcc aactgtcttt 1260
ggtgacgtta aggaagacat gagaattgtc aaagaggaaa tctttggccc tgttgtcact 1320
gtaaccaaat tcaaactctgc cgacgaagtc attaacatgg cgaacgattc tgaatacggg 1380
ttggctgctg gtattcacac ctctaataat aataccgcct taaaagtggc tgatagagtt 1440
aatgcgggta cggctctggat aaacacttat aacgatttcc accacgcagt tcctttcgg 1500
gggttcaatg catctggttt gggcagggaa atgtctgttg atgctttaca aaactacttg 1560
caagttaaag cgggccgtgc caaattggac gagtaaggtc atcaataagc ctggtgtcca 1620
atcgatgctt acatacataa aattaaatat tctgtctctg ttatatattcc acatgtcatc 1680
atttcaaata tatgtacttt aaagaaaata aaataaaaaa taaaattttt ttctcccgat 1740
aatcaatttt ctttaattaat taattgcgtt acgaaacgcg atcgccgacg ccgccgat 1798

```

```

<210> 12
<211> 519
<212> PRT
<213> Saccharomyces cerevisiae

```

```

<220>
<221> misc_feature
<222> (1)..(519)
<223> Saccharomyces cerevisiae ALD4 protein sequence
<400> 12

```

```

Met Phe Ser Arg Ser Thr Leu Cys Leu Lys Thr Ser Ala Ser Ser Ile
1           5           10          15

```

```

Gly Arg Leu Gln Leu Arg Tyr Phe Ser His Leu Pro Met Thr Val Pro
20          25          30

```

```

Ile Lys Leu Pro Asn Gly Leu Glu Tyr Glu Gln Pro Thr Gly Leu Phe
35          40          45

```

```

Ile Asn Asn Lys Phe Val Pro Ser Lys Gln Asn Lys Thr Phe Glu Val
50          55          60

```

```

Ile Asn Pro Ser Thr Glu Glu Glu Ile Cys His Ile Tyr Glu Gly Arg
65          70          75          80

```

```

Glu Asp Asp Val Glu Glu Ala Val Gln Ala Ala Asp Arg Ala Phe Ser
85          90          95

```

```

Asn Gly Ser Trp Asn Gly Ile Asp Pro Ile Asp Arg Gly Lys Ala Leu
100         105         110

```

Tyr Arg Leu Ala Glu Leu Ile Glu Gln Asp Lys Asp Val Ile Ala Ser
 115 120 125
 Ile Glu Thr Leu Asp Asn Gly Lys Ala Ile Ser Ser Ser Arg Gly Asp
 130 135 140
 Val Asp Leu Val Ile Asn Tyr Leu Lys Ser Ser Ala Gly Phe Ala Asp
 145 150 155 160
 Lys Ile Asp Gly Arg Met Ile Asp Thr Gly Arg Thr His Phe Ser Tyr
 165 170 175
 Thr Lys Arg Gln Pro Leu Gly Val Cys Gly Gln Ile Ile Pro Trp Asn
 180 185 190
 Phe Pro Leu Leu Met Trp Ala Trp Lys Ile Ala Pro Ala Leu Val Thr
 195 200 205
 Gly Asn Thr Val Val Leu Lys Thr Ala Glu Ser Thr Pro Leu Ser Ala
 210 215 220
 Leu Tyr Val Ser Lys Tyr Ile Pro Gln Ala Gly Ile Pro Pro Gly Val
 225 230 235 240
 Ile Asn Ile Val Ser Gly Phe Gly Lys Ile Val Gly Glu Ala Ile Thr
 245 250 255
 Asn His Pro Lys Ile Lys Lys Val Ala Phe Thr Gly Ser Thr Ala Thr
 260 265 270
 Gly Arg His Ile Tyr Gln Ser Ala Ala Ala Gly Leu Lys Lys Val Thr
 275 280 285
 Leu Glu Leu Gly Gly Lys Ser Pro Asn Ile Val Phe Ala Asp Ala Glu
 290 295 300
 Leu Lys Lys Ala Val Gln Asn Ile Ile Leu Gly Ile Tyr Tyr Asn Ser
 305 310 315 320
 Gly Glu Val Cys Cys Ala Gly Ser Arg Val Tyr Val Glu Glu Ser Ile
 325 330 335
 Tyr Asp Lys Phe Ile Glu Glu Phe Lys Ala Ala Ser Glu Ser Ile Lys
 340 345 350
 Val Gly Asp Pro Phe Asp Glu Ser Thr Phe Gln Gly Ala Gln Thr Ser
 355 360 365
 Gln Met Gln Leu Asn Lys Ile Leu Lys Tyr Val Asp Ile Gly Lys Asn
 370 375 380

Glu Gly Ala Thr Leu Ile Thr Gly Gly Glu Arg Leu Gly Ser Lys Gly
385 390 395 400

Tyr Phe Ile Lys Pro Thr Val Phe Gly Asp Val Lys Glu Asp Met Arg
405 410 415

Ile Val Lys Glu Glu Ile Phe Gly Pro Val Val Thr Val Thr Lys Phe
420 425 430

Lys Ser Ala Asp Glu Val Ile Asn Met Ala Asn Asp Ser Glu Tyr Gly
435 440 445

Leu Ala Ala Gly Ile His Thr Ser Asn Ile Asn Thr Ala Leu Lys Val
450 455 460

Ala Asp Arg Val Asn Ala Gly Thr Val Trp Ile Asn Thr Tyr Asn Asp
465 470 475 480

Phe His His Ala Val Pro Phe Gly Gly Phe Asn Ala Ser Gly Leu Gly
485 490 495

Arg Glu Met Ser Val Asp Ala Leu Gln Asn Tyr Leu Gln Val Lys Ala
500 505 510

Val Arg Ala Lys Leu Asp Glu
515

<210> 13
<211> 2744
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> misc_feature
<222> (1)..(2744)
<223> *Saccharomyces cerevisiae* cytosolic aldehyde dehydrogenase 6
(ALD6) nucleotide sequence

<400> 13
catatggcgt atccaagccg aaaccctttg ctcattcccc acggaataag gcagccgaca 60
aaagaaaaac gaccgaaaag gaaccagaaa gaaaaaagag ggtgggcgcg ccgcggacgt 120
gtaaaaagat atgcatccag cttctatatc gctttaactt taccgttttg ggcattcgga 180
acgtatgtaa cattgatctc ctcttgggaa cggtagtgat aacagatgag atatagcacc 240
gaccatgtgg gcaaattcgt aataaattcg gggtaggggg gattcaagac aagcaacctt 300
gtagtcagc tcaaacagcg atttaacggg tgagtaacac atcaaacac cgttcgaggt 360
caagcctggc gtgtttaaca agttcttgat atcatatata aatgtaataa gaagtttggt 420
aatattcaat tcgaagtgtt cagtctttta cttctcttgg tttatagaag aaaaaacatc 480
aagaaacatc ttttaacatac acaaacacat actatcagaa tacaatgact aagctacact 540

ttgacactgc	tgaaccagtc	aagatcacac	ttccaaatgg	tttgacatac	gagcaaccaa	600
ccggtctatt	cattaacaac	aagtttatga	aagctcaaga	cggtaagacc	tatcccgtcg	660
aagatccttc	cactgaaaac	accgtttgtg	aggtctcttc	tgccaccact	gaagatgttg	720
aatatgctat	cgaatgtgcc	gaccgtgctt	tccacgacac	tgaatgggct	accaagacc	780
caagagaaaag	aggccgtcta	ctaagtaagt	tggtgacga	attggaaagc	caaattgact	840
tggtttcttc	cattgaagct	ttggacaatg	gtaaaacttt	ggcctttaag	gcccgtaggg	900
atgttaccat	tgcaatcaac	tgtctaagag	atgctgctgc	ctatgccgac	aaagtcaacg	960
gtagaacaat	caacaccggt	gacggctaca	tgaacttcac	caccttagag	ccaatcggtg	1020
tctgtgggtca	aattattcca	tggaactttc	caataatgat	gttggcttgg	aagatcgccc	1080
cagcattggc	catgggtaac	gtctgtatct	tgaaaccgcg	tgctgtcaca	cctttaaatg	1140
ccctatactt	tgcttcttta	tgtaagaagg	ttggtattcc	agctgggtgc	gtcaacatcg	1200
ttccagggtcc	tggtagaact	gttgggtgctg	ctttgaccaa	cgaccaaga	atcagaaaagc	1260
tggtctttac	cggttctaca	gaagtcggta	agagtgttgc	tgctgactct	tctgaatcta	1320
acttgaagaa	aatcactttg	gaactaggtg	gtaagtccgc	ccatttgggtc	tttgacgatg	1380
ctaacattaa	gaagacttta	ccaaatctag	taaacggtat	tttcaagaac	gctgggtcaaa	1440
tttgttcctc	tggttctaga	atttacgttc	aagaaggtat	ttacgacgaa	ctattggctg	1500
ctttcaaggc	ttacttggaa	accgaaatca	aagttggtaa	tccatttgac	aaggctaact	1560
tccaaggtgc	tatcactaac	cgtcaacaat	tcgacacaat	tatgaactac	atcgatatcg	1620
gtaagaaaga	aggcgccaag	atcttaactg	gtggcgaaaa	agttgggtgac	aagggttact	1680
tcacagacc	aaccgttttc	tacgatgtta	atgaagacat	gagaattggt	aaggaagaaa	1740
tttttgacc	agttgtcact	gtcgcaaagt	tcaagacttt	agaagaaggt	gtcgaaatgg	1800
ctaacagctc	tgaattcggg	ctaggttctg	gtatcgaaac	agaatctttg	agcacagggt	1860
tgaaggtggc	caagatgttg	aaggccggta	ccgtctggat	caacacatac	aacgattttg	1920
actccagagt	tccattcggg	ggtgttaagc	aatctggtta	cggtagagaa	atgggtgaag	1980
aagtctacca	tgcatacact	gaagtaaaag	ctgtcagaat	taagttgtaa	tgtaccaacc	2040
tgcatcttct	tccgtcatat	acacaaaata	ctttcatata	aacttacttg	gtcttacgtc	2100
ataaataaat	atgtatacat	ataaattaaa	aaatttgggt	ttatatTTTT	acaaaaagaa	2160
tcgtttactt	catttctccc	ttttaagcga	tacaatccat	gaaaaaagag	aaaaagagag	2220
aacaggcttg	tgcttctttt	aaaacatccc	acacaaaatc	atattgaatt	gaattttaca	2280
tcttaagcta	gtgtacaaca	actgctatat	ccaaagaaaa	ctaactgga	ccgcttttag	2340
agttgagaaa	aaggtttgaa	aaaaatagca	atacaaagac	ttgtttcata	tataaaatac	2400
aggagacaca	ttgagcta	ataacataaa	cactgcgaac	caattccaat	caaaaggtac	2460
acatgagagc	attccccga	gtactgccat	ttcgccatca	gagatcatat	aataacatcc	2520
ttcttcgaac	agtaaggctt	tttggttcat	cactttcttc	ttttgatttc	tctaggcaaa	2580

tgcctaaggt ggaccctgac aataccgctg caatgctact acagaaaaac ttgatccaaa 2640
 gaaacaacat gctctatggg tatggatcag ggacaatacg atgtactttg ctagactcaa 2700
 ctggacgagc caaatcacca ttagtagaga taaaacgtga ggat 2744

<210> 14
 <211> 500
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> misc_feature
 <222> (1)..(500)
 <223> Saccharomyces cerevisiae cytosolic aldehyde dehydrogenase 6
 (ALD6) protein sequence

<400> 14

Met Thr Lys Leu His Phe Asp Thr Ala Glu Pro Val Lys Ile Thr Leu
 1 5 10 15

Pro Asn Gly Leu Thr Tyr Glu Gln Pro Thr Gly Leu Phe Ile Asn Asn
 20 25 30

Lys Phe Met Lys Ala Gln Asp Gly Lys Thr Tyr Pro Val Glu Asp Pro
 35 40 45

Ser Thr Glu Asn Thr Val Cys Glu Val Ser Ser Ala Thr Thr Glu Asp
 50 55 60

Val Glu Tyr Ala Ile Glu Cys Ala Asp Arg Ala Phe His Asp Thr Glu
 65 70 75 80

Trp Ala Thr Gln Asp Pro Arg Glu Arg Gly Arg Leu Leu Ser Lys Leu
 85 90 95

Ala Asp Glu Leu Glu Ser Gln Ile Asp Leu Val Ser Ser Ile Glu Ala
 100 105 110

Leu Asp Asn Gly Lys Thr Leu Ala Leu Ala Arg Gly Asp Val Thr Ile
 115 120 125

Ala Ile Asn Cys Leu Arg Asp Ala Ala Ala Tyr Ala Asp Lys Val Asn
 130 135 140

Gly Arg Thr Ile Asn Thr Gly Asp Gly Tyr Met Asn Phe Thr Thr Leu
 145 150 155 160

Glu Pro Ile Gly Val Cys Gly Gln Ile Ile Pro Trp Asn Phe Pro Ile
 165 170 175

Met Met Leu Ala Trp Lys Ile Ala Pro Ala Leu Ala Met Gly Asn Val
 180 185 190

Cys Ile Leu Lys Pro Ala Ala Val Thr Pro Leu Asn Ala Leu Tyr Phe
 195 200 205
 Ala Ser Leu Cys Lys Lys Val Gly Ile Pro Ala Gly Val Val Asn Ile
 210 215 220
 Val Pro Gly Pro Gly Arg Thr Val Gly Ala Ala Leu Thr Asn Asp Pro
 225 230 235 240
 Arg Ile Arg Lys Leu Ala Phe Thr Gly Ser Thr Glu Val Gly Lys Ser
 245 250 255
 Val Ala Val Asp Ser Ser Glu Ser Asn Leu Lys Lys Ile Thr Leu Glu
 260 265 270
 Leu Gly Gly Lys Ser Ala His Leu Val Phe Asp Asp Ala Asn Ile Lys
 275 280 285
 Lys Thr Leu Pro Asn Leu Val Asn Gly Ile Phe Lys Asn Ala Gly Gln
 290 295 300
 Ile Cys Ser Ser Gly Ser Arg Ile Tyr Val Gln Glu Gly Ile Tyr Asp
 305 310 315 320
 Glu Leu Leu Ala Ala Phe Lys Ala Tyr Leu Glu Thr Glu Ile Lys Val
 325 330 335
 Gly Asn Pro Phe Asp Lys Ala Asn Phe Gln Gly Ala Ile Thr Asn Arg
 340 345 350
 Gln Gln Phe Asp Thr Ile Met Asn Tyr Ile Asp Ile Gly Lys Lys Glu
 355 360 365
 Gly Ala Lys Ile Leu Thr Gly Gly Glu Lys Val Gly Asp Lys Gly Tyr
 370 375 380
 Phe Ile Arg Pro Thr Val Phe Tyr Asp Val Asn Glu Asp Met Arg Ile
 385 390 395 400
 Val Lys Glu Glu Ile Phe Gly Pro Val Val Thr Val Ala Lys Phe Lys
 405 410 415
 Thr Leu Glu Glu Gly Val Glu Met Ala Asn Ser Ser Glu Phe Gly Leu
 420 425 430
 Gly Ser Gly Ile Glu Thr Glu Ser Leu Ser Thr Gly Leu Lys Val Ala
 435 440 445
 Lys Met Leu Lys Ala Gly Thr Val Trp Ile Asn Thr Tyr Asn Asp Phe
 450 455 460

Asp Ser Arg Val Pro Phe Gly Gly Val Lys Gln Ser Gly Tyr Gly Arg
465 470 475 480

Glu Met Gly Glu Glu Val Tyr His Ala Tyr Thr Glu Val Lys Ala Val
485 490 495

Arg Ile Lys Leu
500

<210> 15
<211> 2728
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> misc_feature
<222> (1)..(2728)
<223> *Saccharomyces cerevisiae* ACS1 nucleotide sequence

```

<400> 15
acctcccgcg acctccaaaa tcgaactacc ttcacaatgt cgccctctgc cgtacaatca      60
tcaaaactag aagaacagtc aagtgaatt gacaagttga aagcaaaaat gtcccagtct      120
gcctccactg cgcagcagaa gaaggaacat gagtatgaac atttgacctc ggtcaagatc      180
gtgccacaac ggcccatctc agatagactg cagcccgcaa ttgctacca ctattctcca      240
cacttggacg ggttgagga ctatcagcgc ttgcacaagg agtctattga agaccctgct      300
aagttcttcg gttctaaagc tacccaattt ttaaactggc ctaagccatt cgataagggtg      360
ttcatcccag actctaaaac gggtagggcc tccttccaga acaatgcatg gttcctcaac      420
ggccaattaa acgcctgtta caactgtgtt gacagacatg ccttgaagac ccctaacaag      480
aaagccatta ttttcgaagg tgacgagcct ggccaaggct attccattac ctacaaggaa      540
ctacttgaag aagtttgtca agtggcacia gtgctgactt actctatggg cgttcgcaag      600
ggcgatactg ttgccgtgta catgcctatg gtcccagaag caatcataac cttgttggcc      660
atttcccgta tcggcgccat tcaactccgta gtctttgccg ggttttcttc caactccttg      720
agagatcgta tcaacgatgg ggactctaaa gttgtcatca ctacagatga atccaacaga      780
ggtggttaaag tcattgagac taaaagaatt gttgatgacg cgctaagaga gaccccaggc      840
gtgagacacg tcttggttta tagaaagacc aacaatccat ctggttgctt ccatgcccccc      900
agagatttag attgggcaac agaaaagaag aaatacaaga cctactatcc atgcacaccc      960
gttgattctg aggatccatt attcttggtg tatacgtctg gttctactgg tgcccccaag     1020
ggtgttcaac attctaccgc aggttacttg ctgggagctt tgttgaccat gcgctacact     1080
tttgacactc accaagaaga cgttttcttc acagctggag acattggctg gattacaggc     1140
cacacttatg tggtttatgg tcccttacta tatggttggt ccactttggt ctttgaaggg     1200
actcctgcgt acccaaatta ctcccgttat tgggatatta ttgatgaaca caaagtcacc     1260
caattttatg ttgcccacac tgctttgcgt ttgttgaaaa gagctggtga ttctacatc     1320

```



```

gaaaatcatt ccttaaaatc tttgcgttgc ttgggttcgg tcggtgaacc aattgctgct 1380
gaagtttggg agtgggtactc tgaaaaaata ggtaaaaatg aaatcccat tgtagacacc 1440
tactggcaaa cagaatctgg ttcgcatctg gtcaccccg tcggtggtgg tgtcacacca 1500
atgaaaccgg gttctgcctc attccccttc ttcggtattg atgcagttgt tcttgaccct 1560
aacactgggtg aagaacttaa taccagccac gcagaggggtg tccttgccgt caaagctgca 1620
tggccatcat ttgcaagaac tatttggaat aatcatgata ggtatctaga cacttatttg 1680
aacccttacc ctggctacta tttcactggg gatgggtgctg caaaggataa ggatgggttat 1740
atctggattt tgggtcgtgt agacgatgtg gtgaacgtct ctggtcaccg tctgtctacc 1800
gctgaaattg aggctgctat tatcgaagat ccaattgtgg ccgagtgtgc tgttgtcggg 1860
ttcaacgatg acttgactgg tcaagcagtt gctgcatttg tgggtgttgaa aaacaaatct 1920
aattgggtcca ccgcaacaga tgatgaatta caagatatca agaagcattt ggtctttact 1980
gtagaaaaag acatcgggcc atttgccgca ccaaattga tcattttagt ggatgacttg 2040
cccaagacaa gatctggcaa aattatgaga cgtattttta gaaaaatcct agcaggagaa 2100
agtgaccaac taggcgacgt ttctacattg tcaaaccctg gcattgttag acatctaatt 2160
gattcgggtca agttgtaatg atgatttctt tcctttttat attgacgact tttttttttt 2220
cgtgtgtttt tgttctctta taaccgagct gcttacttat tattatttca ccttctcttt 2280
ttatttatac ttataattat ttattcttta catactgtta caagaaactc ttttctacat 2340
taattgcata aagtgtcaat cagcacatcc tctatatcgc tatcaacaac aaatttgaca 2400
aacctgccta tatcttcagg aacaactgcc gcacgcgtac caccactact tgtgaagtcc 2460
ctggagttaa atatgcactg aaattttacct agccgtttta cacaagacca taatccatcc 2520
atgctatcgc agtatatgat tttgtgttcg tttttcgtct tgcgaaaggc atcctcaatg 2580
gcttgtttca ttgatccatc agtgtggctc gtaggtacca gcaaaaccac ttcacagcg 2640
gcgtactcct ccactttat gggcagtcct tgtatcgact tgctcattat aatacatttg 2700
ctctatcccc gcgtgcttgg ccggccgt 2728

```

```

<210> 16
<211> 713
<212> PRT
<213> Saccharomyces cerevisiae

```

```

<220>
<221> misc_feature
<222> (1)..(713)
<223> Saccharomyces cerevisiae ACS1 protein sequence

```

```
<400> 16
```

```

Met Ser Pro Ser Ala Val Gln Ser Ser Lys Leu Glu Glu Gln Ser Ser
1          5          10          15

```

```

Glu Ile Asp Lys Leu Lys Ala Lys Met Ser Gln Ser Ala Ser Thr Ala

```

Gln Gln Lys₃₅ Lys Glu His Glu Tyr₄₀ Glu His Leu Thr Ser₄₅ Val Lys Ile
Val Pro₅₀ Gln Arg Pro Ile Ser₅₅ Asp Arg Leu Gln Pro₆₀ Ala Ile Ala Thr
His Tyr Ser Pro His Leu₇₀ Asp Gly Leu Gln Asp₇₅ Tyr Gln Arg Leu His₈₀
Lys Glu Ser Ile Glu₈₅ Asp Pro Ala Lys Phe₉₀ Phe Gly Ser Lys Ala Thr₉₅
Gln Phe Leu Asn₁₀₀ Trp Ser Lys Pro Phe₁₀₅ Asp Lys Val Phe Ile₁₁₀ Pro Asp
Ser Lys Thr₁₁₅ Gly Arg Pro Ser Phe₁₂₀ Gln Asn Asn Ala Trp₁₂₅ Phe Leu Asn
Gly Gln₁₃₀ Leu Asn Ala Cys Tyr₁₃₅ Asn Cys Val Asp Arg His Ala Leu Lys
Thr₁₄₅ Pro Asn Lys Lys Ala₁₅₀ Ile Ile Phe Glu Gly₁₅₅ Asp Glu Pro Gly Gln₁₆₀
Gly Tyr Ser Ile Thr₁₆₅ Tyr Lys Glu Leu Leu₁₇₀ Glu Glu Val Cys Gln₁₇₅ Val
Ala Gln Val Leu₁₈₀ Thr Tyr Ser Met Gly₁₈₅ Val Arg Lys Gly Asp Thr Val₁₉₀
Ala Val Tyr₁₉₅ Met Pro Met Val Pro₂₀₀ Glu Ala Ile Ile Thr₂₀₅ Leu Leu Ala
Ile Ser₂₁₀ Arg Ile Gly Ala Ile₂₁₅ His Ser Val Val Phe₂₂₀ Ala Gly Phe Ser
Ser₂₂₅ Asn Ser Leu Arg Asp₂₃₀ Arg Ile Asn Asp Gly₂₃₅ Asp Ser Lys Val Val₂₄₀
Ile Thr Thr Asp Glu₂₄₅ Ser Asn Arg Gly Gly₂₅₀ Lys Val Ile Glu Thr Lys₂₅₅
Arg Ile Val Asp₂₆₀ Asp Ala Leu Arg Glu₂₆₅ Thr Pro Gly Val Arg₂₇₀ His Val
Leu Val Tyr₂₇₅ Arg Lys Thr Asn Asn₂₈₀ Pro Ser Val Ala Phe₂₈₅ His Ala Pro
Arg Asp Leu Asp Trp Ala Thr Glu Lys Lys Lys Tyr Lys Thr Tyr Tyr

290

295

300

Pro Cys Thr Pro Val Asp Ser Glu Asp Pro Leu Phe Leu Leu Tyr Thr
305 310 315 320

Ser Gly Ser Thr Gly Ala Pro Lys Gly Val Gln His Ser Thr Ala Gly
325 330 335

Tyr Leu Leu Gly Ala Leu Leu Thr Met Arg Tyr Thr Phe Asp Thr His
340 345 350

Gln Glu Asp Val Phe Phe Thr Ala Gly Asp Ile Gly Trp Ile Thr Gly
355 360 365

His Thr Tyr Val Val Tyr Gly Pro Leu Leu Tyr Gly Cys Ala Thr Leu
370 375 380

Val Phe Glu Gly Thr Pro Ala Tyr Pro Asn Tyr Ser Arg Tyr Trp Asp
385 390 395 400

Ile Ile Asp Glu His Lys Val Thr Gln Phe Tyr Val Ala Pro Thr Ala
405 410 415

Leu Arg Leu Leu Lys Arg Ala Gly Asp Ser Tyr Ile Glu Asn His Ser
420 425 430

Leu Lys Ser Leu Arg Cys Leu Gly Ser Val Gly Glu Pro Ile Ala Ala
435 440 445

Glu Val Trp Glu Trp Tyr Ser Glu Lys Ile Gly Lys Asn Glu Ile Pro
450 455 460

Ile Val Asp Thr Tyr Trp Gln Thr Glu Ser Gly Ser His Leu Val Thr
465 470 475 480

Pro Leu Ala Gly Gly Val Thr Pro Met Lys Pro Gly Ser Ala Ser Phe
485 490 495

Pro Phe Phe Gly Ile Asp Ala Val Val Leu Asp Pro Asn Thr Gly Glu
500 505 510

Glu Leu Asn Thr Ser His Ala Glu Gly Val Leu Ala Val Lys Ala Ala
515 520 525

Trp Pro Ser Phe Ala Arg Thr Ile Trp Lys Asn His Asp Arg Tyr Leu
530 535 540

Asp Thr Tyr Leu Asn Pro Tyr Pro Gly Tyr Tyr Phe Thr Gly Asp Gly
545 550 555 560

Ala Ala Lys Asp Lys Asp Gly Tyr Ile Trp Ile Leu Gly Arg Val Asp

565

570

575

Asp Val Val Asn Val Ser Gly His Arg Leu Ser Thr Ala Glu Ile Glu
580 585 590

Ala Ala Ile Ile Glu Asp Pro Ile Val Ala Glu Cys Ala Val Val Gly
595 600 605

Phe Asn Asp Asp Leu Thr Gly Gln Ala Val Ala Ala Phe Val Val Leu
610 615 620

Lys Asn Lys Ser Asn Trp Ser Thr Ala Thr Asp Asp Glu Leu Gln Asp
625 630 635 640

Ile Lys Lys His Leu Val Phe Thr Val Arg Lys Asp Ile Gly Pro Phe
645 650 655

Ala Ala Pro Lys Leu Ile Ile Leu Val Asp Asp Leu Pro Lys Thr Arg
660 665 670

Ser Gly Lys Ile Met Arg Arg Ile Leu Arg Lys Ile Leu Ala Gly Glu
675 680 685

Ser Asp Gln Leu Gly Asp Val Ser Thr Leu Ser Asn Pro Gly Ile Val
690 695 700

Arg His Leu Ile Asp Ser Val Lys Leu
705 710

<210> 17
<211> 2287
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> misc_feature
<222> (1)..(2287)
<223> *Saccharomyces cerevisiae* ACS2 nucleotide sequence

<400> 17
acctcccgcg acctccaaaa tcgaactacc ttcacaatga caatcaagga acataaagta 60
gtttatgaag ctcaaacgt aaaggctctt aaggctcctc aacattttta caacagccaa 120
cccggcaagg gttacgttac tgatatgcaa cattatcaag aaatgtatca acaatctatc 180
aatgagccag aaaaattctt tgataagatg gctaaggaat acttgcattg ggatgctcca 240
tacaccaaag ttcaatctgg ttcattgaac aatggtgatg ttgcatgggt tttgaacggt 300
aaattgaatg catcatataa ttgtgttgac agacatgcct ttgctaatacc cgacaagcca 360
gctttgatct atgaagctga tgacgaatcc gacaacaaaa tcatcacatt tggatgaatta 420
ctcagaaaag tttcccaaat cgctggtgtc ttaaaaagct ggggcgttaa gaaaggtgac 480
acagtggcta tctattttgcc aatgattcca gaagcgggtca ttgctatggt ggctgtggct 540

2014_03_12_107345_00466_ST25

cgtattggtg ctattcactc tgttgtcttt gctgggttct ccgctggttc gttgaaagat	600
cgtgtcgttg acgctaattc taaagtgggc atcacttggtg atgaaggtaa aagaggtggt	660
aagaccatca acactaaaaa aattgttgac gaaggtttga acggagtcga tttggtttcc	720
cgtatcttgg ttttccaaag aactggtact gaaggtattc caatgaaggc cggtagagat	780
tactggtggc atgaggaggc cgctaagcag agaacttacc tacctcctgt ttcattgtgac	840
gctgaagatc ctctatTTTT attatacact tccggttcca ctggttctcc aaaggggtgtc	900
gttcacacta cagggtggta tttattaggt gccgctttaa caactagata cgTTTTtgat	960
attcaccag aagatgttct cttcactgcc ggtgacgtcg gctggatcac gggtcacacc	1020
tatgctctat atggtccatt aaccttgggt accgcctcaa taattttcga atccactcct	1080
gcctaccag attatggtag atattggaga attatccaac gtcacaaggc taccatttct	1140
tatgtggctc caactgcttt aagattaatc aaacgtgtag gtgaagccga aattgccaaa	1200
tatgacactt cctcattacg tgtcttgggt tccgtcgggtg aaccaatctc tccagactta	1260
tgggaatggt atcatgaaaa agtgggtaac aaaaactgtg tcatttgtga cactatgtgg	1320
caaacagagt ctggttctca ttttaattgct cttttggcag gtgctgtccc aacaaaacct	1380
ggttctgcta ccgtgccatt ctttgggtatt aacgcttgta tcattgacct tgttacaggt	1440
gtggaattag aaggtaatga tgtcgaagggt gtccttgccg ttaaatacacc atggccatca	1500
atggctagat ctgtttggaa ccaccacgac cgttacatgg atacttactt gaaaccttat	1560
cctggtcact atttcacagg tgatggtgct ggtagagatc atgatggtta ctactggatc	1620
aggggtagag ttgacgacgt tgtaaatgtt tccggtcata gattatccac atcagaaatt	1680
gaagcatcta tctcaaatca cgaaaacgtc tcggaagctg ctgttgctcg tattccagat	1740
gaattgaccg gtcaaaccgt cgttgcatat gtttccctaa aagatggtta tctacaaaac	1800
aacgctactg aagggtgatgc agaacacatc acaccagata atttacgtag agaattgatc	1860
ttacaagtta ggggtgagat tggtcctttc gcctcaccaa aaaccattat tctagttaga	1920
gatctaccaa gaacaaggtc aggaaagatt atgagaagag ttctaagaaa ggttgcttct	1980
aacgaagccg aacagctagg tgacctaact actttggcca acccagaagt tgtacctgcc	2040
atcatttctg ctgtagagaa ccaatttttc tctcaaaaaa agaaataact taaatgagaa	2100
aaatttcgta atgagataaa atttcgctcc ttttctgttt tctattttct attttccaa	2160
cttttgctct attcagttat aaattactat ttatccatca gttaaaaaac aagatctttt	2220
actggtcagc taggaaagcg aaaatacaaa gactttatgc actatccccg cgtgcttggc	2280
cggccgt	2287

<210> 18
 <211> 683
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>

<221> misc_feature

<222> (1)..(683)

<223> *Saccharomyces cerevisiae* ACS2 protein sequence

<400> 18

Met Thr Ile Lys Glu His Lys Val Val Tyr Glu Ala His Asn Val Lys
1 5 10 15

Ala Leu Lys Ala Pro Gln His Phe Tyr Asn Ser Gln Pro Gly Lys Gly
20 25 30

Tyr Val Thr Asp Met Gln His Tyr Gln Glu Met Tyr Gln Gln Ser Ile
35 40 45

Asn Glu Pro Glu Lys Phe Phe Asp Lys Met Ala Lys Glu Tyr Leu His
50 55 60

Trp Asp Ala Pro Tyr Thr Lys Val Gln Ser Gly Ser Leu Asn Asn Gly
65 70 75 80

Asp Val Ala Trp Phe Leu Asn Gly Lys Leu Asn Ala Ser Tyr Asn Cys
85 90 95

Val Asp Arg His Ala Phe Ala Asn Pro Asp Lys Pro Ala Leu Ile Tyr
100 105 110

Glu Ala Asp Asp Glu Ser Asp Asn Lys Ile Ile Thr Phe Gly Glu Leu
115 120 125

Leu Arg Lys Val Ser Gln Ile Ala Gly Val Leu Lys Ser Trp Gly Val
130 135 140

Lys Lys Gly Asp Thr Val Ala Ile Tyr Leu Pro Met Ile Pro Glu Ala
145 150 155 160

Val Ile Ala Met Leu Ala Val Ala Arg Ile Gly Ala Ile His Ser Val
165 170 175

Val Phe Ala Gly Phe Ser Ala Gly Ser Leu Lys Asp Arg Val Val Asp
180 185 190

Ala Asn Ser Lys Val Val Ile Thr Cys Asp Glu Gly Lys Arg Gly Gly
195 200 205

Lys Thr Ile Asn Thr Lys Lys Ile Val Asp Glu Gly Leu Asn Gly Val
210 215 220

Asp Leu Val Ser Arg Ile Leu Val Phe Gln Arg Thr Gly Thr Glu Gly
225 230 235 240

Ile Pro Met Lys Ala Gly Arg Asp Tyr Trp Trp His Glu Glu Ala Ala

245

250

255

Lys Gln Arg Thr Tyr Leu Pro Pro Val Ser Cys Asp Ala Glu Asp Pro
260 265 270

Leu Phe Leu Leu Tyr Thr Ser Gly Ser Thr Gly Ser Pro Lys Gly Val
275 280 285

Val His Thr Thr Gly Gly Tyr Leu Leu Gly Ala Ala Leu Thr Thr Arg
290 295 300

Tyr Val Phe Asp Ile His Pro Glu Asp Val Leu Phe Thr Ala Gly Asp
305 310 315 320

Val Gly Trp Ile Thr Gly His Thr Tyr Ala Leu Tyr Gly Pro Leu Thr
325 330 335

Leu Gly Thr Ala Ser Ile Ile Phe Glu Ser Thr Pro Ala Tyr Pro Asp
340 345 350

Tyr Gly Arg Tyr Trp Arg Ile Ile Gln Arg His Lys Ala Thr His Phe
355 360 365

Tyr Val Ala Pro Thr Ala Leu Arg Leu Ile Lys Arg Val Gly Glu Ala
370 375 380

Glu Ile Ala Lys Tyr Asp Thr Ser Ser Leu Arg Val Leu Gly Ser Val
385 390 395 400

Gly Glu Pro Ile Ser Pro Asp Leu Trp Glu Trp Tyr His Glu Lys Val
405 410 415

Gly Asn Lys Asn Cys Val Ile Cys Asp Thr Met Trp Gln Thr Glu Ser
420 425 430

Gly Ser His Leu Ile Ala Pro Leu Ala Gly Ala Val Pro Thr Lys Pro
435 440 445

Gly Ser Ala Thr Val Pro Phe Phe Gly Ile Asn Ala Cys Ile Ile Asp
450 455 460

Pro Val Thr Gly Val Glu Leu Glu Gly Asn Asp Val Glu Gly Val Leu
465 470 475 480

Ala Val Lys Ser Pro Trp Pro Ser Met Ala Arg Ser Val Trp Asn His
485 490 495

His Asp Arg Tyr Met Asp Thr Tyr Leu Lys Pro Tyr Pro Gly His Tyr
500 505 510

Phe Thr Gly Asp Gly Ala Gly Arg Asp His Asp Gly Tyr Tyr Trp Ile

515

520

525

Arg Gly Arg Val Asp Asp Val Val Asn Val Ser Gly His Arg Leu Ser
530 535 540

Thr Ser Glu Ile Glu Ala Ser Ile Ser Asn His Glu Asn Val Ser Glu
545 550 555 560

Ala Ala Val Val Gly Ile Pro Asp Glu Leu Thr Gly Gln Thr Val Val
565 570 575

Ala Tyr Val Ser Leu Lys Asp Gly Tyr Leu Gln Asn Asn Ala Thr Glu
580 585 590

Gly Asp Ala Glu His Ile Thr Pro Asp Asn Leu Arg Arg Glu Leu Ile
595 600 605

Leu Gln Val Arg Gly Glu Ile Gly Pro Phe Ala Ser Pro Lys Thr Ile
610 615 620

Ile Leu Val Arg Asp Leu Pro Arg Thr Arg Ser Gly Lys Ile Met Arg
625 630 635 640

Arg Val Leu Arg Lys Val Ala Ser Asn Glu Ala Glu Gln Leu Gly Asp
645 650 655

Leu Thr Thr Leu Ala Asn Pro Glu Val Val Pro Ala Ile Ile Ser Ala
660 665 670

Val Glu Asn Gln Phe Phe Ser Gln Lys Lys Lys
675 680

<210> 19
<211> 2137
<212> DNA
<213> Streptomyces sp.

<220>
<221> misc_feature
<222> (1)..(2137)
<223> Streptomyces sp. CL190 npHT7 gene sequence

<400> 19
cctgcaggcc gtcgagggcg cctggaagga ctacgcggag caggacggcc ggctgctgga 60
ggagttcgcg gcgttcgtct accaccagcc gtacacgaag atggcctaca aggcgcaccg 120
ccacctgctg aacttcaacg gctacgacac cgacaaggac gccatcgagg gcgccctcgg 180
ccagacgacg gcgtacaaca acgtcatcgg caacagctac accgcgtcgg tgtacctggg 240
cctggccgcc ctgctcgacc aggcggacga cctgacgggc cgttccatcg gcttcctgag 300
ctacggctcg ggcagcgtcg ccgagttctt ctcgggcacc gtcgtcgccg ggtaccgcga 360
gcgtctgctg accgaggcga accaggaggc gatcgcccgg cgcaagagcg tcgactacgc 420

2014_03_12_107345_00466_ST25

```

cacctaccgc gagctgcacg agtacacgct cccgtccgac ggcggcgacc acgccacccc 480
ggtgcagacc accggcccct tccggctggc cgggatcaac gaccacaagc gcatctacga 540
ggcgcgctag cgacaccctt cggcaacggg gtgcgccact gttcggcgca ccccggtgccg 600
ggctttcgca cagctattca cgaccatttg aggggcgggc agccgcatga ccgacgtccg 660
attccgcatt atcggtagcg gtgcctacgt accggaacgg atcgtctcca acgatgaagt 720
cggcgcgccc gccgggggtg acgacgactg gatcacccgc aagaccggta tccggcagcg 780
tcgctggggc gccgacgacc agggcacctc ggacctggcc acggccgcgg ggcgggcagc 840
gctgaaagcg gcgggcatca cgcccgagca gctgaccgtg atcgcggtcg ccacctccac 900
gccggaccgg ccgcagccgc ccacggcggc ctatgtccag caccacctcg gtgcgaccgg 960
cactgcggcg ttcgacgtca acgcggtctg ctccggcacc gtgttcgcgc tgtcctcggt 1020
ggcgggcacc ctctgtgacc ggggcgggta cgcgctggtc atcggcgcgg acctgtactc 1080
gcgcatactc aaccgggccg accgcaagac ggtcgtgctg ttcggggacg gcgccggcgc 1140
aatggtcctc gggccgacct cgaccggcac gggcccatc gtccggcgcg tcgccctgca 1200
caccttcggc ggcctcaccg acctgatccg tgtgcccgcg ggcggcagcc gccagccgt 1260
ggacacggat ggcctcgacg cgggactgca gtacttcgcg atggacgggc gtgaggtgcg 1320
ccgcttcgtc acggagcacc tgccgcagct gatcaagggc ttcctgcacg aggccggggt 1380
cgacgccgcc gacatcagcc acttcgtgcc gcatcaggcc aacggtgtca tgctcgacga 1440
ggtcttcggc gagctgcatc tgccgcgggc gaccatgcac cggacggtcg agacctacgg 1500
caacacggga gcggcctcca tcccgatcac catggacgcg gccgtgcgcg ccggttcctt 1560
ccggccgggc gagctggtcc tgctggccgg gttcggcggc ggcattggccg cgagcttcgc 1620
cctgatcgag tggtagtcgc ccgtaccacc acagcgggcc ggcgccacct gttccctgcg 1680
ccgggccgcc ctcggggcct ttaggccccca caccgccccca gccgacggat tcagtcgcgg 1740
cagtacctca gatgtccgct gcgacggcgt cccggagagc cggggcgaga tcgcgggccc 1800
ccttctgctc gtccccggcc cctcccgcga gcaccaccg cggcggacgg ccgccgtcct 1860
ccgcgatacg ccgggcgagg tcgcaggcga gcacgccgga cccggagaag ccccccagca 1920
ccagcgaccg gccgactccg tgcgcgccca gggcaggctg cgcgccgtcg acgtcggtag 1980
gcagcaccag gagtcctgc gggccggcgt agaggtcggc cagccggtcg tagcaggtcg 2040
cgggcgcgcc cggcggcggg atcagacaga tcgtgcccgc ccgtcgtgc ctcgccgcc 2100
gcagcgtgac cagcggaatg tcccgccag ctccgga 2137

```

<210> 20
 <211> 325
 <212> PRT
 <213> Streptomyces sp.

<220>
 <221> misc_feature

<222> (1)..(325)

<223> Streptomyces sp. CL190 acetyl-CoA:malonyl-CoA acyltransferase
protein sequence

<400> 20

Arg Phe Arg Ile Ile Gly Thr Gly Ala Tyr Val Pro Glu Arg Ile Val
1 5 10 15

Ser Asn Asp Glu Val Gly Ala Pro Ala Gly Val Asp Asp Asp Trp Ile
20 25 30

Thr Arg Lys Thr Gly Ile Arg Gln Arg Arg Trp Ala Ala Asp Asp Gln
35 40 45

Ala Thr Ser Asp Leu Ala Thr Ala Ala Gly Arg Ala Ala Leu Lys Ala
50 55 60

Ala Gly Ile Thr Pro Glu Gln Leu Thr Val Ile Ala Val Ala Thr Ser
65 70 75 80

Thr Pro Asp Arg Pro Gln Pro Pro Thr Ala Ala Tyr Val Gln His His
85 90 95

Leu Gly Ala Thr Gly Thr Ala Ala Phe Asp Val Asn Ala Val Cys Ser
100 105 110

Gly Thr Val Phe Ala Leu Ser Ser Val Ala Gly Thr Leu Val Tyr Arg
115 120 125

Gly Gly Tyr Ala Leu Val Ile Gly Ala Asp Leu Tyr Ser Arg Ile Leu
130 135 140

Asn Pro Ala Asp Arg Lys Thr Val Val Leu Phe Gly Asp Gly Ala Gly
145 150 155 160

Ala Met Val Leu Gly Pro Thr Ser Thr Gly Thr Gly Pro Ile Val Arg
165 170 175

Arg Val Ala Leu His Thr Phe Gly Gly Leu Thr Asp Leu Ile Arg Val
180 185 190

Pro Ala Gly Gly Ser Arg Gln Pro Leu Asp Thr Asp Gly Leu Asp Ala
195 200 205

Gly Leu Gln Tyr Phe Ala Met Asp Gly Arg Glu Val Arg Arg Phe Val
210 215 220

Thr Glu His Leu Pro Gln Leu Ile Lys Gly Phe Leu His Glu Ala Gly
225 230 235 240

Val Asp Ala Ala Asp Ile Ser His Phe Val Pro His Gln Ala Asn Gly
245 250 255

Val Met Leu Asp Glu Val Phe Gly Glu Leu His Leu Pro Arg Ala Thr
260 265 270

Met His Arg Thr Val Glu Thr Tyr Gly Asn Thr Gly Ala Ala Ser Ile
275 280 285

Pro Ile Thr Met Asp Ala Ala Val Arg Ala Gly Ser Phe Arg Pro Gly
290 295 300

Glu Leu Val Leu Leu Ala Gly Phe Gly Gly Gly Met Ala Ala Ser Phe
305 310 315 320

Ala Leu Ile Glu Trp
325

<210> 21
<211> 1287
<212> DNA
<213> Pseudomonas mevalonii

<220>
<221> misc_feature
<222> (1)..(1287)
<223> Pseudomonas mevalonii HMG-CoA reductase (mvaA) gene sequence

<400> 21
atgagcctcg attccgcct gccgcgtttc cgtaacctgt cccctgccgc ggcctggac 60
cacatcggcc agttgctcgg cctgagccac gacgatgtca gcctgctggc caacgccggt 120
gccctgccga tggacatcgc caacggcatg atcgaaaacg tcacgggcac cttcgagctg 180
ccctatgccg tggccagcaa cttccagatc aatggccgtg atgtgctggt gccgctggtg 240
gtggaagagc cctcgatcgt cgccgctgct tcgtacatgg ccaagctggc ccgtgccaac 300
ggcggcttca ccacctccag cagcgccccg ctgatgcatg cccaggtaca gatcgctggc 360
atacaggacc cgctcaatgc acgcctgagc ctgctgcgcc gcaaagacga aatcattgaa 420
ctggccaacc gcaaggacca gttgctcaac agcctcggcg gcggctgccg cgacatcgaa 480
gtgcacacct tcgccgatac cccgcgtggc ccgatgctgg tggcgcacct gatcgctgat 540
gtacgcgatg ccatgggagc caacaccgtc aataccatgg ccgaggccgt tgcgccgctg 600
atggaagcca tcaccggggg ccaggtagc ctgcgcattc tgtccaacct ggccgacctg 660
cgcctggcca gggcccaggt gcggattact ccgcagcaac tggaaacggc cgaattcagt 720
ggcgaggcag tgatcgaagg catcctcgac gcctacgcct tcgctgcggt cgacccttac 780
cgcgcgcca cccacaacaa gggcatcatg aatggcatcg acccactgat cgtcgccact 840
ggcaacgact ggcgtgcagt ggaagccggc gcccatgcgt atgcctgccg cagtggtcac 900
tacggctcgc tgaccacctg ggaaaaggac aacaacggcc atttggctcg caccctggaa 960
atgccgatgc ccgtaggcct ggtcggcggc gccacaaaa cccatccgct ggcgcaactg 1020

tcgctgcgca tcctcggcgt gaaaacagcc caggcgctcg ctgagattgc cgtggccgta 1080
 ggccctggcgc aaaacctcgg ggccatgcgc gccctggcca ccgaaggcat ccagcgcggc 1140
 cacatggccc tgcatgcgcg caatattgcc gtggtggcgg gcgcccagg cgatgaggtg 1200
 gactgggttg cccggcagtt ggtggaatac cagcagctgc gcgccgaccg cgccgtagca 1260
 ctgctgaaac aaaagcgcg ccaatga 1287

<210> 22
 <211> 428
 <212> PRT
 <213> Pseudomonas mevalonii

<220>
 <221> misc_feature
 <222> (1)..(428)
 <223> Pseudomonas mevalonii hydroxymethylglutaryl -CoA reductase
 protein sequence

<400> 22

Met Ser Leu Asp Ser Arg Leu Pro Ala Phe Arg Asn Leu Ser Pro Ala
 1 5 10 15

Ala Arg Leu Asp His Ile Gly Gln Leu Leu Gly Leu Ser His Asp Asp
 20 25 30

Val Ser Leu Leu Ala Asn Ala Gly Ala Leu Pro Met Asp Ile Ala Asn
 35 40 45

Gly Met Ile Glu Asn Val Ile Gly Thr Phe Glu Leu Pro Tyr Ala Val
 50 55 60

Ala Ser Asn Phe Gln Ile Asn Gly Arg Asp Val Leu Val Pro Leu Val
 65 70 75 80

Val Glu Glu Pro Ser Ile Val Ala Ala Ala Ser Tyr Met Ala Lys Leu
 85 90 95

Ala Arg Ala Asn Gly Gly Phe Thr Thr Ser Ser Ser Ala Pro Leu Met
 100 105 110

His Ala Gln Val Gln Ile Val Gly Ile Gln Asp Pro Leu Asn Ala Arg
 115 120 125

Leu Ser Leu Leu Arg Arg Lys Asp Glu Ile Ile Glu Leu Ala Asn Arg
 130 135 140

Lys Asp Gln Leu Leu Asn Ser Leu Gly Gly Gly Cys Arg Asp Ile Glu
 145 150 155 160

Val His Thr Phe Ala Asp Thr Pro Arg Gly Pro Met Leu Val Ala His
 165 170 175

Leu Ile Val Asp Val Arg Asp Ala Met Gly Ala Asn Thr Val Asn Thr
 180 185 190
 Met Ala Glu Ala Val Ala Pro Leu Met Glu Ala Ile Thr Gly Gly Gln
 195 200 205
 Val Arg Leu Arg Ile Leu Ser Asn Leu Ala Asp Leu Arg Leu Ala Arg
 210 215 220
 Ala Gln Val Arg Ile Thr Pro Gln Gln Leu Glu Thr Ala Glu Phe Ser
 225 230 235 240
 Gly Glu Ala Val Ile Glu Gly Ile Leu Asp Ala Tyr Ala Phe Ala Ala
 245 250 255
 Val Asp Pro Tyr Arg Ala Ala Thr His Asn Lys Gly Ile Met Asn Gly
 260 265 270
 Ile Asp Pro Leu Ile Val Ala Thr Gly Asn Asp Trp Arg Ala Val Glu
 275 280 285
 Ala Gly Ala His Ala Tyr Ala Cys Arg Ser Gly His Tyr Gly Ser Leu
 290 295 300
 Thr Thr Trp Glu Lys Asp Asn Asn Gly His Leu Val Gly Thr Leu Glu
 305 310 315 320
 Met Pro Met Pro Val Gly Leu Val Gly Gly Ala Thr Lys Thr His Pro
 325 330 335
 Leu Ala Gln Leu Ser Leu Arg Ile Leu Gly Val Lys Thr Ala Gln Ala
 340 345 350
 Leu Ala Glu Ile Ala Val Ala Val Gly Leu Ala Gln Asn Leu Gly Ala
 355 360 365
 Met Arg Ala Leu Ala Thr Glu Gly Ile Gln Arg Gly His Met Ala Leu
 370 375 380
 His Ala Arg Asn Ile Ala Val Val Ala Gly Ala Arg Gly Asp Glu Val
 385 390 395 400
 Asp Trp Val Ala Arg Gln Leu Val Glu Tyr His Asp Val Arg Ala Asp
 405 410 415
 Arg Ala Val Ala Leu Leu Lys Gln Lys Arg Gly Gln
 420 425

<210> 23
 <211> 1302
 <212> DNA

<213> Silicibacter pomeroyi

<220>

<221> misc_feature

<222> (1)..(1302)

<223> Silicibacter pomeroyi hydroxymethylglutaryl-CoA reductase gene sequence

<400> 23

```

atgacaggca agacgggtca catcgatggt ttgaactcgc gcattgaaaa gatgcgagat      60
ctcgaccccc cacaacggct ggtgcgcggt gccgaggcgg cgggcctcga gcccgaggcg      120
atcagcgcgc tggcgggtaa cggcgccctg cccctctcgc tggccaacgg gatgatcgag      180
aacgtcatcg gcaaattcga actgccgctg ggcgtggcca cgaatttcac tgtgaacggc      240
cgcgactatc tgatcccgat ggcggtcgaa gagccctcgg tgggtggcggc cgcgtcctat      300
atggcgcgta tcgcgcgga gaatggcgga ttcaccgcgc atggcaccgc gcccttgatg      360
cgcgcccaga tccaggtggt cgggttggtg gatcccgagg gcgcccggca gcgtctcctc      420
gccacaagg ccgcgttcat ggaggcggcg gacgctgtcg atccggtgct tgtcgggctg      480
ggtggcggct gccgcgatat cgaggttcac gtgttcgggg atacgccggt gggcgcgatg      540
gtcgtcctgc acctgatcgt cgatgtgcgc gacgcgatgg gggccaatac ggtcaacacg      600
atggccgaac ggctggcccc cgaggtcgag cggattgccg gtggcaccgt gcggtgcgc      660
atcctgtcga acctcgccga cctgcgattg gtccggggcg ggggtggaact ggccccggaa      720
acactgacaa cgcagggtta tgacggcgcc gacgtggcgc ggggcatggt cgaggcctgc      780
gcgcttgcca tcgtcgacct ctatcgcgcg gcgaccata acaaggggat catgaacggc      840
atcgacccgg tcgtcgtcgc caccggcaat gactggcgcg cgatcgaggc gggtgcccat      900
gcctatgccg cccgcacggg tcattatacc tcgctgacct gctgggaact ggcgaatgac      960
gggcggttg tgggcacgat cgaactgccc ctggcgcttg gccttgctcg cggcgcgacc     1020
aagacgcacc cgaccgcacg ggcggcgctg gccctgatgc aggtagagac tgcaaccgaa     1080
ctggcccagg tcaccgccgc cgtgggtctg gcgcagaaca tggccgcat ccgcgcgctg     1140
gcgaccgaag gcatccagcg cggtcacatg acccttcatg cgcgcaacat cgcgatcatg     1200
gccggcgcaa caggcgccga tatcgaccgc gtcaccggg tcattgtcga agcgggcgac     1260
gtcagcgtgg cccgtgcaaa acaggtgctg gaaaacacct ga                        1302

```

<210> 24

<211> 433

<212> PRT

<213> Silicibacter pomeroyi

<220>

<221> misc_feature

<222> (1)..(433)

<223> Silicibacter pomeroyi hydroxymethylglutaryl-CoA reductase protein sequence

<400> 24

Met Thr Gly Lys Thr Gly His Ile Asp Gly Leu Asn Ser Arg Ile Glu
 1 5 10 15
 Lys Met Arg Asp Leu Asp Pro Ala Gln Arg Leu Val Arg Val Ala Glu
 20 25 30
 Ala Ala Gly Leu Glu Pro Glu Ala Ile Ser Ala Leu Ala Gly Asn Gly
 35 40 45
 Ala Leu Pro Leu Ser Leu Ala Asn Gly Met Ile Glu Asn Val Ile Gly
 50 55 60
 Lys Phe Glu Leu Pro Leu Gly Val Ala Thr Asn Phe Thr Val Asn Gly
 65 70 75 80
 Arg Asp Tyr Leu Ile Pro Met Ala Val Glu Glu Pro Ser Val Val Ala
 85 90 95
 Ala Ala Ser Tyr Met Ala Arg Ile Ala Arg Glu Asn Gly Gly Phe Thr
 100 105 110
 Ala His Gly Thr Ala Pro Leu Met Arg Ala Gln Ile Gln Val Val Gly
 115 120 125
 Leu Gly Asp Pro Glu Gly Ala Arg Gln Arg Leu Leu Ala His Lys Ala
 130 135 140
 Ala Phe Met Glu Ala Ala Asp Ala Val Asp Pro Val Leu Val Gly Leu
 145 150 155 160
 Gly Gly Gly Cys Arg Asp Ile Glu Val His Val Phe Arg Asp Thr Pro
 165 170 175
 Val Gly Ala Met Val Val Leu His Leu Ile Val Asp Val Arg Asp Ala
 180 185 190
 Met Gly Ala Asn Thr Val Asn Thr Met Ala Glu Arg Leu Ala Pro Glu
 195 200 205
 Val Glu Arg Ile Ala Gly Gly Thr Val Arg Leu Arg Ile Leu Ser Asn
 210 215 220
 Leu Ala Asp Leu Arg Leu Val Arg Ala Arg Val Glu Leu Ala Pro Glu
 225 230 235 240
 Thr Leu Thr Thr Gln Gly Tyr Asp Gly Ala Asp Val Ala Arg Gly Met
 245 250 255
 Val Glu Ala Cys Ala Leu Ala Ile Val Asp Pro Tyr Arg Ala Ala Thr
 260 265 270

His Asn Lys Gly Ile Met Asn Gly Ile Asp Pro Val Val Val Ala Thr
 275 280 285

Gly Asn Asp Trp Arg Ala Ile Glu Ala Gly Ala His Ala Tyr Ala Ala
 290 295 300

Arg Thr Gly His Tyr Thr Ser Leu Thr Arg Trp Glu Leu Ala Asn Asp
 305 310 315 320

Gly Arg Leu Val Gly Thr Ile Glu Leu Pro Leu Ala Leu Gly Leu Val
 325 330 335

Gly Gly Ala Thr Lys Thr His Pro Thr Ala Arg Ala Ala Leu Ala Leu
 340 345 350

Met Gln Val Glu Thr Ala Thr Glu Leu Ala Gln Val Thr Ala Ala Val
 355 360 365

Gly Leu Ala Gln Asn Met Ala Ala Ile Arg Ala Leu Ala Thr Glu Gly
 370 375 380

Ile Gln Arg Gly His Met Thr Leu His Ala Arg Asn Ile Ala Ile Met
 385 390 395 400

Ala Gly Ala Thr Gly Ala Asp Ile Asp Arg Val Thr Arg Val Ile Val
 405 410 415

Glu Ala Gly Asp Val Ser Val Ala Arg Ala Lys Gln Val Leu Glu Asn
 420 425 430

Thr

<210> 25
 <211> 1290
 <212> DNA
 <213> Delftia acidovorans

<220>
 <221> misc_feature
 <222> (1)..(1290)
 <223> Delftia acidovorans hydroxymethylglutaryl-CoA reductase
 nucleotide sequence

<400> 25
 atggttgccg attcgcgact gcccaatttc cgcgccctca caccggccca gcgccgggat 60
 ttcttgccg atgcctgcgg cctgtccgat gccgagcgcg ccctgctcgc tgcccccggt 120
 gccctgcccc tggcgctggc cgacggcatg atcgagaacg tgttcggcag cttcgagctg 180
 ccgctgggcg tggccggcaa cttccgcgtc aacggcccgcg acgtgctggt gcccatggcg 240
 gtggaggagc cctcggtggt ggccgccgcc tcgtacatgg ccaagctggc gcgcgaggac 300


```

gggggctttc agacctcaag cacgctgccg ctgatgcgcg cccaggtcca ggtgctgggc 360
gtgaccgatc cacacggcgc ggcctggcc gtgctgcagg cgcgtgcgca gatcatcgag 420
cgcgccaaca gccgcgacaa ggtgctgatc ggcctgggcg gcggtgcaa ggacatcgag 480
gtccatgtct tccccgacac gccgcgcggc cccatgctgg tgggccacct gatcgtggac 540
gtgcgcgacg ccatgggcgc caacaccgtc aacaccatgg ccgaatcggg ggcgccctg 600
gtcgagaaga tcacgggcgg cagcgtgcgg ctgcgcatcc tgtccaacct ggccgacctg 660
cggctggccc gcgcccgcgt gcggtcacg ccgcagacc cggccacgca ggatcgagc 720
ggcgaggaga tcatcgaagg cgtgctggac gcctatacct tcgcgcccat cgaccctac 780
cgcgcgcca cgacaacaa gggaatcatg aacggcatcg acccgtcat cgtggccacg 840
ggcaacgact ggcgcgcggt cgaggccggc gcccatgcct atgccagccg cagcggcagc 900
tacacctcgc tgacgcgctg ggaaaaggat gccggcgggc ccctggtcgg cagcatcgag 960
ctgcccctgc cgggtggcct tgtcggcggc gccaccaaga cccatccgct ggcacgcctg 1020
gcgctgaaga tcatggacct gcagtccgcc cagcagctgg gcgagatcgc cgccgccgtg 1080
ggcctggcgc agaacctggg cgccctgcgc gccctggcca ccgaaggcat tcagcgcggc 1140
cacatggccc tgcacgccc caacatcgcc ctggtggccg gcgccacggg cgacgaggtc 1200
gatgccgtgg cgcgccagct ggccgccgag cagcagctgc gcaccgaccg cgcgctggaa 1260
gtgctggccg cgctgcgcgc cagggcctga 1290

```

```

<210> 26
<211> 429
<212> PRT
<213> Delftia acidovorans

```

```

<220>
<221> misc_feature
<222> (1)..(429)
<223> Delftia acidovorans hydroxymethylglutaryl-CoA reductase protein
sequence

```

```
<400> 26
```

```
Met Val Ala Asp Ser Arg Leu Pro Asn Phe Arg Ala Leu Thr Pro Ala
1          5          10          15

```

```
Gln Arg Arg Asp Phe Leu Ala Asp Ala Cys Gly Leu Ser Asp Ala Glu
          20          25          30

```

```
Arg Ala Leu Leu Ala Ala Pro Gly Ala Leu Pro Leu Ala Leu Ala Asp
          35          40          45

```

```
Gly Met Ile Glu Asn Val Phe Gly Ser Phe Glu Leu Pro Leu Gly Val
          50          55          60

```

```
Ala Gly Asn Phe Arg Val Asn Gly Arg Asp Val Leu Val Pro Met Ala
65          70          75          80

```

Val Glu Glu Pro Ser Val Val Ala Ala Ala Ser Tyr Met Ala Lys Leu
 85 90 95
 Ala Arg Glu Asp Gly Gly Phe Gln Thr Ser Ser Thr Leu Pro Leu Met
 100 105 110
 Arg Ala Gln Val Gln Val Leu Gly Val Thr Asp Pro His Gly Ala Arg
 115 120 125
 Leu Ala Val Leu Gln Ala Arg Ala Gln Ile Ile Glu Arg Ala Asn Ser
 130 135 140
 Arg Asp Lys Val Leu Ile Gly Leu Gly Gly Gly Cys Lys Asp Ile Glu
 145 150 155 160
 Val His Val Phe Pro Asp Thr Pro Arg Gly Pro Met Leu Val Val His
 165 170 175
 Leu Ile Val Asp Val Arg Asp Ala Met Gly Ala Asn Thr Val Asn Thr
 180 185 190
 Met Ala Glu Ser Val Ala Pro Leu Val Glu Lys Ile Thr Gly Gly Ser
 195 200 205
 Val Arg Leu Arg Ile Leu Ser Asn Leu Ala Asp Leu Arg Leu Ala Arg
 210 215 220
 Ala Arg Val Arg Leu Thr Pro Gln Thr Leu Ala Thr Gln Asp Arg Ser
 225 230 235 240
 Gly Glu Glu Ile Ile Glu Gly Val Leu Asp Ala Tyr Thr Phe Ala Ala
 245 250 255
 Ile Asp Pro Tyr Arg Ala Ala Thr His Asn Lys Gly Ile Met Asn Gly
 260 265 270
 Ile Asp Pro Val Ile Val Ala Thr Gly Asn Asp Trp Arg Ala Val Glu
 275 280 285
 Ala Gly Ala His Ala Tyr Ala Ser Arg Ser Gly Ser Tyr Thr Ser Leu
 290 295 300
 Thr Arg Trp Glu Lys Asp Ala Gly Gly Ala Leu Val Gly Ser Ile Glu
 305 310 315 320
 Leu Pro Met Pro Val Gly Leu Val Gly Gly Ala Thr Lys Thr His Pro
 325 330 335
 Leu Ala Arg Leu Ala Leu Lys Ile Met Asp Leu Gln Ser Ala Gln Gln
 340 345 350

Leu Gly Glu Ile Ala Ala Ala Val Gly Leu Ala Gln Asn Leu Gly Ala
 355 360 365

Leu Arg Ala Leu Ala Thr Glu Gly Ile Gln Arg Gly His Met Ala Leu
 370 375 380

His Ala Arg Asn Ile Ala Leu Val Ala Gly Ala Thr Gly Asp Glu Val
 385 390 395 400

Asp Ala Val Ala Arg Gln Leu Ala Ala Glu His Asp Val Arg Thr Asp
 405 410 415

Arg Ala Leu Glu Val Leu Ala Ala Leu Arg Ala Arg Ala
 420 425

<210> 27
 <211> 3059
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i2235 integration construct

<400> 27
 gacggcacgg ccacgcgttt aaaccgcctc gatatttcct gtgagaagtt taaatccact 60
 aagggtttttc attgtttgctg cagatgtgtt tttccattca tcttgaaata tgcactgcta 120
 ttccgcattc cattccccta gtctttttta gttctttccg ttcgaccttc atcgaaaaat 180
 gacaaaacgc gttaggaaca acaaccaatt gcaaacaagc agtgaaacaa aaccatcaag 240
 gcccgaaaat acaagtgtgt actaatacag taagtaggtc aaatacgcaa tgaccaaaga 300
 tgccgtgaat ctagatgctt acaccgtgag cttcatgcct ttctataccg agtatcaagg 360
 accaaccgaa gagtttaagg attacaaatt cgaagatact atttactttc gtggcaagga 420
 actgaagagg gaaaagtctg cgacgccttc cagtagcgat aacacaacta gtaatacctt 480
 cagtaatggc gccatcctct cgggaaacac aataactggc aagatagttt cagtgaataa 540
 ttacgaaaga gagggcactg atcgcaacga attggcgcga ttgcaagaat tgatctccct 600
 catcgatgtc ataaatcagt aaatataagc tcacacgcgg ccagggggag cccgttgagc 660
 cattagtatc aatttgctta cctgtattcc ttactatcc tcctttttct ctttcttgat 720
 aaatgtatgt agattgcgta tatagtttcg tctaccctat gaacatattc ctttttgtaa 780
 tttcgtgtcg tttctattat gaatttcatt tataaagttt atgtacaaat atcataaaaa 840
 aagagaatct ttttaagcaa ggattttctt aacttcttcg gcgacagcat caccgacttc 900
 ggtggtactg ttggaaccac ctaaatacacc agttctgata cctgcatcca aaaccttttt 960
 aactgcatct tcaatggcct taccttcttc aggcaagttc aatgacaatt tcaacatcat 1020
 tgcagcagac aagatagtgg cgatagggtc aaccttattc tttggcaaatt ctggagcaga 1080
 accgtggcat ggttcgtaca aaccaaatac ggtgttcttg tctggcaaag aggccaagga 1140

cgcatgatggc	aacaaaccca	aggaacctgg	gataacggag	gcttcacatcg	agatgatatc	1200
accaaacatg	ttgctggtga	ttataatacc	atttaggtgg	gttggttct	taactaggat	1260
catggcggca	gaatcaatca	attgatgttg	aaccttcaat	gtagggaatt	cggttcttgat	1320
ggtttcctcc	acagtttttc	tccataatct	tgaagaggcc	aaaacattag	ctttatccaa	1380
ggaccaaata	ggcaatggtg	gctcatgttg	tagggccatg	aaagcggcca	ttcttgtgat	1440
tctttgcact	tctggaacgg	tgtattgttc	actatcccaa	gcgacaccat	caccatcgtc	1500
ttcctttctc	ttaccaaagt	aaatacctcc	cactaattct	ctgacaacaa	cgaagtcagt	1560
accttttagca	aattgtggct	tgattggaga	taagtctaaa	agagagtcgg	atgcaaagtt	1620
acatgggtctt	aagttggcgt	acaattgaag	ttctttacgg	attttttagta	aaccttggtc	1680
aggtctaaca	ctaccggtac	cccatttagg	accaccaca	gcacctaaca	aaacggcatc	1740
aaccttcttg	gaggcttcca	gcgctcatc	tggaagtggg	acacctgtag	catcgatagc	1800
agcaccacca	attaaatgat	tttcgaaatc	gaacttgaca	ttggaacgaa	catcagaaat	1860
agctttaaga	accttaatgg	cttcggctgt	gatttcttga	ccaacgtggt	cacctggcaa	1920
aacgacgatc	ttcttagggg	cagacatagg	ggcagacatt	agaatgggtat	atccttgaaa	1980
tatatatata	tattgctgaa	atgtaaaagg	taagaaaagt	tagaaagtaa	gacgattgct	2040
aaccacctat	tggaaaaaac	aataggtcct	taaataatat	tgtcaacttc	aagtattgtg	2100
atgcaagcat	ttagtcatga	acgcttctct	attctatatg	aaaagccggg	tccggcctct	2160
cacctttcct	ttttctccca	atttttcagt	tgaaaaaggt	atatgctgca	ggcgacctct	2220
gaaattaaca	aaaaatttcc	agtcacgaa	tttgattctg	tgcgatagcg	cccctgtgtg	2280
ttctcgttat	gttgaggaaa	aaaataatgg	ttgctaagag	attcgaactc	ttgcatctta	2340
cgatacctga	gtattccac	agttaactgc	ggccaagata	tttcttgaat	caggcgcctc	2400
gctcgccaa	cgccggcgga	cctcttaaat	gagaaaaatt	tcgtaatgag	ataaaatttc	2460
gctccttttc	tgttttctat	tttctatatt	cccaactttt	gctctattca	gttataaatt	2520
actatttatc	catcagttaa	aaaacaagat	cttttactgg	tcagctagga	aagcgaaaat	2580
acaaagactt	tatgcactta	gtgatata	tgtatagata	tatccatttt	tacgcactta	2640
tcatatatct	tagttatcta	aatacaatct	agttattcgt	acacaatcgc	ccctgttatc	2700
cctatagtgg	gaataaagta	atgcactgtg	acgggggttct	tcgcccggga	tagggtaaaa	2760
ggatattgcc	gttcaagaa	acttcgggga	taatcgaata	agataccgag	aaagctattg	2820
ttcgttgtgc	acgtaggatg	tatattgaac	aagcatgacc	agaatctgat	gcattacgag	2880
aaggttacgg	gatgatata	gacctccgaa	gtccatgttg	caaaatgtgc	cgactttccg	2940
cggcgctatt	tggcaciaat	ttcaggagaa	acatcactgt	cggtgttata	gaattccatc	3000
tatattgttt	tccccgtagg	catacgtcga	gcggtgttta	aaccccagcg	cctggcggg	3059

<210> 28
 <211> 8106
 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic: i74804 integration construct

<400> 28

gacggcacgg ccacgcgttt aaaccgcccg ctcgcctcat cccacggga ataaggcagc	60
cgacaaaaga aaaacgaccg aaaaggaacc agaaagaaaa aagagggtgg gcgcgccgcg	120
gacgtgtaaa aagatatgca tccagcttct atatcgcttt aactttaccg ttttgggcat	180
cgggaacgta tgtaacattg atctcctctt gggaacggtg agtgcaacga atgcgatata	240
gcaccgacca tgtgggcaaa ttcgtaataa attcgggggtg agggggattc aagacaagca	300
accttgtagt tcagctcaaa cagcgattta acggttgagt aacacatcaa aacaccgttc	360
gaggtcaagc ctggcgtggt taacaagttc ttgatatcat atataaatgt aataagaagt	420
ttggtaatat tcaattcgaa gtgttcagtc ttttacttct cttgttttat agaagaaaaa	480
acatcaagaa acatctttaa catacacaaa cacatactat cagaatacac gtcgtccaa	540
cgccggcgga ctttcagac gcgactgcct catcagtaag acccgttgaa aagaacttac	600
ctgaaaaaaaa cgaatatata cttagcgttg atgttagcgt caacaacaag aagtttaatg	660
acgcggaggc caaggcaaaa agattccttg attacgtaag ggagttagaa tcattttgaa	720
taaaaaacac gctttttcag ttcgagttta tcattatcaa tactgccatt tcaaagaata	780
cgtaataaat taatagtagt gattttccta actttattta gtcaaaaaat tagcctttta	840
attctgctgt aaccctgaca tgcccaaaat agggggcggg ttacacagaa tatataacat	900
cgtaggtgtc tgggtgaaca gtttattcct ggcattccact aaatataatg gagcccgctt	960
tttaagctgg catccagaaa aaaaaagaat cccagcacca aaatattgtt ttcttcacca	1020
accatcagtt cataggtcca ttctcttagc gcaactacag agaacagggg cacaacagg	1080
caaaaaacgg gcacaacctc aatggagtga tgcaacctgc ctggagtaaa tgatgacaca	1140
aggcaattga cccacgcatg tatctatctc attttcttac accttctatt accttctgct	1200
ctctctgatt tggaaaaagc tgaaaaaaaa ggttgaaacc agttccctga aattattccc	1260
ctacttgact aataagtata taaagacggg aggtattgat tgtaattctg taaatctatt	1320
tcttaaactt cttaaattct acttttatag ttagtctttt ttttagtttt aaaacaccaa	1380
gaacttagtt tcgacctccc gcgacctcca aaatcgaact accttcacaa tggaacattc	1440
tgtaatcgaa ccaactgtgc ccatgccgct accagccatg tttgacgctc catctggtat	1500
tttagctctt ttggacgacg ctgtgcaagc agccacctta gcccaacaac aactaagttc	1560
agttgagttg cgtcagcaag taatcaaagc cataagagtg gccggagaaa ggtatgcaca	1620
agttttggct gaaatggcag ttgctgaaac tgggtatgggt aggggtgggtg ataagtacat	1680
taagaatgtc tctcaagctc gtcatacgcc tgggtatagaa tgtttatcgg ccgaggttct	1740
tacgggtgat aatggcctaa cattgattga aaatgccctt tggggagtcg tagcttcagt	1800
cacgccaagc acaaatccag cagctacggg aattaataat gcaatctcaa tgattgcagc	1860

ggggaattca gtcgtgttcg caccacatcc ttctgccaaa aacgtctcac taaggactat	1920
ttctttactc aacaaggcca ttgtcgctac cggcggccca gaaaatttac tagttagtgt	1980
ggcaaaccct aacatcgaaa ctgcacagag attattcaga tatccgggta ttggattggt	2040
agttgtgaca ggtggtgaag ccgtcgttga agccgctagg aagcatacag ataaaagggt	2100
aattgcagcc ggcgctggta atcctcctgt tgttgtggac gaaactgctg acatacctaa	2160
agccgcaaga gcaattgtca aggggtgctt tttcgacaac aacataattt gtgctgatga	2220
aaaagttttg attgtggtag acagagttgc agatgcacta ttggcagaaa tgcaaagaaa	2280
taacgccgtc ttacttacac ccgaacagac cgaaagacta ctacccgctc ttttgtccga	2340
tattgacgaa cagggcaaag gacgtgtgaa tagagattat gttggaagag atgcggctaa	2400
attagcagcg gctattggtc tggaagttag cgaacatact cgtctactcc tggcagagac	2460
agacgctgat catccattcg ccgtgacgga gctgatgatg ccagtgttac cagtaataag	2520
agtcaagaat gtagatgatg caatcgcat ggaggttaag ctagagtcag gctgcagaca	2580
cacagctgcg atgcactcta ctaatataag aaacttaaat agaattggcta atgccatcaa	2640
tacctctatc tttgtaaaaa atggtccatg tattgcaggt ttgggttttag gcggtgaagg	2700
ttggacttca atgactatta gcaactccgac cgggtgaagg gttacaagcg ctcgtacctt	2760
tgtcagatta agaagggtgtg tcttagtcga catgtttcgg attgcttaag cggccgcgag	2820
taataattat tgcttccata taatatTTTT atatacctct tttttttatg tattagttaa	2880
ttaagtattt ttatctatct gcttatcatt ttcttttcat ataggggggg ttggtgtttt	2940
cttgcccatc agattgatgt cctccaactc ggcaactatt taaaaagggt ttttttgtaa	3000
gagaaggaga agacagatac taaaccatac gttactcgaa aaaaaaaaaa aaaaaatgga	3060
aaaagctgct atcaacaaaa gacggcctca tcaaacctaa agaaaccatg tcagcgtatg	3120
tatatacctt gtaatttacg tttccttaaa tcttctttct actaacgttt tcattattct	3180
atactctatg accaataaaa acagactgta ctttcaaaat ttaccagta ggccagcaaa	3240
taaagaaaat tataccagat tacttctgaa acacattaat cccaacaaca agtatgccat	3300
taatccgtcg ctaccccatc cccgcgtgct tggccggccg tacactgagt aatggtagtt	3360
ataagaaaga gaccgagtta gggacagtta gaggcggtgg agatattcct tatggcatgt	3420
ctggcgatga taaaactttt caaacggcag cccgatcta aaagagctga cagggaaatg	3480
gtcagaaaaa gaaacgtgca cccgcccgtc tggacgcgcc gctcaccgc acggcagaga	3540
ccaatcagta aaaatcaacg gttaacgaca ttactatata tataatatag gaagcattta	3600
atagaacagc atcgtaatat atgtgtactt tgcagttatg acgccagatg gcagtagtgg	3660
aagatattct ttattgaaaa atagcttgct accttacgta caatcttgat ccggagcttt	3720
tctttttttg ccgattaaga attcggtcga aaaaagaaaa ggagagggcc aagagggagg	3780
gcattggtga ctattgagca cgtgagtata cgtgattaag cacacaaagg cagcttgag	3840
tatgtctgtt attaatttca caggtagttc tgggtccattg gtgaaagttt gcggcttgca	3900

gagcacagag gccgcagaat gtgctctaga ttccgatgct gacttgctgg gtattatatg	3960
tgtgccaat agaaagagaa caattgaccc ggttattgca aggaaaattt caagtcttgt	4020
aaaagcatat aaaaatagtt caggcactcc gaaatacttg gttggcgtgt ttcgtaatca	4080
acctaaggag gatgttttgg ctctgggtcaa tgattacggc attgatatcg tccaactgca	4140
tggagatgag tcgtggcaag aataccaaga gttcctcggg ttgccagtta ttaaaagact	4200
cgtattttcca aaagactgca acatactact cagtgcagct tcacagaaac ctcattcgtt	4260
tattccccttg tttgattcag aagcaggtgg gacaggtgaa cttttggatt ggaactcgat	4320
ttctgactgg gttggaaggc aagagagccc cgaaagctta ctttttatgt tagctggtgg	4380
actgacgcca gaaaatgttg gtgatgcgct tagattaaat ggcgttattg gtgttgatgt	4440
aagcggaggt gtggagacaa atggtgtaaa agactctaac aaaatagcaa atttcgtcaa	4500
aaatgctaag aaataggtta ttactgagta gtattttattt aagtattggt tgtgcacttg	4560
cctgcaggcc ttttgaaaag caagcataaa agatctaaac ataaaatctg taaaataaca	4620
agatgtaaag ataatgctaa atcatttggc tttttgattg attgtacagg aaaatataca	4680
tcgcaggggg ttgactttta ccatttcacc gcaatggaat caaacttggt gaagagaaatg	4740
ttcacaggcg catagctac aatgacacgg ccggccaagc acgcggggat ggggtagcga	4800
cggattaatg gcatacttgt tgttgggatt aatgtgtttc agaagtaatc tggataaatt	4860
ttctttattt gctggcctac tgggtaaatt ttgaaagtac agtctgtttt tatttggtcat	4920
agagtataga ataatgaaaa cgtagtaga aagaagattt aaggaaacgt aaattacaag	4980
gtatatacat acgctgacat ggtttcttta ggtttgatga ggccgtcttt tgttgatagc	5040
agctttttcc attttttttt tttttgtttc gagtaacgta tggtttagta tctgtcttct	5100
ccttctctta caaaaaaacc ctttgtaaaa tagtgccgag ttggaggaca tcaatctgat	5160
gggcaagaaa acaccaacc cccctatatg aaaagaaaat gataagcaga tagataaaaa	5220
tacttaatta actaatacat aaaaataaga ggtatataaa aatattatat ggaagcaata	5280
attattactc gcggccgctt aagcaatccg aaacatgtcg actaagacac accttcttaa	5340
tctgacaaag gtacgagcgc ttgtaacacc ttcaccggtc ggagtgctaa tagtcattga	5400
agtccaacct tcaccgccta aacccaaacc tgcaatacat ggaccatttt ttacaaagat	5460
agaggatttg atggcattag ccattctatt taagtttctt atattagtag agtgcacgc	5520
agctgtgtgt ctgcagcctg actctagctt aactgccaat gcgattgcat catctacatt	5580
cttgactctt attactggta aactggcat catcagctcc gtcacggcga atggatgac	5640
agcgtctgtc tctgccagga gtagacgagt atgttcgcta acttccagac caatagccgc	5700
tgctaattta gccgatctc ttccaacata atctctattc acacgtcctt tgccctgttc	5760
gtcaatatcg gacaaaagag cgggtagtag tctttcggtc tgttcgggtg taagtaagac	5820
ggcgttattt ctttgcatth ctgccaatag tgcacgtgca actctgtcta ccacaatcaa	5880
aactttttca tcagcacaaa ttatgttggt gtcgaaagaa gcacccttga caattgctct	5940

tgcggtctta	ggtatgtcag	cagtttcgtc	cacaacaaca	ggaggattac	cagcgccggc	6000
tgcaattaac	cttttatctg	tatgcttcct	agcggttca	acgacggctt	caccacctgt	6060
cacaactaac	aatccaatac	ccggatatct	gaataatctc	tgtgcagttt	cgatgttagg	6120
gtttgccaca	ctaactagta	aattttctgg	gccgccggta	gcgacaatgg	ccttgttgag	6180
taaagaaata	gtccttagtg	agacgttttt	ggcagaagga	tgtggtgcga	acacgactga	6240
attccccgct	gcaatcattg	agattgcatt	attaattacc	gtagctgctg	gatttgtgct	6300
tggcgtgact	gaagctacga	ctccccaaag	ggcattttca	atcaatgtta	ggccattatc	6360
acccgtaaga	acctcggccg	ataaacattc	tataccaggc	gtatgacgag	cttgagagac	6420
attcttaatg	tacttatcca	ccaccctacc	cataccagtt	tcagcaactg	ccatttcagc	6480
caaaacttgt	gcataccttt	ctccggccac	tcttatggct	ttgattactt	gctgacgcaa	6540
ctcaactgaa	cttagttggt	gttgggctaa	ggtggctgct	tgacacagct	cgtccaaaga	6600
gctaaaaata	ccagatggag	cgtcaaacad	ggctggtagc	ggcatgggca	cagttggttc	6660
gattacagaa	tgttccattg	tgaaggtagt	tcgattttgg	aggtcgcggg	aggtcgaaac	6720
taagttcttg	gtgttttaaa	actaaaaaaa	agactaacta	taaaagtaga	atttaagaag	6780
tttaagaaat	agatttacag	aattacaatc	aatacctacc	gtctttatat	acttattagt	6840
caagtagggg	aataatttca	gggaactggg	ttcaaccttt	tttttcagct	ttttccaaat	6900
cagagagagc	agaaggtaat	agaagggtga	agaaaatgag	atagatacat	gcgtgggtca	6960
attgccttgt	gtcatcattt	actccaggca	ggttgcatca	ctccattgag	gttgtgcccc	7020
ttttttgcct	gtttgtgccc	ctgttctctg	tagttgcgct	aagagaatgg	acctatgaac	7080
tgatgggttg	tgaagaaaac	aatattttgg	tgctgggatt	cttttttttt	ctggatgccca	7140
gcttaaaaag	cgggctccat	tatatattag	ggatgccagg	aataaactgt	tcaccagac	7200
acctacgatg	ttatatattc	tgtgtaacct	gccccctatt	ttgggcatgt	acgggttaca	7260
gcagaattaa	aaggctaatt	ttttgactaa	ataaagttag	gaaaatcact	actattaatt	7320
atttacgtat	tctttgaaat	ggcagtattg	ataatgataa	actcgaactg	aaaaagcgtg	7380
ttttttattc	aaaatgattc	taactccctt	acgtaatcaa	ggaatctttt	tgctttggcc	7440
tccgcgtcat	taaacttctt	gttggtgacg	ctaacattca	acgctagtat	atattcgttt	7500
ttttcaggta	agttcttttc	aacgggtctt	actgatgagg	cagtcgcgtc	tgaaagggtcc	7560
gccggcggtg	gacgagcgtg	taccaacctg	catttctttc	cgatcatatac	acaaaatact	7620
ttcatataaa	cttacttggt	cttacgtcat	aaataaatat	gtatacatat	aaattaaaaa	7680
atttggtttt	atatttttac	aaaaagaatc	gtttacttca	tttctccctt	ttaagcgata	7740
caatccatga	aaaaagagaa	aaagagagaa	caggcttggtg	ccttctttta	aacatcccac	7800
acaaaatcat	attgaattga	attttacatc	ttaagctagt	gtacaacaac	tgctatatcc	7860
aaagaaaact	aacgtggacc	gcttttagag	ttgagaaaaa	ggtttgaaaa	aaatagcaat	7920
acaaagactt	gtttcatata	taaaatacag	ggagcacatt	gagctaatat	aacataaaca	7980

ctgcgaacca attccaatca aaaggtacac atgagagcat tcccccgagt actgccat	8040
cgccatcaga gatcatataa taacatcctt cttcgaacgg cggtttaaac gcgtggccgt	8100
gccgtc	8106

<210> 29
 <211> 2404
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i76220 integration construct

<400> 29	
gacggcacgg ccacgcgttt aaaccgccgc acgtgtatgt acggctgtgt aaatatgata	60
atcatctcgg acgaacggcg tagtactctc catcccctaa aaatgttcac gtgtgactgc	120
tccatttcgc cggatgtcga gatgaccccc cccctcaaa aggcactcac ctgctgacat	180
gccgtggcaa atgattgggg tcacccctttt tttctgttat ctctaagatc caaagaaaag	240
taaaaaaaaa aggttggggg acgaattgcc gccgagcctc cgatgccatt attcaatggg	300
tattgcagtt ggggtatagt tcctcgggtg caaatagtcc tcccttcatt ttgtatataa	360
actgggcggc tattctaagc atatttctcc cttaggttat ctggtagtac gttatatctt	420
gttcttatat tttctatcta taagcaaac caaacatata aaactacta gaaagacatt	480
gccccactgt gttcgctcgt ccaacgccgg cggaccttc tcgacgtggg ctttttctt	540
gccatatgga tccgctgcac ggtcctgttc cctagcatgt acgtgagcgt atttcctttt	600
aaaccacgac gctttgtctt cattcaacgt ttcccattgt ttttttctac tattgctttg	660
ctgtgggaaa aacttatcga aagatgacga ctttttctta attctcgttt taagagcttg	720
gtgagcgcta ggagtcactg ccaggtatcg tttgaacacg gcattagtca gggaagtcatt	780
aacacagtcc tttcccgcaa ttttcttttt ctattactct tggcctcctc tagtactctc	840
tatatttttt tatgcctcgg taatgatttt catttttttt tttccacctg gcggatgact	900
cttttttttt cttagcgatt ggcattatca cataatgaat tatacattat ataaagtaat	960
gtgatttctt cgaagaatat actaaaaaat gagcaggcaa gataaacgaa ggcaaagatg	1020
acagagcaga aagccctagt aaagcgtatt acaaatgaaa ccaagattca gattgcatc	1080
tctttaaagg gtgggtcccct agcgatagag cactcgatct tcccagaaaa agaggcagaa	1140
gcagtagcag aacaggccac acaatcgcaa gtgattaacg tccacacagg tatagggttt	1200
ctggaccata tgatacatgc tctggccaag cattccgggt ggtcgctaatt cgttgagtgc	1260
attggtgact tacacataga cgaccatcac accactgaag actgcgggat tgctctcgg	1320
caagctttta aagaggccct aggggccgtg cgtggagtaa aaagggttgg atcaggattt	1380
gcgccttttg atgaggcact ttccagagcg gtggtagatc tttcgaacag gccgtacgca	1440
gtgtcgaac ttggtttgca aaggagaaa gtaggagatc tctcttgca gatgatcccg	1500
cattttcttg aaagctttgc agaggctagc agaattaccc tccacgttga ttgtctgcga	1560

ggcaagaatg atcatcaccg tagtgagagt gcgttcaagg ctcttgcggt tgccataaga	1620
gaagccacct cgccaatgg taccaacgat gttccctcca ccaaagggtgt tcttatgtag	1680
tgacaccgat tatttaaagc tgcagcatac gatatatata catgtgtata tatgtatacc	1740
tatgaatgtc agtaagtatg tatacgaaca gtatgatact gaagatgaca aggtaatgca	1800
tcattctata cgtgtcattc tgaacgaggc gcgctttcct tttttctttt tgctttttct	1860
ttttttttct cttgaactcg aggtccgccg gcgttggacg agcgtgatga tttctttcct	1920
ttttatattg acgacttttt ttttttcgtg tgtttttggt ctcttataac cgagctgctt	1980
acttattatt atttcacctt ctctttttat ttatacttat aattatttat tctttacata	2040
ctgttacaag aaactctttt ctacattaat tgcataaagt gtcaatcagc acatcctcta	2100
tatcgctatc aacaacaaat ttgacaaacc tgcctatatc ttcaggaaca actgccgcat	2160
cgctaccacc actacttggt aagtccttg agtttaatat gcactgaaat ttacctagcc	2220
gttttacaca agaccataat ccatccatgc tatcgcagta tatgattttg tgttcgtttt	2280
tcgtcttgcg aaaggcatcc tcaatggctt gtttcattga tccatcagtg tggctcgtag	2340
gtaccagcaa aaccacttca tcagcggcgt actcctggcg gtttaaacgc gtggccgtgc	2400
cgtc	2404

<210> 30
 <211> 8536
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i73830 integration construct

<400> 30	
gacggcacgg ccacgcgttt aaaccgccac ccagccaagg tagtctaaaa gctaatttct	60
ctaaaaggga gaaagtgggt gattttttat ctgcattat tatatatgca agaatagtta	120
aggtatagtt ataaagtttt atcttaattg ccacatacgt acattgacac gtagaaggac	180
tccattattt ttttcattct agcatactat tattccttgt aacgtcccag agtattccat	240
ttaattgtcc tccatttctt aacgggtgacg aaggatcacc atacaacaac tactaaagat	300
tatagtacac tctcaccttg caactattta tctgacattt gccttacttt tatctccagc	360
ttcccctcga ttttattttt caatttgatt tctaaagctt tttgcttagg cataccaaac	420
catccactca tttaacacct tttttttttt ttcgaagaca gcatccaact ttatacgttc	480
actacctttt tttttacaac aatttcattc ttcacctat gaacgctcgt ccaacgccgg	540
cggacctttc agacgcgact gcctcatcag taagaccgtg tgaaaagaac ttacctgaaa	600
aaaacgaata tatactagcg ttgaatgtta gcgtcaacaa caagaagttt aatgacgcgg	660
aggccaaggc aaaaagattc cttgattacg taaggaggtt agaattattt tgaataaaaa	720
acacgctttt tcagttcgag tttatcatta tcaatactgc ctttcaaag aatacgtaaa	780
taattaatag tagtgatttt cctaacttta tttagtcaaa aaattagcct ttttaattctg	840

ctgtaacccg	tacatgccca	aaataggggg	cgggttacac	agaatatata	acatcgtagg	900
tgtctgggtg	aacagtttat	tcctggcatc	cactaaatat	aatggagccc	gctttttaag	960
ctggcatcca	gaaaaaaaa	gaatcccagc	acaaaatat	tgttttcttc	accaaccatc	1020
agttcatagg	tccattctct	tagcgcaact	acagagaaca	ggggcacaaa	caggcaaaaa	1080
acgggcacaa	cctcaatgga	gtgatgcaac	ctgcctggag	taaatgatga	cacaaggcaa	1140
ttgaccacg	catgtatcta	tctcattttc	ttacaccttc	tattaccttc	tgctctctct	1200
gatttgga	aagctgaaaa	aaaagggtga	aaccagttcc	ctgaaattat	ttccctactt	1260
gactaataag	tatataaaga	cggtaggtat	tgattgtaat	tctgtaaatc	tatttcttaa	1320
acttcttaaa	ttctactttt	atagttagtc	ttttttttag	ttttaaaaca	ccaagaactt	1380
agtttcgacc	ttccgcgacc	tccaaaatcg	aactaccttc	acaatggctg	atttcgattc	1440
taaagaatac	ttggagttag	ttgacaagtg	gtggcgtgcc	accaactact	tgtccgctgg	1500
tatgattttc	ttgaagtcca	accattatt	ctctgttact	aataccccaa	tcaaggccga	1560
agatgtcaaa	gttaaacc	ttggtcactg	gggtactatt	tccggtcaaa	ctttcttata	1620
cgccacgct	aaccgtttga	ttaacaagta	cggctc	atgttttacg	ttggtggtcc	1680
aggtcacggt	ggtcaagtca	tggttactaa	cgcctactta	gacggtgcct	acaccgaaga	1740
ttaccagaa	attactcaag	acatcgaagg	tatgtctcat	ttgttcaagc	gtttctcttt	1800
ccctggtggt	attggttccc	atatgaccgc	tcaaactcca	ggttccttgc	acgaagggtg	1860
tgaattgggt	tactctttgt	cccatgcttt	cgggtgctgtt	ttggacaacc	cagaccaagt	1920
tgcttttgct	gtcgttggtg	atggtgaagc	tgaaactggt	ccatctatgg	cctcttgga	1980
ttccattaag	ttcttaaatg	ccaagaacga	tggtgccgtt	ttgccagttt	tggatttaaa	2040
cggtttcaag	atttccaatc	caaccatttt	ttctagaatg	tctgatgaag	aaattactaa	2100
gttcttcgaa	ggtttgggtt	attcccctag	attcattgaa	aatgatgaca	ttcacgacta	2160
cgccacctac	caccaattgg	ccgctaacat	cttagatcaa	gccatcgaag	acattcaagc	2220
tattcaaaat	gacgccagag	agaatggtaa	atatcaagat	ggtgaaattc	cagcttggcc	2280
tgttattatc	gctagattgc	caaagggttg	gggtggtcca	accacgatg	cttctaataa	2340
tccaattgaa	aactctttca	gagctacca	agttccatta	ccattggaac	aacacgattt	2400
ggccaccttg	ccagaattcg	aagattggat	gaactcttac	aagccagaag	aattattcaa	2460
cgctgatggt	tccttgaagg	atgagttgaa	agctattgcc	ccaaagggtg	ataagagaat	2520
gtctgctaac	ccaatcacca	acggtggtgc	tgacagatcc	gacttgaaat	tgccaaattg	2580
gagagaattc	gctaacgaca	tcaacgacga	taccagaggt	aaggaattcg	ctgactctaa	2640
gagaaacatg	gatatggcta	ctttatccaa	ctatttaggt	gccgtttctc	aattgaaccc	2700
aaccagattc	agattcttcg	gtccagatga	aaccatgtcc	aacagattgt	ggggtttggt	2760
taatgttacc	ccacgtcaat	ggatggaaga	aatcaaggaa	ccacaagatc	aattgttgtc	2820
tccaactggt	cgtatcatcg	attcccaatt	gtctgaacac	caagctgaag	gttggttgga	2880

aggttacact	ttgactggta	gagttgggtat	ctttgcctct	tacgaatctt	tcttgagagt	2940
tgttgatacc	atggctactc	aacatttcaa	gtgggtgcgt	cacgcttccg	aacaagcttg	3000
gagaaatgac	tatccatcct	taaatttgat	cgctacctct	accgctttcc	aacaagatca	3060
taacggttat	actcaccaag	accctgggtat	gttaactcat	ttggccgaga	agaagtctaa	3120
cttcattaga	gaatatttgc	cagccgacgg	taactctttg	ttagccgttc	aagagagagc	3180
tttctctgaa	agacataagg	ttaacttatt	gatcgcttct	aaacaaccaa	gacaacaatg	3240
gttactgtt	gaagaagctg	aagtcttagc	taacgaaggt	ttgaagatta	tcgattgggc	3300
ttctactgct	ccatcttccg	atgttgatat	tacttttgct	tctgccggta	ctgaaccaac	3360
cattgagact	ttggccgcct	tatggttgat	taatcaagct	ttccctgacg	ttaagtttag	3420
atacgttaac	gttgttgaat	tgttaagatt	gcaaaagaaa	tctgaaccaa	acatgaacga	3480
cgaaagagaa	ttatctgccg	aagaatttaa	taagtacttc	caagccgaca	ctccagttat	3540
cttcggtttc	cacgcttacg	aaaacttgat	tgaatctttc	tttttcgaga	gaaagttcac	3600
cggtgatgtc	tatgttcacg	gttatagaga	agatgggtgat	atcactacca	cctacgatat	3660
gagagtctat	tcccacttgg	atcgttttcca	tcaagccaag	gaagccgccg	aaatcttgtc	3720
tgctaacggg	aaaatcgacc	aagccgctgc	cgacaccttt	attgctaaga	tggacgacac	3780
tttggccaaa	cacttccaag	ttactagaaa	tgaaggtaga	gatattgaag	aattcactga	3840
ctggacttgg	tctccattga	agtaagtga	tttactttaa	atcttgcat	taaataaatt	3900
ttctttttat	agctttatga	cttagtttca	atztatatac	tattttaatg	acattttcga	3960
ttcattgatt	gaaagctttg	tgttttttct	tgatgcgcta	ttgcattggt	cttgtctttt	4020
tcgccacatg	taatatctgt	agtagatacc	tgatacattg	tggatgctga	gtgaaatttt	4080
agttaataat	ggaggcgctc	ttaataattt	tggggatatt	ggcttatccc	cgcggtgcttg	4140
gccggccgta	cgaaaatcgt	tattgtcttg	aagggtgaaat	ttctactctt	attaatggtg	4200
aacgttaagc	tgatgctatg	atggaagctg	attgggtctta	acttgcttgt	catcttgcta	4260
atggtcattg	gctcgtgtta	ttacttaagt	tatttgact	cgttttgaac	gtaatgctaa	4320
tgatcatctt	atggaataat	agtgagtggg	ttcaggggcc	ataaagcttt	tcaattcatc	4380
tttttttttt	ttgttctttt	ttttgattcc	ggtttctttg	aaattttttt	gattcggtaa	4440
tctccgagca	gaaggaagaa	cgaaggaagg	agcacagact	tagattggta	tatatacgca	4500
tatgtgggtg	tgaagaaaca	tgaaattgcc	cagtattctt	aaccaactg	cacagaacaa	4560
aaacctgcag	gaaacgaaga	taaatcatgt	cgaaagctac	atataaggaa	cgtgctgcta	4620
ctcatcctag	tcctgttgct	gccaagctat	ttaatatcat	gcacgaaaag	caaacaaact	4680
tgtgtgcttc	attggatggt	cgtaccacca	aggaattact	ggagttagtt	gaagcattag	4740
gtcccaaaat	ttgtttacta	aaaacacatg	tggatatctt	gactgatttt	tccatggagg	4800
gcacagttaa	gccgctaaag	gcattatccg	ccaagtacaa	ttttttactc	ttcgaagaca	4860
gaaaatttgc	tgacattggg	aatacagtca	aattgcagta	ctctgcgggt	gtatacagaa	4920

tagcagaatg	ggcagacatt	acgaatgcac	acgggtgtggt	gggcccaggt	attgttagcg	4980
gtttgaagca	ggcggcggaa	gaagtaacaa	aggaacctag	aggccttttg	atgttagcag	5040
aattgtcatg	caagggctcc	ctagctactg	gagaatatac	taaggggtact	gttgacattg	5100
cgaagagtga	caaagatfff	gttatcggct	ttattgctca	aagagacatg	ggtggaagag	5160
atgaaggtta	cgattgggtg	attatgacac	ccgggtgtggg	tttagatgac	aaggagacg	5220
cattgggtca	acagtataga	accgtggatg	atgtgggtctc	tacaggatct	gacattatta	5280
ttgttggaag	aggactatff	gcaaagggaa	gggatgctaa	ggtagagggt	gaacgttaca	5340
gaaaagcagg	ctgggaagca	tatttgagaa	gatgcggcca	gcaaaactaa	aaaactgtat	5400
tataagtaaa	tgcatgtata	ctaaactcac	aaattagagc	ttcaatttaa	ttatatcagt	5460
tattaccacg	aaaatcgtta	ttgtcttgaa	ggtgaaatff	ctactcttat	taatggtgaa	5520
cgtaagctg	atgctatgat	ggaagctgat	tggtcttaac	ttgcttgtca	tcttgctaata	5580
ggtcatatgg	ctcgtgttat	tacttaagtt	atftgtactc	gttttgaaag	taatgctaata	5640
gatcatctta	tggaataata	gtgaacggcc	ggccaagcac	gcggggatgg	gatgagcttg	5700
gagcaggaag	aatacactat	actggatcta	aagagtacaa	tagatggata	agaatatttg	5760
cagcgcaaaa	aggcttcaag	cttacacaac	acggttttatt	tcgaaataat	atccttctcg	5820
aaagctttaa	cgaacgcaga	atfttcgagt	tattaaactt	aaaatacgct	gaacccgaac	5880
atagaaatat	cgaatgggaa	aaaaaaactg	cataaaggca	ttaaaagagg	agcgaatfff	5940
tttttaataa	aaatcttaata	aatcattaaa	agataaataa	tagtctatat	atacgtatat	6000
aaataaaaaa	tattcaaaaa	ataaaataaa	ctattatfff	agcgtaaagg	atggggaaag	6060
agaaaagaaa	aaaattgatc	tatcgatftc	aattcaattc	aatagatctt	tatccttgtg	6120
cttgtgcctg	aactgcggta	acggcaacaa	ctttgacgat	gtcgtcgact	gaacatcccc	6180
ttgacaaatc	gttgataggt	ttggcaaatc	cctgacatat	aggaccgatg	gcttcggcct	6240
ttgcgaatct	ttggaccaac	ttgtatccga	tgfttctctg	ctggatgtct	gggaagatca	6300
agacatttgc	cttaccagcg	acttttagatc	caggggctft	caaatctgcg	acfttcttaa	6360
ccaatgaggc	gtctaactgc	aattcaccgt	cgatgtctaa	gtcaggccta	gcctccttag	6420
ccaatfttgt	tgcttfttgta	acfttgctga	ctaattcatg	tgaggctgat	cccatggftg	6480
agaatgacaa	catggctacc	cttggctcga	tcttgacaaa	atftcttgca	gtctcagcag	6540
tggtaatgtc	gattgaagat	aactcttcag	cggtaggaca	aacatfttaca	gcgcagtcag	6600
cgaataacaa	aaaaccgtcc	tctccatact	cgcagtcagg	tactgacatc	aagaagactg	6660
atgagacgac	agatgcacct	ggtactgtft	tgacaatctg	caaaccaggc	cttaacaagt	6720
ctcctgtagt	atgtatagca	ccagatacca	aaccgtcagc	gtcacctaac	ttgaccatca	6780
ttgttgcgaa	gtagattggg	tccctgacga	ttftgtcagc	cttctccaag	gtgactcctt	6840
tgftftftct	gatctcgtag	aaagcgfttg	cgtaaccggc	ggtcttagaa	gaagfttctg	6900
ggtcgactat	ctctactccg	gccaaatfta	ctccgaatft	tgcggcgtft	tccttaatga	6960

cagactctga accgaccaag attatgtcgg caataaccgtc cctaataatc tcctctgaag	7020
ccctgatgtt cctctcttcc tcaccctctg ccaaaacgat tttcttcttg tcggccttgg	7080
ccaatccgaa gatattctcc atcaatttca ttgtgaaggt agttcgattt tggaggtcgc	7140
gggaggtcga aactaagttc ttggtgtttt aaaactaaaa aaaagactaa ctataaaagt	7200
agaatttaag aagtttaaga aatagattta cagaattaca atcaatacct accgtcttta	7260
tatacttatt agtcaagtag gggaataatt tcagggaact ggtttcaacc ttttttttca	7320
gctttttcca aatcagagag agcagaaggt aatagaaggt gtaagaaaat gagatagata	7380
catgcgtggg tcaattgcct tgtgtcatca tttactccag gcaggttgca tcaactcatt	7440
gaggttgtgc ccgttttttg cctgtttgtg cccctgttct ctgtagttgc gctaagagaa	7500
tggacctatg aactgatggt tgggtgaagaa aacaatatat ttggtgctggg attctttttt	7560
tttctggatg ccagcttaaa aagcgggctc cattatatat agtggatgcc aggaataaac	7620
tggtcaccca gacacctacg atgttatata ttctgtgtaa cccgccccct attttgggca	7680
tgtacgggtt acagcagaat taaaaggcta attttttgac taaataaagt taggaaaatc	7740
actactatta attatttacg tattctttga aatggcagta ttgataatga taaactcgaa	7800
ctgaaaaagc gtgtttttta ttcaaaatga ttctaactcc cttacgtaat caaggaatct	7860
ttttgccttg gcctccgct cattaaactt cttgttggtg acgctaacat tcaacgctag	7920
tatatattcg tttttttcag gtaagtctt ttcaacgggt cttactgatg aggcatcgc	7980
gtctgaaagg tccgccggcg ttggacgagc gctccatgct ggacttactc gtcgaagatt	8040
tcctgctact ctctatataa ttagacaccc atgttataga tttcagaaaa caatgtaata	8100
atatatggta gcctcctgaa actaccaagg gaaaaatctc aacaccaaga gtcatatctc	8160
gttggaatag cgataaatatc tctttacctc aatcttatat gcatgttatt tgctcttata	8220
attggtctct atttagggaa aaaagtcggt ttgagagctt ctcgcatgt gaaatctcaa	8280
tttgaactgc acgcaaagc tagcccatat cacgaacacc agaaagaaga aatccccaag	8340
gatcgcatac cagagtatgc tctctcatat cgttgagtat gaatgccaat aactgatca	8400
gctttacaag aaacgtaaaa tctggcacga tggtagactg aaatactttc agttaaacia	8460
cagattcatg ctttatacgg aaaaggataa cgttttgtta gctagtgagg cggtttaaac	8520
gcgtggccgt gccgtc	8536

<210> 31
 <211> 9734
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i74810 integration construct

<400> 31	
gacggcacgg ccacgcgttt aaaccgcccg ctcgcctcat cccacggga ataaggcagc	60
cgacaaaaga aaaacgaccg aaaaggaacc agaaagaaaa aagaggggtg gcgcgccgcg	120

gacgtgtaaa aagatatgca tccagcttct atatcgcttt aactttaccg ttttgggcat	180
cggaacgta tgtaacattg atctcctctt gggaacggtg agtgcaacga atgcgatata	240
gcaccgacca tgtgggcaaa ttcgtaataa attcgggggtg aggggggattc aagacaagca	300
accttgtttag tcagctcaaa cagcgattta acggttgagt aacacatcaa aacaccgttc	360
gagggtcaagc ctggcgtggt taacaagttc ttgatatcat atataaatgt aataagaagt	420
ttggtaatat tcaattcgaa gtgttcagtc ttttacttct cttgttttat agaagaaaaa	480
acatcaagaa acatctttaa catacacaaa cacatactat cagaatacac gctcgtccaa	540
cgccggcgga ctttcagac gcgactgcct catcagtaag acccgttgaa aagaacttac	600
ctgaaaaaaaa cgaatatata ctagcgttga atgttagcgt caacaacaag aagtttaatg	660
acgcggaggc caaggcaaaa agattccttg attacgtaag ggagttagaa tcattttgaa	720
taaaaaacac gctttttcag ttcgagttta tcattatcaa tactgccatt tcaaagaata	780
cgtaataaat taatagtagt gattttccta actttattta gtcaaaaaat tagcctttta	840
attctgctgt aaccctgaca tgcccaaaat agggggcggg ttacacagaa tatataacat	900
cgtaggtgtc tgggtgaaca gtttattcct ggcattccact aaatataatg gagcccgctt	960
tttaagctgg catccagaaa aaaaaagaat cccagcacca aaatattgtt ttcttcacca	1020
accatcagtt cataggtcca ttctcttagc gcaactacag agaacagggg cacaacagg	1080
caaaaaacgg gcacaacctc aatggagtga tgcaacctgc ctggagtaaa tgatgacaca	1140
aggcaattga cccacgcatg tatctatctc attttcttac accttctatt accttctgct	1200
ctctctgatt tggaaaaagc tgaaaaaaaa ggttgaaacc agttccctga aattattccc	1260
ctacttgact aataagtata taaagacggg aggtattgat tgtaattctg taaatctatt	1320
tcttaaaactt cttaaaattct acttttatag ttagtctttt ttttagtttt aaaacaccaa	1380
gaacttagtt tcgacctccc gcgacctcca aaatcgaact accttcacaa tggctgattt	1440
cgattctaaa gaatacttgg agttagttga caagtgggtg cgtgccacca actacttgct	1500
cgctggatatg attttcttga agtccaaccc attattctct gttactaata cccaatcaa	1560
ggccgaagat gtcaaagtta aaccaattgg tctctggggg actatttccg gtcaaacttt	1620
cttatacgcc cagcctaacc gtttgattaa caagtacggg ctcaacatgt tttacgttgg	1680
tgggtccaggc cacggtgggtc aagtcattgg tactaacgcc tacttagacg gtgcctacac	1740
cgaagattac ccagaaatta ctcaagacat cgaaggatat tctcatttgt tcaagcgttt	1800
ctctttccct ggtggtattg gttcccatat gaccgctcaa actccagggt ccttgcacga	1860
aggtggtgaa ttgggttact ctttgtccca tgctttcggg gctgttttgg acaaccaga	1920
ccaagttgct tttgctgtcg ttggtgatgg tgaagctgaa actggtccat ctatggcctc	1980
ttggcattcc attaagttct taaatgccaa gaacgatggg gccgttttgc cagttttgga	2040
tttaaacggg ttcaagattt ccaatccaac ctttttttct agaatgtctg atgaagaaat	2100
tactaagttc ttcgaagggt tgggttattc ccctagattc attgaaaatg atgacattca	2160

cgactacgcc	acctaccacc	aattggccgc	taacatctta	gatcaagcca	tcgaagacat	2220
tcaagctatt	caaaatgacg	ccagagagaa	tggtaaatat	caagatggtg	aaattccagc	2280
ttggcctggt	attatcgcta	gattgccaaa	gggttgggggt	ggtccaaccc	acgatgcttc	2340
taataatcca	attgaaaact	ctttcagagc	tcaccaagtt	ccattaccat	tggaacaaca	2400
cgatttggcc	accttgccag	aattcgaaga	ttggatgaac	tcttacaagc	cagaagaatt	2460
attcaacgct	gatggttcct	tgaaggatga	gttgaaagct	attgccccaa	agggtgataa	2520
gagaatgtct	gctaaccxaa	tcaccaacgg	tggtgctgac	agatccgact	tgaaattgcc	2580
aaattggaga	gaattcgcta	acgacatcaa	cgacgatacc	agaggtaagg	aattcgctga	2640
ctctaagaga	aacatggata	tggctacttt	atccaactat	ttaggtgccg	tttctcaatt	2700
gaacccaacc	agattcagat	tcttcggtcc	agatgaaacc	atgtccaaca	gattgtgggg	2760
tttgtttaat	gttaccacac	gtcaatggat	ggaagaaatc	aaggaaccac	aagatcaatt	2820
gttgtctcca	actggtcgta	tcacgattc	ccaattgtct	gaacaccaag	ctgaagggtg	2880
gttgaagggt	tacactttga	ctggtagagt	tggtatcttt	gcctcttacg	aatctttctt	2940
gagagtgtgt	gataccatgg	tcactcaaca	tttcaagtgg	ttgcgtcacg	cttccgaaca	3000
agcttgagga	aatgactatc	catccttaaa	tttgatcgct	acctctaccg	ctttccaaca	3060
agatcataac	ggttatactc	accaagaccc	tggtatgtta	actcatttgg	ccgagaagaa	3120
gtctaacttc	attagagaat	atgtgccagc	cgacggtaac	tctttgttag	ccgttcaaga	3180
gagagctttc	tctgaaagac	ataagggtta	cttattgatc	gcttctaaac	aaccaagaca	3240
acaatgggtc	actgttgaag	aagctgaagt	cttagctaac	gaagggttga	agattatcga	3300
ttgggcttct	actgctccat	cttccgatgt	tgatattact	tttgcttctg	ccggtactga	3360
accaaccatt	gagacttttg	ccgccttatg	gttgattaat	caagctttcc	ctgacgttaa	3420
gtttagatac	gttaacgttg	ttgaattggt	aagattgcaa	aagaaatctg	aaccaaacat	3480
gaacgacgaa	agagaattat	ctgccgaaga	atttaataag	tacttccaag	ccgacactcc	3540
agttatcttc	ggtttccacg	cttacgaaaa	cttgattgaa	tctttctttt	tcgagagaaa	3600
gttcaccggt	gatgtctatg	ttcacggtta	tagagaagat	ggtgatatca	ctaccaccta	3660
cgatatgaga	gtctattccc	acttggatcg	tttccatcaa	gccaaggaag	ccgccgaaat	3720
cttgtctgct	aacggtaaaa	tcgaccaagc	cgctgccgac	acctttattg	ctaagatgga	3780
cgacactttg	gcaaacactc	tccaagttac	tagaaatgaa	ggtagagata	ttgaagaatt	3840
cactgactgg	acttggcttc	cattgaagta	agtgaattta	ctttaaatct	tgcattttaa	3900
taaattttct	ttttatagct	ttatgactta	gtttcaattt	atatactatt	ttaatgacat	3960
tttcgattca	ttgattgaaa	gctttgtgtt	ttttcttgat	gcgctattgc	attgttcttg	4020
tctttttcgc	cacatgtaat	atctgtagta	gatacctgat	acattgtgga	tgctgagtga	4080
aatttttagtt	aataatggag	gcgctcttaa	taattttggg	gatattggct	tatccccgcg	4140
tgcttggccg	gccgtacact	gagtaatggt	agttataaga	aagagaccga	gttagggaca	4200

gtagagggcg	gtggagatat	tccttatggc	atgtctggcg	atgataaaac	ttttcaaacg	4260
gcagccccga	tctaaaagag	ctgacaggga	aatgggtcaga	aaaagaaacg	tgcacccgcc	4320
cgtctggacg	cgccgctcac	ccgcacggca	gagaccaatc	agtaaaaatc	aacgggttaac	4380
gacattacta	tatatataat	ataggaagca	tttaatagaa	cagcatcgta	atatatgtgt	4440
actttgcagt	tatgacgcca	gatggcagta	gtggaagata	ttctttattg	aaaaatagct	4500
tgtcacctta	cgtacaatct	tgatccggag	cttttctttt	tttgccgatt	aagaattcgg	4560
tcgaaaaaag	aaaaggagag	ggccaagagg	gagggcattg	gtgactattg	agcacgtgag	4620
tatacgtgat	taagcacaca	aaggcagctt	ggagtatgtc	tgttattaat	ttcacaggta	4680
gttctgggtcc	attgggtgaa	gtttgctggc	tgcagagcac	agaggccgca	gaatgtgctc	4740
tagattccga	tgctgacttg	ctgggtatta	tatgtgtgcc	caatagaaag	agaacaattg	4800
acccgggttat	tgcaaggaaa	atttcaagtc	ttgtaaaagc	atataaaaat	agttcaggca	4860
ctccgaaata	cttgggtggc	gtgtttcgta	atcaacctaa	ggaggatggt	ttggctctgg	4920
tcaatgatta	cggcattgat	atcgtccaac	tgcatggaga	tgagtcgtgg	caagaatacc	4980
aagagttcct	cggtttgcca	gttattaata	gactcgtatt	tccaaaagac	tgcaacatac	5040
tactcagtgc	agcttcacag	aaacctcatt	cgtttattcc	cttggttgat	tcagaagcag	5100
gtgggacagg	tgaacttttg	gattggaact	cgatttctga	ctgggttgga	aggcaagaga	5160
gccccgaaag	cttacatttt	atgttagctg	gtggactgac	gccagaaaat	gttggtgatg	5220
cgcttagatt	aaatggcggt	attgggtgtg	atgtaagcgg	aggtgtggag	acaaatggtg	5280
taaaagactc	taacaaaata	gcaaatttcg	tcaaaaatgc	taagaaatag	gttattactg	5340
agtagtattt	atttaagtat	tgtttggtga	cttgccgtga	ggccttttga	aaagcaagca	5400
taaaagatct	aaacataaaa	tctgtaaaat	aacaagatgt	aaagataatg	ctaaatcatt	5460
tggctttttg	attgattgta	caggaaaata	tacatcgtag	gggggttgact	tttaccattt	5520
caccgcaatg	gaatcaaact	tggtgaagag	aatgttcaca	ggcgcatagc	ctacaatgac	5580
acggccggcc	aagcacgcgg	ggataagcca	atatccccaa	aattattaag	agcgcctcca	5640
ttattaacta	aaatttcact	cagcatccac	aatgtatcag	gtatctacta	cagatattac	5700
atgtggcgaa	aaagacaaga	acaatgcaat	agcgcatcaa	gaaaaaacac	aaagctttca	5760
atcaatgaat	cgaaaatgtc	attaaaatag	tatataaatt	gaaactaagt	cataaagcta	5820
taaaagaaa	atttatttaa	atgcaagatt	taaagtaa	tcacttactt	caatggagac	5880
caagtccagt	cagtgaattc	ttcaatatct	ctaccttc	ttctagtaac	ttggaagtgt	5940
ttggccaaag	tgctgtccat	cttagcaata	aagggtgtcg	cagcggcttg	gtcgatttta	6000
ccgttagcag	acaagatttc	ggcggcttcc	ttggcttgat	ggaaacgatc	caagtgggaa	6060
tagactctca	tatcgtaggt	ggtagtata	tcaccatctt	ctctataacc	gtgaacatag	6120
acatcaccgg	tgaactttct	ctcgaaaaag	aaagattcaa	tcaagttttc	gtaagcgtgg	6180
aaaccgaaga	taactggagt	gtcggcttgg	aagtacttat	taaattcttc	ggcagataat	6240

tctctttcgt	cgttcatgtt	tggttcagat	ttcttttgca	atcttaacaa	ttcaacaacg	6300
ttaacgtatc	taaacttaac	gtcagggaaa	gcttgattaa	tcaaccataa	ggcggccaaa	6360
gtctcaatgg	ttggttcagt	accggcagaa	gcaaaagtaa	tatcaacatc	ggaagatgga	6420
gcagtagaag	cccaatcgat	aatcttcaaa	ccttcgttag	ctaagacttc	agcttcttca	6480
acagtgaacc	attgttgtct	tggttgttta	gaagcgatca	ataagttaac	cttatgtctt	6540
tcagagaaa	ctctctcttg	aacggctaac	aaagagttac	cgtcggctgg	caaataattct	6600
ctaatagaag	tagacttctt	ctcggccaaa	tgagttaaca	taccagggtc	ttggtgagta	6660
taaccgttat	gatcttggtg	gaaagcggta	gaggtagcga	tcaaatttaa	ggatggatag	6720
tcatttctcc	aagcttggtc	ggaagcgtga	cgcaaccact	tgaaatgttg	agtgaccatg	6780
gtatcaacaa	ctctcaagaa	agattcgtaa	gaggcaaaga	taccaactct	accagtcaaa	6840
gtgtaacctt	ccaaccaacc	ttcagcttgg	tgttcagaca	attgggaatc	gatgatacga	6900
ccagttggag	acaacaattg	atcttggttg	tccttgattt	cttccatcca	ttgacgtggg	6960
gtaacattaa	acaaacccca	caatctgttg	gacatggttt	catctggacc	gaagaatctg	7020
aatctgggtg	ggttcaattg	agaaacggca	cctaaatagt	tgataaaagt	agccatatcc	7080
atgtttctct	tagagtcagc	gaattcctta	cctctggtat	cgtcgttgat	gtcgttagcg	7140
aattctctcc	aatttggcaa	tttcaagtcg	gatctgtcag	caccaccgtt	ggtgattggg	7200
ttagcagaca	ttctcttatc	accctttggg	gcaatagctt	tcaactcatc	cttcaaggaa	7260
ccatcagcgt	tgaataattc	ttctggcttg	taagagttca	tccaatcttc	gaattctggc	7320
aagggtggcca	aatcgtgttg	ttccaatggt	aatggaactt	ggtgagctct	gaaagagttt	7380
tcaattggat	tattagaagc	atcgtgggtt	ggaccacccc	aaccctttgg	caatctagcg	7440
ataataacag	gccaagctgg	aatttcacca	tcttgatatt	taccattctc	tctggcgtca	7500
ttttgaatag	cttgaatgtc	ttcgatggct	tgatctaaga	tgttagcggc	caattggtgg	7560
taggtggcgt	agtcgtgaat	gtcatcattt	tcaatgaatc	taggggaata	acccaaacct	7620
tcgaagaact	tagtaatttc	ttcatcagac	attctagaaa	aaatggttgg	attggaaatc	7680
ttgaaaccgt	ttaaatacaa	aactggcaaa	acggcaccat	cgttcttggc	atttaagaac	7740
ttaatggaat	gccaagaggc	catagatgga	ccagtttcag	cttcaccatc	accaacgaca	7800
gcaaaagcaa	cttggctctg	gttgtccaaa	acagcaccga	aagcatggga	caaagagtaa	7860
cccaattcac	caccttcgtg	caaggaacct	ggagtttgag	cggtcatatg	ggaaccaata	7920
ccaccaggga	aagagaaaac	cttgaacaaa	tgagacatac	cttcgatgtc	ttgagtaatt	7980
tctgggtaat	cttcggtgta	ggcaccgtct	aagtaggcgt	tagtaaccat	gacttgacca	8040
ccgtgacctg	gaccaccaac	gtaaaacatg	ttgagaccgt	acttgttaat	caaacggtta	8100
gcgtgggcgt	ataagaaaag	ttgaccggaa	atagtacccc	agtgaccaat	tggtttaact	8160
ttgacatctt	cggccttgat	tggggtatta	gtaacagaga	ataatgggtt	ggacttcaag	8220
aaaatcatat	cagcggacaa	gtagttgggtg	gcacgccacc	acttgtcaac	taactccaag	8280

tattcttttag aatcgaaatc agccattgtg aaggtagttc gattttggag gtcgcgggag	8340
gtcgaaacta agttcttgggt gttttaaaac taaaaaaaag actaactata aaagtagaat	8400
ttaagaagtt taagaaatag atttacagaa ttacaatcaa tacctaccgt ctttatatac	8460
ttattagtca agtaggggaa taatttcagg gaactggttt caaccttttt tttcagcttt	8520
ttccaaatca gagagagcag aaggtaatag aagggtgaag aaaatgagat agatacatgc	8580
gtgggtcaat tgccttgtgt catcatttac tccaggcagg ttgcatcact ccattgaggt	8640
tgtgcccgtt ttttgccgtg ttgtgcccct gttctctgta gttgcgctaa gagaatggac	8700
ctatgaactg atggttgggtg aagaaaacaa tattttgggtg ctgggattct ttttttttct	8760
ggatgccagc ttaaaaagcg ggctccatta tatttagtgg atgccaggaa taaactgttc	8820
accagacac ctacgatgtt atatatcttg tgtaaccgc cccctatttt gggcatgtac	8880
gggttacagc agaattaaaa ggctaatttt ttgactaaat aaagttagga aaatcactac	8940
tattaattat ttacgtattc ttgaaatgg cagtattgat aatgataaac tcgaactgaa	9000
aaagcgtgtt ttttattcaa aatgattcta actcccttac gtaatcaagg aatctttttg	9060
ccttggcctc cgcgtcatta aacttcttgt tgttgacgct aacattcaac gctagtatat	9120
attcgttttt ttcaggtaa ttcttttcaa cgggtcttac tgatgaggca gtcgcgtctg	9180
aaaggtccgc cggcgttggg cgagcgtgta ccaacctgca tttctttccg tcatatacac	9240
aaaatacttt catataaact tacttgggtc tacgtcataa ataaatatgt atacatataa	9300
attaaaaaat ttggttttat atttttacaa aaagaatcgt ttacttcatt tctccctttt	9360
aagcgataca atccatgaaa aaagagaaaa agagagaaca ggcttgtgcc ttctttaaaa	9420
catcccacac aaaatcatat tgaattgaat ttacatctt aagctagtgt acaacaactg	9480
ctatatccaa agaaaactaa cgtggaccgc ttttagagtt gagaaaaagg tttgaaaaaa	9540
atagcaatac aaagacttgt ttcatatata aaatacaggg agcacattga gctaataata	9600
cataaacact gcgaaccaat tccaatcaaa aggtacacat gagagcattc ccccgagtac	9660
tgccatttcg ccatcagaga tcatataata acatccttct tcgaacggcg gtttaaacgc	9720
gtggccgtgc cgtc	9734

<210> 32
 <211> 7980
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i76221 integration construct

<400> 32	
gacggcacgg ccacgcgttt aaaccgccgc acgtgtatgt acggctgtgt aaatatgata	60
atcatctcgg acgaacggcg tagtactctc catcccctaa aaatgttcac gtgtgactgc	120
tccatttcgc cggatgtcga gatgaccccc cccctcaaa aggcactcac ctgctgacat	180
gccgtggcaa atgattgggg tcatcctttt tttctgttat ctctaagatc caaagaaaag	240

taaaaaaaaa	aggttggggt	acgaattgcc	gccgagcctc	cgatgccatt	attcaatggg	300
tattgcagtt	ggggtatagt	tcctcgggtg	caaatagttc	tcccttcatt	ttgtatataa	360
actgggcggc	tattctaagc	atattttctc	cttaggttat	ctggtagtac	gttatatctt	420
gttcttatat	tttctatcta	taagcaaaac	caaacatata	aaaactacta	gaaagacatt	480
gccccactgt	gttcgctcgt	ccaacgccgg	cggacctttc	agacgcgact	gcctcatcag	540
taagaccggt	tgaaaagaac	ttacctgaaa	aaaacgaata	tatactagcg	ttgaatgtta	600
gcgtaacaa	caagaagttt	aatgacgcgg	aggccaaggc	aaaaagattc	cttgattacg	660
taagggagtt	agaatcattt	tgaataaaaa	acacgctttt	tcagttcgag	tttatcatta	720
tcaatactgc	catttcaaag	aatacgtaaa	taattaatag	tagtgatttt	cctaacttta	780
tttagtcaaa	aaattagcct	tttaattctg	ctgtaaccgg	tacatgcca	aaataggggg	840
cgggttacac	agaatatata	acatcgtagg	tgtctgggtg	aacagtttat	tcctggcatc	900
cactaaatat	aatggagccc	gctttttaag	ctggcatcca	gaaaaaaaaa	gaatcccagc	960
acaaaaatat	tgttttcttc	accaaccatc	agttcatagg	tccattctct	tagcgcaact	1020
acagagaaca	ggggcacaaa	caggcaaaaa	acgggcacaa	cctcaatgga	gtgatgcaac	1080
ctgcctggag	taaatgatga	cacaaggcaa	ttgaccacg	catgtatcta	tctcattttc	1140
ttacaccttc	tattaccttc	tgctctctct	gatttggaag	aagctgaaaa	aaaaggttga	1200
aaccagttcc	ctgaaattat	tcccctactt	gactaataag	tatataaaga	cggtaggtat	1260
tgattgtaat	tctgtaaata	tatttcttaa	acttcttaaa	ttctactttt	atagtttagtc	1320
tttttttttag	ttttaaaaca	ccaagaactt	agtttcgacc	tcccgcgacc	tccaaaatcg	1380
aactaccttc	acaatggaac	attctgtaat	cgaaccaact	gtgcccattg	cgctaccagc	1440
catgtttgac	gctccatctg	gtattttttag	ctctttggac	gacgctgtgc	aagcagccac	1500
cttagcccaa	caacaactaa	gttcagttga	gttgcgtcag	caagtaatca	aagccataag	1560
agtggccgga	gaaaggtatg	cacaagtttt	ggctgaaatg	gcagttgctg	aaactggtat	1620
gggtaggggtg	gtggataagt	acattaagaa	tgtctctcaa	gctcgtcata	cgcttggtat	1680
agaatgttta	tcggccgagg	ttcttacggg	tgataatggc	ctaacattga	ttgaaaatgc	1740
cccttgggga	gtcgtagctt	cagtcacgcc	aagcacaaat	ccagcagcta	cggtaatata	1800
taatgcaatc	tcaatgattg	cagcggggaa	ttcagtcgtg	ttcgaccac	atccttctgc	1860
caaaaacgtc	tcactaagga	ctatttcttt	actcaacaag	gccattgtcg	ctaccggcgg	1920
cccagaaaat	ttactagtta	gtgtggcaaa	ccctaacatc	gaaactgcac	agagattatt	1980
cagatatccg	ggtattggat	tgttagttgt	gacaggtggg	gaagccgtcg	ttgaagccgc	2040
taggaagcat	acagataaaa	ggttaattgc	agccggcgct	ggtaatcctc	ctgttggtgt	2100
ggacgaaact	gctgacatac	ctaaagccgc	aagagcaatt	gtcaaggggtg	cttctttcga	2160
caacaacata	atttgtgctg	atgaaaaagt	tttgattgtg	gtagacagag	ttgcagatgc	2220
actattggca	gaaatgcaaa	gaaataacgc	cgtcttactt	acaccgaac	agaccgaaag	2280

actactaccc	gctcttttgt	ccgatattga	cgaacagggc	aaaggacgtg	tgaatagaga	2340
ttatgttga	agagatgcgg	ctaaattagc	agcggctatt	ggctctggaag	ttagcgaaca	2400
tactcgtcta	ctcctggcag	agacagacgc	tgatcatcca	ttcgccgtga	cggagctgat	2460
gatgccagt	ttaccagtaa	taagagtcaa	gaatgtagat	gatgcaatcg	cattggcagt	2520
taagctagag	tcaggctgca	gacacacagc	tgcatgcac	tctactaata	taagaaactt	2580
aaatagaatg	gctaatagcc	tcaatacctc	tatcttttga	aaaaatggtc	catgtattgc	2640
aggtttgggt	ttaggcgggt	aagggttgac	ttcaatgact	attagcactc	cgaccgggtga	2700
aggtgttaca	agcgcctgta	cctttgtcag	attaagaagg	tgtgtcttag	tcgacatggt	2760
tcggattgct	taagcggccg	cgagtaataa	ttattgcttc	catataatat	ttttatatac	2820
ctcttatttt	tatgtattag	ttaattaagt	atctgttctt	cattttcttt		2880
tcatataggg	ggggttgggt	ttttcttgcc	catcagattg	atgtcctcca	actcggcact	2940
attttacaaa	gggttttttt	gtaagagaag	gagaagacag	atactaaacc	atacgttact	3000
cgaacaaaaa	aaaaaaaaaa	tggaaaaagc	tgctatcaac	aaaagacggc	ctcatcaaac	3060
ctaaagaaac	catgtcagcg	tatgtatata	ccttgtaatt	tacgtttcct	taaatcttct	3120
ttctactaac	gttttcatta	ttctatactc	tatgaccaat	aaaaacagac	tgtactttca	3180
aaatttacc	agtaggccag	caaataaaga	aaattatacc	agattacttc	tgaaacacat	3240
taatcccaac	aacaagtatg	ccattaatcc	gtcgtaccc	catccccg	tgcttggccg	3300
gccgtttctc	gacgtggg	ttttcttg	catatggatc	cgctgcacgg	tcctgttccc	3360
tagcatgtac	gtgagcgtat	ttccttttaa	accacgacgc	tttgtcttca	ttcaacgttt	3420
cccattgttt	ttttctacta	ttgctttgct	gtgggaaaaa	cttatcgaaa	gatgacgact	3480
ttttcttaat	tctcgtttta	agagcttgg	gagcgctagg	agtcactgcc	aggtatcggt	3540
tgaacacggc	attagtcagg	gaagtcataa	cacagtcctt	tcccgcatt	ttctttttct	3600
attactcttg	gcctcctcta	gtacactcta	tattttttta	tgccctcggt	atgattttca	3660
tttttttttt	tccacctagc	ggatgactct	ttttttttct	tagcgattgg	cattatcaca	3720
taatgaatta	tacattatat	aaagtaatgt	gatttcttcg	aagaatatac	taaaaaatga	3780
gcaggcaaga	taaacgaagg	caaagatgac	agagcagaaa	gccctagtaa	agcgtattac	3840
aaatgaaacc	aagattcaga	ttgcgatctc	tttaaaggg	gggtcccctag	cgatagagca	3900
ctcgatcttc	ccagaaaaag	aggcagaagc	agtagcagaa	caggccacac	aatcgcaagt	3960
gattaacgtc	cacacaggta	tagggtttct	ggaccatatg	atacatgctc	tggccaagca	4020
ttccggctgg	tcgctaatac	ttgagtgc	tggtgactta	cacatagacg	accatcacac	4080
cactgaagac	tgcgggattg	ctctcggta	agctttttaa	gaggccctag	gggccgtgcg	4140
tggagtaaaa	aggtttggat	caggatttgc	gcctttggat	gaggcacttt	ccagagcggt	4200
ggtagatctt	tcgaacaggc	cgtacgcagt	tgctgaactt	ggtttgcaaa	gggagaaagt	4260
aggagatctc	tcttgcgaga	tgatcccgca	ttttcttgaa	agctttgcag	aggctagcag	4320

aattaccctc	cacgttgatt	gtctgcgagg	caagaatgat	catcaccgta	gtgagagtgc	4380
gttcaaggct	cttgcggttg	ccataagaga	agccacctcg	cccaatggta	ccaacgatgt	4440
tccctccacc	aaaggtgttc	ttatgtagtg	acaccgatta	tttaaagctg	cagcatacga	4500
tatatataca	tgtgtatata	tgtataccta	tgaatgtcag	taagtatgta	tacgaacagt	4560
atgatactga	agatgacaag	gtaatgcatc	attctatacg	tgtcattctg	aacgaggcgc	4620
gctttccttt	tttctttttg	ctttttcttt	ttttttctct	tgaactcgac	ggccggccaa	4680
gcacgcgggg	atggggtagc	gacggattaa	tggcatactt	gttgttggga	ttaatgtggt	4740
tcagaagtaa	tctgggataa	ttttctttat	ttgctggcct	actgggtaaa	ttttgaaagt	4800
acagtctgtt	tttattgggtc	atagagtata	gaataatgaa	aacgttagta	gaaagaagat	4860
ttaaggaaac	gtaaattaca	aggtatatac	atacgctgac	atggtttctt	taggtttgat	4920
gaggccgtct	tttgttgata	gcagcttttt	ccattttttt	tttttttggt	tcgagtaacg	4980
tatggtttag	tatctgtctt	ctccttctct	tacaaaaaaa	ccctttgtaa	aatagtgccg	5040
agttggagga	catcaatctg	atgggcaaga	aaacaccaac	ccccctata	tgaaaagaaa	5100
atgataagca	gatagataaa	aatacttaat	taactaatac	ataaaaaata	gaggtatata	5160
aaaatattat	atggaagcaa	taattattac	tcgcgggccg	ttaagcaatc	cgaacatgt	5220
cgactaagac	acaccttctt	aatctgacaa	aggtacgagc	gcttgtaaca	ccttcaccgg	5280
tcggagtgc	aatagtcatt	gaagtccaac	cttcaccgcc	taaacccaaa	cctgcaatac	5340
atggaccatt	ttttacaaag	atagaggtat	tgatggcatt	agccattcta	tttaagtttc	5400
ttatattagt	agagtgcac	gcagctgtgt	gtctgcagcc	tgactctagc	tttaactgcca	5460
atgcgattgc	atcatctaca	ttcttgactc	ttattactgg	taacactggc	atcatcagct	5520
ccgtcacggc	gaatggatga	tcagcgtctg	tctctgccag	gagtagacga	gtatgttcgc	5580
taacttccag	accaatagcc	gctgctaatt	tagccgcac	tcttccaaca	taatctctat	5640
tcacacgtcc	tttgccctgt	tcgtcaatat	cggacaaaag	agcgggtagt	agtctttcgg	5700
tctgttcggg	tgtaagtaag	acggcgttat	ttctttgcat	ttctgccaat	agtgcacctg	5760
caactctgtc	taccacaatc	aaaacttttt	catcagcaca	aattatgttg	ttgtcgaaag	5820
aagcaccctt	gacaattgct	cttgcggtt	taggtatgtc	agcagtttcg	tccacaacaa	5880
caggaggatt	accagcgccg	gctgcaatta	accttttatc	tgtatgcttc	ctagcggctt	5940
caacgacggc	ttcaccacct	gtcacaaacta	acaatccaat	acccggatat	ctgaataatc	6000
tctgtgcagt	ttcgatgtta	gggtttgcca	cactaactag	taaattttct	gggccgccgg	6060
tagcgacaat	ggccttggtg	agtaaagaaa	tagtccttag	tgagacgttt	ttggcagaag	6120
gatgtggtgc	gaacacgact	gaattccccg	ctgcaatcat	tgagattgca	ttattaatta	6180
ccgtagctgc	tggatttggtg	cttggcgtga	ctgaagctac	gactccccaa	ggggcatttt	6240
caatcaatgt	taggccatta	tcaccgtaa	gaacctcggc	cgataaacat	tctataccag	6300
gcgtatgacg	agcttgagag	acattcttaa	tgtacttatc	caccacccta	cccataccag	6360

2014_03_12_107345_00466_ST25

tttcagcaac	tgccatttca	gccaaaactt	gtgcatacct	ttctccggcc	actcttatgg	6420
ctttgattac	ttgctgacgc	aactcaactg	aacttagttg	ttgttgggct	aaggtggctg	6480
cttgacacagc	gtcgtccaaa	gagctaaaaa	taccagatgg	agcgtcaaac	atggctggta	6540
gcggcatggg	cacagttggg	tcgattacag	aatgttccat	tgtgaaggta	gttcgatttt	6600
ggaggtcgcg	ggaggtcgaa	actaagttct	tggtgtttta	aaactaaaaa	aaagactaac	6660
tataaaaagta	gaatttaaga	agtttaagaa	atagattttac	agaattacaa	tcaataccta	6720
ccgtctttat	atacttatta	gtcaagtagg	ggaataatth	cagggaactg	gtttcaacct	6780
tttttttcag	ctttttccaa	atcagagaga	gcagaaggta	atagaagggtg	taagaaaatg	6840
agatagatac	atgcgtgggt	caattgcctt	gtgtcatcat	ttactccagg	cagggttgc	6900
cactccattg	aggttgtgcc	cgttttttgc	ctgtttgtgc	ccctgttctc	tgtagttgcg	6960
ctaagagaat	ggacctatga	actgatgggt	gggaagaaa	acaatattht	gggtgtggga	7020
ttcttttttt	ttctggatgc	cagcttaaaa	agcgggctcc	attatattht	gtggatgcca	7080
ggaataaaact	gttcaaccag	acacctacga	tggtatatat	tctgtgtaac	ccgcccccta	7140
ttttgggcat	gtacgggtta	cagcagaatt	aaaaggctaa	ttttttgact	aaataaagtt	7200
aggaaaatca	ctactattaa	ttattttacgt	attctttgaa	atggcagtat	tgataatgat	7260
aaactcgaac	tgaaaaagcg	tgttttttat	tcaaaatgat	tctaactccc	ttacgtaatc	7320
aaggaatctt	tttgcttggg	cctccgcgtc	attaaacttc	ttgttgttga	cgctaacatt	7380
caacgctagt	atatattcgt	ttttttcagg	taagttcttt	tcaacgggtc	ttactgatga	7440
ggcagtcgcg	tctgaaagg	ccgccggcgt	tggaagagcg	tgatgatttc	tttccttttt	7500
atattgacga	cttttttttt	ttcgtgtgtt	ttgtttctct	tataaccgag	ctgcttactt	7560
attattattt	caccttctct	ttttatttat	acttataatt	atttattctt	tacatactgt	7620
tacaagaaac	tcttttctac	attaattgca	taaagtgtca	atcagcacat	cctctatatc	7680
gctatcaaca	acaaatttga	caaacctgcc	tatatcttca	ggaacaactg	ccgcatcgct	7740
accaccacta	cttgtgaagt	ccctggagtt	taatatgcac	tgaaattttac	ctagccgttt	7800
tacacaagac	cataatccat	ccatgctatc	gcagtatatg	atthttgtgt	cgthtttctg	7860
cttgcgaaag	gcacctctca	tggtttgttt	cattgatcca	tcagtgtggc	tcgtaggtac	7920
cagcaaaaacc	acttcatcag	cggcgtactc	ctggcggttt	aaacgcgtgg	ccgtgccgtc	7980

<210> 33
 <211> 13266
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i84022 integration construct

<400> 33	
gacggcacgg	ccacgcgttt aaaccgcaa gtgatgtaac taaatacacg attaccatgg 60
aaattaacgt	acctthttttg tgcgtgtatt gaaatattat gacatattac agaaagggtt 120

cgcaagtcct gtttctatgc ctttctctta gtaattcacg aaataaacct atggttttacg	180
aaatgatcca cgaaaatcat gttattatattt acatcaacat atcgcgaaaa ttcatgtcat	240
gtccacatta acatcattgc agagcaacaa ttcatttttca tagagaaatt tgctactatc	300
accactagt actaccattg gtacctacta ctttgaattg tactaccgct gggcgttatt	360
aggtgtgaaa ccacgaaaag ttcaccataa cttcgaataa agtcgcggaa aaaagtaaac	420
agctattgct actcaaatga ggtttgcaga agcttggtga agcatgatga agcgttctaa	480
acgcactatt catcattaaa tattttaagc tcataaaaatt gtattcaatt cctattctaa	540
atggcctttta tttctattac aactattagc tctaaatcca tctcctcata agcagcaatc	600
aattctatct atactttaaa cgctcgtcca acgccggcgg acctgatgtg tattactagt	660
gtcgacgaca gcattcgccc agtatttttt ttattctaca aaccttctat aatttcaaag	720
tatttacata attctgtatc agtttaatca ccataatata gttttctttg tttagtgcaa	780
ttaatTTTTc ctattgttac ttcgggcctt tttctgtttt atgagctatt tttccgtca	840
tccttccgga tccagatttt cagcttcata tccagattgt gtctacgtaa tgcacgccat	900
cattttaaga gaggacctcc cgcgacctcc aaaatcgaac taccttcaca atgaaacttc	960
ttagtagtat tgagcaggcg tgtgacatct gtagattgaa gaaattgaaa tgtagtaagg	1020
agaagcccaa atgtgcgaaa tgccttaaaa ataattggga atgcagatat agtccgaaga	1080
cgaagcgag tcccttacc cgcgcgcacc ttacggaggt cgagagtcgc cttgagcgcc	1140
ttgagcaact tttccttctt atcttcccca gagaggattt ggatatgatc cttaatgatg	1200
acagtcttca agacattaag gcgcttctta cggggctttt cgtgcaggac aacgtcaaca	1260
aggacgcggt gacggaccgc cttgccagtg tcgaaaccga catgccccctt acgcttcgcc	1320
aacaccgcat ttccgccacg agtagtagtg aggaatcctc caataagggg cagcgccaac	1380
ttaccgtgag tatcgatagt gcggcccacc acgacaatag tacgatcccc cttgacttca	1440
tgccgcgcga cgccttgac gggttcgact ggagttagga agacgatatg agtgacggtc	1500
ttccgtttct taagaccgat ccgaataaca acggtttttt cgggtgatggg agtttgcttt	1560
gcatcttgag aagtatcggg ttcaagcccc agaactatac caatagtaat gtcaatcgct	1620
tgcccacgat gatcaccgac cgctataccc ttgccagtcg cagtacgacg agtagacttt	1680
tgcagtccta cttgaacaac ttccatccgt attgtcccat tgtccatagt cccaccctta	1740
tgatgcttta caacaatcaa atcgagattg ccagtaaaga ccagtggcag attttgttca	1800
attgtattct tgcgatcggg gcgtggtgca ttgaaggtga gaggaccgac attgacgtct	1860
tctattacca gaacgccaag agtcacctta cctccaaagt gtttgaaagt gggagtatta	1920
tccttgacac ggcgcttcac ttgcttagta gatacacgca atggcgccaa aagacgaaca	1980
cctctacaa cttccattcc ttcagtattc gcatggcgat tagtcttggt cttaacgcg	2040
atttgccgag tagtttttcc gactcctcca tccttgagca gcgcagaaga atctggtgga	2100
gtgtgtatag ttgggaaatt cagcttagtc ttttgtacgg gagaagtatt caattgagtc	2160

aaaacacgat	tagttttccc	agtagtgtgg	atgacgtcca	aagaacgacg	acggggccga	2220
cgatttacca	cggtattatc	gagacggcgc	gcttgcttca	ggcttttacg	aagattttacg	2280
agcttgataa	gacggtgacc	gcggaagaag	ccccatttg	cgcaagaag	tgtcttatga	2340
tctgcaacga	aatcgaagaa	gtcagtcgcc	aagcgccgaa	attccttcag	atggacatca	2400
gtacgacggc	ccttacgaac	cttcttaaag	agcatccctg	gcttagtttc	acgcgctttg	2460
agcttaaagt	gaagcaactt	agtttgatta	tctacgtgct	tcgcgacttc	tttaccaact	2520
tcacgcaaaa	gaaaagtcag	cttgagcaag	accagaacga	ccaccagtcc	tacgaggtca	2580
agagatgtag	tattatgctt	tccgacgcgg	cgcagcgcac	cgatcatgag	gtgtcctcct	2640
acatggataa	ccacaacgtg	acgccgtact	tcgcgtggaa	ctgcagttac	tatcttttta	2700
acgcggtgct	tgtgccgatt	aaaacccttt	tgagtaatat	taagagtaac	gccgaaaaca	2760
atgaaacggc	gcagcttctt	cagcagatca	ataccgtcct	tatgcttctt	aagaagcttg	2820
cgaccttcaa	gattcaaacc	tgcgagaagt	atatccaggt	gcttgaggaa	gtgtgcgccc	2880
ccttccttct	tagtcaatgc	gcgattccgc	ttccccacat	ttcctacaat	aactccaacg	2940
gggccgcgat	caagaacatc	gtggggagtg	cgaccattgc	gcagtatccc	accttgcccg	3000
aagagaacgt	gaataacatt	tccgtcaagt	acgtcagtcc	cggtagtggt	gggtccagtc	3060
ccgtcccgt	taagagtggg	gcgtcctttt	ccgaccttgt	gaaacttctt	agtaatagac	3120
cgccgagtag	aaatagtccg	gtcacgattc	cgcgtccac	gcccagtcac	agaagtgtga	3180
cccccttct	tggtcagcaa	cagcaacttc	agagtcttgt	cccgtttacg	cccagtgtcc	3240
ttttcggggg	tgcgaacttc	aaccagtccg	gtaacatcgc	cgactccagt	cttagtttta	3300
cctttaccaa	ttcctccaat	gggcccaatt	tgattacgac	ccagacgaac	agtcaggcct	3360
tgagtcagcc	gatcgcgagt	agtaatgtcc	acgacaattt	tatgaacaac	gagattaccg	3420
cctccaagat	cgacgacggg	aacaacagta	agccgcttag	tcccgggtgg	accgatcaga	3480
ccgcctacaa	tgccttcggg	attaccacgg	gtatgttcaa	cacgaccacg	atggacgacg	3540
tgtacaatta	cctttttgac	gacgaggaca	cgccgccgaa	tccgaagaag	gaatgagcca	3600
attggtgcgg	caattgataa	taacgaaaat	gtcttttaat	gatctgggta	taatgaggaa	3660
ttttccgaac	gtttttactt	tatatatata	tatacatgta	acatatattc	tatacgctat	3720
atcgagaaaa	cgcgatgggt	gggtgacttt	caactcggcg	tatccccgcg	tgcttggccg	3780
gccgtagtta	tgacaattac	aacaacagaa	ttctttctat	atatgcacga	acttgtaata	3840
tggaagaaat	tatgacgtac	aaactataaa	gtaaatatatt	tacgtaacac	atggtgctgt	3900
tgtgcttctt	tttcaagaga	ataccaatga	cgtatgacta	agtttatgta	ttttccaaaa	3960
cctgttttagc	cctggcgaca	gatacgtctc	cggcttcaac	gatgaccctg	gtgaccctgt	4020
caatgtcggc	tccggtggca	ccggccatga	ttgcgatgtt	ccttgcggtg	aagggtcatgt	4080
gtcccccttg	gattccctcg	gttgccaagg	ccctaattgc	ggccatatct	tgagccaaac	4140
caacggcggc	agtaacctgg	gccaactcag	tagcggtttc	gacctgcatt	aaggccaaag	4200

cggccctagc	tgtaggggtga	gtccttggtgg	ctcctcctac	caaaccacaag	gccaaaggca	4260
attcaatggg	accgaccaac	ctaccgtcgt	tggccaactc	ccaccttggtc	aaagaggtgt	4320
aatgtccggg	cctggcgggc	taggcgtggg	ctccagcttc	gatggccctc	cagtcgttac	4380
ctgttgcgac	gacgactggg	tcaattccgt	tcataattcc	cttgttatgg	gttgcgggccc	4440
tgtaaagggc	gactattgct	aaggcgcagg	cttcaaccat	tccccttgca	acgtcggcac	4500
catcgtatcc	ctgggtgggc	aaagtctcag	gggctaactc	aaccctgggt	cttaccaacc	4560
tcaagtcggc	caagttagac	aaaatcctca	acctgacggg	tccaccagcg	atcctctcta	4620
cctctggagc	taacctttca	gccatgggtg	taactgtggt	ggcaccatg	gcgtctctga	4680
catcaacaat	caagtgaat	acgaccattg	caccaacagg	ggtgtcccta	aaaacatgga	4740
cctcaatgtc	tctgcaacca	ccacctaaac	caacaaaaac	tggatctacg	gcattctgctg	4800
cttccatgaa	agcagcctta	tgggccaaca	acctttgcct	agctccttct	gggtctccta	4860
atccgacaac	ttggatttgg	gccctcatta	aagggtgcagt	tccgtgtgcg	gtgaatccac	4920
cgttctctct	agctatcctt	gccatatatg	aggctgcggc	aacaacagat	ggttcctcga	4980
ctgccatagg	tattaagtag	tcccttccgt	tgacgggtgaa	gttgggtggcg	acaccaatg	5040
gcaactcaaa	ttttccgata	acattctcga	tcataccgtt	ggccaatgac	aaaggcaaa	5100
caccgttacc	ggccaatgca	gaaatggctt	caggttccaa	tcctgcgggt	tcggcaaccc	5160
taactaacct	ctgagcagga	tccaagtccc	tcattcttctc	gattccttgag	ttcaatccgt	5220
cgatgtgacc	tgtctttcca	gtcattgtaa	agttagttgg	ttgcgcgact	tcgggtgggg	5280
taagtataga	ggtatattaa	caattttttg	ttgatacttt	tatgacattt	gaataagaag	5340
taatacaaac	cgaaaatggt	gaaagtatta	gttaaagtgg	ttatgcagct	tttgcattta	5400
tatatctgtt	aatagatcaa	aatcatcgc	ttcgttgatt	aattaccca	gaaataaggc	5460
taaaaaacta	atcgattat	tatcctatgg	ttgttaattt	gattcgttga	tttgaagggt	5520
tgtggggcca	ggttactgcc	aatttttctt	cttcataacc	ataaaagcta	gtattgtaga	5580
atctttattg	ttcggagcag	tgcggcgcga	ggcacatctg	cgtttcagga	acgcgaccgg	5640
tgaagaccag	gacgcacgga	ggagagtctt	ccgtcggagg	gctgtcgccc	gctcggcggc	5700
ttctaataccg	tacttcaata	tagcaatgag	cagttaagcg	tattactgaa	agttccaaag	5760
agaagggtttt	tttaggctaa	gataatgggg	ctctttacat	ttccacaaca	tataagtaag	5820
attagatatg	gatatgtata	tgggtgtatt	gccatgtaat	atgattatta	aacttctttg	5880
cgtccatcca	aaaaaaaaag	aacgcacgca	cactcccagc	agacaactag	cttgataatg	5940
tctcagaacg	tttacattgt	atcgactgcc	agaaccccaa	ttggttcatt	ccagggttct	6000
ctatcctcca	agacagcagt	ggaattgggt	gctgttgctt	taaaaggcgc	cttggtctaa	6060
gttcagaat	tggatgcac	caaggatttt	gacgaaatta	tttttggtaa	cgttctttct	6120
gccaatttgg	gccaagctcc	ggccagacaa	gttgctttgg	ctgccggttt	gagtaatcat	6180
atcgttgcaa	gcacagttaa	caaggctctgt	gcattccgcta	tgaaggcaat	cattttgggt	6240

gctcaatcca	tcaaatgtgg	taatgctgat	gttgtcgtag	ctggtggttg	tgaatctatg	6300
actaacgcac	catactacat	gccagcagcc	cgtgcgggtg	ccaaatttgg	ccaaactggt	6360
cttggtgatg	gtgtcgaaag	agatgggttg	aacgatgcgt	acgatgggtct	agccatgggt	6420
gtacacgcag	aaaagtgtgc	ccgtgattgg	gatattacta	gagaacaaca	agacaatttt	6480
gccatcgaat	cctacaaaaa	atctcaaaaa	tctcaaaagg	aaggtaaatt	cgacaatgaa	6540
attgtacctg	ttaccattaa	gggattttaga	ggtaagcctg	atactcaagt	cacgaaggac	6600
gaggaacctg	ctagattaca	cgttgaaaaa	ttgagatctg	caaggactgt	tttccaaaaa	6660
gaaaacggta	ctgttactgc	cgctaacgct	tctccaatca	acgatgggtgc	tgcagccgtc	6720
atcttggttt	ccgaaaaagt	tttgaaggaa	agaatttga	agcctttggc	tattatcaaa	6780
ggttgggggtg	aggccgctca	tcaaccagct	gattttacat	gggctccatc	tcttgcagtt	6840
ccaaaggctt	tgaacatgc	tggcatcgaa	gacatcaatt	ctgttgatta	ctttgaattc	6900
aatgaagcct	tttcggttgt	cggtttggtg	aacactaaga	ttttgaagct	agacccatct	6960
aagggttaatg	tatatggtgg	tgctgttgct	ctaggtcacc	cattgggttg	ttctggtgct	7020
agagtgggtg	ttacactgct	atccatctta	cagcaagaag	gaggtaagat	cggtgttgcc	7080
gccatttgta	atgggtgggtg	tggtgcttcc	tctattgtca	ttgaaaagat	atgattacgt	7140
tctgcgattt	tctcatgatc	tttttcataa	aatacataaa	tatataaatg	gctttatgta	7200
taacaggcat	aatttaaagt	tttatttgcg	attcatcggt	tttcagggtac	tcaaacgctg	7260
agggtgtcct	tttgacttac	ttttccgcct	tggcaagctg	gccgaacctg	caggccgcga	7320
gcgccgatac	gaaaatcggt	attgtcttga	agggtgaaatt	tctactctta	ttaatggtga	7380
acgttaagct	gatgctatga	tggaagctga	ttggtcttaa	cttgcttgct	atcttgctaa	7440
tggtcattgg	ctcgtgttat	tacttaagtt	atgtgtactc	gttttgaacg	taatgctaatt	7500
gatcatctta	tggaataata	gtgagtgggt	tcagggtcca	taaagctttt	caattcatct	7560
tttttttttt	tgttcttttt	tttgattccg	gtttctttga	aatttttttg	attcggtaat	7620
ctccgagcag	aaggaagaac	gaaggaagga	gcacagactt	agattggtat	atatacgcat	7680
atgtggtggt	gaagaaacat	gaaattgccc	agtattctta	acccaactgc	acagaacaaa	7740
aacctgcagg	aaacgaagat	aatcatgtc	gaaagctaca	tataaggaac	gtgctgctac	7800
tcatcctagt	cctgttgctg	ccaagctatt	taatatcatg	cacgaaaagc	aaacaaactt	7860
gtgtgcttca	ttggatgttc	gtaccaccaa	ggaattactg	gagttagttg	aagcattagg	7920
tcccaaaatt	tgtttactaa	aaacacatgt	ggatatcttg	actgattttt	ccatggaggg	7980
cacagttaag	ccgctaaagg	cattatccgc	caagtacaat	tttttactct	tcgaagacag	8040
aaaatttgct	gacattggta	atacagtcaa	attgcagtac	tctgcgggtg	tatacagaat	8100
agcagaatgg	gcagacatta	cgaatgcaca	cgggtgtggtg	ggcccaggta	ttgttagcgg	8160
tttgaagcag	gcggcggaag	aagtaacaaa	ggaacctaga	ggccttttga	tgtttagcaga	8220
attgtcatgc	aagggtctcc	tagctactgg	agaatatact	aagggtactg	ttgacattgc	8280

gaagagtgac	aaagatttttg	ttatcggcctt	tattgctcaa	agagacatgg	gtggaagaga	8340
tgaaggttac	gatttggttga	ttatgacacc	cgggtgtgggt	ttagatgaca	agggagacgc	8400
attgggtcaa	cagtatagaa	ccgtggatga	tgtggtctct	acaggatctg	acattattat	8460
tgttggaaga	ggactatttg	caaaggggaag	ggatgctaag	gtagaggggtg	aacgttacag	8520
aaaagcaggc	tgggaagcat	atttgagaag	atgcggccag	caaaactaaa	aaactgtatt	8580
ataagtaa	gcatgtatac	taaactcaca	aattagagct	tcaattta	tatatcagtt	8640
attaccacga	aaatcgttat	tgtcttgaag	gtgaaatttc	tactcttatt	aatggtgaac	8700
gttaagctga	tgctatgatg	gaagctgatt	ggctttaact	tgcttgatcat	cttgcta	8760
gtcatatggc	tcgtgttatt	acttaagtta	tttgactc	ttttgaacgt	aatgcta	8820
atcatcttat	ggaataatag	tgaacggccg	gccaa	cgaggattga	atgagaaaa	8880
aaatcggttg	ggcttaactt	taaagaaaa	agttgagatt	agattttattg	tgttata	8940
atagatatac	aattctttat	aaaaaaata	tatatata	tcattgttat	taaataa	9000
gttttcctag	tatatagatt	aaaaaactac	tctattaa	gagagctaaa	aaaagcaggc	9060
tgccaaaaaa	ataaagcatt	tatgaagggg	gttcagcaag	atgcaatcga	tgggggaaga	9120
ttatttttta	acatcgtaag	atcttctaaa	tttgtcatc	atgttggtca	agtagtaaac	9180
accactttgc	aaatgctcaa	tggaaccttg	aggtttgaag	ttcttcttca	aatgggcatt	9240
ttctctcaat	tcgatggcag	cttcgtaatc	ctttggagtt	tcggtgattc	tcttggtcaa	9300
tttgtagta	atatctaatt	ccttgataat	atgttggtgac	tcaccaacaa	ttttgcaaga	9360
atatagagat	gcagctaaac	cggaaccgta	agaaaataaa	ccaacacgct	tgcttgtaa	9420
gtcgtcagat	ccaacatagt	ttaatagaga	tgcaaaggcg	gcataaacag	atgcggtgta	9480
catgttacct	gtgtttgttg	gaacaatcaa	agattgggca	actctctctt	tgtggaatgg	9540
cttagcaaca	ttaacaaaag	ttttttcaat	gttcttatc	gttaaagatt	cgtcataatc	9600
gcgagtagct	aattcggcgt	caacttctgg	gaacaattga	ggattggctc	tgaaatcgtt	9660
atatagtaat	ctaccgatg	atgttggtgac	caatttacag	gttggaacat	ggaaaacgtt	9720
gtagtcgaaa	tatttcaaaa	cgttcaaagc	atccgaacca	gcgggatcgc	taaccaaccc	9780
tttagaaata	gccttcttgg	aataactctt	gtaaacttga	tcaagagcct	tgacgtaaca	9840
agttaatgaa	aatgaccat	cgacgtaagg	atattcgctg	gtgaaatctg	gcttgtaaaa	9900
atcgtaggcg	tgttccatgt	aagaagctct	tacagagtca	aatacaattg	gagcatcagg	9960
accgatccac	atagcaacag	taccggcacc	accggttggt	cttgcggcac	ccttatcgt	10020
gatggcaata	tcaccgcaa	ctacaatggc	gtctctacca	tcccatgcgt	tagattcaat	10080
ccagttcaaa	gagttgaaca	acgcgttgg	accaccgtaa	caggcattaa	gcgtgtcaat	10140
accttcgacg	tcagtgtttt	caccaaaaca	ttgcatcaag	acagacttga	cagacttgga	10200
cttgtcaatc	agagtttcag	taccgacttc	taatctacca	atgttggtg	tgatgatgtt	10260
gtaactcttg	atcaacttag	acaaaacagt	tagggacatc	gagtagatat	cttctctgtc	10320

attgacaaaa	gacatgttgg	tttggcccag	accaattgtg	tatttacctt	gagaaacgcc	10380
atcaaatttc	tctagctcag	attgggtgac	acattgagtt	gggatgtaaa	tttggatacc	10440
tttaataaccg	acattttgag	gtctgggtttt	ttgttcagcg	gtctttttgtt	tttttagttc	10500
agtcattttgc	aagtttgtat	tgtgtaattg	ttgttgcttt	tgcggcctaa	gtcttccttt	10560
aataccacac	caacaaagtt	tagttgagag	tttcattgtg	aaggtagttc	gatttttgag	10620
gtcgcgggag	gttacttttt	ttttggatgg	acgcaaagaa	gtttaataat	catattacat	10680
ggcaatacca	ccatatacat	atccatatct	aatcttactt	atatgtttgtg	gaaatgtaaa	10740
gagccccatt	atcttagcct	aaaaaacct	tctctttgga	actttcagta	atacgcttaa	10800
ctgctcattg	ctatattgaa	gtacggatta	gaagccgccg	agcgggcgac	agccctccga	10860
cggaagactc	tcctccgtgc	gtcctgggtc	tcaccggctg	cgttcctgaa	acgcagatgt	10920
gcctcgcgcc	gcactgctcc	gaacaataaa	gattctacaa	tactagcttt	tatggttatg	10980
aagaggaaaa	attggcagta	acctggcccc	acaaccttc	aaatcaacga	atcaaattaa	11040
caaccatagg	ataataatgc	gattagtttt	ttagccttat	ttctggggta	attaatcagc	11100
gaagcgatga	tttttgatct	attaacagat	atataaatgc	aaaagctgca	taaccacttt	11160
aactaatact	ttcaacattt	tcggtttgta	ttacttctta	ttcaaagtgc	ataaaaagtat	11220
caacaaaaaa	ttgttaatat	acctctatac	ttaccccacc	cgaagtcgcg	caaccaacta	11280
actttacaat	gactggaaag	acaggtcaca	tcgacggatt	gaactcaagg	atcgagaaga	11340
tgagggactt	ggatcctgct	cagaggtttag	ttaggggtgc	cgaagccgca	ggattggaac	11400
ctgaagccat	ttctgcattg	gccggtaacg	gtgctttgcc	tttgtcattg	gccaacggta	11460
tgatcgagaa	tgttatcgga	aaatttgagt	tgccattggg	tgtcgccacc	aacttcaccg	11520
tcaacggaag	ggactactta	atacctatgg	cagtcgagga	accatctgtt	gttgccgcag	11580
cctcatatat	ggcaaggata	gctagagaga	acggtggatt	caccgcacac	ggaactgcac	11640
ctttaatgag	ggcccaaadc	caagttgtcg	gattaggaga	cccagaagga	gctaggcaaa	11700
ggttggtggc	ccataaggct	gctttcatgg	aagcagcaga	tgccgtagat	ccagttttgg	11760
ttggtttagg	tggtggttgc	agagacattg	aggtccatgt	ttttagggac	accctgttg	11820
gtgcaatggg	cgtattgcac	ttgattgttg	atgtcagaga	cgccatgggt	gccaacacag	11880
ttaacaccat	ggctgaaagg	ttagctccag	aggtagagag	gatcgtgggt	ggaaccgtca	11940
ggttgaggat	tttgtctaac	ttggccgact	tgaggttggg	aagagccagg	gttgagttag	12000
cccctgagac	tttgaccacc	cagggatacg	atggtgccga	cgttgcaagg	ggaatggttg	12060
aagcctgcgc	cttagcaata	gtcgaccctt	acagggccgc	aaccataaac	aagggaaatta	12120
tgaacggaat	tgaccagtc	gtcgtcgcaa	caggtaacga	ctggagggcc	atcgaagctg	12180
gagcccacgc	ctacgccgcc	aggaccggac	attacacctc	tttgacaagg	tgggagttgg	12240
ccaacgacgg	taggttggtc	ggtaccattg	aattgccttt	ggccttgggt	ttggtaggag	12300
gagccaccaa	gactcacctt	acagctaggg	ccgctttggc	cttaatgcag	gtcgaaaccg	12360

ctactgagtt ggcccagggtt actgccgccg ttggtttggc tcagaatatg gccgcaatta	12420
gggccttggc aaccgaggga atccaaaggg gacacatgac cttacacgca aggaacatcg	12480
caatcatggc cggtgccacc ggagccgaca ttgacagggt caccagggtc atcgttgaag	12540
ccggagacgt atctgtcgcc agggctaaac aggttttggg aaatacataa acttagtcat	12600
acgtcattgg tattctcttg aaaaagaagc acaacagcac catgtgttac gtaaaatatt	12660
tactttatag tttgtacgtc ataatttctt ccatattaca agttcgtgca tatatagaaa	12720
gaattctgtt gttgtaattg tcataactag gtccgccggc gttggacgag cgaatgtgta	12780
tattagttta aaaagttgta tgtaataaaa gtaaaattta atattttgga tgaaaaaac	12840
catttttaga ctttttctta actagaatgc tggagtagaa atacgccatc tcaagataca	12900
aaaagcgta ccggcactga tttgtttcaa ccagtatata gattattatt gggctttgat	12960
caactttcct cagacatc agtaacagtt atcaagctaa atattttacgc gaaagaaaaa	13020
caaataattt aattgtgata cttgtgaatt ttattttatt aaggatacaa agttaagaga	13080
aaacaaaatt tatatacaat ataagtaata ttcatatata tgtgatgaat gcagtcttaa	13140
cgagaagaca tggccttggg gacaactctc ttcaaacc aa cttcagcctt tctcaattca	13200
tcagcagatg ggtcttcgat ttgcaaagca gccaaagcgg cggtttaaac gcgtggccgt	13260
gccgtc	13266

<210> 34
 <211> 13964
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i84026 integration construct

<400> 34	
gacggcacgg ccacgcgttt aaaccgccaa gtgatgtaac taaatacacg attaccatgg	60
aaattaacgt accttttttg tgcgtgtatt gaaatattat gacatattac agaaagggtt	120
cgcaagtcct gtttctatgc ctttctctta gtaattcacg aaataaacct atggttttacg	180
aatgatcca cgaaaatcat gttattattt acatcaacat atcgcgaaaa ttcattgtcat	240
gtccacatta acatcattgc agagcaacaa ttcattttca tagagaaatt tgctactatc	300
accactagt actaccattg gtacctacta ctttgaattg tactaccgct gggcgttatt	360
aggtgtgaaa ccacgaaaag ttcaccataa cttcgaataa agtcgcggaa aaaagtaaac	420
agctattgct actcaaatga ggtttgcaga agcttgttga agcatgatga agcgttctaa	480
acgcactatt catcattaaa tttttaagc tcataaaatt gtattcaatt cctattctaa	540
atggctttta tttctattac aactattagc tctaaatcca tatcctcata agcagcaatc	600
aattctatct atacttttaa cgctcgtcca acgccggcgg acctgatgtg tattactagt	660
gtcgacgaca gcattcgccc agtatttttt ttattctaca aaccttctat aatttcaaag	720
tatttacata attctgtatc agtttaatca ccataatc gttttctttg tttagtgcaa	780

ttaatttttc	ctattgttac	ttcgggctt	tttctgttt	atgagctatt	ttttccgtca	840
tccttccgga	tccagatttt	cagcttcac	tccagattgt	gtctacgtaa	tgcacgccat	900
cattttaaga	gaggacctcc	cgcgacctcc	aaaatcgaac	taccttcaca	atgaaacttc	960
ttagtagtat	tgagcaggcg	tgtgacatct	gtagattgaa	gaaattgaaa	tgtagtaagg	1020
agaagcccaa	atgtgcgaaa	tgccttaaaa	ataattggga	atgcagatat	agtccgaaga	1080
cgaagcgcag	ttcccttacc	cgcgcgcacc	ttacggagggt	cgagagtcgc	cttgagcgcc	1140
ttgagcaact	tttcttctt	atcttcccca	gagaggattt	ggatatgac	cttaagatgg	1200
acagtcttca	agacattaag	gcgcttctta	cggggctttt	cgtgcaggac	aacgtcaaca	1260
aggacgcggt	gacggaccgc	cttgccagtg	tcgaaaccga	catgcccctt	acgcttcgcc	1320
aacaccgcat	ttccgccacg	agtagtagtg	aggaatcctc	caataagggg	cagcgccaac	1380
ttaccgtgag	tatcgatagt	gcgggccacc	acgacaatag	tacgatcccc	cttgacttca	1440
tgccgcgcga	cgccttgac	gggttcgact	ggagtgagga	agacgatatg	agtgacggtc	1500
ttccgtttct	taagaccgat	ccgaataaca	acggtttttt	cggtgatggg	agtttgcttt	1560
gcatcttgag	aagtatcggg	ttcaagcccc	agaactatac	caatagtaat	gtcaatcgct	1620
tgcccacgat	gatcacgcac	cgctataccc	ttgccagtcg	cagtacgacg	agtagacttt	1680
tgcagtccta	cttgaacaac	ttccatccgt	attgtcccat	tgtccatagt	cccaccctta	1740
tgatgcttta	caacaatcaa	atcgagattg	ccagtaaaga	ccagtggcag	attttgttca	1800
attgtattct	tgcgatcggg	gcbgtgtgca	ttgaagggtga	gagtaccgac	attgacgtct	1860
tctattacca	gaacgccaa	agtcacctta	cctccaaagt	gtttgaaagt	gggagtatta	1920
tccttgtcac	ggcgcttcac	ttgcttagta	gatacacgca	atggcgccaa	aagacgaaca	1980
cctcctacaa	cttccattcc	ttcagtattc	gcatggcgat	tagtcttggt	cttaaccgcg	2040
atgtgcccag	tagtttttcc	gactcctcca	tccttgagca	gcbgagaaga	atctgggtgga	2100
gtgtgtatag	ttgggaaatt	cagcttagtc	ttttgtacgg	gagaagtatt	caattgagtc	2160
aaaacacgat	tagttttccc	agtagtgtgg	atgacgtcca	aagaacgacg	acggggccga	2220
cgatttacca	cggtattatc	gagacggcgc	gcttgcttca	ggtctttacg	aagattttacg	2280
agcttgataa	gacggtgacc	gcbgagaagt	ccccatttg	cgcgaagaag	tgtcttatga	2340
tctgcaacga	aatcgaagaa	gtcagtcgcc	aagcgccgaa	attccttcag	atggacatca	2400
gtacgacggc	ccttacgaac	cttcttaaag	agcatccctg	gcttagtttc	acgcgctttg	2460
agcttaaatg	gaagcaactt	agtttgatta	tctacgtgct	tcgcgacttc	tttaccaact	2520
tcacgcaaaa	gaaaagtcag	cttgagcaag	accagaacga	ccaccagtcc	tacgaggtca	2580
agagatgtag	tattatgctt	tccgacgcgg	cgcagcgcac	cgatcatgag	gtgtcctcct	2640
acatggataa	ccacaacgtg	acgccgtact	tcgcgtggaa	ctgcagttac	tatcttttta	2700
acgcggtgct	tgtgccgatt	aaaacccttt	tgagtaatag	taagagtaac	gccgaaaaca	2760
atgaaacggc	gcagcttctt	cagcagatca	ataccgtcct	tatgcttctt	aagaagcttg	2820

cgaccttcaa gattcaaacc tgcgagaagt atatccaggt gcttgaggaa gtgtgcgccc	2880
ccttccttct tagtcaatgc gcgattccgc ttccccacat ttcctacaat aactccaacg	2940
ggtccgcgat caagaacatc gtggggagtg cgaccattgc gcagtatccc accttgcccg	3000
aagagaacgt gaataacatt tccgtcaagt acgtcagtcg cggtagtgtg ggtcccagtc	3060
ccgtcccgtc taagagtggg gcgtcctttt ccgaccttgt gaaacttctt agtaatagac	3120
cgccgagtag aaatagtcgg gtcacgattc cgcgctccac gcccagtcac agaagtgtga	3180
cccccttcct tggtcagcaa cagcaacttc agagtcttgt cccgcttacg cccagtgtcc	3240
ttttcggggg tgcgaacttc aaccagtccg gtaacatcgc cgactccagt cttagtttta	3300
cctttaccaa ttcctccaat gggcccaatt tgattacgac ccagacgaac agtcaggcct	3360
tgagtacgcc gatcgcgagt agtaatgtcc acgacaattt tatgaacaac gagattaccg	3420
cctccaagat cgacgacggg aacaacagta agccgcttag tcccgggtgg accgatcaga	3480
ccgcctacaa tgccttcggg attaccacgg gtatgttcaa cacgaccacg atggacgacg	3540
tgtacaatta cctttttgac gacgaggaca cgccgccgaa tccgaagaag gaatgagcca	3600
attggtgcgg caattgataa taacgaaaat gtcttttaatt gatctgggta taatgaggaa	3660
ttttccgaac gtttttactt tatatatata tatacatgta acatatattc tatacgttat	3720
atcgagaaaa cgcgatgggt gggtgacttt caactcggcg tatccccgcg tgcttggccg	3780
gccgtccgca tgactcaaga gaagcatgtg gtttttgagt ttttttcgtt gaattttcag	3840
gtaaagctca atagttatga caattacaac aacagaattc tttctatata tgcacgaact	3900
tgtaatatgg aagaaattat gacgtacaaa ctataaagta aatattttac gtaacacatg	3960
gtgctgttgt gcttcttttt caagagaata ccaatgacgt atgactaagt ttaggattta	4020
atgcaggtga cggacccatc tttcaaacga tttatatcag tggcgtccaa attgttaggt	4080
ttgttggtt cagcaggttt cctgttggtg gtcatatgac tttgaaccaa atggccggct	4140
gctagggcag cacataagga taattcacct gccaaagcgg cacaggcaac tattcttgct	4200
aattgacgtg cgttggtacc aggagcggta gcatgtgggc ctcttacacc taataagtcc	4260
aacatggcac cttgtggttc tagaacagta ccaccaccga tggtagctac ttcgatggat	4320
ggcatggata cggaaattct caaatcaccg tccacttctt tcatcaatgt tatacagttg	4380
gaactttcga ctttttgtgc aggatcttgt cctaattgcca agaaaacagc tgtcactaaa	4440
ttagctgcat gtgcgttaaa tccaccaaca gaccagcca ttgcagatcc aaccaaattc	4500
ttagcaatgt tcaactcaac caatgcggaa acatcacttt ttaacacttt tctgacaaca	4560
tcaccaggaa tagtagcttc tgcgacgaca ctcttaccac gaccttcgat ccagttgatg	4620
gcagctggtt tttgtcggg acagtagtta ccagaaacgg agacaacctc catatcttcc	4680
cagccatact cttctacat ttgctttaat gagtattcga cacccttaga aatcatattc	4740
atacccattg cgtcaccagt agttgttcta aatctcatga agagtaaadc tcctgctaga	4800
caagtttgaa tatgttgtag acgtgcaaat cttgatgtag agttaaagc ttttttaatt	4860

gcgttttgtc cctcttctga gtctaaccat atcttacagg caccagatct tttcaaagtt	4920
gggaaacgga ctactgggcc tcttgtcata ccataccttag ttaaaacagt tggtgcacca	4980
ccgccagcat tgattgcctt acagccacgc atggcagaag ctaccaaaca accctctgta	5040
gttgccattg gtatatgata agatgtacca tcgataacca aggggcctat aacaccaacg	5100
ggcaaaggca tgtaacctat aacattttca caacaagcgc caaatacgcg gtcgtagtca	5160
taatttttat atggtaaacg atcagatgct aatacaggag cttctgccaa aattgaaaga	5220
gccttcctac gtaccgcaac cgctctcgta gtatcaccta attttttctc caaagcgtac	5280
aaaggtaact taccgtgaat aaccaaggca gcgacctctt tgttcttcaa ttgttttgta	5340
tttccactac ttaataatgc ttctaattct tctaaaggac gtattttctt atccaagctt	5400
tcaatatcgc gggaatcatc ttcctcacta gatgatgaag gtcctgatga gctcgattgc	5460
gcagatgata aacttttgac tttcgatcca gaaatgactg ttttattggg taaaactggg	5520
gtagaagcct tttgtacagg agcagtaaaa gacttcttgg tgacttcagt cttcaccaat	5580
tggtctgcag ccattgtaaa gttagttggg tgcgcgactt cgggtggggg aagtatagag	5640
gtatattaac aattttttgt tgatactttt atgacatttg aataagaagt aatacaaacc	5700
gaaaatgttg aaagtattag ttaaagtggg tatgcagctt ttgcatttat atatctgtta	5760
atagatcaaa aatcatcgct tcgctgatta attaccccag aaataaggct aaaaaactaa	5820
tcgcattatt atcctatggg tggttaatttg attcgttgat ttgaagggtt gtggggccag	5880
gttactgcca atttttcctc ttcataacca taaaagctag tattgtagaa tctttattgt	5940
tcggagcagt gcggcgcgag gcacatctgc gtttcaggaa cgcgaccggg gaagaccagg	6000
acgcacggag gagagtcttc cgtcggaggg ctgtcgcccc ctcggcgggc tctaattcgt	6060
acttcaatat agcaatgagc agttaagcgt attactgaaa gttccaaaga gaaggttttt	6120
ttaggctaag ataatggggc tctttacatt tccacaacat ataagtaaga ttagatatgg	6180
atatgtatat ggtggtattg ccatgtaata tgattattaa acttctttgc gtccatccaa	6240
aaaaaaagta acgcacgcac actcccgaca gacaactagc ttgataatgt ctcagaacgt	6300
ttacattgta tcgactgcca gaacccaat tggttcattc cagggttctc tatcctccaa	6360
gacagcagtg gaattgggtg ctgttgcttt aaaaggcgcc ttggctaagg ttccagaatt	6420
ggatgcatcc aaggattttg acgaaattat ttttggtaac gttctttctg ccaatttggg	6480
ccaagctccg gccagacaag ttgctttggc tgccggtttg agtaatcata tcgttgcaag	6540
cacagttaac aaggctctgt catccgctat gaaggcaatc attttggtg ctcaatccat	6600
caaatgtggg aatgctgatg ttgtcgtagc tgggtggttg gaatctatga ctaacgcacc	6660
atactacatg ccagcagccc gtgcgggtgc caaatttggc caaactgttc ttgttgatgg	6720
tgtcgaaaga gatgggttga acgatgcgta cgatggtcta gccatgggtg tacacgcaga	6780
aaagtgtgcc cgtgattggg atattactag agaacaacaa gacaattttg ccatcgaatc	6840
ctaccaaaaa tctcaaaaat ctcaaaagga aggtaaattc gacaatgaaa ttgtacctgt	6900

taccattaag	ggatttagag	gtaagcctga	tactcaagtc	acgaaggacg	aggaaacctgc	6960
tagattacac	gttgaaaaat	tgagatctgc	aaggactggt	ttccaaaaag	aaaacggtac	7020
tgttactgcc	gctaacgctt	ctccaatcaa	cgatggtgct	gcagccgtca	tcttggtttc	7080
cgaaaaagtt	ttgaaggaaa	agaatttgaa	gcctttggct	attatcaaag	gttggggtga	7140
ggccgctcat	caaccagctg	attttacatg	ggctccatct	cttgcagttc	caaaggcttt	7200
gaaacatgct	ggcatcgaag	acatcaattc	tgttgattac	tttgaattca	atgaagcctt	7260
ttcggttgtc	ggtttgggtga	acactaagat	tttgaagcta	gacccatcta	aggttaatgt	7320
atatggtggt	gctgttgctc	taggtcaccc	attggggtgt	tctggtgcta	gagtggttgt	7380
tacactgcta	tccatcttac	agcaagaagg	aggtgaagtc	ggtgttgccg	ccatttgtaa	7440
tggtgggtgg	ggtgcttcct	ctattgtcat	tgaaaagata	tgattacggt	ctgcgatttt	7500
ctcatgatct	ttttcataaa	atacataaat	atataaatgg	ctttatgtat	aacaggcata	7560
atttaaagtt	ttatttgca	ttcatcggtt	ttcaggtact	caaacgctga	ggtgtgcctt	7620
ttgacttact	tttccgcctt	ggcaagctgg	ccgaacctgc	aggccgcgag	cgccgatacg	7680
aaaatcggtta	ttgtcttgaa	ggtgaaat	ctactcttat	taatggtgaa	cgttaagctg	7740
atgctatgat	ggaagctgat	tggtcttaac	ttgcttgta	tcttgcta	ggtcattggc	7800
tcgtgttatt	acttaagtta	tttgactcg	ttttgaacgt	aatgcta	atcatcttat	7860
ggaataatag	tgagtgggtt	caggggtccat	aaagcttttc	aattcatctt	tttttttttt	7920
gttctttttt	ttgattccgg	tttctttgaa	atttttttga	ttcggtaatc	tccgagcaga	7980
aggaagaacg	aaggaaggag	cacagactta	gattggtata	tatacgcata	tgtggtgttg	8040
aagaaacatg	aaattgcccc	gtattcttaa	cccaactgca	cagaacaaaa	acctgcagga	8100
aacgaagata	aatcatgtcg	aaagctacat	ataaggaacg	tgctgctact	catcctagtc	8160
ctgttgctgc	caagctat	aatatcatgc	acgaaaagca	aacaaacttg	tgtgcttcat	8220
tggatgttcg	taccaccaag	gaattactgg	agttagttga	agcattaggt	cccaaaat	8280
gtttactaaa	aacacatgtg	gatattctga	ctgatttttc	catggagggc	acagttaagc	8340
cgctaaaggc	attatccgcc	aagtacaatt	ttttactctt	cgaagacaga	aaatttgctg	8400
acattggtaa	tacagtcaaa	ttgcagtact	ctgcgggtgt	atacagaata	gcagaatggg	8460
cagacattac	gaatgcacac	ggtgtggtgg	gcccaggtat	tgttagcggg	ttgaagcagg	8520
cggcggaaga	agtaacaaag	gaacctagag	gccttttgat	gttagcagaa	ttgtcatgca	8580
agggctccct	agctactgga	gaatatacta	aggggtactgt	tgacattg	aagagtgaca	8640
aagat	tttgt	ttt	gtt	gtt	gtt	8700
attggttgat	tatgacaccc	ggtgtgggtt	tagatgacaa	gggagacgca	ttgggtcaac	8760
agtatagaac	cgtggatgat	gtggtctcta	caggatctga	cattattatt	gttgaagag	8820
gactat	tttgc	aaagggaagg	gatgctaagg	tagaggggtga	acgttacaga	8880
gggaagcata	tttgagaaga	tgccggccagc	aaaactaaaa	aactgtatta	taagtaa	8940

catgtatact	aaactcacia	attagagctt	caatttaatt	atatcagtta	ttaccacgaa	9000
aatcgttatt	gtcttgaagg	tgaaatttct	actcttatta	atggtgaacg	ttaagctgat	9060
gctatgatgg	aagctgattg	gtcttaactt	gcttgtcatc	ttgctaattg	tcatatggct	9120
cgtgttatta	cttaagttat	ttgtactcgt	tttgaacgta	atgctaata	tcatcttatg	9180
gaataatagt	gaacggccgg	ccaagcacgc	ggggattgaa	tgagaaaaaa	aatcggttgg	9240
gcttaacttt	aaagaaaaaa	gttgagatta	gattttattgt	gttataaata	tagatataca	9300
attctttata	aaaaaaatat	atatatatat	cattgttatt	aaataaagag	ttttcctagt	9360
atatagatta	aaaaactact	ctattaaatg	agagctaaaa	aaagcaggct	gccaaaaaaa	9420
taaagcattt	atgaaggggg	ttcagcaaga	tgcaatcgat	gggggaagat	tattttttaa	9480
catcgtaaga	tcttctaaat	ttgtcatcga	tgttggtcaa	gtagtaaaca	ccactttgca	9540
aatgctcaat	ggaaccttga	ggtttgaagt	tcttcttcaa	atgggcattt	tctctcaatt	9600
cgatggcagc	ttcgtaatcc	tttgagattt	cggtgattct	cttggttaat	ttgttagtaa	9660
tatctaattc	cttgataata	tgttggacgt	caccaacaat	tttgcaagaa	tatagagatg	9720
cagctaaacc	ggaaccgtaa	gaaaataaac	caacacgctt	gccttgtaag	tcgtcagatc	9780
caacatagtt	taatagagat	gcaaaggcgg	cataaacaga	tgcggtgtac	atgttacctg	9840
tgtttggttg	aacaatcaaa	gattgggcaa	ctctctcttt	gtggaatggc	ttagcaacat	9900
taacaaaagt	tttttcaatg	ttcttatcgg	ttaaagattc	gtcataatcg	cgagtagcta	9960
attcggcgtc	aacttctggg	aacaattgag	gattggctct	gaaatcgtta	tatagtaatc	10020
taccgtatga	ttttgtgacc	aatttacagg	ttggaacatg	gaaaacgttg	tagtcgaaat	10080
atttcaaaac	gttcaaagca	tccgaaccag	cgggatcgct	aaccaaccct	ttagaaatag	10140
ccttcttggg	ataactcttg	taaacttgat	caagagcctt	gacgtaacaa	gttaatgaaa	10200
aatgaccatc	gacgtaagga	tattcgctgg	tgaaatctgg	cttgtaaaaa	tcgtaggcgt	10260
gttccatgta	agaagctctt	acagagtcaa	atacaattgg	agcatcagga	ccgatccaca	10320
tagcaacagt	accggcacca	ccggttggtc	ttgcggcacc	cttatcgtag	atggcaatat	10380
caccgcaaac	tacaatggcg	tctctaccat	cccatgcgtt	agattcaatc	cagttcaaag	10440
agttgaacaa	cgcgttggta	ccaccgtaac	aggcattaag	cgtgtcaata	ccttcgacgt	10500
cagtgttttc	accaaacaat	tgcataca	cagacttgac	agacttggac	ttgtcaatca	10560
gagtttcagt	accgacttct	aatctaccaa	ttttgttggg	gtcgatgttg	taactcttga	10620
tcaacttaga	caaaacagtt	agggacatcg	agtagatatc	ttctctgtca	ttgacaaaag	10680
acatgttggg	ttggcccaga	ccaattgtgt	atttaccttg	agaaacgcca	tcaaatttct	10740
ctagctcaga	ttggttgaca	cattgagttg	ggatgtaaat	ttggatacct	ttaataccga	10800
cattttgagg	tctggttttt	tgttcagcgg	tcttttgttt	ttttagttca	gtcatttgca	10860
agtttgtatt	gtgtaattgt	tgttgctttt	gcggcctaag	tcttccttta	ataccacacc	10920
aacaaagttt	agttgagagt	ttcattgtga	aggtagttcg	attttgaggg	tcgcgggagg	10980

ttactttttt	tttggatgga	cgcaaagaag	tttaataatc	atattacatg	gcaataccac	11040
catatacata	tccatatcta	atcttactta	tatgtttgtg	aaatgtaaag	agccccatta	11100
tcttagccta	aaaaaacctt	ctcttttgaa	ctttcagtaa	tacgcttaac	tgctcattgc	11160
tatattgaag	tacggattag	aagccgccga	gcgggcgaca	gccctccgac	ggaagactct	11220
cctccgtgcg	tcctggtcct	caccggtcgc	gttcctgaaa	cgcagatgtg	cctcgcgccg	11280
cactgctccg	aacaataaag	attctacaat	actagctttt	atgggttatga	agaggaaaaa	11340
ttggcagtaa	cctggcccca	caaaccttca	aatcaacgaa	tcaaattaac	aaccatagga	11400
taataatgcg	attagttttt	tagccttatt	tctggggtaa	ttaatcagcg	aagcgatgat	11460
ttttgatcta	ttaacagata	tataaatgca	aaagctgcat	aaccacttta	actaatactt	11520
tcaacatttt	cggttttgat	tacttcttat	tcaaatgtca	taaaagtatc	aacaaaaaat	11580
tggttaata	cctctatact	tacccacccc	gaagtcgcgc	aaccaactaa	ctttacaatg	11640
gctgcagacc	aattggtgaa	gactgaagtc	accaagaagt	cttttactgc	tcctgtacaa	11700
aaggcttcta	caccagtttt	aaccaataaa	acagtcattt	ctggatcgaa	agtcaaaagt	11760
ttatcatctg	cgcaatcgag	ctcatcagga	ccttcatcat	ctagtgagga	agatgattcc	11820
cgcgatattg	aaagcttgga	taagaaaata	cgtccttttag	aagaattaga	agcattatta	11880
agtagtgga	atacaaaaca	attgaagaac	aaagaggtcg	ctgccttggt	tattcacggt	11940
aagttacctt	tgtacgcttt	ggagaaaaaa	ttaggtgata	ctacgagagc	ggttgcggta	12000
cgtaggaagg	ctctttcaat	tttggcagaa	gctcctgtat	tagcatctga	tcgtttacca	12060
tataaaaatt	atgactacga	ccgcgtattt	ggcgcttggt	gtgaaaatgt	tataggttac	12120
atgcctttgc	ccgttggtgt	tataggcccc	ttggttatcg	atggtacatc	ttatcatata	12180
ccaatggcaa	ctacagaggg	ttgtttggtg	gcttctgcca	tgcgtggctg	taaggcaatc	12240
aatgctggcg	gtggtgcaac	aactgtttta	actaaggatg	gtatgacaag	aggcccagta	12300
gtccgtttcc	caactttgaa	aagatctggt	gcctgtaaga	tatggttaga	ctcagaagag	12360
ggacaaaacg	caattaaaaa	agcttttaac	tctacatcaa	gatttgcacg	tctgcaacat	12420
attcaaactt	gtctagcagg	agatttactc	ttcatgagat	ttagaacaac	tactggtgac	12480
gcaatgggta	tgaatatgat	ttctaagggt	gtcgaatact	cattaaagca	aatggtagaa	12540
gagtatggct	gggaagatat	ggaggttgct	tccgtttctg	gtaactactg	taccgacaaa	12600
aaaccagctg	ccatcaactg	gatcgaaggt	cgtggtaaga	gtgtcgtcgc	agaagctact	12660
attcctggtg	atgttgctag	aaaagtgtta	aaaagtgatg	tttccgcatt	ggttgagttg	12720
aacattgcta	agaatttggt	tggatctgca	atggctgggt	ctggttggtg	atttaacgca	12780
catgcagcta	atttagtgac	agctgttttc	ttggcattag	gacaagatcc	tgcacaaaat	12840
gtcgaaagtt	ccaactgtat	aacattgatg	aaagaagtgg	acggtgattt	gagaattttcc	12900
gtatccatgc	catccatcga	agtaggtacc	atcggtggtg	gtactgttct	agaaccacaa	12960
ggtgccatgt	tggacttatt	aggtgtaaga	ggcccacatg	ctaccgctcc	tggtaccaac	13020

gcacgtcaat tagcaagaat agttgcctgt gccgtcttgg caggtgaatt atccttatgt	13080
gctgccctag cagccggcca tttggttcaa agtcatatga cccacaacag gaaacctgct	13140
gaaccaacaa aacctaacaa tttggacgcc actgatataa atcgtttgaa agatgggtcc	13200
gtcacctgca ttaaataccta aacttagtca tacgtcattg gtattctctt gaaaaagaag	13260
cacaacagca ccatgtgtta cgtaaaatat ttactttata gtttgtacgt cataatttct	13320
tccatattac aagttcgtgc atatatagaa agaattctgt tgttgtaatt gtcataacta	13380
ttgagcttta cctgaaaatt caacgaaaaa aactcaaaaa ccacatgctt ctcttgagtc	13440
atgcgagggt ccgccggcgt tggacgagcg aatgtgtata ttagtttaaa aagttgtatg	13500
taataaaagt aaaatttaaat attttggatg aaaaaaacca ttttttagact ttttcttaac	13560
tagaatgctg gagtagaaat acgccatctc aagatacaaa aagcgttacc ggcactgatt	13620
tgtttcaacc agtatataga ttattattgg gtcttgatca actttcctca gacatatcag	13680
taacagttat caagctaaat atttacgca aagaaaaaca aatattttta ttgtgatact	13740
tgtgaatttt attttattaa ggatacaaag ttaagagaaa acaaaattta tatacaatat	13800
aagtaatat catatatatg tgatgaatgc agtcttaacg agaagacatg gccttggtga	13860
caactctctt caaaccaact tcagcctttc tcaattcatc agcagatggg tcttcgattt	13920
gcaaagcagc caaagcggcg gtttaaacgc gtggccgtgc cgtc	13964

<210> 35
 <211> 13963
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: i85207 integration construct

<400> 35	
gacggcacgg ccacgcgttt aaaccgccag ggcaagggtg gcctctactt actccatcga	60
caattcaaga tacagaacct cctccagatg gaatcccttc catagagaga aggagcaagc	120
aactgacca atattgactg ccactggacc tgaagacatg caacaaagtg caagcatagt	180
ggggccttct tccaatgcta atccggtcac tgccactgct gctacggaaa accaacctaa	240
aggtattaac ttcttacta taagaaaatc acacgagcgc ccggacgatg tctctgttta	300
aatggcgcaa gttttccgct ttgtaataata tatttataacc cttttcttct ctcccctgca	360
atataatagt ttaattctaa tattaataat atcctatatt ttcttcattt accggcgcac	420
tctcgcccga acgacctcaa aatgtctgct acattcataa taaccaaag ctcataactt	480
ttttttttga acctgaatat atatacatca catgtcactg ctggtccttg ccgaccagcg	540
tatacaatct cgatagttagg tttcccgttc tttccactcc cgtccgctcg tccaacgccg	600
gcggaccttc acatgtagg accgaattgt ttacaagttc tctgtaccac catggagaca	660
tcaaagattg aaaatctatg gaaagatatg gacggtagca acaagaatat agcacgagcc	720
gcgaagttca tttcgttact tttgatatcg ctcaacta ttgcgaagcg cttcagtgaa	780

aaaatcataa	ggaaaagttg	taaatattat	tggtagtatt	cgtttggtaa	agtagagggg	840
gtaatttttc	ccctttat	tgttcataca	ttcttaaatt	gctttgcctc	tccttttggg	900
aagctatact	tcggagcact	gttgagcgaa	ggctcattag	atatattttc	tgtcattttc	960
cttaacccaa	aaataagggg	aaggggtccaa	aaagcgctcg	gacaactggt	gaccgtgatc	1020
cgaaggactg	gctatacagt	gttcacaaaa	tagccaagct	gaaaataatg	tgtagctatg	1080
ttcagttagt	ttggctagca	aagatataaa	agcaggtcgg	aaatattttat	gggcattatt	1140
atgcagagca	tcaacatgat	aaaaaacct	cccgcgacct	ccaaaatcga	actaccttca	1200
caatgactgc	cgacaacaat	agtatgcccc	atggtgcagt	atctagttac	gccaaattag	1260
tgcaaaacca	aacacctgaa	gacatttttg	aagagtttcc	tgaaattatt	ccattacaac	1320
aaagacctaa	tacccgatct	agtgagacgt	caaatgacga	aagcggagaa	acatgttttt	1380
ctggtcatga	tgaggagcaa	attaagttaa	tgaatgaaaa	ttgtattggt	ttggattggg	1440
acgataatgc	tattggtgcc	ggtaccaaga	aagtttgtca	tttaatggaa	aatattgaaa	1500
agggtttact	acatcgtgca	ttctccgtct	ttattttcaa	tgaacaaggt	gaattacttt	1560
tacaacaaag	agccactgaa	aaaataactt	tcctgatct	ttggactaac	acatgctgct	1620
ctcatccact	atgtattgat	gacgaattag	gtttgaaggg	taagctagac	gataagatta	1680
agggcgctat	tactgcggcg	gtgagaaaac	tagatcatga	attaggtatt	ccagaagatg	1740
aaactaagac	aaggggtaag	tttactttt	taaacagaat	ccattacatg	gcaccaagca	1800
atgaaccatg	gggtgaacat	gaaattgatt	acatcctatt	ttataagatc	aacgctaaag	1860
aaaacttgac	tgtcaacca	aacgtcaatg	aagttagaga	cttcaaattg	gtttcaccaa	1920
atgatttgaa	aactatgttt	gctgacccaa	gttacaagtt	tacgccttgg	tttaagatta	1980
tttgcgagaa	ttacttattc	aactggtggg	agcaattaga	tgacctttct	gaagtggaaa	2040
atgacaggca	aattcataga	atgctataac	aacgcgtcaa	taatataggc	tacataaaaa	2100
tcataataac	tttgttatca	tagcaaaatg	tgatataaaa	cgtttcattt	cacctgaaaa	2160
atagtaaaaa	taggcgacaa	aatccttag	taatatgtaa	actttatttt	ctttattttat	2220
ttacagaact	ctgaatatac	attgattggt	cacatttttt	ttttctcttc	tcaatttccc	2280
ttgattatat	tcaaaagggt	attggcctct	tgaatgtttc	ccactgaatc	cccgcgtgct	2340
tggccggccg	tggagcgacc	tcattgctata	cctgagaaag	caacctgacc	tacaggaaag	2400
agttactcaa	gaataagaat	tttcgtttta	aaacctaaag	gtcactttta	aatttgata	2460
cacttatttt	ttttataact	tatttaataa	taaaaatcat	aaatcataag	aaattcgctc	2520
aaacgaccat	tggatggaca	aagaaggact	tcattgtaaga	tttcatgtca	ccttcggcgt	2580
gagtgaacc	atcgtaaca	gagtataaaa	cttcacacat	tctagccaag	ttgatagctg	2640
gcattaacaa	agggaaatga	acggcggttg	gtctcaaaga	ttctctgtta	ataaccttcc	2700
aggcgtcttc	gacttttcta	gagatgtatt	cacaggcttc	ttcttcagaa	gcaccggatt	2760
ccttagaata	acattcgatg	gaggaggcaa	catgacctct	ttcttggtct	tccttatgag	2820

agacaatatc	atccatcaat	ctaatagataa	cacaagaagc	ttcaacaata	ggtgggtagg	2880
aagaaacca	tttaaaagt	tcctcgtaa	caatgtcacc	tctaccaacg	taagatctag	2940
cagtgatcaa	accgtaggta	ccggtaacca	tggaacaga	catgtactct	tccaaagtag	3000
gcatgtaacc	ttctttcaac	catctggctt	caaccaagta	gtttctgacc	aattccttag	3060
ccatttcctt	aacgtagtgg	atttgataag	ccttaccttc	cttttctaaa	gattcttcca	3120
tttcaacgtg	caagttaacc	aattcttggg	agatcaactt	catgtattct	ggcaacatgt	3180
ccaaacaaga	aatggaccac	ttctcaacgg	cttgagtga	aatttccaat	tcttcgtagg	3240
taccgtagtt	gtcgaaggta	tcatccaaa	cgaccaacca	catacaagac	ttcatcaaga	3300
acattctggg	tctggcatgt	tgtggttcat	agtaaataga	caaaatccag	aagtaacctt	3360
cgacaactct	atcacgaacg	aatggcaatt	tgttttgcaa	gtctaaatct	ttccaccact	3420
tgcagatgtg	agacaattct	ttcttatgca	tggtttgcaa	aacagagaaa	tctaacttag	3480
ccaacttcaa	caaaacctcg	tcgtgagaag	tttcttggtg	gtaaattggc	atatagtgtg	3540
aagcttcgat	tctggccaat	cttcttctca	atggttgctt	caaggcttgg	tggatttggg	3600
ttcttaagga	agagtcacaa	gatggatcct	tggaataaat	gtccaagtga	accttagaga	3660
attccaaagc	gttgtccaag	atggtttcat	cttcgactct	catgaaagca	gcttcgtaca	3720
aggccaagat	accttgagcg	tcgttacaca	aagattcctt	aaatttacct	ttttcgtcca	3780
taaagtcctt	gaaaacacca	gaggagacat	tgaaaccttg	ttgacgcaac	aaacgaaacc	3840
acaaggagat	agattgtaaa	ttttccttat	cgaccatttg	ttcaccgtaa	gtgacatgga	3900
tatgttgtaa	agcttcttcg	atttcttctt	caaatggta	agcaatacct	aaacgttgaa	3960
cagcattgat	taattcgatc	aacttaacat	gttgcatagg	ttcgttagaa	cccttaatat	4020
taatcaattc	cttcttaact	tcctccttta	actcttcgac	taattgcttc	ttcataacca	4080
agtcctctgg	ttcatcgtaa	gtcaaaaatt	gatcaccca	aatggaagcg	ttgaagttag	4140
cggatgtct	aataacgtct	ggcttggtag	aatccttatc	atcgacaaca	attggggaag	4200
tagatggaga	ggaagaaaca	gaggaaatag	gcaaagtgga	cattgtaaag	ttagttggtt	4260
gcgcgacttc	gggtggggta	agtatagagg	tatattaaca	atTTTTTgtt	gatactttta	4320
tgacatttga	ataagaagta	atacaaaccg	aaaatgttga	aagtattagt	taaagtgggt	4380
atgcagcttt	tgcatTTata	tatctgttaa	tagatcaaaa	atcatcgctt	cgctgattaa	4440
ttaccccaga	aataaggcta	aaaaactaat	cgcattatta	tcctatgggt	gttaatttga	4500
ttcgttgatt	tgaaggtttg	tggggccagg	ttactgcaa	tttttctctt	tcataaccat	4560
aaaagctagt	attgtagaat	ctttattgtt	cggagcagtg	cggcgcgagg	cacatctgcg	4620
tttcaggaac	gcgaccggtg	aagaccagga	cgcacggagg	agagtcttcc	gtcggagggc	4680
tgtcgcccg	tcggcggtt	ctaataccgta	cttcaatata	gcaatgagca	gttaagcgta	4740
ttactgaaag	ttcaaagag	aaggTTTTTT	taggctaaga	taatggggct	ctttacattt	4800
ccacaacata	taagtaagat	tagatatgga	tatgtatatg	gtggtattgc	catgtaatat	4860

gattattaaa cttctttgcg tccatccaaa aaaaaagtaa cgcacgcaca ctccccgacag	4920
acaactagct tgataatggc ttcagaaaaa gaaattagga gagagagatt cttgaacggt	4980
ttccctaaat tagtagagga attgaacgca tcgcttttgg cttacggtat gcctaaggaa	5040
gcatgtgact ggtatgccc ctcattgaac tacaacactc caggcggtaa gttaaataga	5100
ggtttgtccg ttgtggacac gtatgctatt ctctccaaca agaccgttga acaattgggg	5160
caagaagaat acgaaaaggt tgctattcta gggttggtgca ttgagttggt gcaggcctac	5220
ttcttggtcg ccgatgatat gatggacaag tccattacca gaagaggcca accatggttg	5280
tacaagggtc ctgaagttgg ggaaattgcc atcaatgacg cattcatggt agaggctgct	5340
atctacaagc ttttgaaatc tcacttcaga aacgaaaaat actacataga tatcaccgaa	5400
ttgttccatg aagtcacctt ccaaaccgaa ttggggccaat tgatggactt aatcactgca	5460
cctgaagaca aagtcgactt gagtaagttc tccctaaaga agcactcctt catagttact	5520
ttcaagactg cttactattc tttctacttg cctgtcgcat tggctatgta cgttgccggt	5580
atcacagatg aaaaggattt gaaacaagcc agagatgtct tgattccatt gggatgaatat	5640
ttccaaattc aagatgacta cttagactgc ttcggtaccc cagaacagat cggtaagatc	5700
ggtacagata tccaagataa caaatgttct tgggtaatca acaaggcatt agaacttgct	5760
tccgcagaac aaagaaagac tttagacgaa aattacggta agaaggactc agtcgcagaa	5820
gccaaatgca aaaagatttt caatgacttg aaaatcgacc agttatacca cgaatatgaa	5880
gagtcgttg ccaaggattt gaaggccaag atctcccaag tcgacgagtc tcgtggcttc	5940
aaagccgacg tcttaactgc gtttttgaac aagggtttaca agagaagtaa atagaactaa	6000
cgtaatcga taaaacatta gatttcagat tagataagga ccatgtataa gaaatatata	6060
cttccactat aatatagtat aagcttacag atagtatctc tcgatctacc gttccacgtg	6120
actagtccaa gaacctgcag gccgcgagcg ccgatacgaa aatcgttatt gtcttgaagg	6180
tgaaatttct actcttatta atggtgaacg ttaagctgat gctatgatgg aagctgattg	6240
gtcttaactt gcttgtcatc ttgctaattg tcattggctc gtgttattac ttaagttatt	6300
tgtactcgtt ttgaacgtaa tgctaattgat catcttatgg aataatagtg agtggtttca	6360
gggtccataa agcttttcaa ttcattcttt ttttttttgt tctttttttt gattccggtt	6420
tctttgaaat ttttttgatt cggtaatctc cgagcagaag gaagaacgaa ggaaggagca	6480
cagacttaga ttggtatata tacgcatatg tgggtgttgaa gaaacatgaa attgccagat	6540
attcttaacc caactgcaca gaacaaaaac ctgcaggaaa cgaagataaa tcatgtcgaa	6600
agctacatat aaggaacgtg ctgctactca tcctagtcct gttgctgcca agctatttaa	6660
tatcatgcac gaaaagcaaa caaacttggt tgcttcattg gatgttcgta ccaccaagga	6720
attactggag ttagttgaag cattaggtcc caaaatttgt ttactaaaaa cacatgtgga	6780
tatcttgact gatTTTTTcca tggagggcac agttaagccg ctaaaggcat tatccgcaa	6840
gtacaatttt ttactcttcg aagacagaaa atttgctgac attggtaata cagtcaaatt	6900

gcagtactct	gcgggtgtat	acagaatagc	agaatgggca	gacattacga	atgcacacgg	6960
tgtggtgggc	ccaggtattg	ttagcggttt	gaagcaggcg	gcggaagaag	taacaaagga	7020
acctagaggc	cttttgatgt	tagcagaatt	gtcatgcaag	ggctccctag	ctactggaga	7080
atatactaag	ggtactgttg	acattgcgaa	gagtgacaaa	gattttgtta	tcggctttat	7140
tgctcaaaga	gacatgggtg	gaagagatga	aggttacgat	tggttgatta	tgacacccgg	7200
tgtgggttta	gatgacaagg	gagacgcatt	gggtcaacag	tatagaaccg	tggatgatgt	7260
ggtctctaca	ggatctgaca	ttattattgt	tggaagagga	ctatttgcaa	agggaagggg	7320
tgctaaggta	gaggggtgaac	gttacagaaa	agcaggctgg	gaagcatatt	tgagaagatg	7380
cggccagcaa	aactaaaaaa	ctgtattata	agtaaataca	tgtatactaa	actcaciaat	7440
tagagcttca	atttaattat	atcagttatt	accacgaaaa	tcgttattgt	cttgaagggtg	7500
aaatttctac	tcttattaat	ggtgaacggt	aagctgatgc	tatgatggaa	gctgattggt	7560
cttaacttgc	ttgtcatctt	gctaattggtc	atatggctcg	tgttattact	taagttatctt	7620
gtactcgttt	tgaacgtaat	gctaattgatc	atcttatgga	ataatagtga	atcggcgctc	7680
gcggcctgca	ggtttcttca	tcctagtatg	tatagcttgt	accattataa	cgaattttat	7740
catgccgccc	aaaggaacaa	tttcaagtac	tatcggaaga	tgaatgggta	gatgttaagc	7800
gcggtcactt	caaacttcac	atttataaag	atgtcacatg	gaccactatt	atctacctta	7860
agttattttat	caagataagt	ttccggatct	ttttctttcc	taacacccca	gtcagcctga	7920
gttacatcca	gccattgaac	cttagaaaat	cttttgtcat	cagcggtttg	agccctaaga	7980
tcaacatctt	gcttagcaat	caatgcaatg	gcgtcataac	caccagcacc	aggtattaag	8040
caagtaagaa	ctccttttaa	ggcttggaac	tcattccaata	agctagtttg	tacgggaggt	8100
tcgatatcgg	caccagattc	tttagttatt	tttctaaagg	aacgtctaata	tgtggcaact	8160
gcatctctaa	cttctgtgat	ctcaggatac	ttttgacagg	tacagtcatt	cctctcaaga	8220
gactcaaata	tctgatcgct	gtaatcgctc	tgagtcctgt	gtaagcgatc	tagtttagat	8280
agtccatcca	taaatctaga	atttgcatga	tcgagttctg	tatatatttt	caagctttcc	8340
ggcatatgcg	aatcatacca	attttttacc	ttctggacca	gttttactgt	ttctgaacca	8400
ttcttaatat	cgcccatcca	taaagttaat	cccgaaggta	aatgggttact	tttaatcggt	8460
atattccagt	cttcttcatt	aaccaaatac	gccagtttac	tgccgtaagt	agcacttcca	8520
atatctggca	aattagagat	taatgcgggt	gggaatcttc	tatatctgat	agatccatat	8580
gctgccgccc	ctacatcaaa	cccgtttcca	attttaccct	gagcttgaca	atgagcaact	8640
tgtgataaat	tatgaataac	ttctctatat	ttgtctacat	tattttccag	gtccgataca	8700
aaaaaggagg	caaagctgt	agttaaaact	gtgactaaac	ctgccgagga	gccagccct	8760
gttttgaggaa	cttcttcaat	tctgtgcgaa	tgaaaactca	atcttctgtt	gccacgatgt	8820
tcggtaacgc	tgtcctcctg	agaatggtag	gcattcatcag	agaaaatatc	aataacgaac	8880
aagtttctat	tgcatgagtc	gtccatgtta	ggcttaaagt	agctaaatac	gttagcgata	8940

actttttcaa	tgaagggtt	cttagatccg	cctatcgaaa	caggaatgaa	gccagtttta	9000
ggacttatat	ggtacagcca	ctcccatct	ttaaattggt	tacttttcac	acgcacttca	9060
aacttatcag	actcttgcaa	tgaaccgtaa	ggatgggcta	cagcatgcat	tcttgccgat	9120
aatccgacta	caaatgcttc	atatttcgga	tctaaaacta	aatatccacc	agctagtaac	9180
gctttccctg	gggcactgaa	ggctctcaac	tctgacatta	tcaagctagt	tgtctgtcgg	9240
gagtgtgctg	gcgttttttt	atcatgttga	tgctctgcat	aataatgccc	ataaatattt	9300
ccgacctgct	tttatatctt	tgctagccaa	actaactgaa	catagctaca	cattattttc	9360
agcttggcta	ttttgtgaac	actgtatagc	cagtccttcg	gatcacggtc	aacagttgtc	9420
cgagcgcttt	ttggaccctt	tcccttat	ttgggttaag	gaaaatgaca	gaaaatatat	9480
ctaagagcc	ttcgctcaac	agtgtccga	agtatagctt	tccaaaagga	gaggcaaagc	9540
aatttaagaa	tgtatgaaca	aaataaagg	gaaaaattac	cccctctact	ttaccaaacg	9600
aatactacca	ataatattta	caacttttcc	ttatgatttt	ttactgaag	cgcttcgcaa	9660
tagttgtgag	cgatatcaaa	agtaacgaaa	tgaacttcgc	ggctcgtgct	atattcttgt	9720
tgctaccgtc	catatctttc	catagatttt	caatctttga	tgtctccatg	gtggtacaga	9780
gaacttgtaa	acaattcgg	ccctacatgt	gaacggccgg	ccaagcacgc	ggggatccga	9840
agcatgtagg	gaggtcatga	tatgaaaaag	caaaagagta	ggcatcaaaa	agtttctcat	9900
tcaagtggta	actgctgtta	aaattaagat	atttataaat	tgaagcttgg	tcgttccgac	9960
caataccgta	gggaaacgta	aattagctat	tgtaaaaaaa	ggaaaagaaa	agaaaagaaa	10020
aatgttacat	atcgaattga	tcttattcct	ttggtagacc	agtctttg	tcaatcaaag	10080
attcgtttgt	ttcttgtggg	cctgaaccga	cttgagttaa	aatcactctg	gcaacatcct	10140
tttgcaactc	aagatccaat	tcacgtgcag	taaagttaga	tgattcaa	tgatggttga	10200
aagcctcaag	ctgctcagta	gtaaatttct	tgtcccatcc	aggaacagag	ccaacaatt	10260
tatagataaa	tgcaaagagt	ttcgactcat	tttcagctaa	gtagtacaac	acagcatttg	10320
gacctgcac	aaacgtgtat	gcaacgattg	tttctccgta	aaactgatta	atggtgtggc	10380
accaactgat	gatacgcttg	gaagtgtcat	tcatgtagaa	tattggaggg	aaagagtcca	10440
aacatgtggc	atggaaagag	ttggaatcca	tcattgtttc	ctttgcaaag	gtggcgaaat	10500
ctttttcaac	aatggcttta	cgcatgactt	caaatctctt	tggtacgaca	tgttcaattc	10560
tttctttaa	tagttcggag	gttgccacgg	tcaattgcat	accctgagtg	gaactcacat	10620
cctttttaat	atcgctgaca	actaggacac	aagctttcat	ctgaggccag	tcagagctgt	10680
ctgcgatttg	tactgccatg	gaatcatgac	catcttcagc	ttttccatt	tcccaggcca	10740
cgtatccgcc	aaacaacgat	ctacaagctg	aaccagaccc	ctttcttgct	attctagata	10800
tttctgaagt	tgactgtgg	aattggtata	acttagcaat	tgagagacc	aatgcagcaa	10860
agccagcagc	ggaggaagct	aaaccagctg	ctgtaggaaa	gttatcttcg	gagacaatgt	10920
ggagtttcca	ttgagataat	gtgggcaatg	aggcgtcctt	cgattccatt	tcctttctta	10980

attggcgtag gtcgcgcaga caattttgag ttctttcatt gtcgatgctg tgtggttctc	11040
catttaacca caaagtgtcg cgttcaaact cagggtgcagt agccgcagag gtcaacgttc	11100
tgaggtcatac ttgcgataaa gtcactgata tggacgaatt ggtgggcaga ttcaacttcg	11160
tgtccctttt cccccaatac ttaagggttg cgatgttgac ggggtgcggtg acggatgctg	11220
tgtaaacggg cattgtgaag gtagttcgat tttggaggtc gcgggagggtt actttttttt	11280
tggatggacg caaagaagtt taataatcat attacatggc aataccacca tatacatatc	11340
catatctaata cttacttata tgttgtggaa atgtaaagag cccattatc ttagcctaaa	11400
aaaaccttct ctttggaact ttcagtaata cgcttaactg ctcatgtcta tattgaagta	11460
cggattagaa gccgccgagc gggcgacagc cctccgacgg aagactctcc tccgtgcgtc	11520
ctggtcttca ccggtcgctg tcctgaaacg cagatgtgcc tcgcgccgca ctgctccgaa	11580
caataaagat tctacaatac tagcttttat ggttatgaag aggaaaaatt ggcagtaacc	11640
tggccccaca aaccttcaaa tcaacgaatc aaattaacaa ccataggata ataatgcgat	11700
tagtttttta gccttatttc tggggtaatt aatcagcgaa gcgatgattt ttgatctatt	11760
aacagatata taaatgcaaa agctgcataa ccactttaac taatactttc aacattttcg	11820
gtttgtatta cttcttattc aaatgtcata aaagtatcaa caaaaaattg ttaatatacc	11880
tctatactta cccacccga agtcgcgcaa ccaactaact ttacaatgtc attaccgttc	11940
ttaacttctg caccgggaaa gggtattatt tttggtgaac actctgctgt gtacaacaag	12000
cctgccgtcg ctgctagtgt gtctgcgttg agaacctacc tgctaataag cgagtcattc	12060
gcaccagata ctattgaatt ggacttcccg gacattagct ttaatcataa gtggtccatc	12120
aatgatttca atgccatcac cgaggatcaa gtaaaactcc aaaaattggc caaggctcaa	12180
caagccaccg atggcttgct tcaggaactc gttagtcttt tggatccggt gttagtcaa	12240
ctatccgaat ccttccacta ccatgcagcg ttttgtttcc tgtatatgtt tgtttgccta	12300
tgcccccattg ccaagaatat taagttttct ttaaagtcta ctttaccat cgggtgctggg	12360
ttgggctcaa gcgcctctat ttctgtatca ctggccttag ctatggccta cttggggggg	12420
ttaataggat ctaatgactt ggaaaagctg tcagaaaacg ataagcatat agtgaatcaa	12480
tgggccttca taggtgaaaa gtgtattcac ggtaccctt caggaataga taacgctgtg	12540
gccacttatg gtaatgccct gctatttgaa aaagactcac ataatggaac aataaacaca	12600
aacaatttta agttcttaga tgatttccca gccattccaa tgatcctaac ctatactaga	12660
attccaaggt ctacaaaaga tcttggtgct cgcgttcgtg tgttggtcac cgagaaattt	12720
cctgaagtta tgaagccaat tctagatgcc atgggtgaat gtgccctaca aggcttagag	12780
atcatgacta agttaagtaa atgtaaaggc accgatgacg aggctgtaga aactaataat	12840
gaactgtatg aacaactatt ggaattgata agaataaatc atggactgct tgtctcaatc	12900
ggtgtttctc atcctggatt agaacttatt aaaaatctga gcgatgattt gagaattggc	12960
tccacaaaac ttaccggtgc tgggtggcggc ggttgctctt tgactttgtt acgaagagac	13020

attactcaag agcaaattga cagtttcaaa aagaaattgc aagatgattt tagttacgag	13080
acatttgaaa cagacttggg tgggactggc tgctgtttgt taagcgcaaa aaatttgaat	13140
aaagatctta aaatcaaac cctagtattc caattatttg aaaataaaac taccacaaag	13200
caacaaattg acgatctatt attgccagga aacacgaatt taccatggac ttcataagct	13260
aatttgcgat aggcatattt tattagttgt ttttaattctt aactgtgtat gaagttttat	13320
gtaataaaga tagaaagaga aacaaaaaaa aatttttctgt agtatcaatt cagctttcga	13380
agacagaatg aaatttaagc agaccatagt atccttgata cattgactca ggtccgccgg	13440
cgttggacga gcgaagcatc ttgccctgtg cttggccccc agtgcagcga acgttataaa	13500
aacgaatact gagtatatat ctatgtaaaa caaccatattc atttcttgtt ctgaactttg	13560
tttacctaac tagtttttaa tttccctttt tcgtgcatgc ggggtgttctt atttattagc	13620
atactacatt tgaaatatca aatttcctta gtagaaaagt gagagaaggt gcactgacac	13680
aaaaaataaa atgctacgta taactgtcaa aactttgcag cagcgggcat ccttccatca	13740
tagcttcaaa catattagcg ttcctgatct tcatacccggt gctcaaaatg atcaaacaaa	13800
ctgttattgc caagaaataa acgcaaggct gccttcaaaa actgatccat tagatcctca	13860
tatcaagctt cctcatagaa cgcccaatta caataagcat gttttgctgt tatcaccggg	13920
tgataggttt gctcaggcgg tttaaacgcg tggccgtgcc gtc	13963

<210> 36
 <211> 10209
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: MS49253 integration construct

<400> 36	
gacggcacgg ccacgcgttt aaaccgccac ccagccaagg tagtctaaaa gctaatttct	60
ctaaaagggga gaaagtgtgt gattttttat ctgcgattat tatatatgca agaatagtta	120
aggtatagtt ataaagtttt atcttaattg ccacatacgt acattgacac gtagaaggac	180
tccattattt ttttcattct agcatactat tattccttgt aacgtcccag agtattccat	240
ttaattgtcc tccatttctt aacgggtgacg aaggatcacc atacaacaac tactaaagat	300
tatagtacac tctcaccttg caactattta tctgacattt gccttacttt tatctccagc	360
ttcccctcga ttttattttt caatttgatt tctaaagctt tttgcttagg cataccaaac	420
catccactca tttaacacct tatttttttt ttcgaagaca gcatccaact ttatacgttc	480
actacctttt tttttacaac aatttcattc ttcacacctat gaacgctcgt ccaacgccgg	540
cggacctttc agacgcgact gcctcatcag taagaccctg tgaaaagaac ttacctgaaa	600
aaaacgaata tatactagcg ttgaatgtta gcgtaacaa caagaagttt aatgacgcgg	660
aggccaaggc aaaaagattc cttgattacg taaggaggtt agaatcattt tgaataaaaa	720
acacgctttt tcagttcgag tttatcatta tcaatactgc catttcaaag aatacgtaaa	780

taattaatag	tagtgatttt	cctaacttta	tttagtcaaa	aaattagcct	tttaattctg	840
ctgtaacccg	tacatgcccc	aaataggggg	cgggttacac	agaatatata	acatcgtagg	900
tgtctgggtg	aacagtttat	tcctggcatc	cactaaatat	aatggagccc	gctttttaag	960
ctggcatcca	gaaaaaaaa	gaatcccagc	acaaaaatat	tgttttcttc	accaaccatc	1020
agttcatagg	tccattctct	tagcgcaact	acagagaaca	ggggcacaaa	caggcaaaaa	1080
acgggcacaa	cctcaatgga	gtgatgcaac	ctgcctggag	taaatgatga	cacaaggcaa	1140
ttgaccacg	catgtatcta	tctcattttc	ttacaccttc	tattaccttc	tgctctctct	1200
gatttggaag	aagctgaaaa	aaaagggttg	aaccagttcc	ctgaaattat	ttccctactt	1260
gactaataag	tatataaaga	cggtaggtat	tgattgtaat	tctgtaaata	tattttcttaa	1320
acttcttaaa	ttctactttt	atagttagtc	tttttttttag	ttttaaaaca	ccaagaactt	1380
agtttcgacc	ttccgcgacc	tccaaaatcg	aactaccttc	acaatgacat	ctccagttat	1440
cggaaactcct	tggaagaagt	tgaacgcccc	agtatctgaa	gaggcaatag	agggtgtcga	1500
caagtattgg	agggtgcta	attacttgtc	aatcggacaa	atctacttga	ggtcaaacc	1560
attaatgaag	gaacctttca	ccagggaaga	tgtaagcat	aggttgggtc	gtcactgggg	1620
aaccacacca	ggattaaact	ttttgattgg	acacatcaac	agattgattg	cagatcacca	1680
acagaacacc	gtcataatca	tgggtccagg	acatggaggt	ccagctggta	ccgcccagtc	1740
ttatttggat	ggtacctata	ccgagtattt	cccaaataat	acaaaggacg	aggcaggttt	1800
acagaagttt	ttcagacagt	tctcttacct	aggaggaatc	ccttcacact	acgctccaga	1860
aacaccaggt	tctattcatg	agggtggtga	attaggatat	gccttatcac	atgcttacgg	1920
agcagtcatg	aacaatcctt	ctttgttcgt	cccagccata	gtaggtgatg	gagaagccga	1980
gaccggtcct	ttagccacag	gttggcaatc	taacaagtta	gtaaacccta	ggactgacgg	2040
aattgtcttg	cctattttgc	atttgaacgg	atacaagatc	gctaacccaa	ccatcttgtc	2100
taggatattc	gacgaggagt	tgcatgagtt	tttccacggt	atgggatacg	agccttatga	2160
gttcgtcgca	ggatttgaca	acgaagacca	tttgtcaatc	cacagaaggt	tcgccgagtt	2220
gtttgagacc	gtctttgacg	agatctgtga	cattaaggca	gctgctcaga	cagacgacat	2280
gaccagacct	ttctatccta	tgataatctt	caggacacct	aagggttgga	cttgccctaa	2340
gtttatagac	ggaaaaaaga	ctgagggatc	atggagatct	catcaagtac	ctttggcatc	2400
tgcaagagat	acagaagctc	acttcgaggt	tttgaaaaat	tggttgaggt	catataagcc	2460
tgaagaattg	ttcgaatgca	atggagctgt	taagccagag	gtaactgctt	ttatgcctac	2520
cggagagtta	agaatcggag	agaatcctaa	cgctaattgt	ggtagaatca	gagaggaatt	2580
gaatttgcct	gcattggagg	attacgaggt	aaaagagggt	gctgaatatg	gtcatggatg	2640
gggtcagttg	gaagcaacca	gaagattagg	tgtttacacc	agggacatta	taaagaacaa	2700
cccagactca	tttaggatct	ttggaccaga	tgaaaccgca	tcaaataagg	tacaggctgc	2760
atatgacgtt	actaataagc	aatgggacgc	tggttactta	tcagcccaag	tagacgaaca	2820

tatggccggtt	acaggtcaag	ttacagagca	attgtctgaa	catcaaattg	aaggattctt	2880
ggaagcttat	ttgttgaccg	gaaggcatgg	aatttgggtca	tcatatgagt	cattcgtaca	2940
tgtcatcgac	tcaatgttaa	atcagcatgc	taagtgggta	gaagccactg	taagagagat	3000
cccatggagg	aaaccaatth	cttcaatgaa	cttattgggt	tcattctcacg	tctggaggca	3060
ggatcataat	ggattttctc	atcaggaccc	aggtgtcaca	tcagttttat	tgaacaagtg	3120
cttcaacaac	gatcacgtta	tcggaattta	ctttcctgtc	gattctaaca	tggtgttagc	3180
tggtgccgag	aagtgttaca	agtctacaga	catgataaac	gccatcattg	ccggaaagca	3240
gccagccgcc	acctgggtta	ccttggtatg	ggcaagggct	gaattggaga	aaggagcagc	3300
cgaatgggag	tgggcctcaa	cagccaagtc	aaatgatgaa	gcacagatag	tattggcttc	3360
agccggtgat	gttctgtctc	aagaaatcat	ggctgtgtcc	gataagttag	atgctatggg	3420
tatcaagttc	aaggttgtca	acgtagtcca	cttgggtcaaa	ttgcagtcta	ccaaagaaaa	3480
tgacgaggcc	atctctgacg	ctgacttcgc	agacttattt	accgaagaca	agccagtatt	3540
attcgcttac	cattcatatg	ccagagatgt	taggggattg	atctatgaca	ggcctaacca	3600
tgacaacttc	aacgtccacg	gatacgaaga	acagggttca	accactaccc	cttatgacat	3660
ggtcagagtc	aacaatattg	acaggtacga	gttgggtcgt	gaagcattga	gaatgatcga	3720
tgacagacaa	tacgcagata	aaatcgacga	attggaggcc	ttcagaaagg	aagcattcca	3780
gtttgcagtt	gataacgggt	acgaccatcc	tgactacacc	gactgggtct	attcaggagt	3840
aaataccaac	aagcagggtg	ctgtttcagc	taccgctgca	actgctgggtg	acaatgaata	3900
aagatctatt	gaattgaatt	gaaatcgata	gatcaatttt	tttcttttct	ctttcccat	3960
cctttacgct	aaaataatag	tttattttat	tttttgaata	ttttttattt	atatacgtat	4020
atatagacta	ttatttatct	tttaatgatt	attaagattt	ttattaaaaa	aaaattcgct	4080
cctcttttaa	tgcttttatg	cagttttttt	ttccatttcg	atatttctat	gttcgggttc	4140
agcgtatttt	aagtttaata	actcgaaaat	tctgcgttcg	ttaaagcttt	cgagaaggat	4200
attatttcga	aataaaccgt	gttgtgtaag	cttgaagcct	ttttgcgctg	ccaatattct	4260
tatccatcta	ttgtactctt	tagatccagt	atagtgtatt	cttctgtctc	caagctcatc	4320
ccatccccgc	gtgcttggtc	ggccgtacga	aaatcggtat	tgtcttgaag	gtgaaatttc	4380
tactcttatt	aatgggtgaac	gttaagctga	tgctatgatg	gaagctgatt	ggctttaact	4440
tgcttgatcat	cttgctaattg	gtcattggct	cgtgttatta	cttaagttat	ttgtactcgt	4500
tttgaacgta	atgctaattg	tcattcttatg	gaataatagt	gagtggtttc	aggggtccata	4560
aagcttttca	attcatcttt	tttttttttg	ttcttttttt	tgattccggt	ttctttgaaa	4620
tttttttgat	tcggtaattct	ccgagcagaa	ggaagaacga	aggaaggagc	acagacttag	4680
attgggtatat	atacgcatat	gtgggtgttg	agaaacatga	aattgcccag	tattcttaac	4740
ccaactgcac	agaacaaaaa	cctgcaggaa	acgaagataa	atcatgtcga	aagctacata	4800
taaggaacgt	gctgtacttc	atcctagtcc	tggtgtgtcc	aagctattta	atatcatgca	4860

cgaaaagcaa	acaaacttgt	gtgcttcatt	ggatgttcgt	accaccaagg	aattactgga	4920
gtagttgaa	gcattaggtc	ccaaaatttg	tttactaaaa	acacatgtgg	atatcttgac	4980
tgatttttcc	atggagggca	cagttaagcc	gctaaaggca	ttatccgcca	agtacaattt	5040
tttactcttc	gaagacagaa	aatttgctga	cattggtaat	acagtcaa	at tgcagtactc	5100
tgcgggtgta	tacagaatag	cagaatgggc	agacattacg	aatgcacacg	gtgtggtggg	5160
cccagggtatt	gttagcgggt	tgaagcaggc	ggcggaagaa	gtaacaaagg	aacctagagg	5220
ccttttgatg	ttagcagaat	tgtcatgcaa	gggctcccta	gctactggag	aatatactaa	5280
gggtactgtt	gacattgcga	agagtgcaca	agattttgtt	atcggtttta	ttgctcaaag	5340
agacatgggt	ggaagagatg	aaggttacga	ttggttgatt	atgacacccg	gtgtgggttt	5400
agatgacaag	ggagacgcat	tgggtcaaca	gtatagaacc	gtggatgatg	tgggtctctac	5460
aggatctgac	attattattg	ttggaagagg	actatttgca	aagggaagg	atgctaagg	5520
agagggtgaa	cgttacagaa	aagcaggctg	ggaagcatat	ttgagaagat	gcggccagca	5580
aaactaaaaa	actgtattat	aagtaa	atgcatact	aactcaca	ttagagcttc	5640
aatttaatta	tatcagttat	taccacgaaa	atcggtattg	tcttgaagg	gaaatttcta	5700
ctcttattaa	tgggtgaacgt	taagctgatg	ctatgatgga	agctgattgg	tcttaacttg	5760
cttgtcatct	tgcta	atggctc	gtgttattac	ttagttatt	tgtactcgtt	5820
ttgaacgtaa	tgcta	atggctc	aataatagtg	aacggccggc	caagcacg	5880
gggatgggat	gagcttgag	caggaagaat	acactatact	ggatctaaag	agtacaatag	5940
atggataaga	atattggcag	cgcaaaaagg	cttcaagctt	acacaacacg	gtttatttcg	6000
aaataatata	cttctcgaaa	gctttaacga	acgcagaatt	ttcgagttat	taaacttaaa	6060
atacgtgtaa	cccgaacata	gaaatatcga	atgggaaaaa	aaaactgcat	aaaggcatta	6120
aaagaggagc	gaattttttt	ttaataaaaa	tcttaataat	cattaaaaga	taaataatag	6180
tctatatata	cgtatataaa	taaaaaatat	tcaaaaaata	aaataaaacta	ttatttttagc	6240
gtaaaggatg	gggaaagaga	aaagaaaaaa	attgatctat	cgattttcaat	tcaattcaat	6300
agatctttat	tcattgtcac	cagcagttgc	agcggtagct	gaaacagcac	cctgcttggt	6360
ggatctttact	cctgaataga	cccagtcggg	gtagtcagga	tggtcgtaac	cgttatcaac	6420
tgcaaaactgg	aatgcttcct	ttctgaaggc	ctccaattcg	tcgattttat	ctgcgtat	6480
gtctgcatcg	atcattctca	atgcttcagc	gaccaactcg	tacctgtcaa	tattgttgac	6540
tctgaccatg	tcataagggg	tagtggttga	accctgttct	tcgtatccgt	ggacgttgaa	6600
gttgtcatgg	ttaggcctgt	catagatcaa	tcccctaaca	tctctggcgt	atgaatggta	6660
ggcgaataat	actggcttgt	cttcggtaaa	taagtctg	aagtcagcgt	cagagatggc	6720
ctcgtcattt	tctttgtag	actgcaattt	gaccaagtcg	actacgttga	caaccttgaa	6780
cttgataccc	atagcatcta	acttatcggc	agcagccatg	atttcttgag	caggaacatc	6840
accggctgaa	gccaatacta	tctgtgcttc	atcatttgac	ttggctgttg	aggccactc	6900

ccattcggct	gctcctttct	ccaattcagc	ccttgccctca	tccaagggtca	accagggtggc	6960
ggctggctgc	tttccggcaa	tgatggcggt	tatcatgtct	gtagacttgt	agcactttctc	7020
ggcaacagct	aacaacatgt	tagaatcgac	aggaaagtaa	attccgataa	cgtgatcggt	7080
gttgaagcac	ttgttcaata	aaactgatgt	gacacctggg	tcctgatgag	aaaatccatt	7140
atgatcctgc	ctccagacgt	gagatgaaac	caataagttc	attgaagaaa	ttggtttcct	7200
ccatgggatc	tctcttacag	tggtttctaa	ccacttagca	tgctgattta	acattgagtc	7260
gatgacatgt	acgaatgact	catatgatga	ccaaattcca	tgctttccgg	tcaacaaata	7320
agcttccaag	aatccttcca	tttgatgttc	agacaattgc	tctgtaactt	gacctgtaac	7380
ggccatatgt	tcgtctactt	gggctgataa	gtaaccagcg	tcccattgct	tattagtaac	7440
gtcatatgca	gcctgtaacc	tatttgatgc	ggtttcatct	ggtccaaaga	tcctaaatga	7500
gtctgggttg	ttctttataa	tgtccctggg	gtaaacacct	aatctttctgg	ttgcttccaa	7560
ctgaccccat	ccatgaccat	attcagcaac	ctcttttacc	tcgtaatcct	ccaatgcagg	7620
caaattcaat	tcctctctga	ttctaccacc	attagcggtta	ggattctctc	cgattcttaa	7680
ctctccggta	ggcataaaaag	cagttacctc	tggtttaaca	gctccatttg	catcgaacaa	7740
ttcttcaggc	ttatatgact	ccaaccaatt	tttcaaaacc	tcgaagtgag	cttctgtatc	7800
tcttgcatg	gccaaaggta	cttgatgaga	tctccatgat	ccctcagtct	tttttccgtc	7860
tataaactta	gggcaagtcc	aacccttagg	tgtcctgaag	attatcatag	gatagaaagg	7920
tctggtcatg	tcgtctgtct	gagcagctgc	cttaatgtca	cagatctcgt	caaagacggt	7980
ctcaaacaac	tcggcgaacc	ttctgtggat	tgacaaatgg	tcttcgttgt	caaatcctgc	8040
gacgaactca	taaggctcgt	atcccatacc	gtggaaaaac	tcatgcaact	cctcgtcaga	8100
tatcctagac	aagatgggtg	ggtagcgat	cttgatccg	ttcaaagtca	aaataggcaa	8160
gacaattccg	tcagtcctag	ggtttactaa	cttgtttagat	tgccaacctg	tggtctaaagg	8220
accggtctcg	gcttctccat	cacctactat	ggctgggacg	aacaaagaag	gattgttcat	8280
gactgctccg	taagcatgtg	ataaggcata	tcctaattca	ccaccctcat	gaatagaacc	8340
tggtgtttct	ggagcgtagt	gtgaagggat	tcctcctggg	taagagaact	gtctgaaaaa	8400
cttctgtaaa	cctgcctcgt	cctttgtaat	atttgggaaa	tactcggtat	aggtaccatc	8460
caaataagac	tgggcggtac	cagctggacc	tccatgtcct	ggacccatga	ttatgacggt	8520
gttctgttgg	tgatctgcaa	tcaatctgtt	gatgtgtcca	atcaaaaagt	ttaatcctgg	8580
tgtggttccc	cagtgaccga	ccaacctatg	cttaacatct	tccttggtga	aaggttcctt	8640
cattaatggg	tttgacctca	agtagatttg	tccgattgac	aagtaattag	cagccctcca	8700
atacttgtcg	acaccctcta	ttgcctcttc	agatactggg	gcgttcaact	tcttccaagg	8760
agttccgata	actggagatg	tcattgtgaa	ggtagtctga	ttttggaggt	cgcgggaggt	8820
cgaaactaag	ttcttggtgt	tttaaaacta	aaaaaaagac	taactataaa	agtagaatat	8880
aagaagttaa	agaaatagat	ttacagaatt	acaatcaata	cctaccgtct	ttatatactt	8940

2014_03_12_107345_00466_ST25

attagtcaag taggggaata atttcagggg actggtttca accttttttt tcagcttttt	9000
ccaaatcaga gagagcagaa ggtaatagaa ggtgtaagaa aatgagatag atacatgcgt	9060
gggtcaattg ccttgtgtca tcattttactc caggcagggtt gcatcactcc attgaggttg	9120
tgcccgtttt ttgcctgttt gtgcccctgt tctctgtagt tgcgctaaga gaatggacct	9180
atgaactgat ggttgggtgaa gaaaacaata ttttgggtgct gggattcttt ttttttctgg	9240
atgccagctt aaaaagcggg ctccattata tttagtggat gccaggaata aactgttcac	9300
ccagacacct acgatgttat atattctgtg taacccgccc cctatttttg gcatgtacgg	9360
gttacagcag aattaaaagg ctaatttttt gactaaataa agttaggaaa atcactacta	9420
ttaattatth acgtattctt tgaaatggca gtattgataa tgataaactc gaactgaaaa	9480
agcgtgtttt ttattcaaaa tgattctaac tcccttacgt aatcaaggaa tctttttgcc	9540
ttggcctccg cgtcattaaa cttcttggtt ttgacgctaa cattcaacgc tagtatatat	9600
tcgttttttt caggtaagtt cttttcaacg ggtcttactg atgaggcagt cgcgtctgaa	9660
aggtccgccc gcgttgacg agcgtccat gctggactta ctcgtcgaag atttcctgct	9720
actctctata taattagaca cccatgttat agatttcaga aaacaatgta ataatatatg	9780
gtagcctcct gaaactacca agggaaaaat ctcaacacca agagctcata ttcgttgtaa	9840
tagcgataat atctctttac ctcaatctta tatgcatgtt atttgctctt ataattggtc	9900
tctatttagg gaaaaagtc ggtttgagag cttctcgca tgtgaaatct caatttgaac	9960
tgcacgcaa agctagccca tttcacgaac accagaaaga agaaatcccc aaggatcgca	10020
tgacagagta tgctctctca tatcgttgag tatgaatgcc aatacactga tcagctttac	10080
aagaaacgta aaatctggca cgatggtaga ctgaaatact ttcagttaaa caacagattc	10140
atgctttata cggaaaagga taacgttttg ttagctagtg aggcggttta aacgcgtggc	10200
cgtgccgtc	10209

<210> 37
 <211> 7257
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic: MS49298 integration construct

<400> 37	
gacggcacgg ccacgcgttt aaaccgccac ccagccaagg tagtctaaaa gctaatttct	60
ctaaaaggga gaaagttggt gattttttat ctcgcattat tatatatgca agaatagtta	120
aggtatagtt ataaagtttt atcttaattg ccacatacgt acattgacac gtagaaggac	180
tccattatth ttttcattct agcatactat tattccttgt aacgtcccag agtattccat	240
ttaattgtcc tccatttctt aacggtgacg aaggatcacc atacaacaac tactaaagat	300
tatagtacac tctcaccttg caactattta tctgacattt gccttacttt tatctccagc	360
ttcccctcga ttttattttt caatttgatt tctaaagctt tttgcttagg cataccaaac	420

catccactca	tttaacacct	tatttttttt	ttcgaagaca	gcatccaact	ttatacgttc	480
actacctttt	tttttacaac	aattttcattc	ttcatcctat	gaacgctcgt	ccaacgccgg	540
cggacctttc	agacgcgact	gcctcatcag	taagaccctgt	tgaaaagaac	ttacctgaaa	600
aaaacgaata	tatactagcg	ttgaatgtta	gcgtcaacaa	caagaagttt	aatgacgcgg	660
aggccaaggc	aaaaagattc	cttgattacg	taagggagtt	agaatcattt	tgaataaaaa	720
acacgctttt	tcagttcgag	tttatcatta	tcaatactgc	catttcaaag	aatacgtaaa	780
taattaatag	tagtgatttt	cctaacttta	tttagtcaaa	aaattagcct	tttaattctg	840
ctgtaacccg	tacatgcccc	aaataggggg	cgggttacac	agaatatata	acatcgtagg	900
tgtctgggtg	aacagtttat	tcctggcatc	cactaaatat	aatggagccc	gctttttaag	960
ctggcatcca	gaaaaaaaa	gaatcccagc	acaaaaatat	tgttttcttc	accaaccatc	1020
agttcatagg	tccattctct	tagcgcaact	acagagaaca	ggggcacaaa	caggcaaaaa	1080
acgggcacaa	cctcaatgga	gtgatgcaac	ctgcctggag	taaatgatga	cacaaggcaa	1140
ttgaccacg	catgtatcta	tctcattttc	ttacaccttc	tattaccttc	tgctctctct	1200
gatttgga	aaagctgaaa	aaaagggtga	aaccagttcc	ctgaaattat	ttccctactt	1260
gactaataag	tatataaaga	cggtaggtat	tgattgtaat	tctgtaaatc	tatttcttaa	1320
acttcttaaa	ttctactttt	atagttagtc	tttttttttag	ttttaaaaca	ccaagaactt	1380
agtttcgacc	ttccgcgacc	ttcaaaatcg	aactaccttc	acaatgaaat	tgatggagaa	1440
tatcttcgga	ttggccaagg	ccgacaagaa	gaaaatcggt	ttggcagagg	gtgaggaaga	1500
gaggaacatc	agggttcag	aggagattat	tagggacggt	attgccgaca	taatcttggt	1560
cggttcagag	tctgtcatta	aggaaaacgc	cgcaaaattc	ggagttaaatt	tggccggagt	1620
agagatagtc	gaccagaaa	cttcttctaa	gaccgccggt	tacgccaacg	ctttctacga	1680
gatcagaaaa	aacaaggag	tcaccttgga	gaaggctgac	aaaatcgta	gggaccat	1740
ctacttcgca	acaatgatgg	tcaagttagg	tgacgctgac	ggtttggtat	ctggtgctat	1800
acatactaca	ggagacttgt	taaggcctgg	tttgacagatt	gtcaaaacag	taccaggtgc	1860
atctgtcgtc	tcacagttct	tcttgatgtc	agtacctgac	tgcgagtatg	gagaggacgg	1920
ttttttgtta	ttcgctgact	gcgctgtaaa	tgtttgcct	accgctgaag	agttatcttc	1980
aatcgcaatt	accactgctg	agactgcaaa	gaatttgtgc	aagatcgagc	caagggtagc	2040
catgttgta	ttctcaacca	tgggatcagc	ctcacatgaa	ttagtcgaca	aggttacaaa	2100
ggcaacaaaa	ttggctaagg	aggctaggcc	tgacttagac	atcgacggtg	aattgcagtt	2160
agacgcctca	ttggttaaga	aggctgcaga	tttgaaagcc	cctggatcta	aagtcgctgg	2220
taaggcaaat	gtcttgatct	tcccagacat	ccaggcagga	aacatcggat	acaagttggt	2280
ccaaagattc	gcaaaggccg	aagccatcgg	tcctatatgt	cagggatttg	ccaaacctat	2340
caacgatttg	tcaaggggat	gttcagtcga	cgacatcgtc	aaagttgttg	ccgttaccgc	2400
agttcaggca	caagcacaag	gataaagatc	tattgaattg	aattgaaatc	gatagatcaa	2460

tttttttctt	ttctctttcc	ccatccttta	cgctaaaata	atagttttatt	ttatTTTTtg	2520
aatatTTTTt	atttatatac	gtatatatag	actattatTT	atctTTtaat	gattattaag	2580
atTTTTatta	aaaaaaaaatt	cgctcctctt	ttaatgcctt	tatgcagttt	TTTTttccca	2640
ttcgatattt	ctatgttcgg	gttcagcgta	TTTTaagttt	aataactcga	aaattctgcg	2700
ttcgTtaaag	ctttcgagaa	ggatattatt	tcgaaataaa	ccgtgtttgtg	taagcttgaa	2760
gcTTTTtg	gctgccaata	ttcttatcca	tctattgtac	tcttttagatc	cagtatagtg	2820
tattcttcct	gctccaagct	catcccatcc	ccgcgtgctt	ggccggccgt	acgaaaatcg	2880
ttattgtctt	gaaggTgaaa	tttctactct	tattaatggT	gaacgttaag	ctgatgctat	2940
gatggaagct	gattggTctt	aacttgcttg	tcatcttgct	aatggTcatt	ggctcgTgtt	3000
attacttaag	ttatttgtac	tcgtTTTTgaa	cgtaatgcta	atgatcatct	tatggaataa	3060
tagtgagtg	tttcagggTc	cataaagctt	ttcaattcat	ctTTTTTTTT	tttgttcttt	3120
TTTTtgattc	cggtttcttt	gaaatTTTTt	tgattcggtA	atctccgagc	agaaggaaga	3180
acgaaggaag	gagcacagac	ttagattggT	atatatacgc	atatgtggTg	ttgaagaaac	3240
atgaaattgc	ccagtattct	taaccCaact	gcacagaaca	aaaacctgca	ggaaacgaag	3300
ataaatcatg	tcgaaagcta	catataagga	acgtgctgct	actcatccta	gtcctgtTgc	3360
tgccaagcta	tttaatatca	tgcacgaaaa	gcaaacaaac	ttgtgtgctt	cattggatgt	3420
tcgtaccacc	aaggaattac	tggagTtagt	tgaagcatta	ggTcccaaaa	tttgtttact	3480
aaaaacacat	gtggatatct	tgactgattt	ttccatggag	ggcacagtta	agccgctaaa	3540
ggcattatcc	gccaagtaca	atTTTTtact	cttcgaagac	agaaaatttg	ctgacattgg	3600
taatacagtc	aaattgcagt	actctgcggg	tgtatacaga	atagcagaat	gggcagacat	3660
tacgaatgca	cacggTgtgg	tgggcccagg	tattgttagc	ggtttgaagc	aggcggcgga	3720
agaagtaaca	aaggaaccta	gaggcctttt	gatgttagca	gaattgtcat	gcaagggctc	3780
cctagctact	ggagaatata	ctaagggTac	tgttgacatt	gcgaagagtg	acaaagattt	3840
tgttatcggc	tttattgctc	aaagagacat	gggtggaaga	gatgaaggTt	acgattggTt	3900
gattatgaca	cccggTgtgg	gttttagatga	caagggagac	gcattgggtc	aacagtatag	3960
aaccgtggat	gatgtggTct	ctacaggatc	tgacattatt	attgttggaA	gaggactatt	4020
tgcaaaggga	agggatgcta	aggtagaggg	tgaacgttac	agaaaagcag	gctgggaagc	4080
atatttgaga	agatgcggcc	agcaaaacta	aaaaactgta	ttataagtaa	atgcatgtat	4140
actaaactca	caaattagag	cttcaattta	attatatcag	ttattaccac	gaaaatcgTt	4200
attgtcttga	aggTgaaatt	tctactctta	ttaatggTga	acgttaagct	gatgctatga	4260
tggaagctga	ttggTcttaa	cttgcttgTc	atcttgctaa	tggTcatatg	gctcgTgtta	4320
ttacttaagt	tatttgtact	cgTTTTgaac	gtaatgctaa	tgatcatctt	atggaataat	4380
agtgaacggc	cggccaagca	cgcggggatg	ggatgagctt	ggagcaggaa	gaatacacta	4440
tactggatct	aaagagtaca	atagatggat	aagaatattg	gcagcgcaaa	aaggcttcaa	4500

gcttacacaa	cacggtttat	ttcgaaataa	tatccttctc	gaaagcttta	acgaacgcag	4560
aattttcgag	ttattaaact	taaaatacgc	tgaacccgaa	catagaaata	tcgaatggga	4620
aaaaaaaaact	gcataaaggc	attaaaagag	gagcgaattt	ttttttaata	aaaatcttaa	4680
taatcattaa	aagataaata	atagtctata	tatacgtata	taaataaaaa	atattcaaaa	4740
aataaaataa	actattattt	tagcgtaaag	gatggggaaa	gagaaaagaa	aaaaattgat	4800
ctatcgattt	caattcaatt	caatagatct	ttatccttgt	gcttgtgcct	gaactgcggt	4860
aacggcaaca	actttgacga	tgtcgtcgac	tgaacatccc	cttgacaaat	cgttgatagg	4920
tttggcaaata	ccctgacata	taggaccgat	ggcttcggcc	tttgcgaaatc	tttggaccaa	4980
cttgatccg	atgtttcctg	cctggatgtc	tgggaagatc	aagacatttg	ccttaccagc	5040
gacttttagat	ccaggggctt	tcaaactctgc	gaccttctta	accaatgagg	cgtctaactg	5100
caattcaccg	tcgatgtcta	agtcaggcct	agcctcctta	gccaattttg	ttgcctttgt	5160
aaccttgtcg	actaatcat	gtgaggctga	tcccatgggt	gagaatgaca	acatggctac	5220
ccttggctcg	atcttgaca	aattctttgc	agtctcagca	gtggtaattg	cgattgaaga	5280
taactcttca	gcggtaggac	aaacatttac	agcgcagtca	gcgaataaca	aaaaaccgtc	5340
ctctccatac	tcgcagtcag	gtactgacat	caagaagact	gatgagacga	cagatgcacc	5400
tggtactgtt	ttgacaatct	gcaaaccagg	ccttaacaag	tctcctgtag	tatgtatagc	5460
accagatacc	aaaccgtcag	cgtcaccta	cttgaccatc	attgttgcca	agtagattgg	5520
gtccctgacg	attttgtcag	ccttctccaa	ggtgactccc	ttgttttttc	tgatctcgta	5580
gaaagcggtg	gcgtaaccgg	cggctctaga	agaagtttct	gggtcgacta	tctctactcc	5640
ggccaaattt	actccgaatt	ttgcggcggt	ttccttaatg	acagactctg	aaccgaccaa	5700
gattatgtcg	gcaataccgt	ccctaataat	ctcctctgaa	gccctgatgt	tcctctcttc	5760
ctcaccctct	gccaaaacga	ttttcttctt	gtcggccttg	gccaatccga	agatattctc	5820
catcaatttc	attgtgaagg	tagttcgatt	ttggagggtcg	cgggagggtcg	aaactaagtt	5880
cttgggtgtt	taaaactaaa	aaaaagacta	actataaaag	tagaatttaa	gaagttaaag	5940
aaatagattt	acagaattac	aatcaatacc	taccgtcttt	atatacttat	tagtcaagta	6000
ggggaataat	ttcaggggac	tggtttcaac	cttttttttc	agctttttcc	aaatcagaga	6060
gagcagaagg	taatagaagg	tgtaagaaaa	tgagatagat	acatgcgtgg	gtcaattgcc	6120
ttgtgtcatc	atttactcca	ggcagggttg	atcactccat	tgaggttgtg	cccgtttttt	6180
gcctgtttgt	gcccctgttc	tctgtagttg	cgctaagaga	atggacctat	gaactgatgg	6240
ttggtgaaga	aaacaatatt	ttggtgctgg	gattcttttt	ttttctggat	gccagcttaa	6300
aaagcgggct	ccattatatt	tagtggatgc	caggaataaa	ctgttcaccc	agacacctac	6360
gatgttatat	attctgtgta	acccgcccc	tattttgggc	atgtacgggt	tacagcagaa	6420
ttaaagggct	aattttttga	ctaaataaag	ttaggaaaat	cactactatt	aattattttac	6480
gtattctttg	aaatggcagt	attgataatg	ataaactcga	actgaaaaag	cgtgtttttt	6540

2014_03_12_107345_00466_ST25

attcaaaatg attctaactc ccttacgtaa tcaaggaatc tttttgcctt ggcctccgcg	6600
tcattaaact tcttggtggt gacgctaaca ttcaacgcta gtatatattc gtttttttca	6660
ggtaagttct tttcaacggg tcttactgat gaggcagtcg cgtctgaaag gtccgccggc	6720
gttggacgag cgctccatgc tggacttact cgtcgaagat ttcttgctac tctctatata	6780
attagacacc catggttatag atttcagaaa acaatgtaat aatatatggt agcctcctga	6840
aactaccaag ggaaaaatct caacaccaag agctcatatt cgttggaata gcgataatat	6900
ctctttacct caatcttata tgcattgttat ttgctcttat aattgggtctc tatttaggga	6960
aaaaagtcgg tttgagagct tctcgcgatg tgaaatctca atttgaactg cacgccaaag	7020
ctagcccatt tcacgaacac cagaaagaag aaatcccaa ggatcgcatg acagagtatg	7080
ctctctcata tcgttgagta tgaatgcaa tacactgatc agctttacaa gaaacgtaaa	7140
atctggcacg atggtagact gaaatacttt cagttaaaca acagattcat gctttatacg	7200
gaaaaggata acgttttggt agctagttag gcggtttaaa cgcgtggccg tgccgctc	7257